

HEALTH TECHNOLOGY ASSESSMENT REPORT

Composite Resin versus Amalgam for Dental Restorations: A Health Technology Assessment

Month, Year
Volume, Issue

PROSPERO Registration Number: CRD42017065861

Cite As: Composite Resin versus Amalgam for Dental Restorations: A Health Technology Assessment. Ottawa: CADTH; 2018 Jan.

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Table of Contents

| | |
|--|----|
| PROTOCOL AMENDMENTS | 8 |
| INTRODUCTION | 9 |
| Policy Question..... | 11 |
| Analytic Framework | 11 |
| Objectives..... | 11 |
| Research Questions | 11 |
| Clinical Review | 11 |
| Economic Review | 11 |
| Patient Perspectives and Experience..... | 11 |
| Implementation Issues..... | 11 |
| Environmental Assessment | 12 |
| Ethics..... | 12 |
| Protocol | 12 |
| CLINICAL REVIEW..... | 12 |
| Methods..... | 12 |
| Review Design..... | 12 |
| Standardized Reporting..... | 12 |
| Literature Search Strategy..... | 12 |
| Study Eligibility | 13 |
| Exclusion criteria..... | 15 |
| Study Selection..... | 15 |
| Data abstraction | 16 |
| Risk of Bias of Included Studies | 17 |
| Assessment of the Body of Evidence | 17 |
| Data Analysis and Reporting | 17 |
| Results..... | 17 |
| Quantity of Research Available | 17 |
| Research Question 1: Efficacy | 17 |
| Research Question 2: Safety | 17 |
| Characteristics of Included Studies | 18 |
| Outcomes and Measures in Included Reports..... | 19 |
| Research Question 1: Clinical Efficacy..... | 19 |
| Research Question 2: Safety..... | 19 |
| Risk of bias of included studies | 21 |
| Research Question 1: Efficacy | 21 |
| Research Question 2: Safety..... | 22 |
| Summary of Study Findings | 23 |
| Research Question 1: Clinical Efficacy..... | 23 |
| Research Question 2: Safety..... | 24 |
| Summary of Results | 27 |
| ECONOMIC EVALUATION | 29 |
| Methods..... | 29 |
| Literature review | 29 |
| Methods overview..... | 29 |
| Type of economic evaluation..... | 30 |
| Target populations and interventions | 31 |
| Perspective..... | 31 |

| | |
|--|-----------|
| Time horizon..... | 31 |
| Model structure..... | 32 |
| Valuing consequences..... | 33 |
| Efficacy (consequences nos. 1 and 2)..... | 33 |
| Hg waste management (consequence no. 3)..... | 34 |
| Patient productivity loss (consequence no. 4)..... | 34 |
| Cost Estimates..... | 34 |
| Dental procedures (consequence nos. 1 and 2)..... | 34 |
| Hg waste management (consequence no. 3)..... | 35 |
| Hourly wages and proportion of the Canadian population employed (consequence no. 4)..... | 35 |
| Sensitivity analysis..... | 36 |
| Model assumptions..... | 37 |
| Model validation..... | 39 |
| Results..... | 39 |
| Key findings..... | 39 |
| Consequence no. 1 – Useful time of a restoration..... | 40 |
| Base case analysis..... | 40 |
| Sensitivity analyses..... | 41 |
| Consequence no. 2 – Lifetime need for replacement..... | 42 |
| Sensitivity Analysis..... | 43 |
| Consequence no. 3 – Hg waste..... | 45 |
| Summary of Results..... | 50 |
| PATIENTS' PERSPECTIVES AND EXPERIENCES REVIEW..... | 52 |
| Methods..... | 52 |
| Literature search..... | 52 |
| Selection criteria..... | 52 |
| Selection method..... | 53 |
| Quality assessment..... | 53 |
| Data extraction..... | 53 |
| Data analysis methods..... | 54 |
| Results..... | 54 |
| Descriptive analysis..... | 54 |
| Critical appraisal of individual studies..... | 55 |
| Meta-synthesis..... | 55 |
| Synthesized finding 1: Something is not working: trying to understand health complaints..... | 56 |
| Synthesized finding 2: Struggle to obtain redress: searching for help, treatment and a reliable diagnosis..... | 58 |
| Synthesized finding 3: Amalgam removal and the journey toward health..... | 59 |
| Summary of Results..... | 60 |
| IMPLEMENTATION ISSUES..... | 62 |
| Methods..... | 62 |
| Data Collection..... | 62 |
| Stage 1: Interviews..... | 62 |
| Stage 2: Literature Search..... | 62 |
| Results..... | 64 |
| Policy..... | 64 |
| Cost Considerations..... | 65 |
| Dental Practice..... | 66 |

| | |
|--|-----|
| Dental Provider | 67 |
| Attitude towards materials and knowledge of underlying pathology | 67 |
| Education and training | 68 |
| Patient preference and dental practice | 69 |
| Patient Considerations | 69 |
| Sociocultural considerations | 69 |
| Patient Cost Considerations | 69 |
| Summary of Results | 70 |
| Conclusion | 71 |
| Knowledge Mobilization | 71 |
| ENVIRONMENTAL IMPACT | 72 |
| Methods | 72 |
| Literature Search | 72 |
| Selection criteria | 73 |
| Data Extraction and Content Analysis | 73 |
| Results | 73 |
| Quantity of Research Available | 73 |
| Content Analysis | 73 |
| Dental Amalgam | 73 |
| Composite Resins | 77 |
| Summary of Results | 78 |
| ETHICS | 79 |
| Methods | 80 |
| Literature Search | 80 |
| Literature screening and selection | 81 |
| Data extraction or abstraction strategy | 82 |
| Analytic approach | 82 |
| Figure 83 | |
| Figure 83 | |
| Summarizing and Presenting Results | 84 |
| Results | 84 |
| Literature Search and Selection | 84 |
| Analysis | 84 |
| Macro Level Issues | 85 |
| Meso Level Issues | 88 |
| Micro Level Considerations | 89 |
| Summary of Results | 92 |
| DISCUSSION | 94 |
| Summary of overall findings | 94 |
| Interpretation | 95 |
| Strengths | 97 |
| Limitations | 97 |
| Directions for Future Research | 100 |
| CONCLUSIONS | 101 |
| REFERENCES | 102 |
| APPENDIX 1: ANALYTICAL FRAMEWORK | 119 |
| APPENDIX 2: LITERATURE SEARCH STRATEGY | 120 |

| | |
|---|-----|
| Grey Literature..... | 130 |
| APPENDIX 3: STUDY SELECTION FLOW DIAGRAMS — CLINICAL REVIEWS | 131 |
| Research Question 1..... | 131 |
| RESEARCH QUESTION 2 | 132 |
| APPENDIX 4: LIST OF INCLUDED STUDIES — CLINICAL REVIEW | 133 |
| Research Question 1..... | 133 |
| Research Question 2..... | 133 |
| APPENDIX 5: LIST OF EXCLUDED STUDIES AND REASONS FOR EXCLUSION — CLINICAL REVIEW..... | 134 |
| Research Question 1..... | 134 |
| Research Question 2..... | 136 |
| APPENDIX 6: CRITICAL APPRAISAL — CLINICAL REVIEW | 140 |
| Research Question 1..... | 140 |
| Research Question 2..... | 140 |
| APPENDIX 7: STUDY AND REPORT CHARACTERISTICS — CLINICAL REVIEW | 141 |
| Research Question 1..... | 141 |
| Research Question 2..... | 142 |
| APPENDIX 8: DETAILED OUTCOME DATA — CLINICAL REVIEW | 150 |
| Summary of Efficacy Outcomes (Research Question 1) | 150 |
| Summary of Safety Outcomes (Research Question 2)..... | 152 |
| APPENDIX 9: SUPPLEMENTAL HEALTH ECONOMICS TABLES AND FIGURES | 167 |
| APPENDIX 10: STUDY SELECTION FLOW DIAGRAM —PATIENTS’ PERSPECTIVES AND EXPERIENCES REVIEW..... | 173 |
| APPENDIX 11: LIST OF EXCLUDED STUDIES AND REASONS FOR EXCLUSION — PATIENTS’ PERSPECTIVES AND EXPERIENCES REVIEW..... | 174 |
| APPENDIX 12: LIST OF INCLUDED STUDIES —PATIENTS’ PERSPECTIVES AND EXPERIENCESREVIEW | 181 |
| APPENDIX 13: CHARACTERISTICS OF INCLUDED STUDIES AND THEIR PARTICIPANTS — PATIENTS’ PERSPECTIVES AND EXPERIENCESREVIEW | 182 |
| APPENDIX 14: QUALITY ASSESSMENT OF INCLUDED STUDIES — PATIENTS’ PERSPECTIVES AND EXPERIENCES REVIEW | 184 |
| APPENDIX 15: META-SYNTHESIS — PATIENT PREFERENCES REVIEW | 185 |
| APPENDIX 16: DESCRIPTIVE THEMES AND ASSOCIATED CATEGORIES — PATIENTS’ PERSPECTIVES AND EXPERIENCES REVIEW..... | 187 |
| APPENDIX 17: INVITATION TO PARTICIPATE IN CONSULTATIONS – IMPLEMENTATION ISSUES REVIEW..... | 191 |
| APPENDIX 18: FLOW DIAGRAM OF LITERATURE SEARCH AND SELECTION PROCESS – ETHICS, LEGAL AND SOCIAL ISSUES REVIEW | 193 |
| APPENDIX 19: HISTORICAL BACKGROUND AND CONTEXT..... | 194 |

Tables

| | |
|--|----|
| Table 1: Study Selection Criteria | 14 |
| Table 2: Harms outcomes in eligible reports..... | 19 |
| Table 3: Overview of endpoints of the consequences and costs..... | 32 |
| Table 4: Average procedure costs for 2 and 3-surface restorations (premolar and molar combined) | 35 |
| Table 5: Description of scenario and sensitivity analyses..... | 36 |
| Table 6: Cost-consequence base-case model assumptions | 37 |
| Table 7: Key findings of the cost-consequence analysis | 39 |
| Table 8: Posterior teeth restoration costs and useful time (probabilistic analysis) | 41 |
| Table 9: Consequence no. 1 scenario and sensitivity analyses | 41 |
| Table 10: Lifetime restoration replacements and costs | 42 |
| Table 11: Consequence no. 2 scenario and sensitivity analyses | 43 |
| Table 12: Result of scenario analyses with crown | 44 |
| Table 13: Hg waste and management costs..... | 46 |
| Table 14: Estimated average (95% CI) procedure times in minutes per restoration material, number of surfaces restored and tooth type (probabilistic analysis) | 46 |
| Table 15: Estimated average (95% CI) productivity loss per restoration material, number of surfaces restored and tooth type – individual with one restoration only (probabilistic analysis)..... | 47 |
| Table 16: Consequence no. 7 scenario and sensitivity analyses | 48 |
| Table 17: Inclusion Criteria | 53 |
| Table 18: Dental Provisions of the Minamata Convention | 85 |

Figures

| | |
|---|-----|
| Figure 1: Consequences included in the analysis..... | 30 |
| Figure 2: Consequence 2 - structure of the patient-level simulation..... | 32 |
| Figure 3: Curve fitting and extrapolation of time to restoration failure from the NECAT data | 40 |
| Figure 4: Cumulative undiscounted costs over time (crown after 3 rd failure scenario)..... | 45 |
| Figure 5: Levels of decision making and types of ethical considerations | 83 |
| Figure 6: Curve fitting and extrapolation of time to restoration failure from the Casa Pia study data | 172 |

Protocol Amendments

| Section | Amendment | Page |
|----------|--|-------|
| Clinical | The calculation of Kappa statistics was limited to the full-text phase of screening only due to the inclusive procedure for title and abstract screening (which rendered any citation deemed eligible by either reviewer to be included for full-text scrutiny), thus precluding the calculation of agreement for these citations. | 17 |
| Clinical | Data abstraction was completed using Microsoft Word tables as opposed to the protocol-specified application, Distiller SR. This was deemed to be a more efficient approach. | 18 |
| Clinical | Additional data for the review of safety were abstracted in accordance with adherence to the PRISMA-Harms checklist and extension paper ¹ | 18-19 |

Introduction

Dental caries is a significant oral health problem worldwide.² While the epidemiology of dental caries across time and populations has changed — due to such factors as economic development, sugar consumption, and community water fluoridation — it remains an important cause of human morbidity, including pain, tooth loss, and downstream sequelae (e.g., school or work absenteeism) that negatively affect the activities of daily life.³ In Canada, data from 2007 show that 57% of children aged six to 11 years; 59% of adolescents aged 12 to 19 years; and 96% of adults have a history of dental caries.⁴

Standard treatment for dental caries aims to restore the structure of the affected tooth using filling material to replace decayed dental tissue.⁵ Amalgam fillings have been widely used for more than 150 years⁶ Some factors supporting the widespread and enduring use of amalgam as a dental restorative material include its strength, durability, and low cost.⁷⁻⁹

However, because amalgam is partly composed of elemental mercury, concerns have persisted over its safety for human health.¹⁰ The surface(s) of dental amalgam fillings are known to release very small amounts of mercury vapour, particularly when stimulated by regular activities such as brushing teeth, chewing, eating hot foods and liquids, and grinding of the teeth.⁹⁻¹¹ Similarly, the placement and removal of amalgam fillings exposes patients and dental personnel to low levels of mercury vapour.¹¹ Mercury is absorbed by and accumulates in bodily organs and tissues, and is known to easily cross the blood-brain and placental barriers. Depending on the level of exposure, mercury can cause significant adverse health effects, including neurological and kidney diseases.¹⁰ For instance, evidence has shown that urinary mercury values of 7 µg Hg/L pose little risk to human health, whereas values of 25 µg Hg/L indicate an increased risk of adverse health effects, and values of ≥50µg Hg/L may result in the onset of sub-clinical and clinical symptoms of mercury poisoning.⁹ While these potential harms have raised concern, current evidence suggests that the levels of mercury exposure from dental amalgam fillings are unlikely to pose a serious risk to human health.⁹

In addition to the potential health effects from mercury contained in dental amalgam, there are concerns regarding the environmental impact of mercury released from amalgam waste generated by dental offices.^{10,12} The placement or removal of amalgam fillings produces amalgam debris, which can be introduced into the environment through wastewater from dental offices.¹² Mercury is designated as a toxic substance under the Canadian Environmental Protection Act, 1999.¹³ Waste management initiatives and requirements introduced in recent years for Canadian dental facilities have contributed to a significant reduction of amalgam waste discharge into the environment.¹⁴ Nonetheless, the perceived health risks and potential environmental impact of dental amalgam, and the mercury it contains, continue to feed a certain amount of debate over its use in dentistry.

On the international front, the United Nations Environment Programme has established the Minamata Convention on Mercury, which aims “to protect the human health and the environment from anthropogenic emissions and releases of mercury and mercury compounds.”¹⁵ In addition to the use of mercury in general, the Minamata Convention addresses the use of

amalgam in dentistry by recommending a phase-down of its use; specifically, parties who have ratified the Convention commit to the adoption of at least two of nine proposed measures.¹⁵ One concern arising from the proposed phasing down of dental amalgam is the impact on the cost of dental care — which is known to be a barrier for some disadvantaged groups in Canada.^{4,9} Canada signed the Minamata Convention in 2013¹⁶ and ratified it in April 2017.¹⁷ The Convention later entered into force internationally on August 16, 2017;¹⁸ as of October 13, 2017, it has been ratified by 84 governments worldwide.¹⁹

Among the alternatives to the use of amalgam as a restorative material for dental caries, composite resin is the most common, having been in use for more than 50 years.²⁰ Initially limited to restorations in anterior teeth, modern composite resin, with its improved formulations and capacity to withstand stress and wear, has been used more commonly in posterior teeth instead of amalgam.²¹ A distinct advantage of composite resin is that it can be colour-matched to the tooth being restored, giving it an aesthetic advantage over the silver, metallic colour of amalgam — a feature that has increased patient demand for dental restorations made of composite resin.^{7,22} However, rates of restoration failure and secondary caries in composite resin restorations have been shown to be higher than those in amalgam restorations.⁶ Further, the placement of restorations made of composite resin involves a more demanding, time-consuming procedure than that for restorations made of amalgam.^{7,22} As with other procedures, the clinician's technique is considered an important factor in the placement of restorations made of composite resin — more so than for those made of amalgam — and may affect the quality, longevity, and outcomes achieved.²² Evidence also suggests that restorations made of composite resin have a higher initial cost compared with those made of amalgam.²³ Similarly, the long-term costs associated with composite resin have been found to exceed those of amalgam -- mostly owing to the shorter median survival time of composite resin restorations and the consequent need for more frequent repair and/or replacement.²³

Concerns have also been raised about the safety of composite resin restorations due to potential toxicity of some composite resin materials that may contain derivatives of bisphenol A (BPA), such as "...bisphenol A diglycidyl methacrylate (bis-GMA) especially, but also bisphenol A dimethacrylate (bis-DMA), polycarbonate-modified bis-GMA (PC bis-GMA), ethoxylated bisphenol A glycol dimethacrylate (bis-EMA) and 2,2-bis[(4-methacryloxy polyethoxy)phenyl]propane (bis-MPEPP)."²⁴ (p. 447) In 2010, the World Health Organization concluded that an unsafe level of exposure to BPA in humans could not be determined given available data, but that dental materials were unlikely to be an important source of exposure to BPA as compared to that from plastic food and drink containers, primarily.²⁵ A more recent publication from the European Food Safety Authorities (EFSA) aligns with the WHO's assessment of BPA exposure from dental materials; it further concludes that, relative to others, dental materials (including composite resin restorations, among others) are not an important source of chronic exposure, and as such that they were not considered in the EFSA's exposure estimates.²⁶ These exposure estimates were used to establish a recommended temporary total daily intake of no more than 4 µg/kg body weight — a threshold that exceeds estimated average daily exposure levels.²⁶

Given Canada's commitment to the Minamata Convention on Mercury and ongoing questions related to dental restoration materials, a comprehensive evaluation of the benefits, harms, and other consequences of dental restorations made of amalgam compared with the primary alternative restoration material (composite resin) is needed.

Policy Question

Should dental amalgam continue to be used in Canada?

Analytic Framework

The analytic framework informing this Health Technology Assessment (HTA) is presented in [Appendix 1](#).

Objectives

The objective of this HTA is to inform the policy question through a comparative assessment of dental amalgam and the most commonly used alternative in Canada i.e., composite resin. Specifically, the HTA aims to address the comparative efficacy and safety, cost-consequence, patient perspectives and experience, ethical and implementation issues, and the environmental impact of dental restorations made of amalgam versus composite resin for the treatment of dental caries.

Research Questions

The HTA addresses the following research questions:

Clinical Review

1. What is the comparative efficacy of direct dental restorations made of composite resin versus amalgam for the treatment of dental caries in permanent, posterior teeth?
2. What is the comparative safety of dental restorations made of composite resin versus amalgam in children and adults?

Economic Review

3. What are the comparative consequences and costs of using dental restorations made of composite resin or amalgam for permanent teeth in Canada?

Patient Perspectives and Experience

4. What are the perspectives and experiences of patients (adults or children), parents of children patients, or caregivers around dental amalgam and composite resin restorations?

Implementation Issues

5. What is the current use of amalgam restorations in Canadian dental practices or programs?
6. What is the current use of composite resin restorations in Canadian dental practices or programs?

7. What factors influence the use of amalgam or composite resin restorations in Canadian dental practices or programs?

Environmental Assessment

8. What are the environmental effects associated with the use of dental amalgams versus composite resin restorations?

Ethics

9. What are the ethical issues associated with the use of dental amalgams compared with the use of composite resin restorations?

Protocol

A detailed protocol was prepared, *a priori*, reviewed by stakeholders external to CADTH, registered with the PROSPERO database (CRD42017065861) and the final version is publicly available.²⁷

Clinical Review

Methods

Review Design

To address the first question, a 2014 Cochrane systematic review (SR)⁶ was updated, with some modifications, due to the consistency of its scope and methods with those planned for the current review. Specifically, the update sought to build upon the findings of the 2014 Cochrane SR by identifying and incorporating eligible studies published since publication of the SR. In general, the methods employed in the original 2014 SR were adhered to, with exceptions to the definition of the population of interest (owing to unit of analysis issues reported in the original SR⁶); search strategy; procedures for title and abstract screening and data abstraction, and; assessing the body of evidence identified (details below).

The second question considered safety outcomes. Due to the limited analysis of safety in the 2014 Cochrane SR which focused its primary analyses on restoration failure,⁶ a *de novo* SR of the evidence describing the comparative safety of dental restorations made of composite resin versus amalgam was conducted.

Standardized Reporting

The report of findings was prepared in consideration of relevant reporting guidelines for SRs i.e., Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)²⁸ and its extension, PRISMA-Harms.¹

Literature Search Strategy

The literature search was performed by an information specialist, using a peer-reviewed search strategy.

Published literature was identified by searching the following bibliographic databases: MEDLINE (1946-) with Epub ahead of print, in-process records and daily updates, via Ovid; Embase (1974-) via Ovid; the Cochrane

Central Register of Controlled Trials via Ovid; and PubMed. Cochrane Oral Health Group's Trials Register and Latin American and Caribbean Health Sciences Literature (LILACS) via BIREME databases were searched only for question 1.

The clinical search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. For question 1, the Cochrane systematic review⁶ search was updated. The main search concepts were dental restoration, dental amalgams and composite resins. For question 1, no methodological search filters were applied. The search was limited to documents published since January 2012 and no language limits were applied. Conference abstracts were included in the search results.

For question 2, the main search concepts were dental amalgams and composite resins. For question 2, a filter was applied to limit retrieval to safety studies. Conference abstracts were excluded from the search results. For the safety search for dental amalgams, the retrieval was not limited to publication year or language. For the safety search for composite resins, the retrieval was limited to documents published since January 2006 but no language limits were applied. See [Appendix 2](#) for the detailed search strategy.

The searches for question 1 and 2 were completed on June 26, 2017. Monthly alerts were established to update the searches until the publication of the final report. Studies identified in the alerts and meeting the selection criteria of the reviews were incorporated into the analysis if identified prior to the completion of the stakeholder feedback period for the final report. Any eligible studies that are identified after the stakeholder feedback period will be described in the discussion, with a focus on comparing the results of these new studies to the results of the analysis conducted for this report.

Grey literature (literature that is not commercially published) was identified by searching the *Grey Matters* checklist (<https://www.cadth.ca/grey-matters>), which includes the websites of health technology assessment agencies, clinical guideline repositories, SR repositories, economics-related resources, and professional associations. Google and other Internet search engines were used to search for additional web-based materials. These searches were supplemented by reviewing the bibliographies of key papers and through contacts with appropriate experts.

Study Eligibility

Eligibility criteria for clinical studies are outlined in Table 1:

Table 1: Study Selection Criteria

| | Question 1 | Question 2 |
|--------------|--|---|
| Population | <ul style="list-style-type: none"> Permanent, posterior teeth affected by dental caries | <ul style="list-style-type: none"> Dental caries patients of any age who have been exposed to dental restorations made of composite resin and/or amalgam Where data are available, subgroups based on the following: <ul style="list-style-type: none"> patient age (if not otherwise defined within the study): <ul style="list-style-type: none"> children (0 to 5 years; 6-11 years; 12-17 years) adults (18 to 64 years) older adults (65 years and older) genetic susceptibility socioeconomic status remote, rural, and urban settings people with developmental/ special needs |
| Intervention | <ul style="list-style-type: none"> Direct, composite resin dental filling restorations, including (where reported) consideration of application techniques: <ul style="list-style-type: none"> type of composite resin materials <ul style="list-style-type: none"> flowable conventional compactable any others not listed bonding materials <ul style="list-style-type: none"> universal adhesives etch-and-rinse self-etch adhesives any others not listed filling techniques <ul style="list-style-type: none"> incremental bulk filling any others not listed application of pins surface areas restored | <ul style="list-style-type: none"> Composite resin as a restorative material for dental caries, including (where reported) consideration of surface areas, i.e., number of: <ul style="list-style-type: none"> restored surface areas surface years |
| Comparator | <ul style="list-style-type: none"> Direct dental amalgam filling restorations, including consideration of application techniques: <ul style="list-style-type: none"> bonded and un-bonded application of pins surface areas restored | <ul style="list-style-type: none"> Amalgam as a restorative material for dental caries including (where reported) consideration of surface areas i.e., number of: <ul style="list-style-type: none"> restored surface areas surface years |
| Outcome | <p>Clinical outcomes restricted to the following:</p> <ul style="list-style-type: none"> primary: <ul style="list-style-type: none"> restoration failure rate* secondary (i.e., reasons for failure): <ul style="list-style-type: none"> secondary caries, restoration fracture tooth fracture | <p>All adverse events, including:</p> <ul style="list-style-type: none"> toxicity sensitivity allergic reaction injury |
| Time Frame | <ul style="list-style-type: none"> January 2012—present (in accordance with an update to Rasines-Alcaraz et al.⁶) | <ul style="list-style-type: none"> January 2007—present |
| Study Design | <ul style="list-style-type: none"> RCTs <ul style="list-style-type: none"> minimum 3-year follow-up | <ul style="list-style-type: none"> RCTs; primary, non-randomized studies that directly compare composite resin and amalgam restorative materials |

* For question 1, in accordance with the original Cochrane SR, restoration failure incorporated data describing restoration survival.⁶

Full-text publications that met the criteria outlined in Table 1 were included.

For question 2, no limits on the age of patients, types of composite resin, or amalgam dental restorations were imposed. Where reported for both treatment groups, exposure was defined by surface area (either number of surface areas per type of material per person), or surface years (number of surfaces per type of material per person weighted by the number of years present) per type of material per person — in accordance with input provided by clinical experts. All adverse events were considered, including toxicity (e.g., mercury levels, bisphenol A levels, and associated neurologic function, renal function, immune function, reproductive function, fetal and neonatal effects, neurobehavioral and psychosocial function, physical development), sensitivity (e.g., oral lesions, post-operative sensitivity, phototoxic reactions), allergic reactions (e.g., oral dermatitis, stomatitis, photoallergic reactions), and injury (e.g., sustained during placement of the restoration).

Exclusion criteria

For question 1, exclusion criteria established in the original SR that was updated for this HTA⁶ were used. Specifically, studies were excluded if they focused on restorations in anterior teeth (where amalgam is rarely used), deciduous teeth, and/or reported only on endodontic restorations. Further, because short-term follow-up in the study of dental restorations is less informative,²⁹ studies with less-than three years of follow-up were excluded. Study designs of interest were limited to randomized controlled trials (RCTs) only.⁶ Further, reports published prior to 2012 were excluded.

For question 2, while no restrictions were imposed on the study follow-up duration, studies that did not report primary research data directly comparing composite resin and amalgam restorations were excluded in order to maximize the scientific rigour of included studies for the review. Consequently, reviews, meta-analyses, and HTAs were also excluded, as were *in vitro* and modelling studies. Further, reports published prior to 2007 were excluded in accordance with clinical expert feedback indicating that composite resin materials have changed over time and comparisons with earlier materials were likely to be less relevant to the present day.

For both questions 1 and 2, eligible sources were full, published or unpublished reports i.e., no conference or meeting abstracts or other summaries that lacked detail describing study methods and findings. Duplicate publications were excluded, as were multiple publications of the same study, unless they provided unique methodological details and/or findings of interest.

Study Selection

Two reviewers (SDK, KS) independently screened titles and abstracts of all citations using standardized criteria operationalized using Distiller SR.³⁰ Title and abstracts deemed potentially relevant by either reviewer were retrieved in full (this approach differed from that employed in the original Cochrane SR whereby all titles and abstracts were independently screened in duplicate by two reviewers.⁶) The same reviewers then independently applied the criteria outlined in Table 1 to each full-text report and compared their selections, resolving all discrepancies through discussion and consensus, and involving a third reviewer (SMM) as necessary. Ongoing discussion amongst reviewers occurred during both phases of screening to review discrepancies and establish consensus on the application of selection criteria.

The protocol²⁷ intended to calculate Kappa statistics for both the title and abstract and full-text phases of screening. The protocol was amended, limiting calculation of Kappa statistics to the full-text phase of screening only. This was due to the inclusive procedure for title and abstract screening that rendered any citation deemed eligible by either reviewer to be included for full-text scrutiny; thereby precluding the calculation of agreement for these citations. Accordingly, overall weighted Kappa statistics measured agreement between reviewers for each review addressing questions 1 and 2, respectively. Calculated values were interpreted as follows: < 0.20 as slight agreement, 0.21 to 0.40 as fair agreement, 0.41 to 0.60 as moderate agreement, 0.61 to 0.80 as substantial agreement and > 0.80 as almost perfect agreement.³¹

Data abstraction

Data from included reports were collected, including:

- First author's name, publication year, country, and funding sources
- Study design, analytical approach and any subgroup analyses of interest
- For question 1:
 - number and types of restorations
 - a description of the intervention, comparator, and, where reported, the application technique(s) used to place the restoration
 - restoration failure rate and reasons for failure (i.e., secondary caries, tooth fracture)
- For question 2:
 - number, age, sex, remote/rural/urban settings, socioeconomic status, and restoration types of study participants (where reported)
 - a description of the intervention, comparator, and, where reported, numbers of surface areas and/or surface years
- Description of outcomes reported, follow-up duration, and study loss to follow-up
- Findings and conclusions regarding the outcomes and subgroups of interest

Data from each included study were abstracted into Microsoft Word tables by one reviewer and verified by a second reviewer with disagreements resolved through discussion and consensus. This approach represented a deviation from the methods used in the original Cochrane SR for which duplicate data abstraction was performed.⁶ Standardized forms were used to inform the data abstraction process.

In accordance with PRISMA-Harms,¹ additional information for question 2 was later abstracted from each of the reports included in this review. Specifically, data describing whether study outcomes were measured actively or passively, and whether causal associations were addressed by study authors was collected. Information on methods for outcomes data collection used in each study were included in the data tables in [Appendix 8](#) and reporting on causal association was considered as part of the discussion.

Risk of Bias of Included Studies

For both questions 1 and 2, the Cochrane Risk of Bias Tool³² was used to assess the included RCTs. The Cochrane Risk of Bias Tool³² solicits judgments for seven items across six domains, considering selection (i.e., random sequence generation and allocation concealment), performance (i.e., blinding of participants and personnel), detection (i.e., blinding of outcome assessors), attrition (i.e., incomplete outcome data), reporting (i.e., selective reporting) and 'other' biases (i.e., as identified). For each item, a judgment of "Low Risk of Bias," "High Risk of Bias," or "Unclear Risk of Bias" was assigned.

Two researchers piloted forms and independently assessed risk of bias for each eligible report identified. Where included reports from a trial were additional to the first, or primary, publication(s), and cited former publications rather than describing the study methods in detail, references to protocols or design/methods papers were used to retrieve these publications and incorporate relevant information into the assessments. Disagreements between reviewers were resolved through discussion and consensus, and involving a third reviewer (SMM) as necessary. While the findings from these assessments were not used to further exclude studies from the review and analyses, they are described alongside the study findings in order to provide context.

Assessment of the Body of Evidence

While the original Cochrane SR conducted an assessment of the body of evidence by outcome using GRADE, neither the review of efficacy nor that of safety for this HTA included assessments using GRADE.

Data Analysis and Reporting

Narrative syntheses were undertaken to describe the direction and size of observed effects across outcomes and studies. This employed the use of detailed data tables describing study characteristics and results ([Appendix 7](#) and [Appendix 8](#), respectively), supplemented by a summary description of the findings of each included study and report by outcome. Following an assessment of clinical and methodological heterogeneity between studies, statistical pooling (meta-analysis) was deemed to be unfeasible.

Results

Quantity of Research Available

Research Question 1: Efficacy

The electronic literature search identified a total of 517 citations, from which 21 were identified as potentially relevant and retrieved for full-text scrutiny. One report was retrieved from the grey literature. Of these 22 potentially eligible reports, one was found to be eligible and included.³³ The report selection process is outlined in [Appendix 3](#) using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram.

The weighted overall Kappa statistic indicated initial agreement at the full-text phase of screening was perfect at 1.0.

Research Question 2: Safety

The electronic literature search identified a total of 5,860 citations, of which 68 were identified as potentially relevant and retrieved for full-text assessment. One report was retrieved from the grey literature. Of these 69 potentially eligible reports, 10 were found to be eligible and included.³³⁻⁴² The report selection process is outlined in [Appendix 3](#) using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram.

The weighted overall Kappa statistic indicated initial agreement at the full-text phase of screening generated a value of 0.49 (95% confidence interval [CI] 0.39 to 0.79) indicating moderate agreement.

Lists of included and excluded citations for both research questions — with details describing the rationale for those excluded — are presented in [Appendix 4](#) and [Appendix 5](#), respectively.

Characteristics of Included Studies

The one report eligible for research question 1 was also one of the 10 reports eligible for research question 2. Thus, across both research questions, 10 unique reports were found. These 10 reports described the results from three unique RCTs, for which characteristics are detailed in [Appendix 7](#).

The first RCT was conducted by Kemaloglu and colleagues.³³ This trial generated one report that was eligible for both research questions. In this trial, 50 teeth were randomly assigned to either amalgam or composite resin restorations in 25 adult patients between the ages of 18 and 60 years. Each patient had at least two carious lesions at baseline, allowing for a split-mouth design where each patient had at least one tooth randomized to amalgam and one tooth randomized to composite resin. Authors report the use of dispersed-alloy amalgam placed with a bonding agent (i.e., Amalgambond), and Quixfil composite resin placed with an etch-and-rinse adhesive system (XP Bond). The techniques used for restoration placement were described in detail and standardized across two dental surgeons. The study was conducted at one clinic site in Turkey. The trial duration of follow-up was three years, and outcomes were measured at 'baseline' (i.e., two weeks post-intervention), three, six, 12 and 36 months. Funding/support was reported as "Nil" (p. 22).³³

The second RCT was the New England Children's Amalgam Trial (NECAT). The NECAT was one of two studies informing the primary analysis of restoration failure in the 2014 Cochrane SR that was updated for question 1.⁶ The NECAT study also generated additional reports describing other outcomes — including five that were exclusively eligible for research question 2.^{34,35,37,39,42} A total of 534 children between the ages of six and 10 years with at least two carious lesions in either deciduous or permanent teeth at baseline were randomized to either type of dental restoration(s) for the duration of the trial. The techniques used for restoration placement were reported as standard procedures which were standardized across sites and practitioners.⁴³ The study was conducted across two sites in the Northeastern United States. The trial duration of follow-up was five years, and it was funded by the National Institute of Dental and Craniofacial Research (U01 DE11886).

The third RCT was the Casa Pia Children's Amalgam trial. The Casa Pia trial was likewise one of the two studies informing the primary analysis of restoration failure in the 2014 Cochrane SR updated as question 1 of the clinical review.⁶ Similarly, the Casa Pia trial generated multiple publications reporting different outcomes that were additional to the primary report of restoration failure — four of which were exclusively eligible for research question 2.^{36,38,40,41} This RCT randomized 507 children between the ages of eight and 12 years with at least one carious lesion at baseline to either amalgam or composite resin restoration(s). The placement of restorations was standardized across dental care providers in the study, and individual treatments were described as being "...essentially randomly assigned..."⁴⁴ (p. 310) across study dentists to account for the possibility of provider effects. The trial was conducted in Portugal within the Casa Pia school system, comprised of seven school sites. Investigators followed both groups for seven years and received funding from the National Institute of Dental and Craniofacial Research (grant U01 DE11894).

Outcomes and Measures in Included Reports

Details describing the outcomes and measures within the included reports in the clinical review can be found in [Appendix 7](#). A summary of these is described below by research question.

Research Question 1: Clinical Efficacy

The one included report³³ addressing efficacy described restoration failure. Study investigators reported the use of modified United States Public Health Service (USPHS) criteria (Ryge).³³ These six criteria included: retention; marginal adaptation; anatomical form; marginal discoloration; surface texture; and secondary caries. For each criterion, a judgment of "Alpha" (i.e., best), "Bravo" or "Charlie" (i.e., worst) was rendered at each of the four follow-up time points – with the exception of retention and secondary caries, for which "Bravo" was not an applicable category. Restoration failure was calculated using a formula that reportedly considered "...the number of unacceptable restorations..." (p. 19). Methods for ascertaining and distinguishing 'acceptable' from 'unacceptable' restorations were not reported.

Research Question 2: Safety

The safety outcomes reported in the ten eligible reports³³⁻⁴² are shown in Table 2.

Table 2: Harms outcomes in eligible reports

| Study | Report | Type of harm | Harm outcome of interest |
|-------------------------------|--------------------------------|-----------------|-----------------------------|
| NECAT | Bellinger 2007 ⁴² | Toxicity | Neuropsychological function |
| | | | Urinary mercury |
| | Bellinger 2008 ³⁵ | | Psychosocial status |
| | Shenker 2008 ³⁷ | | Immune function |
| | Barreregard 2008 ³⁹ | | Renal effects |
| Maserejian 2012 ³⁴ | Physical development | | |
| Casa Pia | Lauterbach 2008 ⁴⁰ | | Neurological symptoms |
| | Woods 2007 ⁴¹ | Urinary mercury | |

| | | | |
|------------------------------|--------------------------|-------------|-----------------------------|
| | Woods 2008 ³⁸ | | Renal effects |
| | Woods 2009 ³⁶ | | Urinary porphyrin excretion |
| Kemaloglu 2016 ³³ | | Sensitivity | Post-operative sensitivity |

Injury

No eligible studies were identified addressing outcomes describing injury.

Allergic reaction

No eligible studies were identified addressing outcomes describing allergic reaction.

Toxicity

Outcomes relevant to toxicity were reported across nine papers³⁴⁻⁴² and included neuropsychological, psychosocial, neurological, immune and renal function, physical development, urinary mercury and porphyrins.

Neuropsychological function was described in one report from the NECAT study using, as its primary outcome measure, administration of the Wechsler Intelligence Scale for Children-Third Edition (WISC-III) at baseline, years three and five.⁴² A secondary measure included the Wechsler Individual Achievement Test (WIAT), also administered at baseline, three and five years. Additional secondary measures included a number of domain-focused tests (detailed in [Appendix 7](#)) administered at one, two and four years.

Psychosocial function was reported in one paper from the NECAT study, using as its primary measure the change in adjusted mean scores between baseline and five years on the parent-reported Child Behavior Checklist (CBCL).³⁵ The CBCL was used to assess changes in mean scores across four composite scales, including competence, internalizing and externalizing behavior problems, and total problem behaviors — each of which is informed by a series of 12 subscales. Study authors also reported use of the child-reported Behavior Assessment System for Children (BASC -SR) at five years follow-up.³⁵

Neurological outcomes were reported in one paper from the Casa Pia study, which annually evaluated neurological hard signs (NHS), as well as the presence of neurological soft signs (NSS) (and their severity, when present) and positional tremor.⁴⁰ Specifically, NHS were defined as indicators of "...damage to specific neural structures and, in clinical practice, are used to localize the site of lesion or dysfunction..." (p. 139)⁴⁰ and NSS were defined as "... subtle signs of central nervous system dysfunction that have no localizing value..." (p. 139)⁴⁰

Immune function was evaluated in one report from the NECAT trial, measured using white blood cell count, B-cell, T-cell, monocyte and neutrophil function measured at baseline, 5-7 days, 6, 12 and 60 months.³⁷

Renal effects were measured in both the NECAT and Casa Pia studies and reported within two included papers — one from each trial.^{38,39} While the NECAT authors reported measurement of markers of glomerular and tubular kidney function, including urinary excretion of albumin, alpha-1-microglobulin, γ -glutamyl transpeptidase (γ -GT), and N-acetyl- β -D-glucosaminidase (NAG) at years one (γ -GT only), three and five³⁹; Casa Pia

investigators measured glutathione S-transferases (GST)- α , GST- π , albumin, and tested for the presence of microalbuminuria in yearly age cohorts.³⁸ These analyses further considered the importance of sex in examining measures of renal function.

Physical development was reported in one study from the NECAT trial using five-year changes in body-mass index (BMI), height, body fat percentage, and initiation of menarche, as well as age at first menarche where observed.³⁴ All measurements and analyses considered sex as a relevant subgroup.

One report from the Casa Pia trial measured urinary mercury levels as its primary outcome, accounting for race, sex and number of amalgam surface areas.⁴¹ Another report from the Casa Pia trial described annual measurement of creatinine-adjusted, geometric mean urinary porphyrin concentrations — including uro-, hepta-, hexa-, penta-, precopro-, and coproporphyrins³⁶ — including a subgroup analysis by age conducted in eight and nine year olds.

Some papers primarily reporting toxicity outcomes also reported number of amalgam surface areas^{37,40-42} and/or urinary mercury levels^{36-39,41,42} per treatment group as exposure variables. And in some of these reports, these variables were used to run additional, secondary, dose-response analyses.^{37,39,42} Where data describing these variables were reported quantitatively to describe the originally randomized treatment groups, they are accordingly detailed in Appendices [7](#) and [8](#).

Sensitivity

Sensitivity was reported in one trial,³³ measured as post-operative pain at baseline (two weeks post-intervention), six, 12 and 36 months using thermal stimuli (i.e., cold) and a patient-reported Visual Analog Scale (VAS) using a line marked from zero to 10 centimetres.

Risk of bias of included studies

A tabulated summary of the risk of bias assessments using the Cochrane Risk of Bias tool³² appears in [Appendix 6](#). Overall, each of the included studies exhibited some risk of bias. In particular, risk of performance bias was high in all of the included studies, owing to the visually-discernible difference between composite resin and amalgam restorations; consequently, it was impossible to blind participants and personnel to the use of these interventions. Notably, this confers the potential for some residual risk (however unlikely) that patient or provider knowledge of the intervention they were exposed to could impact behavior that may then affect the harms outcomes measured. An overall trend was that reports of the NECAT trial^{34,35,37,39,42} generally demonstrated a lower risk of bias compared with those from the Casa Pia^{36,38,40,41} or Kemalglu³³ trials. A summary of the risk of bias assessments is reported below by research question.

Research Question 1: Efficacy

The risk of selection bias in the report by Kemalglu et al.³³ was variable across items within this domain i.e., investigators appropriately generated the random sequence (low risk of bias) but did not clearly report their

approach to allocation concealment (unclear risk). With respect to the efficacy outcome of restoration failure, the risk of detection bias was high, since outcome assessors could not be blinded. The risk of attrition bias was unclear, since a judgment could not be rendered concerning the reporting of incomplete outcome data (i.e., five of 25 patients were reported as having been lost to follow-up; no reasons for this were reported and it was unclear whether this could be related to restoration failure).³³ Similarly, the trial was judged to have an 'unclear' risk of reporting bias because it could not be ascertained whether the outcomes were pre-specified. Lastly, the trial demonstrated a 'high' risk of other potential sources of bias owing to discordance between the stated outcome and measures of interest and the analyses and conclusions reported.

Research Question 2: Safety

Concerning the NECAT trial and four of its five reports included in this review^{34,35,39,42} (supplemented by relevant methods references^{35,42,43,45,46} to inform critical appraisal of the study methods), risk of selection bias was deemed to be 'low.' One report from a sub study of immune function, however, described soliciting consent from 257 of 534 study participants, and recruiting only 66 (citing the fear of blood draws as the primary reason for refusal).³⁷ This lack of clarity was deemed to constitute an 'unclear' risk of selection bias — primarily as the approach to selecting the 257 invited participants was not described and the implications for random sequence generation and allocation concealment were similarly unclear. Likewise, blinding of outcome assessors was reported in all of the NECAT papers,^{34,35,37,39,42} earning a judgment of 'low' risk of bias for this item and, by extension, for the domain assessing detection bias. As for attrition bias, three of the five of the NECAT papers^{34,35,42} earned a 'low' risk of bias in this domain. In the remaining two,^{37,39} one reported the findings of their primary, comparative analyses of amalgam and its effects on renal outcomes with large numbers of missing patient data and an insufficient explanation as to the reason for this,³⁹ earning this report a 'high' risk of bias. And the risk of attrition bias was deemed to be 'unclear' in another NECAT report investigating the immunotoxic effects of amalgam,³⁷ where reasons for missing data — and their potential impact on bias — were not clearly reported. Reporting bias was judged to be 'low' in four of the five NECAT reports.^{34,35,39,42} The remaining NECAT report³⁷ was deemed to warrant a 'high' risk of reporting bias owing to apparent discordance between pre-specified outcomes and those described in the reports of findings. Finally, there were no additional sources of bias identified in four of the five included NECAT reports,^{34,35,37,39} whereas one report described ITT analyses but failed to provide details as to their procedure for handling missing data⁴² which resulted in an 'unclear' risk of bias judgement for this report.

The Casa Pia trial — as reported in the four papers included in this review^{36,38,40,41} and the referenced methods publications consulted^{44,47,48} — neither reported their methods for random sequence generation nor allocation concealment transparently, earning this trial a judgment of 'unclear' for risk of selection bias. The blinding of outcome assessors was neither reported clearly in any of the reports,^{36,38,40,41} nor their referenced methods publications, necessitating a judgment of 'unclear' for risk of detection bias. Incomplete and missing data were identified across all four of the included reports.^{36,38,40,41} In two of these, the numbers analyzed were not reported, rendering a judgement of 'unclear' risk of attrition bias.^{38,41} The

other two reports both indicated large numbers of missing data – ranging from 149 missing at the end of follow-up from 479 analyzed at baseline in the report of porphyrin excretion,³⁶ to 278 missing at the end of follow-up from 506 analyzed at baseline from the report of neurological outcomes.⁴⁰ Reasons for missing data were not described in the former report³⁶ and were described as being related to the availability of study participants during outcome measurement time points in the latter paper.⁴⁰ While missing data were reasonably balanced between groups in both papers, the lack of an explanation for the missing data in the paper describing porphyrin excretion earned this report an ‘uncertain’ risk of attrition bias.³⁶ For the other report,⁴⁰ the magnitude of data missing and its unclear effect on the outcomes reported – particularly considering the reported rationale for its missingness – earned this report a ‘high’ risk of attrition bias. Reporting bias was judged to be ‘low’ in two of the four Casa Pia papers.^{38,41} In two of the remaining included reports,^{36,40} a ‘high’ risk of reporting bias was ascertained, owing to apparent discordance between pre-specified outcomes and those described in the reports of findings. Finally, no additional sources of bias were identified in three of the four included reports from the Casa Pia trial.^{36,38,40} The remaining report⁴¹ was deemed to have an ‘unclear’ risk of bias, as some of the reported analyses were not pre-specified.

Since the risk of selection bias in the trial by Kemaloglu et al. was independent of the outcome, the resulting assessment of low risk of bias for randomization and unclear risk of bias for allocation concealment is the same as described earlier. The risks of other biases were, however, unique to the safety outcome of post-operative sensitivity. In particular, the risk of detection bias for the safety outcome was unclear in this trial; investigators described the assessment of post-operative sensitivity as blind.³³ Nevertheless, the procedure for operationalizing a blinded assessment of post-operative sensitivity was neither clearly reported, nor intuitively ascertainable. As with the risk of attrition bias concerning efficacy (above), the risk of attrition bias was likewise unclear as it concerned post-operative sensitivity (i.e., 5 of 25 patients were reported as lost to follow-up), however reasons for this were not reported and it was unclear whether this could be related to post-operative sensitivity.³³ Similarly, the trial earned an ‘unclear’ risk of reporting bias because it was not apparent whether the outcomes were pre-specified, as no protocol was available. Finally, this trial was deemed to be at a ‘high’ risk of other potential sources of bias owing to its lack of clarity in reporting the post-operative sensitivity i.e., rather than report scores, or differences in mean scores, variations in scores across time were reported as ‘ranks’ (p. 21).³³

Summary of Study Findings

Research Question 1: Clinical Efficacy

Detailed findings from the 2014 Cochrane SR can be found in the report by Rasines Alcaraz et al.⁶ Our report describing the update to this SR includes a brief summary of its findings (below), but focuses on describing the evidence identified since its 2013 search.

The 2014 Cochrane SR identified seven eligible trials, of which two employed parallel group designs and five were split-mouth designs. The SR authors judged all seven trials to be at high risk of bias, emphasizing important limitations with the five split-mouth studies; consequently, their

primary analyses were based on the two parallel studies — the NECAT and Casa Pia trials. These two RCTs contributed a total of 3,265 composite restorations (753 from the NECAT and 892 from the Casa Pia trial) and 1,935 amalgam restorations (509 from the NECAT and 856 from the Casa Pia trial) across five- and seven-year durations of follow-up, respectively.⁶ Their results (based on a GRADE rating of low quality evidence) demonstrated that, when compared to amalgam, composite resin restorations were associated with statistically significantly higher failure rates (risk ratio [RR] 1.89; 95% CI 1.52 to 2.35, $P < 0.001$) and risk of secondary caries (RR 2.14; 95% CI, 1.67 to 2.74, $P < 0.001$). There was no statistically significant difference between treatments in the risk of restoration fracture (RR 0.87; 95% CI 0.46 to 1.64, $P = 0.66$). While assessments of heterogeneity for the primary analyses of restoration failure and secondary caries indicated that heterogeneity was significant ($P \leq 0.005$), the authors explained that because the directions of these effects were consistent across both RCTs for these outcomes, meta-analyses were undertaken.⁶ In subgroup analyses of the five split-mouth studies, the direction of treatment effect for failure rate was consistent with that of the primary analysis, whereas there was no difference in secondary caries risk found between composite resin and amalgam restorations.

In updating the Cochrane SR, one eligible RCT was identified, the results of which are presented in detail in [Appendix 8](#). Though the trial authors reportedly measured restoration failure, the manner in which they presented the data precluded statistical pooling with those in the Cochrane SR; specifically, it was unclear how the data from the clinical evaluations were used to inform the reported findings. Nevertheless, based on an analysis of 40 teeth from 20 patients (five were lost to follow-up), the authors concluded that the “overall failure rate ... was 0%” (p. 19) after up to three years of follow-up.³³ Similarly, the proportion of “Alpha” ratings (i.e., no caries) was 100% for both amalgam and composite resin restorations at all follow-up time points in the study, suggesting that zero events of secondary caries occurred in both arms of the trial.

Research Question 2: Safety

Toxicity

Neuropsychological evaluations were carried out on a variable number of children in the NECAT trial depending on the outcome measure/subscale, ranging from between 328 and 436 of the 534 children randomized. The evaluations found no statistically significant difference between treatment groups on any overall measure of neuropsychological function.⁴² However, ITT analyses indicated a statistically significant between-group difference on two subscales (i.e., the Number-Letter Memory scale of the WRAML favoured the amalgam group [$P = 0.002$]; and, the ‘Part B: time to complete’ subsection of the Trail-Making Test favoured the composite resin group [$P = 0.002$]).

Authors of this report from the NECAT also described urinary mercury levels and amalgam surface areas at five years of follow-up for each treatment group, primarily using these values as predictors to run additional, secondary analyses describing neuropsychological findings as a function of these exposures.⁴² Both predictors were reported by randomized treatment group, however, and the urinary mercury levels were deemed particularly relevant in terms of assessing comparative safety; a significantly higher level

of urinary mercury was found in children randomized to amalgam at five years of follow-up i.e., 0.9 µg/g creatinine (range, 0.1 to 5.7 µg/g creatinine) as compared to children in the composite group i.e., 0.6 µg/g creatinine (range, 0.1 to 2.9 µg/g creatinine) [$P < 0.001$].⁴² In another report from the Casa Pia trial, urinary mercury levels were reported as a primary outcome of interest.⁴¹ Children in both treatment groups had comparable urinary mercury levels at baseline i.e., 1.5 µg/L (SD ± 1.2; range 0.1 to 7.7) for amalgam and 1.4 µg/L (SD ± 1.1; range 0.0 to 8.6) for composite resin. Urinary mercury levels became significantly higher in children assigned to amalgam through years two to six, with a peak level of 3.2 µg/L in year two post-intervention [$P < 0.001$] (levels for the composite resin group were only reported graphically and not quantitatively).⁴¹ Notably however, in follow-up year seven, urinary mercury in the amalgam group had dropped to a level comparable with that of baseline (reported qualitatively and graphically only). Importantly, the difference between treatment groups was no longer statistically significant [$P = 0.07$], indicating a reduction in urinary mercury excretion in those receiving dental amalgam restorations across time.⁴¹ Subgroup analyses of sex differences in urinary mercury excretion also found statistically significantly higher levels in females treated with amalgam as compared to males; whereas no sex difference was observed in the composite resin group. Detailed data describing the findings reported on the originally randomized treatment groups (i.e., using dental material type as the predictor) are presented in [Appendix 8](#).

Psychosocial evaluations were completed on a subset of children in the NECAT study (i.e., 395 for the CBCL and 426 for the BASC-SR analyses).³⁵ While no statistically significant group difference was identified by the competence or externalizing behaviour composite scales, a statistically significant group difference was found by both the internalizing behaviour ($P = 0.03$) and total problem behaviour ($P = 0.007$) composite scales — both differences favouring the amalgam group, with greater deficits observed in the composite resin group. The BASC-SR evaluations produced four global scores derived from a series of subscales and compared five-year follow up results across treatment groups. Similarly, these analyses indicated no statistically significant difference between groups in two of the four global scores (i.e., school and clinical maladjustment). However, the remaining two global scores indicated a statistically significant between-group difference that, favoured the amalgam group (i.e., personal adjustment [$P = 0.005$] and the emotional symptoms index [$P = 0.05$]). Detailed data — including those describing subscale results as reported — are presented in [Appendix 8](#).

Neurologist-administered, annual evaluations of neurological symptoms in the Casa Pia trial — including the presence of neurological hard signs, soft signs and positional tremor — found no statistically significant difference between the amalgam and composite resin treatment groups at any point in time.⁴⁰ Between years three and seven, additional measurements were taken to evaluate the severity of neurological soft signs observed; likewise, these assessments showed no statistically significant between-group differences in scores at any point in time. Data are detailed in [Appendix 8](#).

Immune function was measured in a sub study of the NECAT that analyzed data for 59 of 257 children invited to participate (35 from the amalgam group and 31 from the composite resin group). Authors report that the characteristics of children in the sub study were similar to those of the overall study population.³⁷ Measurement of total white cell counts, T-cell, B-

cell, neutrophil and monocyte responsiveness indicated no statistically significant differences between treatment groups at any one of five points in time across the five-year study follow up ([Appendix 8](#)).

The physical development of children was also compared across groups in the NECAT study, including 474 of the 534 children originally randomized.³⁴ The authors report no between-group differences in age-adjusted, mean BMI-for-age Z-scores, body fat percentage or height over the five-year study follow-up. Additional, exploratory analyses of menarche outcomes in females were restricted to one study site, and investigated 113 participants. These analyses indicated that girls in the composite resin group were statistically significantly less likely to have reached menarche during study follow up compared with those in the amalgam group (hazard ratio [HR] = 0.57, 95% CI 0.35 to 0.95, $P = 0.03$). Nonetheless, an examination of age at first menarche indicated no statistically significant difference between treatment groups among those who had reached first menarche ($P = 0.48$). Data are presented in [Appendix 8](#).

Renal function was measured in both the NECAT and Casa Pia trials and described in two reports – one from each study -- included in the clinical review.^{38,39} In the paper generated from the NECAT study,³⁹ 490 children were included in the primary analyses where no statistically significant group difference in biomarker levels or prevalence of high biomarker values was reported. However, the authors do report statistically significantly higher odds of microalbuminuria (MA) observed in the amalgam group in a repeat-measures logistic regression analysis of years three and five ($P = 0.03$). Notably, the authors suggest this finding may be due to chance or confounding and should be further investigated for corroboration. In particular, they concede that albuminuria is common in the general population – including in children – and can occur as the result of everyday exposures such as extreme physical exertion or infections causing fever.³⁹ Notably, in their report of renal function, authors from the Casa Pia trial report on microalbuminuria in yearly age cohorts and found no difference between the treatment groups.³⁸ Similarly, no statistically significant between-group differences were found in measures of all other renal biomarkers. Detailed data for both studies and their measures are tabulated in [Appendix 8](#).

Another report generated from the Casa Pia trial presented the urinary porphyrin excretion in 479 children (i.e., all those for whom porphyrin data were available).³⁶ No statistically significant differences were found in any of the primary analyses comparing the randomized treatment groups, nor in a series of subgroup analyses (i.e., by age, race and sex). The authors emphasized “incipient increases” (p. 895) observed in a subgroup analyses of eight and nine year old participants; however, they conceded that the observed, non-statistically significant effects are far below the threshold at which renal function is expected to be affected. While little quantitative data were reported (i.e., findings regarding porphyrin levels were presented within graphs and significance test results were reported qualitatively), data from the report are presented in [Appendix 8](#).

Sensitivity

The report of post-operative pain from Kemaloglu and colleagues³³ did not provide data describing raw VAS scores observed between restoration types. However, the report did describe the results of significance tests

between restoration types, indicating no between-group differences in post-operative pain at baseline (two weeks post-intervention), six or 12 months ($P > 0.05$).³³ Nonetheless, the authors report that VAS scores were found to differ significantly ($P < 0.05$), at the 36-month evaluation, favouring composite resin restorations. The data, as abstracted from the article, are presented in [Appendix 8](#).

Summary of Results

Evidence from 10 eligible reports, representing three unique studies, was identified, assessed and summarized to answer two independent research questions that queried clinical efficacy and safety. Of the 10 reports, one was eligible for the SR update addressing efficacy -- a 2016 split-mouth RCT which analyzed restoration performance in 40 teeth with an unclear or high risk of bias in most domains assessed (this study was also eligible for the question addressing safety, as below).³³ The original 2014 SR⁶ meta-analyzed data from two parallel-group RCTs describing 3,010 teeth in children, and found a statistically significantly higher risk of failure in composite resin versus amalgam restorations. Authors of the 2016 split-mouth RCT found zero events of restoration failure in either treatment arm and concluded that "Judging from the results, survival rate was 100% for both of the restoration types and they were found to be successful." (p. 20).³³ While it is interesting that the findings from the 2016 split-mouth RCT contrast with those of the 2014 Cochrane SR, the conclusions of the former are not thought to impact those of the latter for the following reasons: (i) reporting of the data in the 2016 split-mouth RCT was inconsistent with the conclusions drawn by the authors; (ii) the sample size of the newer RCT was sufficiently small so as to preclude any impact on the findings of the original Cochrane SR; (iii) the three-year length of follow-up in the 2016 split-mouth RCT was considerably shorter than the five- and seven-year follow-up of the NECAT and Casa Pia trials, respectively (which formed the basis of the primary analyses for the Cochrane SR) and may have been insufficient for events of restoration failure to be observed; (iv) the lack of events in both arms of the 2016 split-mouth RCT would have no effect on the findings of the pooled, primary analysis of the original Cochrane SR (and the value of incorporating such findings, in itself, is a source of methodological debate⁴⁹). Thus, the findings from our update do not essentially change those reported in the 2014 SR,⁶ the conclusions from which therefore remain current.

All 10 reports identified in the *de novo* SR addressing safety were generated from RCTs comparing dental amalgam and composite resin restorations and described either toxicity or sensitivity outcomes in a combined 1,081 patients ranging from six to 60 years of age. Assessments identified a risk of performance bias in all of the studies due to the visible distinction between the interventions under study, in addition to risks of bias from other domains that varied across papers. Statistically significant differences in urinary mercury excretion between composite resin and amalgam patients were reported in both the NECAT⁴² and Casa Pia⁴¹ trials through to five and six years of follow up, respectively. Notably, urinary mercury levels at seven years follow-up in the Casa Pia trial were found to no longer differ significantly between treatment groups ($P = 0.07$)⁴¹, suggesting that mercury exposure from dental amalgam restorations may attenuate across time. While one paper from the Casa Pia trial found no between-group differences in any measures of renal effects,³⁸ and three of four measures of renal

function used in the NECAT similarly indicated no statistically significant differences,³⁹ the prevalence of microralbuminuria was found to be statistically significantly higher in the amalgam-treated group in years three and five ($P = 0.03$); authors conceded that this could be due to either a causal association or chance.³⁹ Arguably, the lack of concordance across the two RCTs with regard to findings of microralbuminuria may support the NECAT authors' latter proposed explanation. Similarly, while four of five measures of physical development in the NECAT (i.e., five-year changes in body-mass index; body fat percentage; height; age at first menarche) indicated no between-group differences, a subgroup analysis of menarche initiation in females at one study site showed a statistically significantly greater probability in the amalgam as compared to the composite resin group ($P = 0.03$).³⁴ Authors from this study concluded that no significant group differences were found, but that further research into menarche outcomes may be warranted.³⁴ Likewise, while 10 of 12 measures of neuropsychological function in the NECAT identified no between-group differences, one subscale from each of the remaining two measures suggested a statistically significant difference ($P = 0.002$, for both subscales) — one favouring the amalgam and the other the composite resin group — leading authors to conclude that no important differences were observed.⁴² Again, in an evaluation of psychosocial outcomes from the NECAT, two of four sub-scores for both the primary and secondary measures indicated no statistically significant group difference, whereas the other two sub-scores for both measures did indicate statistically significant differences ($P \leq 0.05$) — all of which favoured the amalgam group i.e., scores were less favourable among those in the composite resin group.³⁵ Authors concluded that amalgam did not poorly affect psychosocial function, and that, for some measures, seemed to be associated with improvements.³⁵ And while post-operative sensitivity did not differ between amalgam and composite resin restorations at two weeks, six and 12 months of follow-up; however, a statistically significant difference was reported at 36 months of follow-up, favouring the composite resin group.³³ Finally, no statistically significant differences between treatment groups were observed in evaluations of neurological symptoms,⁴⁰ immune function,³⁷ and urinary porphyrin excretion.³⁶ .

Economic Evaluation

This section addresses Research Question 3:

What are the comparative consequences and costs of using dental restorations made of composite resin or amalgam for permanent posterior teeth in Canada?

Methods

Literature review

A literature review was conducted to identify previously published economic models on dental restoration with amalgams or with composite resin. In total, 11 economic evaluations were identified that addressed the economic value of various dental restoration procedures or caries management programs.

One model estimated the financial impact of introducing an amalgam ban over a 15 year period in the US.⁵⁰ All other analyses were cost-effectiveness analyses using a decision-tree, a Markov cohort model or a patient-level simulation.⁵¹⁻⁶⁰ Two had a time horizon shorter than 15 years^{57,58} while the majority of remainder adopted a lifetime perspective. A description of these published models can be found in [Appendix 9](#).

None of the models identified compared amalgam to composite resin for the restoration of permanent posterior teeth over a lifetime horizon within a Canadian setting. Therefore, a *de novo* economic model was constructed to address Research Question 3. Existing economic models provided insights towards developing the model structure, in determining appropriate model assumptions, and possible sources of data inputs relating to disease prognosis.

Methods overview

The objective of the economic analysis was to evaluate the comparative consequences and costs associated with composite resin and amalgam as restorative materials for permanent, posterior teeth, within a Canadian societal perspective.

As mentioned in the protocol, the outcomes of interest in the cost-consequence analysis were dependent on the results of the clinical and environmental review.²⁷ At the time of the protocol development, these were expected to include the average lifespan of dental restorative material, the rates of adverse events and the level of exposure to toxic material over patients' lifetime or, if the data were limited, over a period shorter than the lifespan of the dental restoration.


Seven consequences were identified based on the literature review and in consultation with clinical experts involved in the review: useful life of a restoration; lifetime need for restoration replacement; mercury (Hg) waste management; Hg/BPA exposure; adverse events; patient preference; patient productivity loss. Upon completion of the clinical and economic literature reviews, no information was available to support the consideration of three of the seven consequences. The following three consequences were not explored in the cost-consequence analysis given the reasons listed below:

- Hg/BPA exposure: no clinical consequences that could be modelled from the clinical review.
- Adverse events: could not be modelled given the findings from the clinical review.
- Patient preferences/utilities: no information on utility measurements in patients with amalgam and/or composite resin restorations of the posterior teeth was identified.

Therefore, the cost-consequence analysis focused on the four consequences listed in Figure 1.

The original level of analysis was expected to be the individual restored tooth; however, during the research phase it was determined that this level of analysis was not appropriate for all consequences. For example, using the country level for Hg waste management may be more meaningful than from a single tooth in view of the small quantities of Hg used for a restoration. Similarly, for productivity loss, the patient-level made more sense as it reflects his/her time spent going to the dentist. The analysis for each consequence are reported under different time horizons. The level of analysis and time horizon used for each consequence is listed in Figure 1.

Figure 1: Consequences included in the analysis



Type of economic evaluation

A cost-consequence analysis was considered the most appropriate approach for this assessment in order to capture the health- and non-health-related consequences associated with different restorative materials for dental caries. Although this approach does not comply to existing Canadian guideline in the conduct of economic evaluations, it was deemed to be the best approach for this decision problem.⁶¹ Given the policy question, this represents a unique situation whereby the information of interest to decision-

makers can vary depending on their role. The cost-consequence analysis permits decision-makers to identify those consequences that are of interest and relevance to them and to perform a trade-off between these consequences. Furthermore, some of the non-health consequences, in particular on the environment, cannot be adequately captured by a cost-utility analysis (i.e., limited literature or guidance on how to link environmental concerns as outcomes in an economic model). By looking at the health- and non-health related consequences and costs, this economic evaluation captures broader societal consequences and costs (i.e., Hg waste management) that may be important considerations to some decision-makers.

Therefore, a cost-consequence analysis was the chosen approach for this assessment. In a cost-consequence analysis, the consequences (health- and non-health-related) and their respective costs are analysed and presented separately in a disaggregated fashion. Seven important and clinically meaningful outcomes were of interest to this review, although only four (Figure 1) could be included in the final model due to lack of data.

Target populations and interventions

The economic analysis focused on Canadians in need of an initial restoration to a posterior tooth. Analyses were performed at the tooth level for consequence nos. 1 and 2. As the clinical data sources used for consequence nos. 1 and 2 included studies exclusively performed in children, the target population was further refined to Canadian children for these two consequences. For consequence no. 3 (i.e., waste management), the level of analysis was the Canadian population given the broad environmental impacts associated with different materials for dental restoration. The level of analysis was that of the individual for consequence no. 4 (productivity loss).

According to the clinical experts consulted, 2- and 3-surface restorations are the most commonly performed restorations of posterior permanent teeth (Dr. Carlos Quiñonez, Faculty of Dentistry, University of Toronto; Dr. Shahrokh Esfandiari, Faculty of Dentistry, McGill University; personal communication, 2017 Dec 04). Therefore, all analyses at the tooth and individual-level were conducted to reflect this information.

The two interventions compared in this analysis were amalgam and composite resin used as restorative materials for permanent posterior teeth affected with caries. These two interventions are described in Table 3.

Perspective

The primary perspective of this analysis was societal. In Canada, only 5.5% of the population is covered by a public dental program.⁶² The societal perspective includes consideration of the impact of different dental restoration material to third-party-payers, such as private dental insurances, and the dental fees paid out-of-pocket by Canadians who do not have private dental insurance.

Time horizon

The time horizon varied according to the nature of the consequence. For consequence no. 1 (useful life of a restoration), the time horizon was defined until restoration failure. For consequence no. 2 (lifetime need for restoration

replacement), a lifetime horizon was used. In this case a 1.5% discount rate per annum was applied after the first year to costs and consequences in the base case analysis (0% and 5% discounting in sensitivity analyses).⁶¹ For consequence no. 3 (Hg waste management), the time horizon was 1 year. Finally, for consequence no. 4 (productivity loss), the time horizon captured in the cost-consequence analysis reflected the duration of the initial restorative dental procedure. No discounting was therefore necessary for consequences 1, 3 and 4.

Model structure


Table 3 gives an overview of the clinical and cost endpoints included in each of the 4 consequences as well as the respective sources of data used in the analysis. More details on the data sources can be found under the Valuing consequences (page 33) and Cost Estimates sections (page 34) as well as in [Appendix 9](#). With the exception of consequence no. 2, the value of the consequences was based on calculations described in the Valuing consequences section rather than through more extensive modelling.

Table 3: Overview of endpoints of the consequences and costs

| No | Consequence | Clinical/ Humanistic or other endpoints | Data source | Costs | Data source |
|----|---|---|--|--|---|
| 1 | Useful life of a restoration | <ul style="list-style-type: none"> • Time to secondary restoration | <ul style="list-style-type: none"> • Clinical review | <ul style="list-style-type: none"> • Cost of restoration | <ul style="list-style-type: none"> • Dental fee schedules |
| 2 | Lifetime need for restoration replacement | <ul style="list-style-type: none"> • Number of replacements needed over the lifetime of the tooth | <ul style="list-style-type: none"> • Clinical review | <ul style="list-style-type: none"> • Total costs of restorations over the lifetime of a tooth | <ul style="list-style-type: none"> • Dental fee schedules |
| 3 | Hg waste management | <ul style="list-style-type: none"> • Amount of Hg waste per restoration • Amount of Hg waste by restoration removed • Amount of Hg escaping in the waste water | <ul style="list-style-type: none"> • Environmental review | <ul style="list-style-type: none"> • Amalgam separator costs (acquisition, maintenance, waste disposal; Hg released in the environment) | <ul style="list-style-type: none"> • Clinical expert |
| 4 | Patient productivity loss | <ul style="list-style-type: none"> • Time loss due to dental procedure | <ul style="list-style-type: none"> • Duration of dental procedure | <ul style="list-style-type: none"> • Cost of time loss | <ul style="list-style-type: none"> • National statistics on income |

A patient-level Markov state-transition simulation was performed to address consequence no. 2 (lifetime need for restoration replacement). This was necessary to calculate the expected number of dental restorations over the lifetime of a patient's tooth. The model simulated 5,000 individual children with an average age of 7.9, of which 51% were males.^{63,64} The model progressed based on time to next restoration, and once the age of the patient's next restoration was calculated, the model would assess whether the patient would have remained alive up to that age using Canadian life tables.⁶⁵ The structure of the model is shown in Figure 2. Because information on the natural history of subsequent tooth restorations was identified from the published literature was limited, assumptions were made on time-to-failure of each subsequent restoration and how restoration failure would be managed. These assumptions are described in Table 6.

Figure 2: Consequence 2 - structure of the patient-level simulation



All calculations were performed using Microsoft Excel 2010. Probabilistic analysis was used for all calculations except for consequence no. 3, which was deterministic.

Valuing consequences

Efficacy (consequences nos. 1 and 2)

The clinical review identified one study in addition to those included in the primary analysis of a previously published systematic review.⁶ However, after discussion with the clinical review team and the clinical experts in dentistry consulted as part of this review, the NECAT, one of the two studies included in systematic review mentioned above, was judged to be a more appropriate trial to inform the base case of the cost-consequence analysis based on the following.^{33,63}

- The NECAT was conducted in the USA (New England area) while the others were conducted either in Turkey or in Portugal for the Casa Pia study.^{33,63,66} Thus, the clinical characteristics of the NECAT were felt to be more generalizable to the patient characteristics in Canada.
- As noted in the Clinical Review, the NECAT generally demonstrated a lower risk of bias compared to the Casa Pia or the Kemalglu studies.^{6,33,63,66}
- The Casa Pia study had implemented a dental caries prevention program at the study's initiation that could have confounded the observed results.⁶⁶
- The Kemalglu study was small (n= 25 patients) compared to the NECAT (n= 534 patients).^{33,63}

Time to restoration replacement was the main efficacy parameter for consequences nos. 1 and 2. In the NECAT, replacements were performed for new caries (i.e., carious surface different from the one previously restored on the same tooth), recurrent caries, fracture, restoration loss or other (not otherwise specified) causes.⁶³ In agreement with the clinical experts, repairs reported in the NECAT were not considered in the economic model as restoration failure since the number of repairs reported was low (i.e., 2 in the amalgam group and 21 in the composite resin group).⁶³ The survival curve from the NECAT was digitalized using Ditigitzeit (Trialware, Germany). A mathematical model was fitted to the curve using the methods and tools developed by Hoyle and Tierney in order to extrapolate the survival curve beyond the 5 years of the study as well as to account for parameter uncertainty.^{67,68} The average time to restoration failure and its standard deviation (SD) were calculated from the extrapolated data and

used to determine consequence no. 1 (useful time of a restoration) and incorporated as a model input to estimate consequence no. 2 (lifetime need for restoration replacement). Although some evidence on the natural history of tooth restoration was found in the medical literature, it was insufficient to allow modelling to a patient's lifetime.⁶⁹⁻⁷³ Therefore, it was assumed that the time-to-failure for each subsequent restoration was independent of any prior restoration to that tooth and it was further assumed that the restoration material for any subsequent replacement would be the same as the previous procedure (see Table 6).

Hg waste management (consequence no. 3)

The sources of Hg waste from an amalgam restoration are multiple and have been described in the literature.⁷⁴ A detailed assessment of amalgam, and hence mercury, waste in Canada has been made in the environmental section of this report (see Environmental impact). Results of the environmental assessment (i.e., Hg waste generated from amalgam placement and removal, Hg waste captured by chair-side traps and amalgam separators, Hg waste capture by wastewater treatment plants and Hg waste reaching surface waters) have been used for this consequence.

Patient productivity loss (consequence no. 4)

No study reporting patient or caregiver productivity loss was identified through the literature review. However, as the travel time to the dental office, the waiting time at the dental office and post-procedure recovery are not expected to be impacted by the choice of dental restoration material, the time required to complete the dental procedure should reflect the incremental difference in productivity loss between restoration materials.

Three studies reporting the time to perform amalgam and/or composite restorations were identified.^{58,75,76} One of them reported a summary measure combining amalgam and composite resin restorations and therefore could not be used.⁷⁶ One study performed in 1992 in more than 2,000 2- and 3-surface amalgam restorations in the Netherlands estimated the average total treatment time (i.e., tooth preparation, packing, carving, polishing) to be 24.3 minutes (95%CI: 11.3 to 46.5) and 30.0 minutes (95%CI: 15.6 to 59.0) for 2-surface and 3-surface amalgam restorations respectively.⁷⁵ About 75% of the restorations in that study were performed in posterior teeth.

Tobi et al., using data from a clinical study, reported a median procedure time of 39 minutes for a composite restoration of premolars compared to 22 minutes for an amalgam restoration (i.e., 1.8 times greater).⁵⁸ Median procedure time values for molars were 52 and 25 minutes for composite and amalgam restorations, respectively (i.e., 2.1 times greater). These ratios were not felt to be reflective of current practice times by the two experts in dentistry involved in this review. Rather, based on feedback from the clinical experts, it was suggested that the procedure time for a composite resin would take 15% longer than an amalgam restoration (Dr. Carlos Quiñonez: personal communication, 2017 Dec 04; Dr. Shahrokh Esfandiari: personal communication, 2017 Dec 04). This value was used in the analysis of this consequence.

Cost Estimates

Dental procedures (consequence nos. 1 and 2)

The costs of dental procedures were obtained from two different sources: i) public dental programs; and ii) suggested dental procedure fees (for private patients) from provincial dental associations as a proxy of fees paid by private insurances and patients who pay dental services out-of-pocket. Public dental programs or dental associations were contacted (maximum 2 attempts) when the fee guide for dental procedures was not publicly available on their respective website. In the base case analysis, the fees for 2- and 3-surface restorations to permanent posterior teeth retrieved from private and public programs were averaged separately for amalgam and composite resin (all tooth types combined) for private and public programs and then combined into a Canadian weighted average based on a 5.5:94.5 ratio of public:private coverage of the Canadian population (Table 4).⁶²

Table 4: Average procedure costs for 2 and 3-surface restorations (premolar and molar combined)

| | Public | | Private | | Canadian weighted average | |
|---------|----------|-----------------|----------|-----------------|---------------------------|-----------------|
| | Amalgam | Composite resin | Amalgam | Composite resin | Amalgam | Composite resin |
| Average | \$130.46 | \$180.39 | \$170.74 | \$209.34 | \$168.52 | \$207.75 |
| SD | \$26.83 | \$41.11 | \$21.59 | \$36.26 | \$21.88 | \$36.53 |

NA= not available; SD= standard deviation

A similar approach was taken to determine the restoration, crown and extraction costs to inform sensitivity analysis for consequence 2.

Hg waste management (consequence no. 3)

The costs of Hg waste can be subdivided into the cost of amalgam waste management at the dental clinic, the attributable costs at the waste water management plant level and the costs of managing the consequences of Hg reaching surface water. However, in view of the performance of amalgam separators in removing Hg from dental waste water, the last two elements were felt to generate insignificant costs and thus the analysis for this consequence focused on the costs at the dental clinic. An American publication, provided the framework for estimating the costs of amalgam separators and waste disposal.⁷⁷ Elements and values were adjusted to reflect a Canadian setting. In particular, the acquisition and installation costs of an amalgam separator were estimated to be \$2,000 while the annual maintenance costs (i.e., waste collection containers and recycling services) were estimated at \$2,200 according to feedback from one of the clinical expert involved in this review (Dr. Shahrokh Esfandiari: personal communication, 2017 Aug 08). Considering a useful life of 5 years for the amalgam separator, costs were annualized to a single dental clinic. They were then multiplied by the estimated number of dental clinics in Canada to determine the annual costs of managing Hg waste in Canada.⁷⁸ It was assumed that the costs of dental Hg waste recycling and/or disposal was factored in the price of the amalgam separator maintenance costs (i.e. recycling services) and therefore, no other costs related to the disposal/recycling of Hg waste were added.

Hourly wages and proportion of the Canadian population employed (consequence no. 4)

The national hourly average salary for 15 years old and over from September 2017 obtained from Statistics Canada was multiplied by the

percentage of employed individuals and the time required for dental restorative procedures in order to estimate the productivity loss in consequence no. 4.^{79,80}

All costs were inflated to 2017 using the consumer price index as needed.⁸¹

Sensitivity analysis

All calculations, except those for consequence no. 3 (Hg waste management), were performed in a probabilistic fashion (5,000 iterations) to account for parameter uncertainty.

In addition, the scenario and sensitivity analyses described in Table 5 were performed for consequence 1 (useful time of a restoration), consequence 2 (lifetime need for restoration replacement) and consequence 4 (productivity loss).

Table 5: Description of scenario and sensitivity analyses

| Scenario/sensitivity analysis description | Consequence | | | Justification |
|--|-------------|---|---|---|
| | 1 | 2 | 4 | |
| Using the Casa Pia study results (rather than NECAT results) for the time-to-failure | X | X | | To address parameter uncertainty |
| Extreme value analysis of the main efficacy parameter: smallest and largest difference between groups using lower and upper limits of 95%CI from NECAT | X | X | | To address parameter uncertainty |
| All surface average restoration costs | X | X | | To address structural (i.e., unknown natural history of an initial restoration in a child) and parameter uncertainty |
| Weighted average procedure costs based on one province amalgam procedure statistics based on the number of surfaces and type of tooth. | X | X | | To address structural (i.e., unknown natural history of an initial restoration in a child) and parameter uncertainty (i.e., incomplete Canadian data set of procedure fees) |
| Upper and lower limits of 95% CI for age at initial restoration | | X | | To address structural uncertainty, i.e., unknown average age at initial restoration in Canada |
| 0% discounting | | X | | As per CADTH economic analysis guidelines |
| 5% discounting | | X | | As per CADTH economic analysis guidelines |
| Exploratory: crown after 2 nd and 3 rd restoration failure | | X | | To address structural uncertainty, i.e., unknown natural history of an initial restoration in a child |
| Exploratory: extraction after 3 rd restoration failure | | X | | To address structural uncertainty, i.e., public programs which do not cover crowns and root canal treatments |
| Upper and lower limits of 95% CI for procedure time | | | X | To address parameter uncertainty |
| Minimum and maximum values for average hourly wages | | | X | To address parameter and structural uncertainty (i.e., unknown confidence interval) |
| Upper and lower limits of procedure time multiplier (for composite resin restorations) | | | X | To address parameter and structural uncertainty (i.e., unknown value and confidence interval) |

In view of the limited information describing the natural history of a tooth restoration in the medical literature, the base case model did not take into consideration that in real life, subsequent restorations tend to become larger in size and, after a certain number of replacements, a crown may be the best or most feasible option. To account for this, exploratory scenarios were developed where it was assumed that a crown was placed after the 2nd or 3rd failure based on feedback from the two clinical experts in dentistry involved in this review (Dr. Carlos Quiñonez: personal communication, 2017 Dec 04; Dr. Shahrokh Esfandiari: personal communication, 2017 Dec 04). One publication was found on the natural history of a crown.⁶⁹ The success rate at 10 years (i.e., latest timepoint available) was taken from that study.⁶⁹ In this scenario, once the crown has failed, the tooth was assumed to be extracted. A variant of this exploratory scenario was performed where the tooth was extracted after the 3rd restoration failure to address the fact that some public programs do not cover crown placement.

Due to lack of data, planned sensitivity analyses on population subgroups (i.e., children, adults, elderly) and settings (remote, rural and urban) were not performed. Furthermore, no sensitivity analysis was performed for consequence no. 3. The calculations consequence no. 3 were based upon come from the Environmental Impact section which performed deterministic calculations whereby, parameters involved in the calculation had no associated variability.

All inputs and sensitivity analysis parameters are listed in [Appendix 9](#).

Model assumptions

The following assumptions made for this cost-consequence analysis are presented in Table 6.

Table 6: Cost-consequence base-case model assumptions

| Assumption | Consequence | | | | Justification and potential impact on results |
|---|-------------|---|---|---|---|
| | 1 | 2 | 3 | 4 | |
| 2- and 3-surface restorations are assumed to represent the most frequently performed restorations in both publicly and privately paid dental services. | X | X | | | This might be an underestimation of the average restoration size in particular in public programs. These programs are mostly in place for low income individuals/families and epidemiological studies suggest these subpopulations have poorer oral health. The incidence of tooth caries has been shown to be related to income level and access to dental care. ⁸² This potential underestimation has been addressed in the sensitivity analyses. |
| The average cost of restoration was calculated by assuming an equal number of 2 and 3- surface restorations being performed equally on premolar and molars. | X | X | | | This might be an underestimation of costs as restorations to molar teeth are likely more frequent as per the opinion of the two clinical experts in dentistry involved in this review (Dr. Carlos Quiñonez: personal communication, 2017 Aug 08; Dr. Shahrokh Esfandiari: personal communication, 2017 Aug 08). Furthermore, this might result in an overestimation of composite resin restoration costs as some public programs do not cover composite resin restorations to posterior teeth. This has been addressed in the sensitivity analyses. |
| Dental fees obtained are assumed to be representative of those jurisdictions in which dental fee lists were not available. | X | X | | | See sensitivity analyses for alternative cost assumptions |

| Assumption | Consequence | | | | Justification and potential impact on results |
|---|-------------|---|---|---|--|
| | 1 | 2 | 3 | 4 | |
| Time to restoration failure was assumed to be independent of the number of surfaces restored (i.e., 2 and 3 surfaces) or type of tooth (i.e., molar vs. premolar) | X | X | | | The NECAT reported that the size of the restoration had an impact on the time to restoration failure. However, no information was available on the relationship between the number of surfaces restored and the time to restoration failure. Similarly, no information was found on the relationship between the type of tooth and the time-to-failure. Multiple sensitivity analyses have been performed to try to address this. |
| Patient age at the time of the first restoration on a permanent posterior tooth was assumed to be similar to that of the NECAT population, i.e., 7.9 years old. | | X | | | No information was found on the age of Canadian children at the time of the first restoration to a permanent posterior tooth. However, the two clinical experts in dentistry involved in this review agreed that the value from the NECAT was likely applicable to Canada (Dr. Carlos Quiñonez: personal communication, 2017 Aug 08; Dr. Shahrokh Esfandiari: personal communication, 2017 Aug 08). |
| Gender split of 7.9 years old children was assumed to be equal to that of the 5-9 years old Canadian population | | X | | | There is no reason to believe that children having a restoration to a permanent posterior tooth would have a different gender split. |
| The same restoration material was used for subsequent restorations | | X | | | According to the clinical experts in dentistry consulted in this review, there is a growing trend towards replacing existing amalgam restorations with composite resin (Dr. Carlos Quiñonez: personal communication, 2017 Aug 08; Dr. Shahrokh Esfandiari: personal communication, 2017 Aug 08). Given the limited data on the proportion of patients switching to composite resin, and the fact that switching would blur the results of the analysis, the model assumed that the same material would be used for all subsequent restoration failures. This was not further tested in sensitivity analysis. |
| Subsequent restorations were assumed to fail at the same rate as the initial restoration | | X | | | Limited information on the natural history of a tooth restoration was found on the time to failure of subsequent dental restorations. It is uncertain if this assumption is close to the reality as one might suspect that, as restoration margins grow in size with replacement, the risk of failure also increases. Alternative time to failure values (i.e., lower and upper level of 95%CI) were used in sensitivity analyses. |
| Subsequent restorations were assumed to be of the same size of the initial restoration | | X | | | Limited information on the natural history of a tooth restoration was found on the size of subsequent restoration. This assumption is unlikely to be reflective of the reality as it is well accepted that restorations will be larger with subsequent repairs. This is likely to bias the composite resin arm more than the amalgam arm as composite resin restorations are more expensive and have a shorter time-to-failure, hence this assumption might be underestimating the composite resin restoration costs. See sensitivity analyses for alternative natural history tested. |
| Amalgam separator-related costs reported by one dentist are representative of costs throughout Canada | | | X | | Values reported by the dentist consulted were consistent with information found on the internet. |
| Dividing the number of dentists using amalgam by the average number of dentists per clinic gives an adequate representation of the number of dental clinics in Canada that have an amalgam separator. | | | X | | It is unknown how close this assumption is to the reality. As this is used to calculate the costs of amalgam separation, this value may be under or overestimated. |
| Procedure time for a composite resin restoration is 15% longer than for an amalgam restoration | | | | X | No recent information to populate this parameter has been found in the medical literature. It is generally agreed that composite resin restorations take more time, but using this |

| Assumption | Consequence | | | | Justification and potential impact on results |
|---|-------------|---|---|---|--|
| | 1 | 2 | 3 | 4 | |
| | | | | | assumption may under or over estimate the productivity loss with composite resin restorations. The uncertainty around this parameter has been addressed by using a large range of possible values (+5% to +30% longer) in the probabilistic analysis and scenario analyses using the lower and upper values of this range. |
| Travel time to the dental clinic and waiting time at the dental clinic are assumed to be irrelevant for the purpose of this analysis | | | | X | Both travel time to the clinic and waiting time at the clinic are not expected to vary with dental restoration material and therefore it is likely appropriate to omit them if one is interested in the incremental difference in productivity between these two procedures. |
| Productivity lost was based on time off formal work. The averages of the lowest and highest provincial hourly wages were assumed to be a good proxy of the variability of the average Canadian hourly wage and were assumed to represent the lower and upper limits of the 99.7% distribution | | | | X | Statistics Canada does not report variability of their estimates. This assumption allowed including the average wage in the probability sensitivity analysis. This particular method generated the closest average hourly wage value to the value reported by Statistics Canada. |

Model validation

Face validity of the model was achieved through consultation with two Canadian clinical experts in dentistry throughout the research phase, to ensure that the model was consistent with Canadian practice, that the best available data sources were used, that no significant evidence was omitted and that results were consistent with their expectations and what is known in the medical literature. Internal validity was ensured by testing extreme parameter values. The model results were compared to other models in the dental field for cross-validity. Where possible, results were compared to other similar estimations for external validity.

Results

Key findings

Given the clinical and non-clinical outcomes that can be affected by the choice of restoration material for a posterior dental restoration, a cost-consequence analysis was performed. Table 7 highlights the key quantitative findings.

Table 7: Key findings of the cost-consequence analysis

| Consequence | Amalgam | | Composite Resin | |
|---|---|-------------------------------------|------------------------------|-------------------------------------|
| | Consequence Average (95%CI) | Canadian total cost Average (95%CI) | Consequence Average (95%CI) | Canadian total cost Average (95%CI) |
| Time horizon of analysis: Lifespan of first restoration | | | | |
| 1. Useful time of restoration | 132.9 months (101.3, 164.7) | \$169 (\$146, \$196) | 95.9 months (83.4, 108.4) | \$210 (\$162, \$267) |
| Time horizon of analysis: Patient's lifetime† | | | | |
| 2. Lifetime need for replacement | 4.0 replacements* (3.1, 4.6) | \$682* (\$511, \$840) | 5.7 replacements* (4.5, 6.2) | \$1,191* (\$842, \$1,564) |
| Time horizon of analysis: 1 year | | | | |
| 3. Hg waste management** | 2.51 kg of Hg per year reaching surface water | \$16.63 million | Not applicable | Not applicable |

| Consequence | Amalgam | | Composite Resin | |
|--|--|---|---|---|
| | Consequence Average (95%CI) | Canadian total cost Average (95%CI) | Consequence Average (95%CI) | Canadian total cost Average (95%CI) |
| Time horizon of analysis: Dental procedure | | | | |
| 4. Productivity loss | From 23.7 min (10.3, 47.7) for a 2-surface restoration on a premolar to 36.0 min (17.1, 66.3) for a 3-surface restoration on a molar | \$7.17 (\$2.64, \$15.52) to \$10.91 (\$4.47, \$22.49) | From 27.3 min (11.7, 55.4) for a 2-surface restoration on a premolar to 41.5 min (19.8, 76.7) for a 3-surface restorations on a molar | \$8.26 (\$3.03, \$18.10) to \$12.25 (\$5.85, \$22.64) |

All analyses probabilistic unless specified

† Assuming a patient age similar to the NECAT study (mean age: 7.9 years; gender: 51% male)

*1.5% discounted

**Deterministic analysis

Details on each consequence are reported below.

Consequence no. 1 – Useful time of a restoration

Base case analysis

When a Weibull distribution was fitted to the survival data on restoration replacement rates from the NECAT, the average time to failure was estimated at 132.5 ± 16.2 months (11.0 ± 1.4 years) for amalgam restorations and 95.8 ± 6.5 months (8.0 ± 0.5 years) for composite resin restorations.⁶³ Figure 3 shows the results of the curve fitting and extrapolation of the time to restoration failure based on the data from the NECAT. Table 8 shows the results of the expected lifespan and cost for the initial restoration, based on 5,000 probabilistic iterations.

Figure 3: Curve fitting and extrapolation of time to restoration failure from the NECAT data




Table 8: Posterior teeth restoration costs and useful time (probabilistic analysis)

| | | Amalgam Average (95%CI) | Composite resin Average (95%CI) | Difference (composite resin – amalgam) |
|---------------------|--|----------------------------|------------------------------------|--|
| Consequence | Useful time (months) | 132.3 (101.3, 164.7) | 95.9 (83.4, 108.4) | -36.4 |
| Cost of restoration | Canadian, Public:Private mix: 5.5:94.5 | \$169 (\$146, \$196) | \$210 (\$162, \$267) | \$41 |
| | Private only | \$171 (\$146, \$200) | \$211 (\$161, \$272) | \$40 |
| | Public only | \$133 (\$88, \$196) | \$186 (\$113, \$285) | \$53 |

Sensitivity analyses

As noted previously, the clinical review identified another study, Casa Pia, which was considered less generalizable to the Canadian setting. A sensitivity analysis was planned with the data from this study. The Casa Pia study reported restoration failure differently than the NECAT, i.e., due to secondary caries (the vast majority of failures) and due to restoration/tooth fracture separately.⁶⁶ Fitting a Weibull distribution to the survival curve on years since restoration due to secondary caries and extrapolating, gave an estimated average time-to-failure of 1,288.0 ± 146.3 months (107.3 ± 12.2 years) for amalgam restorations and 903.5 ± 130.8 months (75.3 ± 10.9 years) for composite resin restorations. After discussion with the clinical experts in dentistry involved in this review, it was felt that these results were neither realistic nor clinically meaningful (Dr. Carlos Quiñonez: personal communication, 2017 Nov 22; Dr. Shahrokh Esfandiari: personal communication, 2017 Nov 22). Therefore the sensitivity analysis using the Casa Pia study was not performed. The curve fitting figures from the Casa Pia study can be found in [Appendix 9](#).

All other scenario and sensitivity analyses, described in Table 5 were performed as planned. Results were robust to sensitivity analyses and are displayed in Table 9. Using the lower and upper limits of the 95% CI of the time-to-failure had little impact on the estimated useful life of both amalgam and composite resin restorations. All scenarios resulted in composite resin restorations being approximately \$40 to \$50 more expensive than amalgam restorations despite a useful life of approximately 36 months (3 years) shorter.

Table 9: Consequence no. 1 scenario and sensitivity analyses

| | Amalgam | | Composite resin | | Difference (composite resin - amalgam) | |
|--|--------------------------------------|------------------------------|--------------------------------------|------------------------------|--|-------|
| | Time (months) Average (95% CI) | Costs Average (95% CI) | Time (months) Average (95% CI) | Costs Average (95% CI) | Time (months) | Costs |
| Canadian (private:public mix) perspective | | | | | | |
| Base case | 132.3 (101.3, 164.7) | \$169 (\$146, \$196) | 95.9 (83.4, 108.4) | \$210 (\$162, \$267) | -36.4 | \$40 |
| Extreme value analysis: smallest time-to-failure difference between groups | 131.1 (99.2, 162.4) | \$169 (\$145, \$196) | 96.3 (83.7, 108.9) | \$210 (\$162, \$268) | -34.8 | \$41 |
| Extreme value analysis: largest | 134.0 (101.0, 166.1) | \$169 (\$145, \$195) | 95.5 (82.6, 108.1) | \$209 (\$160, \$269) | -38.5 | \$41 |

| | Amalgam | | Composite resin | | Difference (composite resin - amalgam) | |
|---|--------------------------------|------------------------|--------------------------------|------------------------|--|-------|
| | Time (months) Average (95% CI) | Costs Average (95% CI) | Time (months) Average (95% CI) | Costs Average (95% CI) | Time (months) | Costs |
| time-to-failure difference between groups | | | | | | |
| Average of all surfaces restoration costs | 132.4 (100.9, 164.2) | \$188 (\$121, \$282) | 95.8 (83.0, 108.8) | \$236 (\$139, \$379) | -36.6 | \$48 |
| Weighted average procedure costs based on one province amalgam procedure statistics on size of surface restored | 132.5 (101.3, 164.0) | \$153 (\$96, \$227) | 95.7 (83.0, 108.6) | \$191 (\$112, \$306) | -36.8 | \$38 |

Consequence no. 2 – Lifetime need for replacement

The patient-level simulation estimated that, with an average time-to-failure of 11.0 ± 1.4 years for an amalgam restoration, an average of 7.8 (95%CI, 5.0 to 9.0) restorations would be performed on a tooth restored with amalgam when the initial restoration is done in a 7.9 years old child (1.5% discounted: 4.0 restorations; 95%CI, 3.1 to 4.6). If composite resin is used, assuming an average time-to-failure of 8.0 ± 0.5 years, an average of 10.7 (95%CI, 7.0 to 12.0) restorations would be needed on the initial restoration in a child of the same age (1.5% discounted average: 5.7; 95%CI, 4.5 to 6.2). Lifetime discounted costs in the Canadian perspective would be \$682 (95%CI, \$511 to \$840) for amalgam restorations and \$1,191 (95%CI, \$842 to \$1,564) for composite resin restorations. Assuming a 1.5% discount rate, 1.7 additional replacements for composite restorations (2.9, undiscounted) would be needed and would result in an additional lifetime discounted costs of around \$509 (\$929, undiscounted). Results for the private and public perspectives are shown in Table 10.

Table 10: Lifetime restoration replacements and costs

| | Amalgam Average (95%CI) | Composite Resin Average (95% CI) | Difference (composite resin – amalgam) |
|--|----------------------------|----------------------------------|--|
| Number of restoration replacements – undiscounted | 7.8 (5.0 to 9.0) | 10.7 (7.0 to 12.0) | 2.9 |
| Number of restoration replacements – 1.5% annual discount rate | 4.0 (3.1 to 4.6) | 5.7 (4.5 to 6.2) | 1.7 |
| Lifetime costs - 1.5% discounted | | | |
| Canadian (public:private mix – 5.5:94.5) | \$682 (\$511 to \$840) | \$1,191 (\$842 to \$1,564) | \$509 |
| Private | \$690 (\$518 to \$854) | \$1,199 (\$842 to \$1,593) | \$509 |
| Public | \$536 (\$320 to \$809) | \$1,054 (\$608 to \$1,658) | \$518 |
| Lifetime costs - Undiscounted | | | |
| Canadian (public:private mix – 5.5:94.5) | \$1,322 (\$848 to \$1,700) | \$2,251 (\$1,384 to \$3,064) | \$929 |
| Private | \$1,339 (\$854 to \$1,727) | \$2,266 (\$1,383 to \$3,127) | \$927 |
| Public | \$1,040 (\$560 to \$1,621) | \$1,991 (\$1,047 to \$3,216) | \$951 |

Sensitivity Analysis

Similar to consequence no. 1, the planned sensitivity analysis using the data from the Casa Pia study was not performed as the curve fitting led to estimates of average time-to-failure that were not felt to be realistic. Results from all other sensitivity analyses specified in Table 5 are presented in Table 11 and the results are in line with the base case results, i.e., 2.8 to 3.0 additional restoration replacements with composite resin for additional discounted costs around \$500. The 5% discounting scenario gave the smallest difference between composite resin and amalgam, while assuming a 0% discounting gave the largest difference.

Table 11: Consequence no. 2 scenario and sensitivity analyses

| | Amalgam | | Composite resin | | Difference (composite resin - amalgam) | |
|--|--|-----------------------------------|--|-----------------------------------|--|-------|
| | Discounted number of restoration replacements (95% CI) | Discounted costs Average (95% CI) | Discounted number of restoration replacements (95% CI) | Discounted costs Average (95% CI) | Number of restoration replacement | Costs |
| Canadian (private:public mix) perspective | | | | | | |
| Base case | 4.0 (3.1 to 4.6) | \$682 (\$511 to \$840) | 5.7 (4.5 to 6.2) | \$1,191 (\$842 to \$1,564) | 1.7 | \$509 |
| Extreme value analysis: smallest time-to-failure difference between groups | 4.1 (3.2 to 4.7) | \$690 (\$515 to \$850) | 5.7 (4.4 to 6.2) | \$1,187 (\$846 to \$1,567) | 1.6 | \$497 |
| Extreme value analysis: largest time-to-failure difference between groups | 4.0 (3.1 to 4.5) | \$673 (\$510 to \$829) | 5.7 (4.4 to 6.2) | \$1,196 (\$841 to \$1,563) | 1.7 | \$523 |
| Average of all surface restoration costs | 4.0 (3.1 to 4.6) | \$762 (\$455 to \$1,165) | 5.7 (4.4 to 6.2) | \$1,343 (\$758 to \$2,164) | 1.7 | \$582 |
| Weighted average procedure costs based on province amalgam procedure statistics on size of surfaces restored | 4.0 (3.2 to 4.6) | \$613 (\$375 to \$945) | 5.7 (4.5 to 6.2) | \$1,072 (\$621 to \$1,725) | 1.7 | \$459 |
| Lower limit of 95% CI for age at initial restoration | 4.0 (3.1 to 4.6) | \$681 (\$508 to \$838) | 5.7 (4.5 to 6.2) | \$1,194 (\$845 to \$1,583) | 1.7 | \$513 |

| | Amalgam | | Composite resin | | Difference (composite resin - amalgam) | |
|---|--|-----------------------------------|--|-----------------------------------|--|-------|
| | Discounted number of restoration replacements (95% CI) | Discounted costs Average (95% CI) | Discounted number of restoration replacements (95% CI) | Discounted costs Average (95% CI) | Number of restoration replacement | Costs |
| Upper limit of 95% CI of age at initial restoration | 4.0 (3.1 to 4.6) | \$681 (\$517 to \$838) | 5.7 (4.5 to 6.2) | \$1,185 (\$839 to \$1,550) | 1.7 | \$504 |
| 0% discounting | 7.8 (5.0 to 9.0) | \$1,322 (\$848 to \$1,700) | 10.7 (7.0 to 12.0) | \$2,251 (\$1,384 to \$3,064) | 2.9 | \$929 |
| 5% discounting | 1.4 (1.2 to 1.6) | \$234 (\$184 to \$290) | 2.1 (1.9 to 2.2) | \$434 (\$329 to \$564) | 0.7 | \$200 |


The scenario where a crown was installed after the 3rd restoration failure led to expected costs that were similar to the base case in the amalgam group (i.e., \$696 vs \$682 in the base case), but lowered the expected cost in the composite resin group (i.e., \$846 vs \$1,191 in the base case). One important difference between restoration materials in the lifetime analysis is the time at which the costs are incurred. This is illustrated for the crown scenario in Figure 4, which shows that lifetime undiscounted costs are slightly higher and happen earlier with composite resin than with amalgam. Other important differences are the time at which a crown is installed and the time at which the tooth is extracted. In the crown at 3rd failure scenario, a crown was estimated to be installed once an individual reaches an average of 41.0 years old when the initial restoration was made of amalgam compared to 31.9 years old if the initial restoration was made with composite resin. The tooth would be extracted in 21 to 22% of individuals at an average age of 48.4 years old with amalgam and 39.4 years old with composite resin. In comparison, in the crown at 2nd failure, crown placement and/or extraction occur about 10 years earlier. In both of these scenarios, the bulk of the costs are from crown placement. Table 12 also shows a variance of the crown scenario for public programs that do not cover crown placement. This scenario resulted in the lowest cost estimates of all scenarios analyzed. However, the patient would lose their tooth at an average age of 41.1 years old with amalgam compared to 31.8 years old with composite resin.

Table 12: Result of scenario analyses with crown

| | Amalgam | Composite Resin |
|---|------------------------|------------------------|
| Crown at 2nd failure | | |
| Total number of failures (n, 95%CI) | 2.2 (2.0, 3.0) | 2.2 (2.0, 3.0) |
| Restoration failures | 2.0 (2.0, 2.0) | 2.0 (2.0, 2.0) |
| Crown failures | 0.2 (0.0, 1.0) | 0.2 (0.0, 1.0) |
| Lifetime 1.5% discounted costs (average, 95%CI) | | |
| Canadian | \$651 (\$363, \$1,139) | \$742 (\$423, \$1,272) |
| Private | \$656 (\$354, \$1,173) | \$747 (\$413, \$1,308) |
| Public | \$536 (\$291, \$941) | \$649 (\$363, \$1,099) |
| Canadian undiscounted costs (average, 95%CI) | \$876 (\$480, \$1,553) | \$917 (\$513, \$1,592) |
| Restoration costs | \$169 (\$145, \$196) | \$210 (\$162, \$268) |

| | Amalgam | Composite Resin |
|---|------------------------|------------------------|
| Crown costs | \$678 (\$292, \$1,339) | \$678 (\$292, \$1,339) |
| Extraction costs | \$29 (\$0, \$133) | \$28 (\$0, \$133) |
| Age at crown (average, 95%CI) | 30.0 (25.3, 34.5) | 23.8 (20.7, 27.0) |
| Age at extraction (average, 95% CI) | 29.4 (23.9, 36.6) | 31.3 (26.1, 38.3) |
| Crown at 3rd failure | | |
| Total number of failures (n, 95%CI) | 3.2 (3.0, 4.0) | 3.2 (3.0, 4.0) |
| Restoration failures | 3.0 (3.0, 3.0) | 3.0 (3.0, 3.0) |
| Crown failures | 0.2 (0.0, 1.0) | 0.2 (0.0, 1.0) |
| Lifetime 1.5% discounted costs (average, 95%CI) | | |
| Canadian | \$696 (\$447, \$1,142) | \$846 (\$548, \$1,357) |
| Private | \$703 (\$439, \$1,171) | \$853 (\$540, \$1,394) |
| Public | \$582 (\$352, \$957) | \$738 (\$48, \$1,175) |
| Canadian undiscounted costs (average, 95%CI) | | |
| Restoration costs | \$338 (\$289, \$392) | \$420 (\$324, \$533) |
| Crown costs | \$680 (\$289, \$1,389) | \$581 (\$292, \$1,389) |
| Extraction costs | \$27 (\$0, \$134) | \$28 (\$0, \$134) |
| Age at crown (average, 95%CI) | 41.0 (35.6, 46.2) | 31.9 (28.6, 35.1) |
| Age at extraction (average, 95% CI) | 48.4 (41.7, 56.3) | 39.4 (33.8, 47.6) |
| Extraction at 3rd failure | | |
| Total number of failures (n, 95%CI) | 3.0 (3.0, 3.0) | 3.0 (3.0, 3.0) |
| Restoration failures | 3.0 (3.0, 3.0) | 3.0 (3.0, 3.0) |
| Lifetime 1.5% discounted costs (average, 95%CI) | | |
| Public | \$270 (\$192, \$378) | \$382 (\$253, \$556) |
| Public undiscounted costs (average, 95%CI) | | |
| Restoration costs | \$267 (\$174, 400) | \$372 (\$225, \$572) |
| Extraction costs | \$100 (\$63, \$151) | \$100 (\$63, \$151) |
| Age at extraction (average, 95%CI) | 41.1 (35.6, 46.4) | 31.8 (28.5, 35.2) |

Figure 4: Cumulative undiscounted costs over time (crown after 3rd failure scenario)



Consequence no. 3 – Hg waste

According to the calculations performed in the environmental section of this report, it is estimated that a total of 1,848 kg of mercury - through amalgam

placement (292.9 kg) and removal (1,555 kg) - flows into the wastewater systems of dental clinics in Canada each year. Of that, most of it would be captured by chair-side traps and amalgam separators, leaving 30.3 kg per year to be discharged into the sewage system. Some of it would later be captured by wastewater treatment plants. Thus, it is estimated that dentistry contributes 2.51 kg (including 1.0 kg from the incineration of dental clinic biosolids) out of the total of 4,470 kg of Hg that reaches Canadian surface waters each year.

The annualized cost of amalgam separator (acquisition, installation, operation and maintenance) was estimated at \$2,498. As per the environmental section it is estimated that 13,232 general practitioners and 750 specialist dentists use amalgam in their practice. Using 2.1 as the average number of dentists per clinic means that there are roughly 6,658 dental clinics in Canada.⁷⁸ As each clinic requires one amalgam separator, overall, it is estimated that approximately \$16,634,696 is spent each year in Canada by dental practices on amalgam separators. Results for consequence no. 3 are displayed in Table 13.

Table 13: Hg waste and management costs

| Hg waste produced by dental clinics | | Hg waste management costs | |
|--|-----------------|---|----------------|
| Number of Canadian dentists using amalgam | 13,982 | Number of Canadian dentists using amalgam | 13,982 |
| <i>General practitioners</i> | <i>13,232</i> | <i>General practitioners</i> | <i>13,232</i> |
| <i>Specialists</i> | <i>750</i> | <i>Specialists</i> | <i>750</i> |
| Amount of Hg waste from dental restorations | 1,847.9 kg | <i>Average number of dentists per clinic</i> | 2.1 |
| <i>Form amalgam placement</i> | <i>292.9 kg</i> | <i>Average number of dental clinics</i> | 6,658 |
| <i>From amalgam removal</i> | <i>1,555 kg</i> | Average annual amalgam separator costs (calculated over 5 years; discount rate: 1.5%) | \$2,498 |
| Amount of Hg waste captured by chair-side traps and amalgam separators | 1,818 kg | Annual costs for Canadian dental clinics | \$16.6 million |
| Amount captured by wastewater treatment plants | 28.7 kg | | |
| Amount of Hg waste reaching surface waters | 2.51 kg | | |
| <i>From wastewater</i> | <i>1.51 kg</i> | | |
| <i>From incineration of biosolid</i> | <i>1.0 kg</i> | | |

Consequence no. 4 – Productivity loss

The procedure time for 2- and 3-surface restorations in premolars and molars was estimated to range between 23.7 minutes (95% CI, 10.3 to 47.7) for a 2-surface amalgam restoration on a premolar to 41.5 minutes (95% CI, 19.8 to 76.7) for a 3-surface composite resin restoration on a molar. Further details can be found in Table 13.

Table 14: Estimated average (95% CI) procedure times in minutes per restoration material, number of surfaces restored and tooth type (probabilistic analysis)

| Surfaces restored | Amalgam | | Composite resin | | Difference | |
|-----------------------|---|------------------------|---|------------------------|--|-------|
| | Average procedure time in minutes (95%CI) | | Average procedure time in minutes (95%CI) | | In minutes (composite resin – amalgam) | |
| | Premolar | Molar | Premolar | Molar | Premolar | Molar |
| 2-surface restoration | 23.7 (10.3 to 47.7) | 29.7 (12.9 to 59.9) | 27.3 (11.7 to 55.4) | 34.2 (14.8 to 69.6) | 3.6 | 4.5 |
| 3-surface restoration | 28.1 (13.4 to 51.8) | 36.0 (17.1 to 66.3) | 32.4 (15.4 to 59.6) | 41.5 (19.8 to 76.7) | 4.3 | 5.5 |

Using an average hourly wage of \$26.96 (Min: \$13.19, max: \$46.38) and 65.7% as the proportion of the population in the workforce, the productivity loss was estimated to vary between \$7.17 (95%CI, \$2.64 to \$15.52) for a 2-surface amalgam restoration of a premolar to \$12.25 (95% CI, \$5.85 to \$22.64) for a 3-surface composite resin restoration of a molar. Further details are given in Table 15. Thus, a composite restoration requires between 3.6 to 5.5 additional minutes to perform and generates less than \$2 in productivity loss.

Table 15: Estimated average (95% CI) productivity loss per restoration material, number of surfaces restored and tooth type – individual with one restoration only (probabilistic analysis)

| Number of surfaces | Amalgam Average (95%CI) | | Composite resin Average (95%CI) | | Difference (composite resin – amalgam) | |
|--------------------|-----------------------------|------------------------------|---------------------------------|------------------------------|--|--------|
| | Premolar | Premolar | Premolar | Molar | Premolar | Molar |
| 2-surface | \$7.17 (\$2.64, \$15.52) | \$9.00 (\$3.32, \$19.49) | \$8.26 (\$3.03, \$18.10) | \$10.36 (\$3.78, \$22.54) | \$1.09 | \$1.36 |
| 3-surface | \$8.52 (\$3.49, \$17.56) | \$10.91 (\$4.47, \$22.49) | \$9.56 (\$4.55, \$17.60) | \$12.25 (\$5.85, \$22.64) | \$1.04 | \$1.34 |

Sensitivity analyses on the procedure times and hourly wages as specified in Table 5 are displayed in Table 16. The sensitivity analyses showed that the incremental time loss could be as low as 1.2 minute for a 2-surface premolar to as high as 10.9 minutes for a 3-surface premolar. Consequently, incremental productivity loss could be as low as \$0.51 to as high as \$2.89.

1 **Table 16: Consequence no. 7 scenario and sensitivity analyses**

| Scenario | | Amalgam | | Composite resin | | Difference (composite resin – amalgam) | |
|--|-----------------------------------|--------------------------------|------------------------------|--------------------------------|-------------------------------|--|--------|
| Number of Surfaces | Consequence | Premolar Average (95%CI) | Molar Average (95%CI) | Premolar Average (95%CI) | Molar Average (95%CI) | Premolar | Molar |
| Lower limit of amalgam procedure time | | | | | | | |
| 2-surface | Time loss (minutes): 2-surface | 11.1 (4.7, 22.9) | 14.0 (6.0, 28.7) | 12.8 (5.4, 26.4) | 16.1 (6.8, 32.8) | 1.7 | 2.1 |
| | Productivity loss: 2-surface | \$3.37 (\$1.25, \$7.40) | \$4.23 (\$1.56, \$9.29) | \$3.88 (\$1.44, \$8.48) | \$4.87 (\$1.80, \$10.66) | \$0.51 | \$0.64 |
| 3-surface | Time loss (minutes): 3-surface | 14.7 (7.3, 26.7) | 18.8 (9.4, 34.2) | 16.9 (8.4, 30.9) | 21.7 (10.8, 39.5) | 2.2 | 2.8 |
| | Productivity loss: 3-surface | \$4.46 (1.87, \$9.26) | \$5.71 (\$2.39, \$11.87) | \$4.99 (\$2.47, \$9.12) | \$6.39 (\$3.18, \$11.65) | \$0.53 | \$0.68 |
| Upper limit of amalgam procedure time | | | | | | | |
| 2-surface | Time loss (minutes): 2-surface | 45.7 (19.1, 92.4) | 57.4 (24.0, 116.0) | 52.7 (21.8, 105.4) | 66.1 (27.5, 133.2) | 6.9 | 8.7 |
| | Productivity loss: 2-surface | \$13.82 (\$5.17, \$30.69) | \$17.36 (\$6.49, \$38.53) | \$15.91 (\$5.91, \$35.28) | \$19.99 (\$7.49, \$44.55) | \$2.09 | \$2.63 |
| 3-surface | Time loss (minutes): 3-surface | 55.8 (27.4, 101.1) | 71.5 (35.0, 129.5) | 64.2 (31.4, 115.9) | 82.3 (40.1, 148.9) | 8.4 | 10.8 |
| | Productivity loss: 3-surface | \$16.85 (\$7.18, \$33.91) | \$21.59 (\$9.19, \$43.44) | \$18.95 (\$9.27, \$34.19) | \$24.28 (\$11.85, \$43.92) | \$2.10 | \$2.70 |
| Lower limit of hourly wages | | | | | | | |
| 2-surface | Time loss (minutes): 2-surface | 23.6 (10.1, 46.3) | 29.7 (12.7, 58.1) | 27.2 (11.6, 53.6) | 34.3 (14.5, 67.8) | 3.6 | 4.5 |
| | Productivity loss: 2-surface | \$3.50 (\$1.30, \$7.59) | \$4.39 (\$1.63, \$9.53) | \$4.03 (\$1.50, \$8.75) | \$5.06 (\$1.88, \$11.11) | \$0.53 | \$0.67 |
| 3-surface | Time loss (minutes): 3-surface | 28.2 (14.0, 50.6) | 36.1 (17.9, 64.8) | 32.5 (15.9, 58.3) | 41.6 (20.6, 75.3) | 4.3 | 5.5 |
| | Productivity loss: 3-surface | \$4.18 (\$1.76, \$8.50) | \$5.35 (\$2.26, \$10.89) | \$4.69 (\$2.30, \$8.41) | \$6.01 (\$2.97, \$10.88) | \$0.51 | \$0.65 |
| Upper limit of hourly wages | | | | | | | |
| 2-surface | Time loss (minutes): 2-surface | 23.5 (10.1, 47.8) | 29.7 (12.7, 60.0) | 27.2 (11.6, 54.6) | 34.1 (14.5, 68.8) | 3.5 | 4.4 |
| | Productivity loss: 2-surface | \$12.28 (\$4.53, \$27.13) | \$15.41 (\$5.69, \$34.07) | \$14.11 (\$5.17, \$31.43) | \$17.73 (\$6.55, \$39.21) | \$1.84 | \$2.31 |
| 3-surface | Time loss (minutes): 3-surface | 28.3 (13.9, 52.0) | 36.3 (17.8, 66.7) | 32.6 (15.8, 60.3) | 41.7 (20.0, 77.1) | 4.2 | 5.4 |

| Scenario | | Amalgam | | Composite resin | | Difference (composite resin – amalgam) | |
|--|--------------------------------|------------------------------|------------------------------|------------------------------|-------------------------------|---|--------|
| Number of Surfaces | Consequence | Premolar Average (95%CI) | Molar Average (95%CI) | Premolar Average (95%CI) | Molar Average (95%CI) | Premolar | Molar |
| | Productivity loss: 3-surface | \$14.66 (\$6.11, \$29.81) | \$18.78 (7.83, \$38.18) | \$16.53 (\$8.01, \$30.60) | \$21.17 (\$10.17, \$39.15) | \$1.86 | \$2.39 |
| Lower limit of time procedure ratio | | | | | | | |
| 2-surface | Time loss (minutes): 2-surface | 23.7 (10.2, 42.7) | 29.8 (12.8, 59.2) | 24.9 (10.6, 49.3) | 31.3 (13.3, 62.5) | 1.2 | 1.5 |
| | Productivity loss: 2-surface | \$7.18 (\$2.61, \$15.64) | \$9.02 (\$3.27, \$19.63) | \$7.55 (\$2.75, \$16.38) | \$9.48 (\$3.47, \$20.85) | \$0.36 | \$0.47 |
| 3-surface | Time loss (minutes): 3-surface | 28.1 (14.0, 51.5) | 36.0 (17.9, 66.0) | 29.5 (14.7, 54.1) | 37.9 (18.7, 68.8) | 1.4 | 1.8 |
| | Productivity loss: 3-surface | \$8.50 (\$3.65, \$17.25) | \$10.88 (\$4.67, \$22.09) | \$8.72 (\$4.33, \$15.95) | \$11.18 (\$5.51, \$20.29) | \$0.22 | \$0.29 |
| Upper limit of time procedure ratio | | | | | | | |
| 2-surface | Time loss (minutes): 2-surface | 23.6 (10.0, 47.6) | 30.7 (13.0, 62.1) | 30.7 (13.0, 62.1) | 38.6 (16.1, 78.1) | 7.1 | 8.9 |
| | Productivity loss: 2-surface | \$7.18 (\$2.62, \$15.76) | \$9.34 (3.42, \$20.55) | \$9.34 (\$3.42, \$20.55) | \$11.73 (\$4.24, \$25.87) | \$2.16 | \$2.71 |
| 3-surface | Time loss (minutes): 3-surface | 28.2 (13.8, 51.0) | 36.7 (17.8, 66.5) | 36.7 (17.8, 66.5) | 47.0 (22.9, 84.5) | 8.5 | 10.9 |
| | Productivity loss: 3-surface | \$8.56 (\$3.57, \$17.30) | \$10.82 (\$5.25, \$19.63) | 10.82 (\$5.25, \$19.63) | \$13.86 (\$6.76, \$24.92) | \$2.26 | \$2.89 |

2

Summary of Results

A cost-consequence model was deemed to be more appropriate for the economic analysis comparing amalgam and composite resin restorations of permanent posterior teeth. Seven consequences were originally identified, but due to lack of evidence to allow modelling, three of the seven consequences were excluded, leaving the following consequences evaluated: useful time of a restoration, lifetime need for restoration replacement, annual waste management, and productivity loss during restoration.

Using the NECAT, the useful time of an amalgam restoration for a permanent posterior tooth was estimated to be 11.0 ± 1.4 years at an estimated average Canadian cost of \$169 (95%CI, \$146 to \$196) compared to 8.0 ± 0.5 years at an estimated average Canadian cost of \$210 (95%CI, \$162 to \$267) for a composite resin restoration, assuming a 2- or 3-surface restoration.

As time-to-failure is longer with amalgam restorations, an average of 7.8 replacements (95% CI, 5.0 to 9.0) would be needed on an initial amalgam restoration compared to 10.7 replacements for an initial composite resin restoration (95% CI, 7.0 to 12.0) throughout the lifetime of a 7.9 year old child (discounted values: 4.0 and 5.7 for amalgam and composite resin respectively). Lifetime discounted Canadian costs were estimated to be \$682 (95%CI, \$511 to \$840) for amalgam restorations compared to \$1,191 (95%CI, \$842 to \$1,564) for composite resin restorations. Previous estimations of lifetime dental restoration costs in the UK (1997£) ranged from £303.70 when the initial restoration was made of amalgam to £709.85 when the initial restorations was made of composite resin.⁸³ More recent values from a US insurer estimated lifetime costs (all restoration materials combined) to range between \$2,108 for a premolar and \$2,187 for a molar.⁸⁴ None of these estimations used discounting. In comparison, our estimated undiscounted costs were \$1,322 for amalgam and \$2,251 for composite resin in the base case and \$1,046 and \$1,128 for amalgam and composite resin respectively in the crown scenario. Caution is required in interpreting the results from this consequence given the number of simplifying assumptions required due to the limited data on natural history of subsequent replacements following a failed restoration.

It is estimated that amalgam restorations contribute 2.51 kg out of the total of 4,470 kg of Hg that reach Canadian surface waters each year. Amalgam separators have been instrumental in reducing the amount of Hg discharged into waste water by dentists. This has been achieved at an estimated total annual cost of \$16.63 million for Canadian dental clinics.

Finally, more time is needed to perform a composite resin restoration, mainly due to the need for stepwise polymerization of the resin.⁸⁵ Using dental procedure time as a proxy for patient/caregiver time loss, time loss was estimated to vary between 23.7 minutes (95%CI, 10.3 to 47.7) and 36.0 minutes (95% CI, 17.1 to 66.3) for amalgam restorations and between 27.3 minutes (95%CI, 11.7 to 55.4) and 41.5 minutes (95%CI, 19.8 to 76.7) for composite resin restoration of a posterior tooth. Using the average Canadian hourly wage, productivity loss was estimated to vary between \$7.17 (95% CI, \$2.64 to \$15.52) and \$10.91 (95%CI, \$4.47 to \$22.49) for an amalgam

52 restoration and between \$8.26 (95% CI, \$3.03 to \$18.10) and \$12.25
53 (95%CI, \$5.85 to \$22.64) for a composite restoration for two-surface
54 premolar and three-surface molar restoration respectively. Hence, it is
55 estimated that composite resin restorations of the posterior teeth would take
56 between 3.6 to 5.5 additional minutes to perform depending on the size of
57 the restoration and type of tooth and this would generate an incremental
58 productivity loss under \$2 per restoration. Although these numbers do not
59 take into account the time required to reach the dentist office and the waiting
60 time at the dentist office, travel and wait time is not expected to vary
61 according to the restoration material used. Therefore, using procedure time
62 may be a sufficient proxy to estimate the difference in productivity lost
63 between restoration materials. Economies of scale if more than one
64 restoration were to be done at the same clinic visit have not been factored in
65 the analysis. In the oral health component of the most recent Canadian
66 health survey, over a third of respondents reported taking an average of
67 3.54 hours (95%CI, 3.23 to 3.86) for dental check-ups or problem with their
68 teeth.⁶²The estimate includes more than just tooth restoration (e.g., oral
69 exam, imaging, oral hygiene, prevention, etc) and did not report time-loss
70 separately for different methods of dental restoration.

71 This analysis shows that, on average, amalgam restorations have a longer
72 life and cost less. Furthermore, given the longer life of an amalgam
73 restoration, the exploratory analysis indicated that a crown or tooth
74 extraction was predicted to occur much later in life than if composite resin
75 was used. Although a composite resin restoration takes slightly more time to
76 perform, the impact on patient or caregiver productivity is minimal. On the
77 other hand, using amalgam for posterior tooth restoration requires dental
78 clinics to be equipped with amalgam separators to avoid Hg waste from
79 reaching Canadian surface waters. These have significant costs to dental
80 clinics, but, these costs are likely already factored in the dental fees as
81 dental clinics have been using amalgam separators for several years.

82

83

84
85
86
87
88
89
90
91

92
93
94
95

96
97
98
99
100
101
102

103
104
105
106

107
108
109
110

111
112
113
114
115
116
117
118

119

120
121
122
123
124
125
126
127
128

Patients' Perspectives and Experiences Review

The objective of this systematic review was to understand patients' experiences and perspectives on the use of amalgam or composite resin restorations, as well as that of their parents and caregivers. The specific review question was: What are the perspectives and experiences of patients (adults or children), parents of child patients, or caregivers around dental amalgam and composite resin restorations?

Methods

Literature search

The literature search was performed by an information specialist, using a peer-reviewed search strategy.

Published literature was identified by searching the following bibliographic databases: MEDLINE (1946-) with Epub ahead of print, in-process records and daily updates, via Ovid; Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCO; and Scopus. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were dental amalgams and composite resins.

Methodological filters were applied to limit retrieval to qualitative studies or studies relevant to patient perspectives. Retrieval was not limited by publication year or language. See [Appendix 2](#) for the detailed search strategy.

One search for qualitative studies was completed on June 8, 2017 and a separate search for studies describing patient perspectives was completed on July 20, 2017. Regular alerts were established to update the searches until the publication of the final report.

Grey literature (literature that is not commercially published) was identified by searching the Grey Matters checklist (<https://www.cadth.ca/grey-matters>), which includes the websites of health technology assessment agencies, clinical guideline repositories, SR repositories, and professional associations. Google and other Internet search engines were used to search for additional web-based materials. These searches were supplemented by reviewing the bibliographies of key papers and through contacts with appropriate experts.

Selection criteria

Eligible studies were primary English-language qualitative studies and mixed-methods studies with separate reporting of a qualitative component and participant voice data that addressed the review question. Only the qualitative components of mixed-method studies were eligible. The quantitative component of mixed-methods studies were ineligible, as were studies based on quantitative data or following a quantitative design, including surveys. For the purpose of this review, qualitative studies were studies that focused on qualitative data including, but not limited to, designs such as phenomenology, grounded theory, ethnography, action research,

129 and feminist research. Studies that have multiple publications using the
 130 same data set were included if they reported on distinct research questions;
 131 duplicate publications using the same data with the same findings were
 132 excluded. To be eligible, studies must have explored or assessed
 133 participants' own perspectives directly, not indirectly (i.e., through another
 134 person). Table 17 describes the eligibility criteria used in this review.

135 **Table 17: Inclusion Criteria**

| | |
|-------------------------------|---|
| Population | Patients (adults or children) with experiences or perspectives around dental amalgam and composite resin restorations |
| Phenomenon of Interest | <ul style="list-style-type: none"> • The patients' perspectives on and experience with the use of mercury/amalgam for dental restoration compared with the use of composite resin restoration for either themselves or their children • The patients' perspectives on and experience with the use of composite resins for dental restoration for either themselves or their children • The patients' perspectives on and experience with the use of mercury/amalgam for dental restoration for either themselves or their children |
| Context | The persons' sense of their own well-being or the well-being of their children in relation to the choice of dental restoration material (amalgam or composite resins). |
| Study Design | Studies that focused on qualitative data including, but not limited to, designs such as phenomenology, grounded theory, ethnography, action research, and feminist research. Mixed-method studies were included if these studies had a qualitative component and participant voice data that addressed this review question. |

136

137 **Selection method**

138 Citations were screened by two independent reviewers using the Covidence
 139 data management software⁸⁶ in accordance with the criteria outlined in
 140 Table 17. The process of screening entailed two phases. First, the full set of
 141 citations was screened based on title and abstract (if available). Following
 142 that, potentially eligible citations were screened based on full-text reading.
 143 Any discrepancies were resolved by consultation with a third reviewer.

144 The final set of studies were exported from Covidence and imported into
 145 SUMARI — the Joanna Briggs Institute (JBI) software designed to manage
 146 the process of evidence synthesis.⁸⁷ The SUMARI software houses the
 147 templates for critical appraisal and data extraction, and stores the studies
 148 included in the review, facilitating the process of evidence synthesis (either
 149 meta-analysis or meta-synthesis). In this review, we conducted a meta-
 150 synthesis of the qualitative evidence.

151 **Quality assessment**

152 Qualitative papers selected for retrieval were assessed by two independent
 153 reviewers for methodological quality using the JBI Qualitative Assessment
 154 and Review Instrument (JBI-QARI).⁸⁸ Standardized criteria assess congruity
 155 between philosophical perspective, research questions research methods
 156 used, and results reported, as well as the potential influence of the
 157 researcher on the research, adequate representation of participants' voices,
 158 and whether conclusions flow from the data and the analysis. Any
 159 disagreements that arose between the reviewers were resolved through
 160 discussion, or with a third reviewer. No studies were excluded based on an
 161 assessment of methodological quality.

162 **Data extraction**

163 Both descriptive study data and study results were extracted from papers
164 included in the review by two independent reviewers using the standardized
165 data extraction tool from JBI-QARI. The extracted data were stored in the
166 QARI software and included specific details about the interventions,
167 populations, study methods, and results of significance to the review
168 question objectives. These descriptive data were summarized and
169 presented in a table of characteristics of included studies.

170 Data analysis methods

171 Primary research of qualitative evidence typically generates one or more
172 themes that reflect the participants' voices on the topic. Results that relate to
173 this systematic review question were extracted from the included study
174 reports. These qualitative research results, called findings in the JBI
175 methodology of synthesis, were pooled using JBI-QARI⁸⁸ into a set of
176 relevant themes. The process of pooling involves the aggregation or
177 synthesis of findings to generate a set of statements that represent that
178 aggregation, through assembling the findings rated according to their quality,
179 and categorizing these findings on the basis of similarity in meaning.⁸⁹ The
180 question "What is the essence of meaning that each finding represents?"
181 guides the aggregative process and helps the team generate the categories.
182 These categories were then subjected to a meta-synthesis to produce a
183 single comprehensive set of synthesized findings that can be used as a
184 basis for evidence-based practice.

185 Results

186 The search strategy located 1800 citations (PRISMA Diagram – [Appendix](#)
187 [10](#)). After 26 duplicates were removed 1774 citations were screened against
188 title and abstract. From this set, 1622 citations were excluded as being
189 irrelevant and 152 studies were read in full to assess eligibility. Of this set,
190 147 studies were excluded as being either wrong outcomes or wrong
191 research design (i.e., quantitative research in design) ([Appendix 11](#)). Five
192 papers covering four studies were included as the final set ([Appendix 12](#)).
193 The papers by Sjursen et al., (2014, 2015)^{90,91} are companion papers.

194 Descriptive analysis

195 The publication dates ranged from 2004 to 2016. Based on the country of
196 the lead author, two studies originated in Sweden (Marell⁹², Stahlacke⁹³),
197 two papers (one study) in Norway (Sjursen 2014⁹⁰, 2015⁹¹) and one study in
198 New Zealand (Jones⁹⁴). The total number of participants was 71. Of this
199 total set, there were 27 women and nine men, while the same seven women
200 and five men were included in both studies by Sjursen.^{90,91} One study
201 (Jones⁹⁴) included 35 participants but did not specify participants' sex. Two
202 studies reported participants' age ranges (Marell⁹² and Sjursen^{90,91}) and
203 combined those ages ranged from 37 to 65 years old. All participants were
204 in the role of patients, representing themselves. No one was in the parental
205 role representing the experience of children. Qualitative research
206 methodologies included one grounded theory (Marell⁹²). The other studies
207 did not specify a specific qualitative methodology. Data collection methods
208 included semi-structured interviews and one study conducted seven focus
209 groups (Jones⁹⁴). Data analysis included thematic analyses (Sjursen
210 2014⁹⁰, 2015⁹¹, Jones⁹⁴), one study used content analysis (Stahlacke⁹³),
211 and the grounded theory study (Marell⁹²) used a constant comparative

212 method to establish codes, categories, properties and dimensions. See
213 Characteristics of Included Studies table in [Appendix 13](#).

214 It is important to note that the four included studies represent a focus on
215 patients' experiences with amalgam, and specifically health complaints and
216 symptoms that people attribute to dental amalgam. No studies were located
217 that addressed patients' experiences with composite resins. Furthermore,
218 the research questions of the included studies focus on patients' negative
219 experiences and health complaints with amalgam only. While patient
220 selection is not clearly reported in all the studies, we may assume based on
221 the research questions (see Appendix 13) that patients' participation in these
222 studies was based on their willingness to discuss their symptoms,
223 complaints and other problems they perceived or attributed as related to
224 dental amalgam.

225 **Critical appraisal of individual studies**

226 Overall the quality of the studies was high ([Appendix 14](#)). All four studies
227 obtained a "no" for the first question which addresses the congruency
228 between philosophical perspective and research methodology because no
229 philosophical perspective was clearly reported by the authors of any of the
230 included studies. All studies, however, included a sufficient description of
231 their study objectives and methods, to allow for an assessment of the
232 methodological congruence between research questions and research
233 methods (Q2), data collection (Q3), data analysis (Q4) and interpretation of
234 results (Q5). In all cases, studies were assessed as methodologically
235 congruent, supporting the credibility of the data and analysis. Further
236 questions that were answered "yes" for all studies include obtaining ethical
237 approval (question 9) and that the conclusions drawn from the research flow
238 from the analysis and interpretation of the data (question 10). Question 8
239 reflects the adequate representation of the participants' voices and one
240 study (Jones⁹⁴) obtained an "unclear" in this appraisal, while the remaining
241 studies provided sufficient detail to warrant an assessment describing the
242 adequate representation of participants, and their voices. The study report
243 by Jones⁹⁴ failed to provide a statement of researcher positioning culturally
244 or theoretically (Q6), and researcher reflexivity (Q7), indicating that the
245 influence of the researcher on the analysis and interpretation of data may
246 not have been adequately accounted for and that may call into question the
247 credibility and confirmability of the analysis. Given the similarity in results
248 across included studies, however, this does not appear to be a concern in
249 this instance and may be an issue of poor study reporting as opposed to
250 poor study conduct.

251 Although a small number of studies were identified to inform the policy
252 question, these studies were of assessed to be of high methodological
253 quality and thus are able to provide strong evidence of the patients'
254 experiences as they relate to amalgam restorations and the particular
255 experience of health complaints perceived to be attributable to amalgam
256 restorations. No studies were located that investigated patients' experiences
257 with composite resins, which suggests that the body of evidence identified
258 as eligible for this review does not provide a complete view of patient
259 perspectives as they relate to the policy question.

260 **Meta-synthesis**

261 Twenty-three findings were extracted from the included studies. These
262 findings were aggregated into five categories which in turn were aggregated
263 into three synthesized findings. The relationship between findings,
264 categories and synthesized findings is depicted in [Appendix 15](#) and
265 [Appendix 16](#).

266 The process of aggregation is a pooling together of common concepts
267 across all the studies, bearing in mind that those statements that reflect
268 different or contrary opinions must also be represented. All participants were
269 adults and two of the studies provided an age range of between 37 and 65
270 years old. The participants were for the most part in the prime of their
271 working careers and the situations they described reflected their need to
272 juggle their working and family lives all the while struggling with a variety of
273 symptoms, some described as debilitating others described as wearying,
274 and all that they attributed to dental amalgam restorations. There is no
275 single set of symptoms that all participants describe, and no clarity as to the
276 primary cause of these symptoms which participants perceived to be the
277 result of amalgam restorations. Some participants report allergic reactions
278 such as burning and lesions in the mouth, whereas others have more
279 systemic ailments such as pain and fatigue. It is important to note that these
280 four studies focused only on health complaints and symptoms that
281 participants attribute to amalgam restorations and that no qualitative studies
282 were identified that investigated positive experiences with amalgam or either
283 positive or negative experiences with composite resins. In this case, these
284 studies cannot support a causal relationship between amalgam and negative
285 health complaints and the lack of literature does not mean a lack of positive
286 experiences.

287 *Synthesized finding 1: Something is not working: trying to*
288 *understand health complaints*

289 This synthesized finding highlights the participants' need to comprehend and
290 make sense of a myriad of different symptoms they were experiencing,
291 which ultimately they attributed to be as a result of their amalgam
292 restorations. It was generated by three categories and a total of 16 findings.

293 **Category 1 - Range of ill health experiences – oral, somatic, mental,**
294 **long term**

295 The following studies contributed to this category: Sjørusen⁹¹ 2015;
296 Stahlacke;⁹³ Jones;⁹⁴ and Sjørusen⁹⁰ 2014.

297 Before linking their experiences to dental amalgam, participants reported
298 multiple symptoms and described feeling puzzled and overwhelmed by their
299 complaints. Some participants more immediately perceived their complaints
300 to be associated with their amalgam restorations while for others, this
301 association was not immediately apparent. The confusion expressed by
302 many participants was due to their initial lack of understanding of the source
303 of their complaints. Across the four studies it was clear that there were a
304 range of symptoms being reported, with some symptoms such as pain being
305 common throughout. Many participants reported issues directly related to
306 the mouth. For example, one participant mentioned “you feel sore and have
307 so many, many blisters in the mouth, I had, you know” (Stahlacke⁹³ p. 125).
308 Others described a combination of symptoms such as pain and more
309 general or vague symptoms. This participant's quote not only illustrates the
310 range of experiences but also the struggle to understand the reason for the
311 poor health:

312 “I was in so much pain, and I also felt, for a while, that I had such a poor
313 memory (sighs). I cannot say if that was because of stress caused by having
314 to fight the pain, but I did feel ‘out of it’ in a way. I really did” (Sjursen⁹¹ 2015
315 p. 4)

316 It was common for participants to report a decrease in their social life as a
317 result of their symptoms, some feeling too bad to engage in interactions
318 while others did not feel as if they had the strength. Consequently,
319 loneliness and depression were common experiences too.

320 In her study, Jones⁹⁴ concludes that the psychological problems described
321 by participants were twofold: i) problems that may be attributed to mercury
322 toxicity: memory loss, mood swings, and loss of sensation; and ii) problems
323 related to the consequences of having symptoms that were not readily
324 diagnosed namely self-efficacy; the social stigma of being labelled a
325 hypochondriac; the concomitant loss of social support; and the stigma of
326 being referred for psychological or psychiatric assessment (Jones⁹⁴).
327 “Participants in some focus groups spoke about suicidal thoughts, including
328 praying to die and dreaming of death.” (Jones⁹⁴ p. 145),

329 **Category 2 - Identifying the source of the symptoms**

330 Three studies contributed to this category: Sjursen⁹⁰ 2014; Marell;⁹² and
331 Sjursen⁹¹ 2015.

332 Participants described that following amalgam restorations they had a feeling
333 their whole bodily and psychological functioning was influenced from the
334 outside, which they described as a feeling of being poisoned. They searched
335 for causes and reasons that might explain their experiences. Often
336 participants related their constellation of symptoms to other illnesses they
337 had experienced before. Given the somewhat vague nature of these
338 symptom constellations they were often compared to the experience of
339 being ill with influenza. For example, one participant described symptoms as
340 being like an experience of the flu and established a connection of these
341 symptoms with his or her teeth – although we are not privy to the rationale
342 that has made this connection:

343 “that it might have some connection with my teeth that I was often so terribly
344 tired, had pains in my body and felt dizzy and nauseous, had problems
345 roughly like what you think of if you get the flu.” (Stahlnacke⁹³ p.125)

346 In their attempt to understand their conditions, participants did their own
347 research, talking with others who might help or guide them to some
348 answers. Driven by the sense of ‘being poisoned’ many participants hunted
349 for information about poisoning and mercury poisoning in particular. They
350 typically reported identifying resonance with the symptom picture of mercury
351 poisoning which they felt provided some clarity to their experience. One
352 such participant described this process:

353 “And when I was at the specialty unit, I contacted the organization for
354 amalgam poisoning and I read everything I could get my hands on. And then
355 I felt that I had all the complaints (laughs).” (Sjursen⁹⁰ 2014 p. 223)

356 **Category 3 - Input from trusted others as guidance**

357 The studies by Sjursen⁹⁰ 2014 and Stahlnacke⁹³ contributed to this category.

358 In their attempt to identify the cause of their symptoms participants often
359 turned to others for guidance. Some participants received input and
360 guidance from trusted others who directed them towards what they felt could
361 be the cause of their symptoms. This made the guidance easier to accept.
362 One participant reported that he was guided by his wife who was a dental
363 assistant, another participant received guidance from the dentist:

364 “Well, it was the dentist who first put me on to the idea, you know. (. . .) He
365 saw how bad my teeth were and how much pain I was in. (. . .) I described
366 how I felt at the time, how painful it was and how it burned and ached, you
367 know.” (Sjursen 2014⁹⁰ p. 222)

368 In some cases, the trusted other also provided direction in terms of how to
369 address the problem. In this instance the participant’s dentist instructed the
370 participant to remove the amalgam indicating that he or she would not feel
371 better until that was done:

372 “I had all the amalgam removed and my dentist said, you have to get rid of it,
373 you won’t get better before that, he said” (Stahlacke⁹³ p. 127)

374 The move to treatment of the amalgam-related illness is addressed in this
375 next synthesized finding.

376 *Synthesized finding 2: Struggle to obtain redress: searching for*
377 *help, treatment and a reliable diagnosis.*

378 This synthesized finding describes the interactions with the health care
379 system and was generated by one category and a total of three findings.

380 **Category 4 - Encounters with health care professionals**

381 Four studies contributed to this category: Marell;⁹² Stahlacke,⁹³ Sjursen⁹¹
382 2015; and Jones.⁹⁴

383 Many participants were uncertain about the cause of their complaints and
384 sought out health care professionals, including family physicians and
385 dentists, to help diagnose, explain and treat their ailments; the encounters
386 were sometimes good, but more often than not frustrating. One participant
387 was well supported by the healthcare professional and was therefore
388 pleased by the encounter: “I got affirmation, she told me a lot about the
389 disease, she told me exactly how to act and, and what, what was important
390 to do.” (Stahlacke⁹³ p.128)

391 However, many other participants struggled with their physicians or dentists,
392 who they perceived to be dismissive when no clear diagnosis was evident.
393 One such participant clearly illustrates her devastation at being dismissed:

394 “I remember I was crying when I walked away from the doctor. I figured
395 there was something wrong with me, but nothing was shown, all the
396 investigations and tests showed nothing. They said that I’m healthy even
397 though I feel like this!” (Marell⁹² p. 4)

398 Jones reported that her participants “had ‘every test in the book’ from blood
399 counts to scans. As the tests never showed anything abnormal, many had
400 been told by doctors that they were ‘making it up’... As illness persisted
401 without a medical label or as a psychosomatic condition, these people
402 experienced the negative social stigma of being labelled ‘a hypochondriac’.”
403 (Jones⁹⁴ p. 146)

404 Participants who engaged with healthcare professionals who practiced
405 alternative health care (not further specified) were generally pleased with
406 the support and care they received from these professionals.

407 It is important to reiterate that the included studies focused on participants'
408 negative experiences related to amalgam restorations, with many of their
409 complaints being general and vague in nature and hence likely difficult to
410 diagnose. Consequently, it is understandable that their interactions with
411 health care professionals may not have been viewed as consistently
412 positive.

413 *Synthesized finding 3: Amalgam removal and the journey toward*
414 *health.*

415 This synthesized finding portrays the journey, the change of restorative
416 material and the path forward toward health. It was generated by one
417 category and a total of six findings.

418 **Category 5 - Deamalgamation and detox**

419 Three studies contributed to this category: Jones;⁹⁴ Stahlacke;⁹³ and
420 Sjursen⁹¹ 2015.

421 Participants chose one of several options once they identified what they
422 considered to be the cause of their illness. Some elected to remove all
423 amalgam restorations and replace them with composite resin restorations,
424 others elected to become edentulous. Still others did not remove any of their
425 amalgam restorations, with the cost associated with the procedure being
426 identified as a barrier.

427 Besides cost, for those participants who reported negative experiences
428 associated with amalgam restorations, the journey of removing amalgam
429 was also fraught with difficulty. For some participants, the process of having
430 the amalgam fillings replaced and the time immediately afterwards was often
431 a period of intense adverse reaction. It is important to note these adverse
432 reactions were assumed by participants to be associated with the removal of
433 the amalgam restorations, although no supporting external evidence to
434 confirm the assumption was reported. One participant clearly described an
435 adverse reaction during that period:

436 "Sometimes when I had amalgam fillings replaced I felt absolutely terrible
437 afterwards. Sometimes I even had to stay home from work. (. . .) I was in
438 pain, I was frightfully tired, and I felt nauseated. (Short pause) It was
439 obnoxious." (Sjursen⁹⁰ 2014 p. 221)

440 Jones reported that after deamalgamation and detoxification, the participants
441 in her study were

442 "surprised both at the return of lost sensation and the speed of recovery.
443 They had not anticipated any immediate benefits but reported the lifting of
444 the 'brain fog', improved smell and taste, an absence of colds and flu
445 symptoms and the end of the metallic taste. This was equated with a major
446 health gain." (Jones⁹⁴ p. 146).

447 However, for some participants this return to feeling healthy took a little
448 longer. One participant explains the length of time before they were feeling
449 better: "I can still feel a little now but I've become much better, but it

450 probably took, once all the amalgam was away, it took about two years”
451 (Stahlnacke⁹³ p. 127)

452 With a constellation of symptoms that tend to be vague, some participants
453 were uncertain of the role of amalgam removal in their change of health
454 status. One participant explained that he or she would need to have psychic
455 powers to know for sure:

456 “This amalgam removal, I do believe it has had an effect, together with all the
457 other things. But I would have to have psychic abilities to know exactly how.
458 As I have told you, there are still periods in which I feel quite poorly and
459 beside myself, but I do feel much better now. I really do.” (Sjursen⁹¹ 2015 p.
460 6)

461 Participants also mentioned that removal of their amalgam restorations was
462 like ‘a worry crossed off the list’ in that they would not have to be concerned
463 about it with regard to their future health (Sjursen⁹¹ 2015).

464 What was clear to most participants was the perceived need to follow the
465 amalgam removal process with a structured detoxification program. Jones
466 commented that in her study and the seven focus groups she conducted to
467 discuss this process with her participants,

468 “every group had some participants who mentioned a ‘bath’ metaphor as a
469 heuristic that explained deamalgamation and detox. Their body was likened
470 to a bath, and dental amalgams likened to a dripping tap. For a person with
471 dental amalgams, the tap was turned on, but with amalgam removal the tap
472 was turned off. In the metaphor, this left ‘water in the bath’ and it needed to
473 be drained. To detox was to ‘pull the plug’.” (Jones⁹⁴ p. 144)

474 **Summary of Results**

475 While the research question was formulated to engage a qualitative
476 research synthesis to understand the patients’ experiences around both
477 amalgam and composite restorations, four studies that focus on health
478 complaints attributable to dental amalgams were located. No studies were
479 identified that focused on experiences with composite restorations, nor
480 experiences with amalgams other than health complaints. The results
481 therefore describe a narrow set of experiences, and are not generalizable to
482 the broader set of experiences with either restoration material. It’s possible
483 that descriptions of the patients’ perspectives with amalgam as well as
484 composite resin restorations lie in the quantitative research evidence. Hence
485 this qualitative synthesis cannot address the entire research question on
486 patients’ perspectives and experiences. However, through the integration of
487 the participants’ voices it does provide insight and understanding into the
488 experience of those patients who feel they have been afflicted due to their
489 amalgam restorations and their struggle to address and resolve this
490 experience.

491 Through a focus on patients with amalgam restorations and their
492 experiences of perceived adverse reactions to the amalgam, this review
493 highlights their struggle to be understood and believed as they search for a
494 cause for their sense of ill health. Once determined to resonate with the
495 symptoms of mercury poisoning some patients identified the option to follow
496 the path of deamalgamation and detoxification. Although for some this was
497 described as a difficult path and one that may not provide immediate health

498
499
500

gain, this path did appear to provide relief from worry of a potential toxic influence on health at a later stage.

501
502
503
504
505
506
507
508
509
510
511
512
513
514
515

516
517
518
519
520
521
522

523
524

525
526
527
528

529
530
531
532
533
534
535
536

537

538
539

540
541
542
543
544

Implementation Issues

This section addressed the following research questions:

Research Question 5: What is the current use of amalgam restorations in Canadian dental practices or programs?

Research Question 6: What is the current use of composite resin restorations in Canadian dental practices or programs?

Research Question 7: What factors influence the use of amalgam or composite resin restorations in Canadian dental practices or programs?

Research questions 5 to 7 aimed to gather information around relevant implementation considerations for using dental amalgams and composite resin fillings in Canada. Implementation considerations may include policies, funding, dental care practices, and considerations relevant to dental providers and patients including considerations for special groups of patients, such as those in rural or remote settings or of low socioeconomic status.

Methods

To understand the current context and implementation issues or considerations associated with the use of dental amalgams and composite resin fillings in Canadian dental care settings telephone consultations and a review of the published literature were conducted. A survey of stakeholders was not performed as information from the literature and consultations were expected to be sufficient.

Data Collection

Stage 1: Interviews

Interviews were conducted with targeted experts and stakeholders identified through the clinician networks managed by CADTH to provide a general overview of policy, funding, practice, and issues related to using dental amalgams and composite resins in dental care settings in Canada.

To guide the interviews, a semi-structured interview guide was used (Appendix 17). Interview questions related to implementation were developed based on the research questions and the type of expert being consulted. Interviews were conducted by phone by a CADTH staff member, and follow-up questions or clarifications were conducted by email. Notes were taken during the interviews and copies of email correspondence were retained for the purpose of subsequent analysis. Written consent to publish comments and names, where required, was obtained.

Stage 2: Literature Search

The literature search was performed by an information specialist, using a peer-reviewed search strategy.

Published literature was identified by searching the following bibliographic databases: MEDLINE (1946-) with Epub ahead of print, in-process records and daily updates, via Ovid and Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCO. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's

545 MeSH (Medical Subject Headings), and keywords. The main search
546 concepts were dental amalgams and composite resins. The search strategy
547 for the dental amalgam and composite resin concepts were based on the Q2
548 search strategy.

549 A methodological filter was applied to limit retrieval to studies relevant to
550 implementation issues. Additionally, the search was limited to articles related
551 to the Canadian context. Retrieval was not limited by publication year or
552 language. The search strategy is available upon request.

553 The search was completed on June 29, 2017. Monthly alerts were
554 established to update the searches until the publication of the final report.
555 Studies identified in the alerts and meeting the selection criteria of the
556 review will be incorporated into the analysis if they are identified prior to the
557 completion of the stakeholder feedback period of the final report. Any
558 studies that are identified after the stakeholder feedback period will be
559 described in the discussion, with a focus on comparing the results of these
560 new studies to the results of the analysis conducted for this report.

561 Grey literature (literature that is not commercially published) was identified
562 by searching the *Grey Matters* checklist (<https://www.cadth.ca/grey-matters>),
563 which includes the websites of health technology assessment agencies,
564 clinical guideline repositories, SR repositories, economics-related resources,
565 and professional associations. Google and other Internet search engines
566 were used to search for additional web-based materials. These searches
567 were supplemented by reviewing the bibliographies of key papers and
568 through contacts with appropriate experts.

569 **Eligibility Criteria**

570 We included English- and French-language reports that described
571 implementation and context issues, including barriers and facilitators,
572 associated with the use of dental amalgams and composite resins in dental
573 care settings in Canada. Literature was limited to Canadian-only studies, or
574 studies discussing the Canadian context, published after 2000. This decision
575 was made because the Canadian context for the use of dental amalgam and
576 resin composites was primarily of interest for this HTA, and recent literature
577 was reviewed to more accurately reflect the current landscape and available
578 materials of dentistry. The choice of restricting by year differs from the
579 original protocol, and was an *ad hoc* decision by the researchers, based on
580 the lack of relevance of older articles to current dental practice context. The
581 year 2000 was chosen as this was the year that Environment Canada
582 started conducting studies on mercury-based wastes from dental offices.
583 One year before that, in 1999, an endorsement of a Canada-wide standard
584 on mercury for dental amalgam waste took place.⁹⁵

585 **Screening and Selection of Articles for Inclusion**

586 Articles were screened and selected for inclusion based on the eligibility
587 criteria by one reviewer. First, titles and abstracts were reviewed to identify
588 potentially relevant papers. At this level of screening, only one reviewer
589 needed to include the article for it to move to full text screening.

590 Then, one reviewer screened the full text of all potentially relevant reports
591 retrieved for definitive determination of eligibility, and ineligible reports were
592 excluded from data extraction.

593

594 **Data Extraction**
595 Data extraction was performed by one reviewer. The data were extracted to
596 a Microsoft Word table and included bibliographic details of included papers,
597 reported implementation barriers and facilitators, and other key findings
598 related to implementation and relevant context information.

599 **Data analysis methods**
600 A narrative summary of the findings was written by one reviewer. Wherever
601 possible, the findings were categorized based on the INTEGRATE-HTA
602 framework.⁹⁶ A description of varying factors that both facilitate and impede
603 the use of both amalgam restorations and resin composite restorations is
604 presented.

605 **Results**
606 Five stakeholders in dental care in Canada were consulted for their feedback
607 on the extent of use of dental amalgams and composite resins as well as the
608 context of use and implementation issues related to these materials. These
609 stakeholders represented the following areas in dentistry:
610 academia/research, hospital dentistry, private practice, the Canadian Dental
611 Association, a publicly funded dental program in Nunavut).

612 The implementation literature search yielded 220 citations. Out of these, nine
613 English-language reports that described implementation and context issues,
614 including barriers and facilitators, associated with the use of dental
615 amalgams and composite resins in dental care settings in Canada were
616 eligible for inclusion. All included studies were Canadian literature or had
617 relevant information pertaining to the Canadian context.⁹⁷⁻¹⁰⁵ Included
618 studies provided information on teaching of restorations in dental
619 schools,^{98,100-102,105} patient specific care, patient concerns, or patient or
620 provider preferences,^{99,100,102-104} minimally invasive dentistry,^{100,105} contra-
621 indications for materials,^{97,104} and cost of materials or funding.^{102,103} Five of
622 the nine relevant studies were published prior to 2012.^{98,100-102,104}

623 Relevant information from the literature and the stakeholder consultations as
624 it relates to each of the INTEGRATE-HTA context and implementation
625 domains is described below. The findings best fit within the following
626 INTEGRATE-HTA framework's implementation and context domains of
627 'policy', 'funding/cost', 'organization and structure', 'provider', and
628 'sociocultural'.

629 No data was identified regarding the current use of amalgam and composite
630 resin in Canada. Findings from the literature search and interviews are
631 focused on considerations around the use of these restorative materials
632 (research question 7).

633 **Policy**

634 The consultations with stakeholders identified that, in Canada, there is no
635 specific policy in place to dictate the use of one material over another in
636 dental practices. According to the Canadian Dental Association (CDA), the
637 current status of practice in Canada is that "dentists should use the most
638 appropriate material for the patient, in consultation with the patient" (Dr.
639 Benoit Soucy, Canadian Dental Association, Ottawa, ON: personal
640 communication, 2017 Sep 7).

641 However, a “changing dynamic” in the use of these materials, which is
642 mainly driven by a “significant environmental context” was reported (Dr.
643 Carlos Quinonez: personal communication, 2017 Aug 22). Canada signed
644 the Minamata Convention agreement in 2013; however, the Canadian
645 agreement does not exclude the use of dental amalgams in Canadian dental
646 practices. To address the environmental issues related to the toxicity of
647 mercury from dental amalgam waste, the CDA established a Memorandum
648 of Understanding (MoU) with Environment Canada in 2002.¹⁰⁶ This MoU
649 established the use of best management practices for dental amalgam
650 waste for all dental practices in Canada. According to this agreement, all
651 dental practices across the country that generate amalgam waste are
652 mandated to purchase amalgam separators to address the release of
653 mercury (also a regulation by the Royal College of Dentists of Canada).
654 With a coordinated educational effort by the CDA and Environment Canada
655 on pollution prevention plans for dental offices, it is estimated that as of
656 2012, approximately 97% of dental offices in Canada followed best
657 management practices for amalgam disposal.¹⁴

658 In Canada, most dentists (approximately 90%-95%) are in private practice
659 (Dr. Benoit Soucy: personal communication, 2017 Sep 7). However, public
660 dental programs are available for different groups of patients who do not
661 have access to dental coverage benefits. In Nunavut, for example, most
662 dental care is provided through public dental health programs and all Inuit
663 patients (approximately 90% of the population) are covered by the non-
664 insured health benefits program (NIHB), provided by Health Canada. This
665 program does not dictate use of any particular material and the choice of
666 materials rests with the dental provider (Dr. Ronald Kelly, Department of
667 Health, Government of Nunavut, personal communication, 2017 Sep 20).

668 However, it has been reported that in some provinces, such as Quebec,
669 patients under 10 years of age who are covered by the government-funded
670 provincial dental plan are less likely to have a posterior restoration with a
671 composite resin, since the provincial dental plan covers only the cost for
672 amalgam restorations in the posterior teeth.¹⁰²

673 Cost Considerations

674 Several aspects of cost considerations as they relate to the use of these
675 materials were discussed with stakeholders and were also reported in the
676 literature (limited reporting).^{102,103} The majority of dental practices in Canada
677 are private. In addition to material suitability, durability and safety, factors
678 that may be of importance to private practitioners in Canada are cost
679 considerations, margins of profit, and efficiency of practice, and these
680 factors may contribute to dentist decision-making regarding the choice of
681 material. Fee guides are available in each province across Canada, though
682 those only provide suggestions for fees for restoration procedures.

683 When it comes to choosing a material over another, dentists may charge a
684 higher fee for using composite resin over amalgam. Stakeholders in our
685 consultations discussed that fees charged by dental practices often
686 correspond to i) direct costs (i.e., composite resin is more expensive to
687 purchase compared to amalgam), ii) indirect costs (i.e., composite
688 manipulation is “technique-sensitive”, takes longer to apply, and requires
689 more adjunct devices compared to an amalgam restoration) and iii) the
690 failure rate of the restoration (i.e., in many cases, the restoration with a

691 composite material will fail more often than amalgam and as such it will have
692 to be restored more frequently). So, while in some provinces (e.g., Ontario)
693 the suggested fee guides for composite and amalgam restorations do not
694 differ by a lot, it is possible that a dental practice using mostly composite
695 materials will have more revenue due to an increased frequency of
696 restorations (Dr.Susan Sutherland, Sunnybrook Health Sciences Centre,
697 Canadian Association of Hospital Dentists,Toronto, ON: personal
698 communication, 2017 Aug 24).

699 During consultations it was mentioned that because amalgam separators are
700 considered mandatory for use in many if not all jurisdictions, all dental clinics
701 should be equipped with these devices. In Nunavut, not all clinics have
702 amalgam separators, and composite resins may be utilized in preference to
703 amalgam for this reason (Dr. Ronald Kelly: personal communication, 2017
704 Sep 20).

705 In Nunavut, contractors are responsible for buying the consumable materials
706 to be used in dental clinics, “and may buy these materials in bulk (at a better
707 price)” (Dr. Ronald Kelly: personal communication, 2017 Sep 20). As
708 shipping materials between communities in the North is difficult, purchasing
709 and shipping only one type of restoration material may also contribute to the
710 efficiency of the shipping process and help keep the costs down (Dr. Ronald
711 Kelly: personal communication, 2017 Sep 20).

712 In our consultations, it was mentioned that overall, with composite
713 restorations, there may be a financial incentive for dental practices as they
714 may yield a larger margin of profit when they perform this procedure.

715 Due to the changing properties of composites, reimbursement policies for
716 public dental programs are changing as well. It is reported that some public
717 programs (such as the Quebec Health Insurance provincial dental plan for
718 children under 10) reimburse amalgam restorations in posterior teeth, and
719 esthetic restorations in anterior teeth.¹⁰⁷

720 Dental Practice

721 According to Lynch et al,^{100,105} the dental field as a whole has moved to more
722 “minimally invasive” dentistry practices. Using composites obviates the need
723 to remove sound tooth tissue for retention (i.e., resin composite requires less
724 tooth removal than amalgams), which reduces the subsequent risk of tooth
725 fracture, and reinforces the remaining tooth substance.^{100,101,103,105}

726 During our consultations it was acknowledged that in some dental practices,
727 the option of amalgam is not offered to patients (only offer restorations with
728 composite resin). Possible reasons behind this and other dental practice-
729 related issues that may affect the use of these materials included health-
730 related concerns related to mercury in amalgams, dental practice efficiency
731 cost, and profit.

732 In terms of mercury-related health concerns, dental providers in our
733 consultations reported that this is not a concern for dentists and their
734 patients as mercury is not used in its pure state. However, it was recognized
735 that some dental practices advertise themselves as “green” or “holistic”
736 dental practices, not offering amalgam as an option, or encourage
737 collaborating with physicians for “detoxification” from amalgam fillings.⁹⁹
738 These practices, which are not supported by scientific evidence, are not

739 supported by the CDA (Dr. Benoit Soucy: personal communication, 2017
740 Sep 28).

741 As reported in our consultations, for dental practices, efficiency matters and
742 when there is only one material, one type of equipment and one technique
743 that the dentist (and dental practice staff such as dental hygienists) has to
744 focus on efficiency improves. In addition, it was also discussed that using
745 only one material keeps the cost under control as well and leads to a good
746 return of investment. However, even for those practices that focus on one
747 material (i.e., composite) are required to have amalgam separators, because
748 they still generate amalgam waste when they perform removal of amalgam
749 restorations (Dr. Benoit Soucy: personal communication, 2017 Sep 28).

750 In terms of potential health concerns for dental staff, dentists in our
751 consultations reported that they believe these are being addressed
752 sufficiently as there are modern and safe methods of handling (amalgam
753 comes in a capsule already mixed with other materials) and disposing
754 excess mercury (suction at dental separator), and as such, the exposure to
755 mercury for dental practitioners is likely minimal.

756 Other alternatives for materials were mentioned (e.g. glass ionomer
757 [contains fluoride] and porcelain).

758 **Dental Provider**

759 *Attitude towards materials and knowledge of underlying pathology*

760 The properties, clinical indications and contra-indications of amalgams and
761 composite resins are important parameters to consider prior to using these
762 materials in dental practice.^{103,104} Overall, amalgams and composites are
763 two different materials (with different compositions and properties) that
764 behave differently depending on the oral environment and degree of
765 susceptibility to caries and decay.

766 Dentists in our consultations indicated that amalgam is used in cases where
767 other materials are not indicated (i.e., higher risk for restoration failure) and
768 esthetic considerations are not a concern. In general, it was reported that
769 amalgams perform better in oral environments with high susceptibility to
770 caries, where there are difficulties with moisture control and when a big
771 restoration is needed (amalgam restorations last longer). On the other hand,
772 for a patient with low caries susceptibility, composites may perform better.
773 For better performance and maintenance, composite materials also need a
774 “dry tooth bed” (i.e., no saliva, no blood). If this is not the case, it was
775 discussed that amalgam is a more suitable and “predictable” material (Dr.
776 Benoit Soucy: personal communication, 2017 Sep 7).

777 Patient profile is an important consideration for restoration material choice.
778 For example, patients with special needs or geriatric patients for whom oral
779 hygiene cannot be reinforced, amalgams are a more suitable option since
780 the presence of constant plaque in such an oral environment damages the
781 adhesive bonds (i.e., chemical bonds formed by composite). (Dr. Shahrokh
782 Esfandiari: personal communication, 2017 Sep 1). One stakeholder working
783 mainly with patients over 50 years of age with multiple medical problems
784 reported that she changed her practice for posterior teeth from using
785 primarily composites to using more amalgams as she found that she
786 encountered an increased rate of recurrent decay in this population and a

787 need for frequent replacements. In this stakeholder's experience,
788 composites do not last as long, are more expensive and they also cause
789 sensitivities (Dr. Susan Sutherland: personal communication, 2017 Aug 24).

790 However, it is reported that over the past few years improvements in bonding
791 agents have increased the "predictability" of resin materials, and this
792 improvement in the material is one contributor to its increased use.¹⁰¹⁻¹⁰⁴
793 Stakeholders also discussed that by using the appropriate light-curing
794 device, newer composites can be placed more quickly than amalgams and
795 the restoration is more effective (i.e., easier to set, better adhesion to the
796 tooth).

797 *Education and training*

798 Stakeholders discussed the sociocultural and educational shift that has taken
799 place regarding using amalgams and composite resins in dentistry.

800 During the consultations it was discussed that despite the fact that dentists
801 are trained to provide the most appropriate treatment for patients, strong
802 patient preference for "white teeth" (i.e., aesthetic-oriented society),
803 combined with an inherent professional ethos in dentistry for cosmetic care
804 may contribute to the increased use of composites in dental practices.

805 Stakeholders reported that to their knowledge, dental schools teach dental
806 restorations with both materials (emphasis of teaching is equal for both
807 materials) and dentists are trained in both the benefits and disadvantages of
808 amalgams and composite resins.¹⁰² However, it was also reported that
809 depending on school philosophy, one material may be favoured over
810 another. According to Lynch et al.,¹⁰¹ in 2006, teaching for amalgam and
811 resin composites in Canadian dental schools was reported to be
812 approximately equal (i.e., 50/50). By 2012, an increase in teaching
813 composite resin filling techniques was reported and both U.S. and Canadian
814 dental students were gaining more experience in placing posterior resin-
815 based fillings.¹⁰⁵ It was also mentioned that in Canadian dental schools there
816 was increased pressure to use and teach posterior resin composite
817 restorations as a result of the discussions by Health Canada regarding the
818 safety of amalgam restorations.¹⁰²

819 Where dental practitioners train and the type of continuing education they
820 receive is important. For example, during their training, new dentists are
821 often exposed to clinicians who teach them what they do (i.e., most arguably
822 use composites). Depending on the level of expertise and comfort, dentists
823 will be teaching more of what they are comfortable with. If dentists are not
824 taught or trained well on using one material, they will gravitate towards using
825 the material they are more familiar with (Dr. Carlos Quinonez: personal
826 communication, 2017 Aug 22; Dr. Sharokh Esfandiari: personal
827 communication; 2017 Sep 1).

828 In our consultations, it was also reported that an age and cohort effect may
829 be a consideration when choosing one material over another. For example,
830 newer dentists may want to try new products, ("to be modern, sophisticated
831 providers") and adhere to what are perceived as "non-toxic" materials thus
832 also satisfying patients' preference (Dr. Carlos Quinonez: personal
833 communication, 2017 Aug 22). More experienced dentists or dentists of an
834 older generation would perhaps advocate for more frequent use of amalgam
835 (Dr. Sharokh Esfandiari: personal communication; 2017 Sep 1). Continuing
836 education on restoration materials was also reported as important to dental

837 practice given that composite materials continue to evolve (i.e., new
838 versions of composites are developed) at a fast pace.

839 *Patient preference and dental practice*

840 In addition to clinical expertise (skills and competencies of dentists) and level
841 of evidence on each of these materials, patient preference contributes
842 significantly to a dentist's decision to use one material over another.
843 According to one stakeholder, "dental care is a private industry where the
844 patient is the buyer and as such, they have a very strong decision-making
845 power. As a patient/customer, you are buying a health product". (Dr.
846 Sharokh Esfandiari: personal communication; 2017 Sep 1) It was discussed
847 that although it wasn't identified in the literature regarding patient
848 preferences (see Patients' Perspectives and Experiences section) students
849 need to be cognisant of the drive regarding white fillings and part of a
850 dentist's job is to educate patients about their options and allow patients to
851 ask questions about them so that there is a clear understanding around what
852 each technology can provide to them. However, during the consultations, it
853 was also mentioned that often, dentists oblige with patient preference for
854 one material while on the other hand, dentist preference for composite is
855 stronger and often the choice is not even presented to the patient.

856 **Patient Considerations**

857 *Sociocultural considerations*

858 While not identified in the qualitative literature (see Patients' Perspectives
859 and Experiences section) patient preference for "white fillings" was
860 described as a significant factor influencing the increased use of composite
861 resins over amalgam in dental practices. Stakeholders and literature findings
862 report that patient preference for composites over amalgams is mainly
863 driven by esthetic and health concerns.¹⁰⁰⁻¹⁰⁴ Other considerations reported
864 in our consultations include concerns for toxicity and safety (i.e., patients
865 think that composites are safer than amalgams) as well as cost (when dental
866 care fees are not covered by insurance).

867 As reported during the consultations, the socio-cultural trend for "straight,
868 white teeth" combined with a perception of health hazards associated with
869 amalgams is often driving a strong patient preference for white fillings. In
870 many cases, patients "demand" composites even in posterior teeth, without
871 really having a solid understanding of the treatment options as well as the
872 potential risks of composites (Dr. Benoit Soucy: personal communication;
873 2017 Sep 7). Many patients also request to change all of their amalgam
874 restorations with composite resins "despite the fact that the amount of
875 mercury in the fillings is low" (Dr. Sharokh Esfandiari: personal
876 communication; 2017 Sep 1). This shift in patient culture has taken place
877 approximately over the last 20-25 years when the public became aware
878 (through patient advocacy groups and media) that dental amalgams contain
879 mercury and started being concerned for having amalgams in their mouths.
880 Though not identified in the qualitative literature, the experts consulted also
881 noted that environmental concerns are also present among patients.

882 *Patient Cost Considerations*

883 In addition, as dental care for most Canadians is not covered by public plans,
884 patients are responsible for paying for their treatment. Therefore, the aspect

885 of financial considerations or reimbursement options is important in their
886 treatment preference.

887 In Nunavut, even though many people present cases for which dental
888 amalgam would have been the preferred material to use (due to risk factors,
889 oral health etc.), composite is still the most frequently used direct restorative
890 material (an estimate of approximately 80-90% of restorations) (Dr. Ronald
891 Kelly: personal communication; 2017 Sep 20).

892 On the other hand, it was reported that when patients are offered information
893 regarding the benefits and the clinical appropriateness of using amalgams,
894 esthetic concerns usually do not overrule health concerns and potential
895 benefits (Dr. Susan Sutherland: personal communication; 2017 Aug 24). A
896 survey of Canadian dental schools revealed that many course directors state
897 that they provide guidelines on the choice of restoration material for varying
898 clinical cases, but patients ultimately make the material choice in their faculty
899 clinics.¹⁰² Patients need to understand risks associated with having more
900 restorations or adverse effects associated with using composites as well.

901 **Summary of Results**

902 There are factors that influence use of one type of restorative material over
903 another.

904
905 Across Canadian jurisdictions, there are no specific policies that dictate the
906 use of dental amalgam or the use of resin composites.

907 Geographical location (e.g., the north of Canada) can be a factor, and often
908 limits available materials. Shipping multiple materials to remote Northern
909 communities is costly and inefficient, so often providers only ship resin
910 composites, limiting the use of amalgams in these areas.

911 The majority of dentists in Canada are in private practice. Factors such as
912 margin of profit and efficiency of practice are therefore additional
913 considerations for many Canadian dentists, and can affect the decision
914 making process for restorations.

915 The dentistry field often practices “minimally invasive” dentistry, which
916 makes composite resin an attractive option as it obviates the need to remove
917 a lot of sound tooth tissue when compared to amalgams. Dentistry education
918 in universities does not appear to focus on one restoration over another, but
919 dentists may choose to use materials that they are more comfortable with,
920 that are newer and “more sophisticated”, or that their supervising dentist
921 primarily used.

922 Patient profile and clinical indications are of importance to dentists when
923 deciding on which restoration to use, as amalgam and resin composites
924 have different mechanical properties. These properties can make some
925 patients contra-indicated for certain materials. There is a large socio-cultural
926 and patient pressure to provide restorations that maintain a “straight, white”
927 appearance of teeth for the patient. As the patient is the customer and has a
928 strong decision-making power regarding their care, this can affect the
929 decision for a provider to use resin composites over amalgams.

930

931
932
933
934
935
936
937
938
939
940
941
942
943
944

945

946
947
948
949

950

Conclusion

There are many factors that influence the use of one type of restorative material over another. These include dental policies, funding and reimbursement, the dental provider setting (public or private), provider attitudes and perceptions, provider education and training, patient perceptions, education and preferences and sociocultural attitudes towards dental restoration materials. It is expected that dental providers educate patients about the most appropriate choice of restoration for their clinical case, but patients may make choices based on a variety of reasons, such as what materials are reimbursed and are available in their area, esthetic concerns, health concerns and what is recommended by their dentist. Ultimately, each individual case and patient are different, which means these factors can both act as barriers or facilitators to the use of different restoration materials in Canada.

Knowledge Mobilization

The implementation issues identified will guide the development of knowledge mobilization activities, tools, and tactics to support the implementation of any resulting decisions or changes to the health care system or health service delivery.

951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996

Environmental Impact

This section addressed research question 8: What are the environmental effects associated with the use of dental amalgams versus composite resin restorations?

The dental profession relies upon a variety of materials and processes to achieve their goals, though these are not without some risk to the environment. Here we focus on environmental risks associated with the two main restorative materials used in dentistry – amalgam and composite resins.

A comparative assessment of potential environmental effects associated with the use of dental amalgams versus composite resins will take guidance from the Canadian Environmental Assessment Act, 2012¹⁰⁸ and the US Environmental Protection Agency Ecological Risk Assessment framework.¹⁰⁹

Methods

Literature Search

The literature search was performed by an information specialist, using a peer-reviewed search strategy.

Published literature was identified by searching the following bibliographic databases: MEDLINE (1946-) with Epub ahead of print, in-process records and daily updates, via Ovid; and Embase (1974-) via Ovid; Scopus and Toxnet. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. Most subject headings were focused and most keywords were limited to title only. The main search concepts were dental amalgams and composite resins. The search strategy for the dental amalgam and composite resin concepts were based on the Q2 search strategy.

Methodological filters were applied to limit retrieval to studies related to environmental assessment. Retrieval was not limited by publication year, but was limited to the English or French language. Conference abstracts were excluded from the search results. The search strategy is available upon request.

The search was completed on June 16, 2017. Monthly alerts were established to update the searches until the publication of the final report. Studies identified in the alerts and meeting the selection criteria of the review will be incorporated into the analysis if they are identified prior to the completion of the stakeholder feedback period of the final report. Any studies that are identified after the stakeholder feedback period will be described in the discussion, with a focus on comparing the results of these new studies to the results of the analysis conducted for this report.

Grey literature (literature that is not commercially published) was identified by searching the *Grey Matters* checklist (<https://www.cadth.ca/grey-matters>), which includes the websites of health technology assessment agencies, clinical guideline repositories, SR repositories, and professional associations. Google and other Internet search engines were used to search for additional web-based materials. These searches were supplemented by

| | |
|------|---|
| 997 | reviewing the bibliographies of key papers and through contacts with |
| 998 | appropriate experts. |
| 999 | Selection criteria |
| 1000 | One reviewer screened the titles and abstracts of all citations retrieved from |
| 1001 | the literature search. For citations that appeared eligible for inclusion (an a |
| 1002 | <i>priori</i> listing of keywords that would guide our search are provided in the |
| 1003 | project protocol ²⁷), the full text of these articles were retrieved and assessed |
| 1004 | (by the same reviewer) to determine eligibility. We focused our search on |
| 1005 | papers published since 2006 to cover the most relevant period (i.e., |
| 1006 | declining use of dental amalgam coupled with the emergence of the use of |
| 1007 | composite resins), and those based in relevant comparison countries |
| 1008 | (Canada, US, Australia, New Zealand, UK, and members of the European |
| 1009 | Economic Area). The clinical use, material composition, and/or |
| 1010 | environmental impact of amalgam and resins have changed over preceding |
| 1011 | decades, and thus we limited our search to recent years to focus on the |
| 1012 | most pertinent literature. |
| 1013 | Articles that provided insights into the potential environmental impact |
| 1014 | associated with dental amalgam and composite resin restorations were |
| 1015 | included. For example, the impact may relate to mercury exposure from |
| 1016 | dental amalgams and bisphenol A present in composite resins. However, to |
| 1017 | enable a comparative assessment, we did not restrict our search to papers |
| 1018 | that examined both amalgams and resins, but explored each topic |
| 1019 | independently. |
| 1020 | Based on our initial findings and review of the literature, further searches to |
| 1021 | identify additional information on the environmental impact of dental |
| 1022 | amalgams and composite resin restorations were conducted by reviewing |
| 1023 | key papers cited in the documents retrieved. |
| 1024 | Data Extraction and Content Analysis |
| 1025 | From each relevant article, the bibliographic details (authors, year of |
| 1026 | publication) and issues related to the environmental impact identified were |
| 1027 | captured by one reviewer. For both amalgam and composite resin, we then |
| 1028 | categorized the findings into key risk assessment criteria, namely hazard |
| 1029 | identification (e.g., what potentially toxic chemicals are present in the |
| 1030 | material), exposure assessment (e.g., how might key receptors be exposed), |
| 1031 | and toxicology (e.g., what are the potential toxic effects). The findings were |
| 1032 | summarized narratively, and when possibly quantitative estimates were |
| 1033 | derived to try and best reflect the current situation in Canada. |
| 1034 | Results |
| 1035 | Quantity of Research Available |
| 1036 | The literature search identified 1,684 unique citations and 12 articles were |
| 1037 | identified from other sources. One reviewer reviewed 56 full-text articles, |
| 1038 | and 19 were included in this review. |
| 1039 | Content Analysis |
| 1040 | <i>Dental Amalgam</i> |
| 1041 | Dental Amalgam – Hazard Identification |

1042 Dental amalgam is a powdered alloy that consists of mercury combined with
1043 silver, tin, and copper (among other elements). Environmental risks have
1044 exclusively focused on mercury, and thus is the focus here. Mercury is a
1045 naturally occurring element that exists in three chemical forms: elemental or
1046 metallic mercury (Hg^0), inorganic mercury compounds (Hg^{2+} , Hg^{1+}), or
1047 organic mercury compounds with the main form being methylmercury
1048 (MeHg).¹¹⁰ Dental amalgam is approximately 50 percent elemental mercury
1049 by weight.

1050 Mercury is a global pollutant of concern that is now being acted upon via the
1051 United Nations (UN) Minamata Convention of which Canada is a signatory.
1052 Worldwide an estimated 5,500 to 8,900 tons of mercury enters the
1053 atmosphere each year.¹¹¹ Much of this mercury is released due to
1054 anthropogenic activities, and this includes cremation that may be attributable
1055 to dental amalgams (0.2 % of global releases). In Canada, total mercury
1056 emissions in 2010 were estimated to be 4,470 kg per year (<0.1% of global
1057 releases) of which 91 kg was attributable to cremation.

1058 While the amount of mercury released from the Canadian dental sector is
1059 relatively small on a global scale, environmental and human health concerns
1060 exist as mercury is firmly established to be persistent, toxic, and
1061 bioaccumulative. All forms of mercury are innately toxic though the chemical
1062 form of mercury is critical in understanding its environmental fate and
1063 ultimately its risk. In the dental clinic, elemental mercury is used though
1064 upon release into the environment it is oxidized to inorganic mercury. As
1065 elaborated upon below, this inorganic mercury can be released into the
1066 wastewater stream and eventually the broader aquatic ecosystem. Within
1067 aquatic ecosystems inorganic forms of mercury can be methylated by
1068 certain bacteria into methylmercury. This is noteworthy since methylmercury
1069 (unlike the other forms of mercury) is bioavailable and biomagnifies two to
1070 10 times in fish and shellfish.¹³ Consumption of contaminated fish and
1071 shellfish is the main source of mercury exposure to most human populations
1072 and many wildlife, and there is ample evidence of exposure-related adverse
1073 health outcomes in these species.^{112,113} In Canada the issue of mercury
1074 contamination is a particularly sensitive one.¹³ For example, fish
1075 consumption guidelines exist in many jurisdictions thus impacting sport and
1076 recreational fishing opportunities for many Canadians, and key traditional or
1077 country foods consumed by First Nations and Inuit communities are often
1078 contaminated with unsafe amounts of mercury.¹³

1079 The Canadian Environmental Protection Act designates mercury and its
1080 compounds as toxic substances under Schedule 1, and the chemical is also
1081 covered nationally under the Fisheries Act, the Hazardous Products Act, and
1082 guidelines of the Canadian Food Inspection Agency. The Canadian Council
1083 of Ministers of the Environment has determined that environmental levels of
1084 mercury across Canada warrant efforts to reduce atmospheric and
1085 waterborne emissions of mercury and mercury compounds, derived from
1086 both deliberate uses (such as in dentistry) and from incidental releases. At
1087 the Provincial and municipality levels there also exist various pieces of
1088 legislations and bylaws limiting mercury releases into the environment.

1089 **Dental Amalgam – Exposure Assessment**

1090 As mentioned above, contamination of aquatic ecosystems by mercury is the
1091 main route of exposure to most human populations and many wildlife
1092 species. Given that several sources of mercury exist across Canada, and

1093 that both Canada and the sector are relatively small contributors, here we
1094 aimed to estimate how much mercury was being discharged into aquatic
1095 ecosystems by the Canadian dental sector. To achieve this we adapted
1096 calculations performed in the United States in a study that was sponsored by
1097 the American Dental Association.¹¹⁴ The calculations performed here for
1098 Canada rely upon several inputs and assumptions detailed in the
1099 aforementioned U.S.-based report, and are supplemented with Canadian
1100 figures when possible. According to the Canadian Dental Association,⁷⁸
1101 there were 19,563 licensed dentists in the country in 2010. Of these,
1102 approximately 89% (n=17,411) were in general practice. From the U.S.
1103 study we assumed that 76% of these dentists (n=13,232) used amalgam.
1104 The remaining 11% of Canadian dentists were assumed to be specialists. Of
1105 these specialists, it was assumed by the American Dental Association that
1106 pediatric dentists, prosthodontists, and endodontists only use amalgam and
1107 that these dentists comprise approximately 35% of all specialists. Thus, in
1108 Canada we estimated that there were 750 of these particular specialists, and
1109 conservatively estimated that all of these individuals used amalgam.

1110 In the U.S. it was estimated in 1999 that general dentists placed 713
1111 restorations per year and that specialty dentists placed 440 restorations per
1112 year. Applying these numbers to Canadian results in an estimated 9,764,521
1113 (approximately 9.8 million) restorations placed per year though this number
1114 is likely over-estimated given the declining use of amalgams. Assuming that
1115 the average mercury content in a double spill of amalgam is approximately
1116 450 mg,¹¹⁴ here we estimated that 4.4 metric tons of mercury (4,394.1 kg)
1117 are used annually in the Canadian dental sector. We note, however, a
1118 footnote on page 3 of a report by the Canadian Council of Ministers of the
1119 Environment that “approximately 1.3 tonnes per year of mercury in new
1120 filling material is placed each year in the mouths of Canadians...”⁹⁵

1121 Not all the amalgam is used during placements, and the left-over (“non-
1122 contact”) amalgam waste can range from 15 to 50%.¹¹⁴ Using 25% as an
1123 approximate value, we estimated that 1.1 metric tons of non-contact
1124 amalgam waste was generated that could be recycled. During the placement
1125 process, it was estimated that approximately 30 mg of mercury per
1126 placement was lost to the dental clinic’s wastewater system, and thus across
1127 Canada this would amount to approximately 292.9 kg per year of mercury.

1128 Mercury may also be lost when amalgams are removed. In Ontario,¹¹⁵ it was
1129 estimated in 2002 that general dentists removed an average of 412
1130 amalgams per year (versus 710 per year and 440 per year in the U.S. by
1131 general and specialty dentists, respectively).¹¹⁴ Scaling the Ontario numbers
1132 across Canada resulted in an estimated 5,760,682 (approximately 5.8
1133 million) amalgams being removed per year by general and specialty
1134 dentists. The U.S. study estimated the average mercury content in a
1135 removed amalgam to be approximately 300 mg and that 90% of this mercury
1136 to be released into the clinic’s wastewater system. Thus, we estimate that
1137 approximately 1.6 metric tons (1,555kg) of mercury to be discharged each
1138 year into the clinic’s wastewater system during the removal of amalgams.

1139 To sum the aforementioned paragraphs, we estimated that mercury
1140 discharge from amalgam placements (292.9 kg per year) and removals
1141 (1,555 kg per year) into internal wastewater systems of dental clinics in
1142 Canada total 1,848 kg per year. This is in alignment with a footnote in page
1143 3 of a report by the Canadian Council of Ministers of the Environment that

1144 mentions “a report for Environment Canada... suggests as much as 2
1145 tonnes per year may be generated”. We also note that these estimates
1146 reflect data and assumptions that may be approximately 15 to 20 years old,
1147 and with the declining use of amalgam that the actual values now may be
1148 lower.

1149 The Canadian Council of Ministers of the Environment have established a
1150 national standard to aid in the reduction of dental amalgam waste into the
1151 environment.⁹⁵ Above we calculated the amount of mercury generated from
1152 the placement and removal of amalgam. While some of this mercury may be
1153 captured through chairside traps and vacuum filters, a substantial amount of
1154 mercury may be released into the public sewage system without added
1155 protections. The U.S. study¹¹⁴ estimated that clinics with both a chair-side
1156 trap and a vacuum filter captured approximately 81% of the amalgam.
1157 Amalgam separators have emerged as a practical and affordable technology
1158 to capture mercury within clinics (e.g., those compliant with ISO 11143:2008
1159 achieve at least a 95% removal efficiency).¹¹⁶

1160 In Ontario, a 2002 study estimated that 22% of clinics in the province had
1161 amalgam separators and that these were 98.9% efficient,¹¹⁵ though a more
1162 recent national assessment by Environment Canada¹⁴ of 1,250 dental clinics
1163 polled found that 97% of them were equipped with ISO-certified amalgam
1164 separators. Based on this, we estimated that the amount of mercury
1165 captured within the clinic would be 1,848 kg of mercury per year thus leaving
1166 30.3 kg per year left for discharge into the sewage system. Earlier estimates
1167 for Canada by two consulting firms (i.e., 686 kg per year, O’Conner
1168 Associates Environmental Inc.; 781 kg per year, CC Doiron & Associates)
1169 were higher though we noted that these earlier estimates (~late 1990s) may
1170 not have considered the ubiquity of amalgam separating technologies. Also,
1171 the aforementioned Environment Canada survey from 2012¹⁴ calculated that
1172 75 kg of mercury was released (down from 1,879 kg in 2000) from dental
1173 clinics though we were unable to review that particular report to compare our
1174 methodologies. Nonetheless both calculations showed levels to be much
1175 lower than previously estimated.

1176 Potential environmental risks need to consider the amount of mercury that is
1177 ultimately released into surface waters. Assuming the mercury capture
1178 efficiency of sewage treatment plants is 95% based on a U.S. study,¹¹⁵ here
1179 we estimated that 1.5 kg of mercury per year (of the 30.3 kg per year
1180 released into the sewage system) would be discharged into Canadian
1181 surface waters. Some of the mercury captured by the sewage treatment
1182 plant would be removed as grit solids or biosolids. Using inputs and
1183 calculations outlined in the U.S. study,¹¹⁵ we estimated that an addition 1 kg
1184 of mercury may be released into surface waters following the incineration of
1185 some biosolid waste. In total, we estimated that 2.5 kg of mercury per year
1186 ultimately flows into Canadian surface waters as a result of amalgam usage.
1187 To put this into context, the 2013 UNEP Global Mercury Assessment
1188 calculations for Canada estimated mercury releases across the country to
1189 be 4,470 kg per year.

1190 **Dental Amalgam – Toxicology**

1191 The amount of mercury entering Canadian aquatic ecosystems as a result of
1192 amalgam use is relatively small. Aside from one study on goldfish,¹¹⁷ we
1193 were not able to identify studies that specifically characterized the potential
1194 toxicity of amalgam-related mercury releases towards an ecological

1195 receptor. Nonetheless, there is a robust body of literature documenting the
1196 environmental impacts of mercury towards a range of biotic receptors in the
1197 Canadian environment,¹³ hence the overall concern as exemplified by a
1198 global policy instrument (Minamata Convention). It has been established that
1199 all forms of mercury are toxic, and that in particular they disrupt the structure
1200 and function of the nervous system.¹¹⁰ Across Canada there have been case
1201 reports of mercury-poisoned fish, birds and mammals, and these were
1202 related to past exposures to relatively high levels of mercury.¹³ Nowadays
1203 such exposures are rare though there is strong scientific consensus that
1204 chronic exposure of fish and wildlife to relatively low-levels of mercury is
1205 associated with subtle, yet ecologically meaningful, changes in reproduction
1206 and behavior.¹³

1207 *Composite Resins*

1208 **Composite Resins – Hazard Identification and Toxicity**

1209 The use of amalgam as a dental filling material is declining and being
1210 substituted with a range of alternate restorative materials.¹¹⁸ The major
1211 types of alternate restorative dental materials include composites, glass
1212 ionomers, gold foil, gold alloy, metal-ceramic crowns and gallium alloys.
1213 Despite possible benefits, the general consensus, consistent with the
1214 findings of the Clinical Review, is that these alternate materials are more
1215 expensive than amalgam and less durable. Furthermore, the safety of these
1216 materials has not been well studied. While these materials contain
1217 chemicals that are known to be toxic, the environmental fate of the
1218 chemicals in these materials as well as their exposure routes and adverse
1219 effects towards human and environmental health are poorly understood.¹¹⁸
1220 As such, the lack of information and data negates the possibility to perform a
1221 detailed evidence-based environmental risk assessment of such materials.

1222 For resin-based composites in particular, a number of chemicals have been
1223 identified that may be released during the restoration's lifecycle, from
1224 manufacturing to placement to removal and disposal. These chemicals are
1225 largely monomers and include chemicals like 2-hydroxyethyl methacrylate
1226 (HEMA), triethylene glycol dimethacrylate (TEGMA), or bisphenol-A
1227 containing monomers such as bisphenol A glycidyl methacrylate (bis-GMA).
1228 Except for bisphenol-A, there is limited information on the other chemicals in
1229 terms of potential exposures, hazards, and risks.

1230 The toxicology of bisphenol-A has been thoroughly reviewed by several
1231 expert committees, including a Food and Agriculture Organization/World
1232 Health Organization Expert group.¹¹⁹ There is ample evidence of toxicity
1233 from animal studies, and a growing body of epidemiological data pointing
1234 towards exposure-related adverse effects towards neurodevelopment and
1235 reproductive health. Once in the environment bisphenol A can degrade
1236 relatively quickly though continual source inputs mean that ecosystem
1237 components, including fish and wildlife, can be chronically exposed. Societal
1238 and scientific concerns related to bisphenol A motivated the Canadian
1239 Government to include the chemical in Batch 2 of its Chemicals
1240 Management Plan (CMP), following which it was concluded that exposures
1241 to bisphenol A be kept as low as possible especially for newborns and
1242 infants.

1243

1244

1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259

Composite Resins – Exposure Assessment

Concerning bisphenol A, given its endocrine disrupting properties there have been concerns about exposures within the Canadian population. For example, the 2007-2009 Canadian Health Measures Survey revealed that 91% of the population had detectable urinary bisphenol-A levels with an average measured level of 1.2ug/L¹²⁰ though this is almost 50% of what was found across the U.S. via their National Health and Nutrition Examination Survey (NHANES). A number of bisphenol A sources exist (mainly contaminated food and water), and while this can include composite resins, within the dental community organizations such as the American Dental Association and U.S. Food and Drug Administration conclude that there is no threat to human health from its use in restorations.¹²¹ For example, Kingman et al. (2012) found that BPA levels in saliva and urine of patients increased after restoration placement but that these levels returned to baseline within approximately one day of placement.¹²²

1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272

While the potential environmental effects of BPA are numerous and despite some initial studies to understand releases, unlike our assessment above for mercury there is limited information to able to calculate how much BPA enters the environment from dentistry and ultimately causes risk to fish and wildlife.¹²³ Nonetheless, Environment and Climate Change Canada along with Health Canada have concluded that “BPA is entering or may enter the environment in a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity and that constitute or may constitute a danger in Canada to human life or health”¹²⁴. In the aforementioned Federal Environmental Quality Guideline for Bisphenol A, environmental measurements (e.g., levels in water and sediment) of the chemical across Canada are reported upon and related to guidance values.

1273

Summary of Results

1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290

The dental profession relies upon a variety of materials and processes to achieve their goals, though these are not without some risk to the environment. Our review focused on the environmental risks associated with the two main restorative materials used in dentistry – amalgam and composite resins. For amalgam, the presence of mercury has been of concern for decades. While mercury has been established as a chemical that is persistent, bioaccumulative, and toxic, the relative small contribution of mercury into the Canadian ecosystem from use in dentistry as well as the over-time declines in its use suggest that the potential impacts on the environment are much less than other sources. There is increasing use of composite materials as dental fillings though relatively little is known about most of these chemicals, and in particular their fate in the environment and downstream impacts on the ecosystem. Most attention and information is on bisphenol-A, and while this chemical has been shown to contaminate ecosystems and disrupt fish and wildlife health, linking potential impacts back to the Canadian dental sector is not possible with the current state of knowledge.

1291

1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303

1304
1305
1306
1307
1308
1309
1310

1311
1312
1313

1314
1315
1316
1317

1318
1319
1320
1321

1322
1323

1324
1325
1326

1327

1328
1329
1330
1331
1332

1333
1334
1335
1336
1337
1338

Ethics

The purpose of this analysis is to identify and reflect upon key ethical, legal and social considerations relevant to addressing the central policy question of this HTA, namely, “Should dental amalgam continue to be used in Canada?” This question is a natural sequela to the United Nations Environment Programme (UNEP) Minamata Convention on Mercury which proposes a phase down of mercury by national governments according to local need (Table 18).^{125,126} While the other sections of this HTA often touch upon broadly ethical concerns, the aim of this analysis is to make such issues explicit and to identify others that may be relevant to any recommendations with regard to the continued use of dental amalgam in Canada.

The issues raised in this section necessarily go beyond narrowly defined ethical concerns to encompass broader legal and social considerations. It is common in the ethics literature, across a broad range of health related issues, to refer to ELSI (ethical, legal, and social issues) when addressing broader values related considerations. Hence this discussion will touch upon broader historical, social and legal considerations that serve to shape and inform the ethical issues identified.

The aim of this analysis is to address research question 9: What are the ethical issues associated with the use of dental amalgams compared with the use of composite resin restorations?

Considering the way in which dental services are provided and covered in Canada and the general ethical issues motivating this HTA, there are several broad ethical questions to consider when comparing amalgam versus composites:

1. a) What is the appropriate balance between government oversight/intervention versus individual control and/or responsibility (for both providers and recipients) with regard to the choice between amalgams or composites?
- b) How do we balance competing values in this regard (e.g. financial costs, aesthetic preference, health and safety, environmental protection)?
2. Does the manner in which dental care is funded (i.e. through private or public insurance) affect the manner in which various value preferences and concomitant ethical concerns are characterized and addressed?

These and other ELSI related questions will guide the analysis to follow.

This HTA presents a number of unique challenges due in no small part to the protracted nature of the amalgam debate. A historical overview of the amalgam debate is provided in Appendix 19. Although dental amalgam has been used in dentistry for over 150 years, questions about its suitability as a restorative material have been continuous to the present day.¹²⁷⁻¹³²

This lack of consensus presents particular challenges for the weighing of evidence and arguments in the amalgam debate. Society grants certain privileges to self-regulating professional bodies like dentistry (e.g. establishing admission standards, setting professional practice standards, enforcing discipline, etc.) based on the esoteric body of knowledge which members of the profession ostensibly hold. In return for granting such

1339 privileges, society expects professional bodies to exercise certain fiduciary
1340 responsibilities for the broader public good including the provision of safe
1341 and appropriate services. However, when there is strong and persistent
1342 disagreement about a key element of the knowledge base for which that
1343 profession is responsible, the public is understandably confused and
1344 potentially vulnerable. Such is the case with dental amalgam as the
1345 knowledge claims of those on either side of the debate are dismissed and/or
1346 disputed by those who hold the contrary view, even as each side often
1347 questions the integrity and/or the professional competency of the other.¹³³⁻¹⁴⁰
1348 When such matters cannot be sorted satisfactorily within a professional body
1349 they often find their way into the courts as evidenced by numerous legal
1350 challenges in various jurisdictions over the past several decades.¹⁴¹⁻¹⁴⁷

1351 In what follows we will explore some of these ongoing tensions, challenges
1352 and controversies with a view to identifying an ethically sound way forward
1353 for Canada with regard to the use of dental amalgam.

1354 **Methods**

1355 This ELSI analysis draws on the other sections of the HTA that have
1356 systematically reviewed the literature on various aspects of the dental
1357 amalgam versus composite resins controversy. The Clinical Review,
1358 Economic Evaluation, Patient Preferences and Experiences Review,
1359 Implementation Issues, and the Environmental Assessment have analysed
1360 available evidence according to prescribed selection criteria, and insofar as
1361 that evidence base serves to highlight relevant ELSI germane to this
1362 discussion, the present analysis draws upon those reviews. However, while
1363 other sections of this HTA have been purposively narrow in their selection
1364 criteria, generally focusing on literature from the recent past and, in some
1365 cases, drawing materials primarily from the North American context so as to
1366 approximate the Canadian situation, the literature search for this ELSI
1367 review has been purposely broad. This is due in part to the historical nature
1368 of the amalgam controversy that has been ongoing for the better part of a
1369 century and a half. Inasmuch as ELSI reviews are primarily about values
1370 which evolve, take shape and become engrained over long periods of time,
1371 a longer perspective is necessary. Values are informed by facts, but they are
1372 also subject to pressure from political, cultural and other social forces.¹⁴⁸⁻¹⁵⁰
1373 The fact that the concerns with amalgam use have been raised not only in
1374 North America and Europe, but in other industrialized and developing
1375 nations as well¹⁵¹⁻¹⁵⁸ is important to a general understanding and
1376 appreciation of how firmly entrenched attitudes and values have become
1377 around the amalgam issue throughout a large part of the industrialized
1378 world. Indeed major international bodies such as the World Health
1379 Organization and the Fédération Dentaire Internationale (FDI) have issued
1380 joint statements over the years on the amalgam issue.¹⁵⁹⁻¹⁶¹ Hence, a much
1381 broader literature review was undertaken with a view to laying bare some of
1382 the deep and persistent features of the ongoing amalgam debate.

1383 **Literature Search**

1384 The literature search was performed by an information specialist, using a
1385 peer-reviewed search strategy.

1386 Published literature was identified by searching the following bibliographic
1387 databases: MEDLINE with Epub ahead of print, in-process records and daily

| | |
|------|---|
| 1388 | update, via Ovid and Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCO. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were dental amalgams and composite resins. The search strategy for the dental amalgam and composite resin concepts were based on the Q2 search strategy. |
| 1389 | |
| 1390 | |
| 1391 | |
| 1392 | |
| 1393 | |
| 1394 | |
| 1395 | Methodological filters were applied to limit retrieval to studies related to ethical, legal and social issues. Retrieval was not limited by publication year but was limited to the English or French language. The search strategy is available upon request. |
| 1396 | |
| 1397 | |
| 1398 | |
| 1399 | The search was completed on July 18, 2017. Monthly alerts were established to update the searches until the publication of the final report. Studies identified in the alerts and meeting the selection criteria of the review were incorporated into the analysis if they identified prior to the completion of the stakeholder feedback period of the final report. Any studies that are identified after the stakeholder feedback period will be described in the discussion, with a focus on comparing the results of these new studies to the results of the analysis conducted for this report. |
| 1400 | |
| 1401 | |
| 1402 | |
| 1403 | |
| 1404 | |
| 1405 | |
| 1406 | |
| 1407 | Grey literature (literature that is not commercially published) was identified by searching the <i>Grey Matters</i> checklist (https://www.cadth.ca/grey-matters), which includes the websites of health technology assessment agencies, clinical guideline repositories, SR repositories, economic-related repositories, and professional associations. Google and other Internet search engines were used to search for additional web-based materials. These searches were supplemented by reviewing the bibliographies of key papers and through contacts with appropriate experts. |
| 1408 | |
| 1409 | |
| 1410 | |
| 1411 | |
| 1412 | |
| 1413 | |
| 1414 | |
| 1415 | In addition, the literature search also examined a variety of other sources that were identified through a separate electronic search of articles from the ethics and clinical science literature. While addressing ELSIs indirectly these sources of information raised and/or shed light on a variety of ELSI issues related to the amalgam versus composite resins controversy. Additional relevant literature was also found using less systematic searching of both indexed and grey literature sources. |
| 1416 | |
| 1417 | |
| 1418 | |
| 1419 | |
| 1420 | |
| 1421 | |
| 1422 | Literature screening and selection |
| 1423 | The selection of relevant literature proceeded in two stages. In the first stage, the title and abstracts of citations was screened for relevance by a single reviewer. Articles were categorized as "retrieve" or "do not retrieve," according to the following criteria: |
| 1424 | |
| 1425 | |
| 1426 | |
| 1427 | <ul style="list-style-type: none"> • Provides normative analysis of an ethical issue arising in the use of amalgams or resins when treating dental caries |
| 1428 | |
| 1429 | |
| 1430 | <ul style="list-style-type: none"> • Presents empirical research directly addressing an ethical issue arising in the use of amalgams or resins when treating dental caries |
| 1431 | |
| 1432 | <ul style="list-style-type: none"> • Explicitly identifies but does not analyze or investigate empirically an ethical issue arising in the use of amalgams or resins when treating dental caries. |
| 1433 | |
| 1434 | |

1435 The goal in a review of bioethics literature is to canvass what arises as an
1436 ethical issue from a broad range of relevant perspectives. As such, the
1437 quality of normative analysis did not figure in the article-selection criteria;
1438 any identification of an issue by the public, patients, health care providers,
1439 researchers, or policy-makers was of interest whether or not it was
1440 presented through rigorous ethical argumentation. For example, academic
1441 ethicists may focus on certain issues related to theoretical trends in their
1442 discipline, while an opinion piece by a clinical or policy leader or a patient
1443 may bring to the fore ethical questions that are neglected by academic
1444 ethicists but are highly pertinent to the assessment of the technology in the
1445 relevant context. Despite the different standards of normative argumentation
1446 for each kind of report, the importance of the issues raised cannot be
1447 assessed solely by these standards and so literature cannot be excluded
1448 based on methodological standards.

1449 In the second stage, the full-text reports were reviewed by the same single
1450 reviewer. Reports that met the above criteria were included in the analysis,
1451 and those that did not meet the criteria were excluded.

1452 Data extraction or abstraction strategy

1453 The bibliographic details for each report (e.g., author, publication date,
1454 journal) the potential ethical issues raised, and the report's conclusions
1455 (issues identified, values at stake identified through normative analysis,
1456 solutions proposed, and their normative justification, if presented), for those
1457 reports that explicitly raised and addressed an ethical issue, were
1458 summarized in a table.

1459 Analytic approach

1460 This analysis draws most directly on two classic perspectives that are well
1461 established in the health ethics literature, namely the
1462 utilitarian/consequentialist approach, and the deontological/duty based
1463 approach. The former focuses more directly on the overall consequences of
1464 particular courses of action and deals with questions of individual rights and
1465 duties and considerations of social justice only indirectly. Conversely, the
1466 deontological approach gives priority to considerations of individual rights
1467 and concomitant duties while treating overall utility (i.e. the greatest good for
1468 the greatest number) as of only secondary importance. Put otherwise, from
1469 a deontological perspective the most important consequence is whether
1470 individual rights are properly honored and accounted for irrespective of
1471 whether some supposedly greater good might be accomplished by ignoring
1472 or overriding the rights of certain individuals. While these two theoretical
1473 approaches are often treated as contrary there is a well-established tradition
1474 within contemporary health care ethics that treats them as
1475 complementary.¹⁶²

1476 In practice, whether one relies primarily on consequentialist or deontological
1477 considerations is often dictated by the context in which a particular issue
1478 arises. Consequentialist considerations generally take priority in the public
1479 health domain, where the overall good of the population as a whole is the
1480 focus. In the current context the broader public health concerns related to
1481 mercury contamination and the contribution of dental waste to this problem
1482 as reflected in the Minamata Convention are best viewed through a
1483 consequentialist lens. In the clinical context, on the other hand, the rights of
1484 individual patients to be informed about the nature of the materials that are


1485 being put into their mouths,^{163,164} and the concomitant duties of dental
1486 professionals to provide that information in a clear and unbiased manner,
1487 are best viewed from a deontological perspective which generally favours
1488 the rights of the individual over some perceived broader public good. This
1489 tension is particularly evident in the current context when attempting to
1490 balance the overall utility for society when making policy decisions about
1491 dental amalgam as opposed to the rights of individual citizens. Were the
1492 policy decision made to discontinue use of dental amalgam out of
1493 environmental concerns, for example, this could undermine the individual
1494 dentist's or patient's right to use/choose a less expensive and potentially
1495 more durable restorative material. Conversely, if the policy decision was
1496 made to continue the use of dental amalgam because of its perceived
1497 overall economic benefits based on reduced costs and greater durability,
1498 this would require that appropriate efforts be made to respect the
1499 autonomous rights of individual patients to be informed of various restorative
1500 options while placing concomitant duties on dentists to provide such
1501 information in an unbiased manner. This ELSI review aims to explore such
1502 values tensions and the factors that might inform one policy decision as
1503 opposed to another.

1504 As the foregoing indicates, an ELSI analysis of dental amalgam versus
1505 composite resins raises a variety of issues. For the purposes of analysis and
1506 reporting, this broad range of issues will be divided into macro, meso, and
1507 micro concerns. Macro concerns are generally policy related issues that are
1508 handled at a population level through legislation such as the Canada Health
1509 Act or by a government agency such as Health Canada, Environment
1510 Canada or related provincial ministries. In the current case the Minamata
1511 Convention pushes such macro concerns to the level of international law.
1512 Meso level considerations are those that concern mid-level institutions and
1513 bodies. The Canadian Dental Association is an example of a meso level
1514 entity, as are various municipal authorities that are at times tasked with
1515 implementing environmental policy decisions in the local context. At the
1516 micro level we consider the impact that various policy options with regard to
1517 dental amalgam would have on individual patients and/or practitioners.

1518 Figure 5 illustrates the analytic process and the dynamic relationship
1519 between consequentialist and deontological considerations. The inverted
1520 pyramid captures the idea that the issues under consideration range from
1521 broad public policy concerns to more narrow concerns of individual patients
1522 and practitioners.

1523 **Figure 5: Levels of decision making and types of ethical considerations**

Macro, Meso, and Micro Considerations



1524

1525

1526

1527

1528

1529

1530

1531

1532

While the foregoing has singled out consequentialist and deontological ethical perspectives as particularly relevant to the ELSI analysis offered here, other ethical perspectives will occasionally inform elements of this discussion. Virtue theory, for example, focuses on desirable qualities of character that contribute to virtuous persons and professions.¹⁶² Insofar as elements of this discussion bear on the character of various professional bodies and/or the individuals that comprise those bodies, considerations of virtue may be relevant.

1533

Summarizing and Presenting Results

1534

1535

1536

1537

1538

1539

1540

1541

1542

1543

The reporting of ethical issues will follow the key values identified or issues being explored and will be determined by the values and issues that are identified. For example, the results were summarized according to a principlist framework (issues concerned with autonomy, beneficence, non-maleficence, and justice) or by categorizing moral concerns as micro-, meso-, and macro-level issues. Regardless of the framework selected, the implications of the choice of framework on how the findings are presented and interpreted will be described. In addition, where the report undertakes analysis that is not derived from the peer-reviewed literature will be noted in the interests of transparency.

1544

Results

1545

Literature Search and Selection

1546

1547

1548

1549

1550

1551

1552

1553

1554

The literature search yielded 913 records. After removing duplicates, reviewing record abstracts, and appraising full text articles of potentially relevant articles from both the database search and supplemental searches, a total of 14 articles were identified that explicitly acknowledge “ethics” related to the use of amalgam or composite dental restorations.¹⁶⁵⁻¹⁷⁸ See Appendix 18 for a flow chart describing the literature search and selection process. No single article completely answered the research questions and none compared the overall risks and benefits of amalgam and composite resin dental restorations.

1555

Analysis

1556 *Macro Level Issues*

1557 Macro level ELSI analyses draw upon utilitarian/consequentialist ethics

1558 models that emphasize the overall good for society as a whole when setting

1559 social policy. Overarching political bodies and their agencies are generally

1560 the entities responsible for determining what constitutes the general social

1561 good in any given sphere, and for establishing laws and/or promoting social

1562 policies designed to achieve those ends. While concerns regarding

1563 individual rights generally do not figure prominently in macro level analyses,

1564 broader issues of social justice that may run contrary to direct utilitarian

1565 calculations may be relevant.

1566 Although the debate regarding the safety of dental amalgam as a restorative

1567 material continues as far as its clinical utility is concerned, the contribution of

1568 dental amalgam to overall environmental load of mercury has emerged as

1569 one aspect of that controversy where some semblance of a consensus has

1570 emerged (Appendix 19). As a signatory to the United Nations Environment

1571 Programme (UNEP) Minamata Convention, the government of Canada has

1572 adopted a macro level policy that keeps the country in step with the

1573 international community, while aiming to ensure that Canadian citizens are

1574 appropriately protected. The Minamata Convention contains nine

1575 recommendations regarding dental amalgam (Table 18), all of which are

1576 germane to particular ELSI.

1577 **Table 18: Dental Provisions of the Minamata Convention**

Part II: Products subject to Article 4, paragraph 3

| Mercury-added products | Provisions |
|------------------------|---|
| Dental amalgam | <p>Measures to be taken by a Party to phase down the use of dental amalgam shall take into account the Party's domestic circumstances and relevant international guidance and shall include two or more of the measures from the following list:</p> <ul style="list-style-type: none"> (i) Setting national objectives aiming at dental caries prevention and health promotion, thereby minimizing the need for dental restoration; (ii) Setting national objectives aiming at minimizing its use; (iii) Promoting the use of cost-effective and clinically effective mercury-free alternatives for dental restoration; (iv) Promoting research and development of quality mercury-free materials for dental restoration; (v) Encouraging representative professional organizations and dental schools to educate and train dental professionals and students on the use of mercury-free dental restoration alternatives and on promoting best management practices; (vi) Discouraging insurance policies and programmes that favour dental amalgam use over mercury-free dental restoration; (vii) Encouraging insurance policies and programmes that favour the use of quality alternatives to dental amalgam for dental restoration; (viii) Restricting the use of dental amalgam to its encapsulated form; (ix) Promoting the use of best environmental practices in dental facilities to reduce releases of mercury and mercury compounds to water and land. |

1578

1579 Source: "From Minamata Convention on Mercury, by United Nations. ©United Nations [2013]. Reprinted with the permission of the United Nations."¹²⁶

1580 The relatively small contribution of mercury into the Canadian ecosystem

1581 from use in dentistry suggests that the potential impacts on the environment

1582 are much less than other sources (see the Environmental Review).

1583 Nonetheless, over the past 15 years Canada has taken significant steps to

1584 set a Canada-wide standard to reduce releases of mercury in waste

1585 amalgam from dental practices.⁹⁵ As of 2012, 97% of dental offices in
1586 Canada were following best management practices for amalgam disposal
1587 (see Implementation Issues).¹⁴ While the Minamata Convention includes
1588 provisions for the phase down of amalgam, concerns have been raised that
1589 these provisions are voluntary and do not include binding targets. “. . . [T]he
1590 international community should begin exploring ways to strengthen the
1591 implementation of the dental amalgam treaty provisions,” states one recent
1592 commentary, “by establishing binding phase-down targets and milestones as
1593 well as exploring financing mechanisms to support treaty measures.”¹⁷⁹ It
1594 has been noted, for example, that while the use of amalgam separators are
1595 mandated, some may choose to forego them because of added costs. As
1596 noted in the review of Implementation Issues, not all practices in Nunavut
1597 are reported to have installed them. Inasmuch as concerns about mercury
1598 exposure are often exacerbated in First Nation’s communities that rely more
1599 heavily on fish in their daily diets, this may be a particular area of concern.¹⁸⁰

1600 Public health policy is another macro level instrument that can affect both
1601 the manner in which dental services are provided as well as the choice of
1602 materials used for restorations.¹⁸¹ The UNEP has observed that addressing
1603 imbalances in insurance schemes can contribute to the phase down of
1604 amalgam use. Many European countries which have introduced policies to
1605 either prohibit or significantly restrict the use of dental amalgam include
1606 either universal coverage of dental services or make other significant
1607 provisions for dental coverage.¹⁸² A recent population-based study
1608 assessing factors that influenced dentist’s choice of composite resin or
1609 amalgam in posterior direct restorations showed that choices were
1610 influenced by the type of payment available.¹⁸³ As noted elsewhere in this
1611 HTA, some government funded provincial dental plans will cover only
1612 amalgam restorations in posterior teeth (see Implementation Issues).¹⁰² Not
1613 only do such policies affect on-going efforts to reduce amalgam use as it
1614 pertains to environmental concerns, but they restrict patient’s (or
1615 consumer’s, depending on the view one takes) rights to make informed
1616 choices with regard to the type of restorative materials that are placed in
1617 their mouths. Indeed the Minamata Convention directs the parties to
1618 discourage insurance policies and programs that favour amalgam use over
1619 mercury-free dental restorations.¹²⁶

1620 In Canada only about 5% of dental services are publicly financed.¹⁸¹
1621 Addressing public funding of dental services will be especially important if
1622 efforts to reduce amalgam use are successful, as the increased costs
1623 associated with composite resins could prove prohibitive for many who
1624 require restorative treatment but are not covered through a public or private
1625 insurance plan. Inasmuch as dental care is not included in the Canada
1626 Health Act and health care is a provincial responsibility in any case, close
1627 collaboration between the federal, provincial, and territorial governments will
1628 be necessary to effect positive oral health outcomes for all Canadians as a
1629 downstream effect of the Minamata Convention.

1630 The dental profession in Canada has lobbied successfully over the years to
1631 protect and advance its own interests. For example, dentists argued
1632 successfully that it would be more cost-effective for government to limit the
1633 direct delivery of publicly financed dental care, allowing for its delivery
1634 through private clinics.¹⁸¹ Pressure from the profession has also impacted
1635 the nature of publicly funded services in Canada, including payment for
1636 composite restorations in some provincial plans.¹⁸¹ Such macro-level

1637 policies have important downstream consequences as public fee schedules
1638 often pay less for amalgams, thus providing a provider incentive to use
1639 composites. But inasmuch as the risk of secondary caries is purported to be
1640 significantly higher with composites than with amalgams, as noted in the
1641 Clinical Review, composites may not be the most appropriate choice for high
1642 caries populations which are often served through publicly financed
1643 programs (See also the Economic Impact section).¹⁸¹ On the other hand,
1644 public financing of alternative materials provides more options for individual
1645 consumers with regard to the choice of restorative materials whether for
1646 aesthetic or safety reasons. Nevertheless, the Minamata Convention
1647 encourages national entities to promote “cost-effective and clinically
1648 effective mercury-free alternatives . . .” (Table 18)¹²⁶

1649 Many in the population are poorly informed or simply unaware of the range
1650 of potential issues (environmental or otherwise) related to amalgam use.¹⁸²
1651 One recommendation endorsed by Health Canada’s stakeholder panel in
1652 1996 was that “a public and professional information package be prepared
1653 to make the public more capable . . . of making informed dental health
1654 choices.”¹⁰ Health Canada and Environment Canada might consider
1655 combining efforts to raise public awareness of environmental mercury
1656 concerns in general, and of the contribution to the environmental load
1657 contributed both from dental amalgam waste, and from persons with
1658 amalgam fillings through human waste (feces and urine), crematoria, and so
1659 forth.^{131,182} Another means of raising public awareness might include a link
1660 on the Public Health Agency of Canada website that vets and posts links to
1661 current research so the consuming public has access to reliable sources of
1662 information on the on-going issue of amalgam safety.

1663 Given the lack of consensus about what would constitute ‘valid evidence’ of
1664 safe or unsafe levels of mercury exposure from dental amalgams, various
1665 professional bodies with differing views may be unable to provide an
1666 impartial and comprehensive overview of all the available evidence. As such
1667 it is incumbent on the macro level institutions represented by government to
1668 ensure the consuming public has ready access to the full range of scientific
1669 evidence on the subject presented in an impartial, comprehensible, and
1670 readily accessible manner. Indeed, the current HTA might be viewed as a
1671 macro level effort to address the micro level needs of the Canadian
1672 population in this regard. Some states and municipalities in the U.S. provide
1673 ‘fact sheets’ that dentists are required to provide to patients,¹⁶⁹ and a
1674 number of U.S. states have enacted informed consent legislation.¹⁸⁴ Similar
1675 measures might be appropriate for Canadian jurisdictions as well.

1676 With the trend toward lower use of amalgam whether out of environmental,
1677 aesthetic or personal health preferences on the part of consumers, there is a
1678 continuing need for alternative restorative materials. Although it does not
1679 figure centrally in the current analysis, safety issues related to composite
1680 resins factor into this discussion as well.¹⁸⁵⁻¹⁸⁸ One of the recommendations
1681 of the Minamata Convention is that parties promote research and
1682 development of quality mercury-free materials for dental restorations.¹²⁶ To
1683 that end Canada’s major research bodies might ear-mark additional
1684 research funding to expedite efforts in the continuing development of safe,
1685 effective, and economically viable restorative materials.

1686 Finally, given the on-going controversy surrounding amalgam safety,
1687 Canada might consider leveraging current research efforts to cast further

1688 light on these issues. For example, the Canadian Longitudinal Study on
1689 Aging is currently following some 50,000 Canadian men and women
1690 between ages of 45 and 85 for at least 20 years from the time of recruitment,
1691 with a view to understanding the development of health and disease during
1692 the aging process.¹⁸⁹ Collecting base line information about dental health,
1693 number and types of fillings, etc. might provide basic epidemiological data to
1694 inform on-going research with regard to mercury toxicity and potential
1695 associations with other chronic illnesses.

1696 *Meso Level Issues*

1697 Many of the meso-level ELSI related to the amalgam question, hinge on the
1698 role of dentistry within the Canadian context and the extent to which
1699 members of the profession portray and conduct themselves as either health
1700 care professionals or as business entrepreneurs.¹⁸¹ Is dentistry a health care
1701 profession or a business? The answer is ambiguous both within the dental
1702 profession and for the public at large. On the one hand, dentists portray
1703 themselves as health professionals, providing an essential health care
1704 service.¹⁹⁰ In exchange for the privilege of self-regulation, dental
1705 professionals bear certain fiduciary responsibilities including putting patient
1706 interests over self-interest.^{140,163} On the other hand, the majority of dentists
1707 are in private practice with the primary aim of operating a successful
1708 enterprise.^{152,181} As such, as discussed in the review of Implementation
1709 Issues, “cost considerations, margins of profit, and efficiency of practice are
1710 important parameters that contribute to decision-making regarding choice of
1711 material.” This role ambiguity can affect patient/client interests.

1712 The issue of financial conflicts of interest has figured prominently in the
1713 amalgam controversy from the outset, with each side accusing the other of
1714 opportunistically taking advantage of a vulnerable and unsuspecting public.
1715 In the 1990s dental associations in both the U.S. and Canada addressed the
1716 emerging issue of dentists apparently taking advantage of patient’s
1717 perceived anxieties about amalgam toxicity by offering to replace them with
1718 composites.^{134,136,191} Amalgam supporters argue that their continued
1719 defense of amalgam effectively cost them billions in lost income had they
1720 simply remained silent on the issue and joined in the practice of removing
1721 and replacing serviceable amalgams.^{172,192} However, not all dentists who
1722 oppose amalgam have done so out of economic self-interest, citing reasons
1723 including ongoing concerns about amalgam toxicity.

1724 It is difficult to assess the relative weight of these competing claims.
1725 Inasmuch as the dental profession has lobbied successfully over the years
1726 to promote its financial interests, and given that there is, on the face of it, a
1727 financial incentive for dental practices to promote composite resins as they
1728 may yield a larger profit margin (Implementation Issues), it is curious that
1729 professional bodies like the ADA and CDA have consistently lobbied for the
1730 continued use of amalgam.^{172,193} Is this out of economic self-interest or out
1731 of genuine concern for the best interests of patients? The answer is probably
1732 both. For example, it is noted in the Implementation Issues section that it is
1733 more efficient for a practice to focus on one material, with one type of
1734 equipment and one technique. Focusing on one material thus provides a
1735 better return on investment. This may explain some of the early resistance to
1736 composite resins as an older generation of dentists who were unfamiliar with
1737 these newer materials found them difficult to work with and did not want to
1738 bear the additional costs of new equipment and training.¹³⁵ As composite
1739 technology has been perfected, and dental schools have focused more on

1740 the latest techniques in training the next generation of practitioners, the
1741 ability to place composites more quickly has advanced, increasing the
1742 financial incentive to use them. At the same time patients/consumers have
1743 increasingly demanded composites for aesthetic reasons,¹⁹⁴ and dentists
1744 have been willing to comply, again highlighting the business model of
1745 modern dentistry. Be that as it may, another recommendation of the
1746 Minamata Convention is that representative professional organizations and
1747 dental schools should be encouraged to educate and train dental
1748 professionals on the use of mercury-free dental restoration alternatives and
1749 on promoting best management practices (Table 18).

1750 There is much ambiguity in the messaging being sent to patients/consumers
1751 regarding amalgam safety including the persistent use of the term 'silver
1752 amalgam' as opposed to the more appropriate 'mercury amalgam'. On the
1753 one hand patients are told there are no mercury related health concerns for
1754 dentists or their patients as "mercury is not used in its pure state"
1755 (Implementation Issues). On the other hand, dentists are instructed in
1756 "modern and safe methods of handling . . . and disposing excess mercury"
1757 such that "exposure to mercury for dental practitioners is minimal"
1758 (Implementation Issues).¹⁷⁴ If there are no health concerns when mercury is
1759 not in its 'pure state', why must dentists take special precautions in handling
1760 it?^{135,138,195} In a similar vein Health Canada's position statement on dental
1761 amalgams states that current evidence does not link ill health with amalgam,
1762 yet cautions against using amalgam with young children, pregnant women
1763 and patients with impaired kidney function, implying there some concern that
1764 some vulnerable populations could be at risk.^{177,196} The CDA has long
1765 recognised its ethical obligation to provide accurate and complete
1766 information to the consuming public including "an obligation to inform
1767 patients of possible concerns."¹⁶³

1768 Irrespective of the patient safety issues, the continuing use of dental
1769 amalgam contributes to the global demand for mercury.¹⁹⁷ In light of the
1770 Minamata Convention it is incumbent on the dental profession to support the
1771 use of alternative materials while reducing the use of amalgam except in
1772 exceptional circumstances.¹²⁶

1773 *Micro Level Considerations*

1774 ELSI considerations at the micro level focus more directly on issues of
1775 individual rights and responsibilities. The primary concern in this regard is
1776 the patient's/consumer's right to make informed decisions about the
1777 restorative materials that will be placed in (or alternatively, removed from)
1778 their mouths, and the concomitant duties on the part of dental professionals
1779 to fully inform their patients/clients and to honor their patient's/client's
1780 informed decisions.^{10,164,198} Given the potential toxicity of both the restorative
1781 materials under review (whether amalgam or composite resins), regulatory
1782 authorities should ensure an adequate standard of information disclosure is
1783 established. A related micro level issue involves the individual dentist's right
1784 to conscientious refusal with regard to fulfilling individual patient/consumer
1785 requests that he/she believes could be harmful to the patient.¹⁶⁹

1786 The ethical principle of respect for autonomy underlies the doctrine of
1787 informed consent. However, the standard of information disclosure
1788 necessary to fulfill an ethical obligation in this regard is contingent on the
1789 context in which the matter of consent arises. Here again, the fact that
1790 individual dentists conduct themselves both as health care professionals and

1791 as profit making businesses is relevant, as the standard of information
1792 disclosure necessary to fulfill informed consent requirements differs between
1793 business and health care environments.

1794 In a business relationship both seller and buyer are understood to be looking
1795 out for their economic self-interests. In this context the seller meets his/her
1796 autonomy obligations by fairly representing the nature of the product being
1797 sold. The purchaser has a concomitant responsibility to protect his/her own
1798 autonomy by becoming an informed consumer. In the health care
1799 environment, however, an unequal level of knowledge is assumed between
1800 professional and patient such that the professional bears a fiduciary
1801 responsibility to ensure the patient is fully informed about any products or
1802 interventions on offer. The patient, by comparison, has a lesser obligation
1803 with regard to positively advancing his/her autonomy by virtue of the relative
1804 ignorance he/she has vis-à-vis the professional practice.¹⁷⁰

1805 Historically the dental profession in North America has struggled with the
1806 matter of patient autonomy and informed consent. In the 1990s, when public
1807 concerns about amalgam safety were on the rise, some dentists questioned
1808 the need to respect patient autonomy. “Autonomy could be dangerous”
1809 argues one commentator, if a dentist removes a serviceable filling because
1810 a patient requests it out of supposed misplaced concerns regarding
1811 safety.^{166,199} Another argues that informed consent should not apply to
1812 amalgam as they do not represent a significant risk.²⁰⁰ Yet another advises
1813 that if patients ask whether mercury is poisonous they should be told that
1814 when combined with other metals, as in dental amalgam, mercury becomes
1815 ‘biologically inactive.’²⁰¹

1816 Professional codes continue to emphasize the importance of informed
1817 consent.^{190,202,203} However some individuals question whether the profession
1818 is meeting its legal and ethical obligations in this regard. One legal scholar
1819 argues: “. . . the dental profession has basically ignored its duty to disclose
1820 material risks and has taken overt measures to ban its members from
1821 discussing potential risks with patients.”¹³³ (p. 294) One U.S. commentator
1822 suggests federal and state legislation should be passed to ensure that
1823 consent forms are given to patients receiving amalgam restorations.¹⁶⁷

1824 The standard of information disclosure for health care practitioners in
1825 Canada was established in *Reibl v. Hughes* in what is now known as the
1826 “modified objective test.”²⁰⁴ Essentially this means that a health professional
1827 can neither rely on the common practice within the profession as it pertains
1828 to information disclosure (i.e. ‘the professional practice standard’), nor can
1829 they rely on a standard that divulges as much information as a hypothetical
1830 ‘reasonable person’ would expect to receive (i.e. ‘the reasonable person
1831 standard’). Instead *Reibl v Hughes* established that the health professional
1832 must disclose as much information as a reasonable person in the patient’s
1833 situation would need in order to make an informed decision (‘the modified
1834 objective test’). This standard puts the onus on the health professional to
1835 know something of the individual patient’s current circumstances in
1836 discussing various health options so as to tailor the information accordingly.
1837 With the expansion of genetic testing and the advent of “personalized
1838 medicine,” this could have implications for informed consent for dental
1839 services. That is, if genetic research identifies certain genetic profiles that
1840 predispose some patients to a higher sensitivity to mercury amalgams, for
1841 example, or that establish a connection between certain genetic profiles,

1842 mercury exposure, and the development of some chronic illnesses,^{205,206} it
1843 may be incumbent on dental professionals to inform patients of such
1844 potential risks and/or recommend genetic testing for those with a family
1845 history that includes certain chronic conditions.

1846 Herein lies the conundrum with regard to informed consent for dental
1847 consumers. Given dentistry's ambiguous role as either health care
1848 profession or commercial enterprise, and given the ongoing concerns
1849 expressed within dentistry and within the scientific community about the
1850 long-term safety of amalgam, it is unlikely that there will be wide agreement
1851 any time soon on either standards of information disclosure, or on what
1852 constitutes fully informed consent for patients/consumers with regard to
1853 restorative materials. The following representative sample of statements
1854 summarizes the tension nicely: "As of now, there is no credible, valid
1855 scientific evidence that dental amalgam harms humans other than those
1856 who might be allergic to its contents. To suggest otherwise is not true and,
1857 therefore, unethical."¹⁷¹ Alternatively, "In the past 10 years research has
1858 shown that the amount of mercury released is more than previously
1859 believed, and that amalgams contribute to a person's overall exposure to
1860 mercury."¹⁷⁷ Finally, "Although the issue of amalgam safety is still under
1861 debate, the preponderance of evidence suggests that Hg [i.e., mercury]
1862 exposure from dental amalgams may cause or contribute to many chronic
1863 conditions."²⁰⁷

1864 Another micro level issue closely related to the matter of informed consent,
1865 concerns the question of conscientious refusal on the part of dentists with
1866 regard to complying with patient's requests. Here again the matter of
1867 professional role versus business relationship affects when and how this
1868 right (or responsibility) on the part of the dentist is interpreted and exercised.
1869 Professional codes generally advise dentists that the best interests of the
1870 patient are paramount and that they are not obligated to do anything they
1871 believe is not in the best interests of their patients, even if the patient
1872 insists.¹⁶⁹ This ostensibly was the underlying rationale for the resistance to
1873 patient autonomy noted earlier in this discussion, and serves as well as the
1874 justification for the ADA and CDA policies that prohibit dentists from
1875 removing and replacing amalgams out of perceived safety concerns on the
1876 part of patients. Assuming that the majority of dentists do have the best
1877 interests of their patients in mind, the conscientious refusal to do something
1878 they believe is a potential harm to their patient is understandable and
1879 morally defensible. However, this is true of dentists on either side of the
1880 amalgam debate, and as such, any censuring of 'green dentists' could be,
1881 morally problematic.

1882 Finally the matter of stigmatisation as it relates to patients who believe their
1883 chronic health problems could be related to amalgam fillings is another
1884 micro level concern [See Patient Experiences and Perspectives]. Patients
1885 with otherwise unexplainable symptoms such as chronic fatigue or
1886 fibromyalgia are often labelled as hypochondriacs, as suffering from mental
1887 illness, and so forth.²⁰⁸⁻²¹³ It has been suggested that closer collaboration
1888 between physicians and dental professionals might lead to greater insights
1889 on a variety of intractable health issues.⁹⁴ All patients deserve to be treated
1890 with respect, irrespective of the opinions of individual practitioners. At the
1891 very least, given the intractable differences of opinion on amalgam safety
1892 and its potential concomitant health effects, pro-amalgam dentists might be

1893 advised to refer recalcitrant patients to so-called 'green dentists' if they
1894 themselves feel uncomfortable with those discussions.

1895 **Summary of Results**

1896

Macro Level

Environmental Concerns Despite disagreement regarding the issue of amalgam toxicity and patient safety, there is a broad consensus about the need to reduce the environmental impact of mercury from all sources, including dental amalgam. Canada's decision to be a signatory to the UNEP Minamata Convention is an appropriate macro-level policy response in this regard.

As a sequela to the Minamata Convention it is incumbent on the federal government to ensure that all dental practices comply with directives regarding the handling and disposal of amalgam waste. This could be particularly important with regard to vulnerable populations in Canada's north.

Public Funding of Dental Care The choice of restorative materials is affected by the manner in which dental services are funded. Although the amount of publicly funded dental care in Canada is relatively small, it affects the most vulnerable populations. Funding policies should neither unfairly restrict access to particular dental services nor affect individual patient choices with regard to restorative materials whether for environmental, aesthetic, safety, or other reasons.

Public Health Education/Information The public should be properly educated about the environmental impacts of mercury from all sources, including the impact of dental amalgam waste. Up to date and accurate reporting on any safety related issues is also necessary.

In keeping with the Minamata Convention, the federal government should promote "cost-effective and clinically effective mercury-free alternatives . . ."

Federal funding of research The Minamata Convention promotes research and development of quality mercury-free alternatives for dental restoration. Canada's major research funding agencies might earmark funds for ongoing research on alternative materials and on related health risks and concerns from all materials.

Meso Level

Role ambiguity of dental professionals The ambiguous nature of the primary role of the dental profession affects the nature of the professions' relationship with the consuming public, and the role of regulators vis-à-vis the dental profession (i.e. health promotion vs consumer protection). Such ambiguity has implications for other meso and micro level issues including professional responsibility, patient vulnerability, and consumer choice.

Financial conflicts of interest Financial incentives may affect the choices of individual dentists with regard to the recommendation/use of restorative materials. Patients/consumers may be vulnerable in this regard, and deserve protection through appropriate government bodies. [See Macro Level Issues]

Clear Communication Use of the term 'silver amalgam' is inappropriate when the primary material in dental amalgam is mercury

Micro Level

Informed Consent The standard of information disclosure necessary to fulfill an ethical obligation to respect an autonomous right to make an informed choice differs between business and health care environments. Hence, the appropriate standard is related to the relationship between dental professionals and the public. [See Meso Level Issues]

Conscientious refusal Any dental professional (irrespective of view on amalgam safety) has the right to refuse to provide a service s/he genuinely believes to be a potential harm to the patient/consumer.

Stigmatization of Patients Patients/consumers who explore the possible connection between amalgam and chronic health care conditions should be treated with respect and not stigmatized as malingerers, as mentally challenged, or otherwise maligned.

1897
1898

1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948

Discussion

Summary of overall findings

The clinical review of efficacy was addressed by updating a 2014 Cochrane SR that meta-analyzed data from two parallel-group RCTs describing 3,010 teeth in children ranging in age from six to 12 years at baseline.⁶ Authors of the Cochrane SR found a statistically significantly higher risk of restoration failure in composite resin versus amalgam restorations (RR 1.89, 95% CI 1.52 to 2.35, $P < 0.001$). Our 2017 update identified one eligible split-mouth RCT published in 2016 which analyzed restoration performance in 40 teeth.³³ Due to heterogeneity, these findings could not be pooled with data from the 2014 Cochrane SR. Authors of the 2016 RCT found zero events of restoration failure in both treatment arms, concluding that amalgam and composite resin restorations are both clinically acceptable.³³ Nonetheless, due to small sample size and methodological limitations of the study identified in the update, the conclusions of the 2014 SR remain current.

Our *de novo* systematic review of the comparative safety of dental amalgam versus composite resin restorations identified ten eligible reports representing three unique RCTs. Statistically significant differences in urinary mercury excretion were reported in two trials through to five and six years of follow up, respectively; though, levels in the amalgam groups did not exceed those considered to be toxic (i.e., 7 µg Hg/L.⁹). Notably, urinary mercury levels were measured to seven years of follow-up in one of these two trials, and were no longer found to differ significantly between treatment groups ($P = 0.07$).⁴¹ Some statistically significant differences were observed between amalgam and composite resin groups using certain measures of renal, neuropsychological and psychosocial function, physical development and post-operative sensitivity; however, the observed effects were inconsistent across outcomes, measures and/or time, favouring one or the other group either variably and/or inconsistently — suggesting the findings could have resulted from either a causal association or chance. Finally, no statistically significant differences between treatment groups were observed in evaluations of neurological symptoms, immune function, and urinary porphyrin excretion.

A cost-consequence model found that the useful time of a two- to three-surface posterior amalgam restoration exceeded that of a composite resin restoration. Likewise, the average Canadian cost and lifetime discounted costs for amalgam restorations were estimated to be lower than those for composite resin restorations. And while the use of amalgam incurs additional costs to dental clinics by way of the need for amalgam separators to manage waste, the time associated with the clinical placement of composite resin restorations is greater and likewise incurs additional costs.

The review of patient experiences was designed to integrate the experiences of patients with amalgam and/or composite resin restorations. However, a paucity of qualitative research in this area resulted in the identification of four studies (reported in five papers) — none of which described any experiences with composite resin restorations. All included studies focused on patients with amalgam restorations and their experiences of perceived adverse reactions. Thematic analyses highlighted the patients' struggle to be understood and believed as they searched for a cause of their sense of ill health. Following from this, the experience of deamalgamation

1949 and detox was described as a difficult one that may not provide immediate
1950 health gain, but provided some relief from the worry of a potential toxic
1951 influence on health.

1952 The implementation review found that there are factors that influence the
1953 use of one type of restorative dental material over another. For instance, in
1954 Canada, there is no explicit policy in any jurisdiction that dictates the use of
1955 dental amalgam or resin composites. Notably, the majority of dentists in
1956 Canada are in private practice where factors such as margin of profit and
1957 efficiency of practice are additional considerations and can affect the
1958 decision making process for restorations. Nonetheless, dentistry education
1959 in universities does not appear to focus on one restoration over another, but
1960 dentists may choose to use materials that they are more comfortable with,
1961 that are newer and “more sophisticated”, or that their supervising dentist
1962 primarily used. Importantly, geographic location (e.g., the north of Canada)
1963 can be a factor, and often limits available materials. Finally, patient profile
1964 and clinical indications are of importance to dentists when deciding on which
1965 restoration to use, as amalgam and resin composites have different
1966 mechanical properties that may be contra-indicated in some patients.
1967 Further, there is a large socio-cultural and patient pressure to provide
1968 restorations that maintain a “straight, white” appearance of teeth for the
1969 patient, regardless of other factors.

1970 The environmental impact review found that the risks associated with dental
1971 restorative materials are better described for amalgam as opposed to
1972 composite resin. For amalgam, the presence of mercury has been of concern
1973 for decades. While mercury has been established as a chemical that is
1974 persistent, bioaccumulative, and toxic, the relative small contribution of
1975 mercury into the Canadian ecosystem from use in dentistry as well as the
1976 over-time declines in its use suggest that the potential impacts on the
1977 environment are much less than from other sources. There is increasing use
1978 of composite materials as dental fillings, though relatively little is known
1979 about most of these chemicals, and in particular their fate in the environment
1980 and downstream impacts on the ecosystem. Most attention and information
1981 is on bisphenol-A, and while this chemical has been shown to contaminate
1982 ecosystems and disrupt fish and wildlife health, linking potential impacts
1983 back to the Canadian dental sector is not possible with the current state of
1984 knowledge.

1985 **Interpretation**

1986 The highest-quality clinical evidence to-date has consistently shown dental
1987 amalgam to be superior to composite resin in terms of efficacy, durability
1988 and risk of secondary caries.⁶

1989 Further, the most rigorous comparative evidence available indicates that
1990 the safety of amalgam and composite resin restorations is comparable with
1991 regard to a variety of health outcomes. Our findings corroborate those that
1992 have informed the current perspective on dental amalgam use in Canada by
1993 Health Canada¹⁰ and the Canadian Dental Association.²¹⁴ In fact, while
1994 much of the evidence addressing safety showed no, or very little, difference
1995 between amalgam and composite resin groups, most of that which indicated
1996 any one statistically significant finding using a particular outcome measure
1997 favoured one or the other group variably, resulting in no discernible effect
1998 pattern.

1999 Likewise, the cost-consequence analysis using time-to-failure favoured
2000 amalgam over composite resin as a dental restorative material, based on
2001 estimates of lifetime discounted Canadian cost — findings that corroborate
2002 those generated by a similar study in the UK.⁸³ While the cost of amalgam
2003 separators adds to the cost of providing amalgam restorations, the
2004 increased time associated with placing composite resin restorations⁸⁵ also
2005 introduces increased cost to dental clinics and their practitioners. As the
2006 review of implementation issues has shown, these latter cost considerations
2007 may impact the decision making process for choice of restorative material —
2008 particularly for dental professionals, as no explicit policy currently dictates
2009 their use of amalgam or composite resin material.

2010 Given these evidentiary considerations presented within the current HTA,
2011 the controversy described herein by the ELSI review may at first appear
2012 puzzling. Nonetheless, as that review has illustrated, values — and the
2013 macro, meso and micro level considerations that underlie them — are
2014 informed by facts, but they are also subject to pressure from political,
2015 cultural and other social forces.¹⁴⁸⁻¹⁵⁰ In the case of dental amalgam, the
2016 considerable bodies of literature — and rhetoric^{215,216} — that have been
2017 generated on both sides of the debate present a distinct challenge to the
2018 establishment of a truly objective safety profile for dental amalgam. In
2019 addition, the relative lack of scientific evidence addressing the potential toxic
2020 and environmental harms that composite resin may introduce — given its
2021 bisphenol-A content, for instance — support the assertion that factors
2022 additional to scientific evidence play an important role in the questions
2023 surrounding the use of dental materials.

2024 Considering the particularly contentious macro- and meso-level challenges
2025 described, it may be that the micro-level clinical interface of dental care
2026 provider and patient is where conversations about the benefits and potential
2027 harms of various dental materials are best to occur. Particularly as patient
2028 profiles and clinical indications are of particular importance to providers,
2029 alongside the significant socio-cultural pressures to maintain a “straight,
2030 white” appearance of teeth for the patient, regardless of other factors. And
2031 while the available qualitative evidence informing the patient experiences
2032 review was limited to those few patients who complain of illness that they
2033 perceive was caused by dental amalgam restorations, it remains incumbent
2034 upon care providers to listen and hear the concerns of all patients, and to
2035 transparently provide the best available information to make informed — and
2036 shared, if the patient so desires — decisions as to the optimal dental
2037 material for a given situation.²¹⁷

2038 Undoubtedly, this ideal of a shared, clinical decision making encounter within
2039 which to address the best use of dental restorative materials, is challenged
2040 in the face questions that persist about the safety of dental restoration
2041 materials. This may be exacerbated by the private practice model under
2042 which the majority of dentistry operates in Canada, and the various issues
2043 identified within our implementation and ELSI reviews that arise within this
2044 context.

2045 Even so, the “changing dynamic” in Canada — as described within our
2046 review of implementation issues — may render dental amalgam less of an
2047 option in the future. And this will likely be supported by Canada’s recent
2048 ratification of the Minamata Convention.¹⁷ While it remains undisputed that
2049 mercury is a chemical that is persistent, bioaccumulative, and toxic, the

2050 small contribution from Canadian dentistry suggests that the potential
2051 impacts on the environment are much less than from other sources. Despite
2052 this, the global political impetus and associated activities intended to phase-
2053 down and -out mercury are likely to have important influences on the
2054 practice of dentistry and its use of amalgam as a restorative material in the
2055 future.²¹⁸

2056 **Strengths**

2057 The clinical reviews of efficacy and safety limited eligibility criteria to studies
2058 comparing dental amalgam with composite resin, so as to maximize the
2059 scientific rigour underpinning our findings. For the SR update of efficacy, the
2060 2014 Cochrane SR was deemed to be of high quality using AMSTAR; and
2061 Cochrane SRs are considered the 'gold standard' in systematic
2062 reviews.^{219,220} The update to this review aimed to reproduce the methods
2063 applied to the efficacy outcome from the original review,⁶ and were likewise
2064 rigorous in their search and synthesis of the best available evidence.
2065 Because the authors of the Cochrane SR acknowledged their limited review
2066 of adverse effects – particularly citing the need to include observational
2067 studies – the review of safety for this HTA included a broad and
2068 comprehensive search strategy. Study eligibility was not limited to trial
2069 evidence and considered a broad range of study designs, provided they
2070 reported on evidence of a direct comparison between dental amalgam and
2071 composite resin restorations. The majority of patients described in the
2072 studies eligible for our analysis of safety were children, where arguably any
2073 effect from either dental amalgam or composite resin restorations may be
2074 more readily manifest as they developed. The review methods were
2075 conducted and reported in consideration of PRISMA²²¹ and PRISMA-
2076 Harms.¹ Findings from both reviews are based on the results reported from
2077 studies with a minimum of three years of follow up.

2078 Broad literature searches and eligibility criteria were used to inform the
2079 economic evaluation, PPE, environmental, implementation and ELSI
2080 reviews. The economic evaluation contributes a novel cost consequence
2081 model to the Canadian context. The PPE section sought qualitative studies
2082 in order to inform an in-depth analysis of patients' experiences with
2083 amalgam and composite resin restorations. The implementation review
2084 collected information from a variety of sources to identify the most salient
2085 barriers and facilitators to the implementation of these interventions in the
2086 Canadian context. The environmental review likewise sought a broad base
2087 of literature and offers Canadian decision makers a novel assessment of the
2088 contributions of the Canadian dental profession to the burden of mercury
2089 contamination – particularly as the Minamata Convention has recently been
2090 ratified and its implications are considered. And finally, the ELSI review
2091 similarly used broad selection criteria to include a wide range of literature on
2092 the issues under investigation. It thus provides a broad historical overview of
2093 the longstanding controversy regarding amalgam safety including reference
2094 to the literature on both sides of the debate (See Appendix 19).

2095 **Limitations**

2096 Despite a comprehensive search, available clinical evidence describing
2097 direct comparisons of amalgam and composite resin restorations was
2098 limited, rendering few eligible studies for our clinical review. Thus, while the
2099 decision to focus on comparative studies provided the most compelling

2100 evidence describing the relative safety of amalgam versus composite resin
2101 restorations, it also resulted in the exclusion of peripherally relevant studies
2102 examining the safety of these materials in isolation (e.g., dose response
2103 studies); though, these would have provided limited insight into the
2104 comparative safety of amalgam and composite resin.

2105 All studies included in the clinical review exhibited some risk of bias –
2106 always due to the inability of investigators to blind patients and research
2107 personnel, and often due to poorly reported methods and findings in other
2108 domains of the Cochrane Risk of Bias tool. Further, assessment of causality
2109 has been identified as an important part of conducting and reporting studies
2110 of safety and/or harms.¹ In our review of safety, we found that, while none of
2111 the 10 reports from the three included studies described an assessment of
2112 causation, one report from the NECAT³⁵ and one from the Casa Pia study³⁸
2113 made reference to causation, stating that the randomized design allowed for
2114 causal inference of psychosocial outcomes³⁵ and renal function,³⁸
2115 respectively. Another report generated from the NECAT study³⁷ explicitly
2116 stated that amalgam was found to not be a cause of immune deficiency, but
2117 likewise failed to describe any formal or other assessment of causality. And
2118 lastly, another report from the NECAT³⁹ briefly mentioned a possible causal
2119 association between amalgam exposure and microalbuminuria in their
2120 discussion, but again did not describe a formal assessment of causality, and
2121 offers another explanation i.e., that their finding may be due to chance. The
2122 remaining papers included in our review of safety make no explicit mention
2123 of causation.^{34-36,40,41}

2124 Most findings from both reviews were reported in children, allowing for
2125 limited generalizability to the wider population. Studies included in both the
2126 Cochrane SR's analysis of efficacy and our review of safety (i.e., NECAT
2127 and Casa Pia) were initiated in the late 1990's, possibly rendering the
2128 composite resin materials used at that time obsolete compared with those in
2129 use today. Extending from this, the integration of studies across time may be
2130 misleading due to advances in dental techniques, tools and materials.
2131 Studies included in both of the reviews did not explicitly or consistently
2132 report data on restoration size, which limited the interpretation of the findings
2133 in terms of this variable. Studies were sufficiently heterogeneous in their
2134 methods and measures, as well as deemed to be at a high or unclear risk of
2135 bias for multiple domains of the Cochrane RoB tool, such that meta-
2136 analyses could not be undertaken. The length of follow up in all included
2137 studies may have been insufficient to adequately evaluate the outcomes
2138 under investigation. Finally, authors of included studies were not contacted
2139 for additional information and/or where clarity was needed.

2140 As with all economic analyses, the results were limited by both the quality
2141 and quantity of data available to inform model inputs. We were faced with a
2142 significant lack of data for this analysis and this represents a major limitation.
2143 We did not have access to patient-level data from the NECAT study, and
2144 thus were limited to the published evidence from that study. This forced us
2145 to digitalize the published survival curves and hence might have increased
2146 uncertainty. Furthermore, it limited our possibilities in terms of modeling
2147 (e.g., failure rate according to type of tooth or number of surfaces restored,
2148 etc). We were not able to find enough information on the natural history
2149 following a failed tooth restoration and had to make assumptions that
2150 significantly limit the face validity of the results. Although our set of dental
2151 fees from the public programs is almost complete, the one for privately

2152 funded services was limited; in particular we were not able to obtain
2153 suggested fees from the two largest provinces (i.e., Ontario and Quebec).
2154 Furthermore, we were not able to find a good source of information on the
2155 procedure time for composite resin restorations and had to base the analysis
2156 on feedback from the clinical experts consulted in this review. Despite these
2157 limitations, this analysis represents a first estimation, using the best
2158 evidence available, of the costs and consequences of using amalgam and
2159 composite resin for restoration of permanent posterior teeth and the findings
2160 overall remained robust to most sensitivity analyses.

2161 Although the research question for the patient experiences review sought
2162 experiences related to both amalgam and composite resin, the limited
2163 eligible qualitative evidence described only negative experiences with
2164 amalgam, indicating that some patients have perceived illness from
2165 amalgam fillings. Importantly, quantitative studies in this area have
2166 suggested that patients with these experiences represent a very small
2167 minority^{222,223} and often have additional health concerns as compared to
2168 those within the general population – even following the removal of amalgam
2169 fillings.^{224,225} This highlights an additional limitation i.e., the cause of
2170 ailments in patients informing the findings of the studies included in our
2171 review were unknown; thus, the appropriateness of a diagnosis of mercury
2172 poisoning cannot be ascertained. We therefore do not know if the chosen
2173 strategy of amalgam replacement would have any effect on the patients'
2174 health. Further, we are missing the experiences of children, adolescents and
2175 the elderly – and importantly for this HTA, the experiences of Canadian
2176 dental patients. This may be a particularly important limitation, as removal of
2177 amalgam fillings and detoxification are not recommended by the Canadian
2178 Dental Association and so, the findings of the studies included in this section
2179 of the HTA may lack any transferability to the Canadian context. In addition,
2180 there are other outcomes that speak to the experiences of patients with
2181 dental restorations – such as deterioration of the restoration and length of
2182 time to repair or new restorations are needed, or length of time to the loss of
2183 the tooth. Finally, the patient preference for "white fillings" identified in the
2184 review of implementation issues was not addressed by any of the studies
2185 identified by the patient experiences review, suggesting an important gap in
2186 the qualitative evidence base addressing patient experiences with these
2187 dental materials.

2188 For the implementation issues literature review, Canadian studies only were
2189 searched for and included. Because of this restriction, studies that may be
2190 relevant to the Canadian context but were not authored in Canada were
2191 therefore missing from the analysis. Additionally, only one reviewer
2192 extracted, and analyzed the data from the literature. One of the limitations of
2193 having a single reviewer is that there is no opportunity for discussion of
2194 literature, or potential for challenges to the initial analyses. Over half of the
2195 relevant literature articles were greater than five years old and mostly
2196 focused on patient factors and the education of providers. Additionally,
2197 although all of the studies had information on the Canadian context, 6 of the
2198 studies were specifically Canadian only. In the consultations, some of the
2199 limitations were the small stakeholder sample size, which was not randomly-
2200 recruited, and the lack of representation from private practitioners or
2201 patients.

2202 The greatest limitation of the environmental impact review was similarly a
2203 dearth of available, relevant information. While for estimates concerning

2204 mercury use and release from amalgams there are several studies to draw
2205 from, in many cases the estimates are outdated, may not accurately reflect
2206 the current situation, and are likely over-estimates given the continuing
2207 decreasing trend towards the use of amalgam. For composite resins there
2208 are no strong or relevant data sets available, and thus it is not possible to
2209 perform any meaningful calculations to characterize the environmental
2210 source, fate, exposure, and hazard associated with these materials.

2211 **Directions for Future Research**

2212 Given the limitations and risk of bias in much of the body of evidence
2213 addressing potential toxicity from amalgam and/or composite resin
2214 restorations, there remains a need for methodologically rigorous studies that
2215 focus on broader populations and pursue longer-term follow-up than those
2216 included in our clinical review of the evidence. For instance, considering the
2217 finding from the Casa Pia trial that no statistically significant difference was
2218 found in urinary mercury levels at seven years follow-up (while a significant
2219 group difference was found at all other time points), a longer term of follow-
2220 up may be able to illuminate any potential reduction (or not) in exposure
2221 over time. In addition, given the concerns identified around genetic
2222 susceptibility to materials used in dental restorations — either amalgam or
2223 composite resin²²⁶⁻²²⁸ — rigorous, comparative and controlled clinical
2224 research in this area may be further warranted.

2225 Likewise, the current economic analysis highlights the need for better quality
2226 evidence. As dental claims to both private insurance and public programs in
2227 Canada require reporting at the patient's tooth level (e.g., tooth number,
2228 surface repaired, time since last restoration), these programs represent an
2229 untapped source of evidence. These databases could be used to perform
2230 comparative effectiveness studies (e.g., amalgam versus composite resin
2231 restorations, comparison of different clinical pathways), and epidemiological
2232 studies (e.g., natural history of tooth restorations, prevalence studies, etc)
2233 that can help better support the modelling of long-term outcomes. As dental
2234 fee codes are the same throughout Canada, except for one province, it
2235 might also be possible to combine these databases of patient-level data all
2236 into a single Canadian database for broad Canadian population analyses.
2237 Such analyses would provide up-to-date evidence, albeit observational, in a
2238 real-life setting that could inform dental health policy-making.

2239 Given the significant gaps in the qualitative evidence base, the experiences
2240 of patients with composite resins — as well as those with amalgam
2241 restorations who are not selected based on their complaints associated with
2242 said-restorations — will be important; as will be an increase of the age range
2243 of participants to provide the perspectives of children, adolescents and the
2244 elderly. Future research efforts might also focus on the barriers and
2245 facilitators of implementing both restorative materials in private practice.
2246 Additionally, areas of the INTEGRATE-HTA framework which were not well
2247 represented by the literature or consultations in this report could also be
2248 explored in the future.

2249 Concerning the impact of dental materials on the environment, it would be
2250 useful to better characterize the contemporary use of mercury within the
2251 dental sector so that relevant estimates of environmental risk may be
2252 generated. This would also aid in Canada's commitment towards the
2253 Minamata Convention. Concerning composite resins, there is a significant

2254 need for detailed research on the matter covering all aspects of their
2255 potential environmental risk across the entire life cycle. There is also a need
2256 to understand the use practices of various composite materials across the
2257 Canadian dental sector. Following use within the clinic, there is likewise a
2258 need to understand their potential releases of materials (and chemicals)
2259 across their entire life cycle into ecosystems and ultimately their fate and
2260 behavior in various media. Next, there is a need to better understand
2261 potential exposure by biota to various materials (and chemicals) and whether
2262 such exposures are associated with adverse health outcomes.

2263 Given the Minamata Convention's call to phase down the use of amalgam in
2264 dentistry — as well as uncertainties around the effects of bisphenol-A in
2265 composite resin — future research may better be focused on innovation and
2266 the development of dental materials that can demonstrably offer improved
2267 efficacy and safety over those currently used in contemporary dentistry.²²⁹

2268 Conclusions

2269 The use of dental amalgam has been a source of debate for over a century.
2270 With the advent of newer dental materials — including composite resin —
2271 and growing concern globally over the environmental effects of mercury in
2272 general (including from dentistry), there is increasing pressure to reduce the
2273 use of amalgam for dental restorations. This shift is arguably manifested
2274 most notably in the United Nations' Minamata Convention on Mercury,¹⁵ that
2275 aims to protect human health from the toxic effects of mercury by phasing-
2276 down (and in some cases, -out) its use in a variety of industries and settings
2277 — including dentistry.

2278 Given the findings of this HTA that describe both advantages and
2279 disadvantages of amalgam dental restorations compared with those made
2280 from composite resin — as well as uncertainty associated with a dearth of
2281 robust evidence in this area — the question as to whether amalgam should
2282 continue to be used in Canada may best be considered within the current
2283 global context.

2284

2285

References

- 2286
2287
1. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. *BMJ*. 2016 Feb 1;352:i157.
- 2288
2. Oral health. Geneva: World Health Organization; 2012 Apr. (Fact sheet; no. 318).
- 2289
2290
3. Frazao P. Epidemiology of dental caries: when structure and context matter. *Braz Oral Res*. 2012;26 Suppl 1:108-14.
- 2291
2292
2293
4. Summary report on the findings of the oral health component of the Canadian Health Measures Survey: 2007-2009 [Internet]. Ottawa: Health Canada; 2010. [cited 2017 Mar 8]. Available from: <http://publications.gc.ca/pub?id=9.693377&sl=0>
- 2294
2295
5. Hurst D. Amalgam or composite fillings--which material lasts longer? *J Evid Based Dent Pract*. 2014 Jun;15(2):50-1.
- 2296
2297
2298
6. Rasines Alcaraz MG, Veitz-Keenan A, Sahrman P, Schmidlin PR, Davis D, Ihezor-Ejiofor Z. Direct composite resin fillings versus amalgam fillings for permanent or adult posterior teeth. *Cochrane Database Syst Rev*. 2014 Mar 31;(3):CD005620.
- 2299
2300
7. Dhar V, Hsu KL, Coll JA, Ginsberg E, Ball BM, Chhibber S, et al. Evidence-based update of pediatric dental restorative procedures: dental materials. *J Clin Pediatr Dent*. 2015;39(4):303-10.
- 2301
2302
2303
8. Bharti R, Wadhvani KK, Tikku AP, Chandra A. Dental amalgam: an update. *J Conserv Dent [Internet]*. 2010 Oct [cited 2017 Feb 10];13(4):204-8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010024/>
- 2304
2305
2306
9. Nicolae A, Ames H, Quinonez C. Dental amalgam and urinary mercury concentrations: a descriptive study. *BMC Oral Health [Internet]*. 2013 Sep 9 [cited 2018 Jan 15];13:44. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847647>
- 2307
2308
10. The safety of dental amalgam [Internet]. Ottawa: Health Canada; 1996. [cited 2018 Jan 5]. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/md-im/dent_amalgam-eng.pdf
- 2309
2310
2311
2312
11. Scientific Committee on Emerging and Newly Identified Health Risks. The safety of dental amalgam and alternative dental restoration materials for patients and users [Internet]. Luxembourg (LX): European Commission; 2015. [cited 2017 Mar 8]. Available from: https://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_046.pdf
- 2313
12. Hiltz M. The environmental impact of dentistry. *J Can Dent Assoc*. 2007 Feb;73(1):59-62.
- 2314
2315
13. Canadian mercury science assessment: report [Internet]. Ottawa: Government of Canada Publications; 2016. [cited 2017 Sep 8]. Available from: <http://publications.gc.ca/site/eng/9.810484/publication.html>
- 2316
2317
2318
14. Performance report: pollution prevention notice for dental amalgam waste [Internet]. Ottawa: Environment and Climate Change Canada; 2015. [cited 2017 Dec 15]. Available from: <http://ec.gc.ca/Publications/default.asp?lang=En&xml=2112BA70-28A9-4F01-9187-9D62BA327868>
- 2319
2320
2321
2322
15. Minamata Convention on Mercury: text and annexes [Internet]. Nairobi (Kenya): United Nations Environment Programme; 2013. [cited 2017 Mar 8]. Available from: http://www.mercuryconvention.org/Portals/11/documents/Booklets/Minamata%20Convention%20on%20Mercury_booklet_English.pdf
- 2323
2324
16. Minamata Convention on Mercury [Internet]. Ottawa: Environment and Climate Change Canada; 2016. [cited 2017 Mar 8]. Available from: <https://www.ec.gc.ca/international/default.asp?lang=En&n=5C03713D-1>
- 2325
2326
17. News release, the Government of Canada ratifies the Minamata Convention on Mercury [Internet]. Ottawa: Government of Canada; 2017 Apr 7. [cited 2017 May 4]. Available from:

- 2327 https://www.canada.ca/en/environment-climate-change/news/2017/04/the_government_ofcanadaratifiestheminamataconventiononmercury.html
2328
- 2329 18. News release, the 50-ratification milestone required for the Minamata Convention on Mercury to enter into
2330 force was reached on 18 May 2017! [Internet]. Geneva: UN Environment; 2017. [cited 2017 Jun 5]. Available
2331 from:
2332 [http://mercuryconvention.org/News/50ratificationmilestonereachedon18May2017/tabid/5938/language/en-](http://mercuryconvention.org/News/50ratificationmilestonereachedon18May2017/tabid/5938/language/en-US/Default.aspx)
2333 [US/Default.aspx](http://mercuryconvention.org/News/50ratificationmilestonereachedon18May2017/tabid/5938/language/en-US/Default.aspx)
- 2334 19. Minamata convention on Mercury. Countries: list of signatories and future parties [Internet]. Geneva: UN
2335 Environment; 2017. [cited 2017 Jun 1]. Available from:
2336 <http://mercuryconvention.org/Countries/tabid/3428/language/en-US/Default.aspx>
- 2337 20. Attin T, Hannig C, Wiegand A, Attin R. Effect of bleaching on restorative materials and restorations--a
2338 systematic review. *Dent Mater.* 2004 Nov;20(9):852-61.
- 2339 21. Hickel R, Manhart J. Longevity of restorations in posterior teeth and reasons for failure. *J Adhes Dent.*
2340 2001;3(1):45-64.
- 2341 22. Sadowsky SJ. An overview of treatment considerations for esthetic restorations: a review of the literature. *J*
2342 *Prosthet Dent.* 2006 Dec;96(6):433-42.
- 2343 23. Composite resin and amalgam dental filling materials: a review of safety, clinical effectiveness and cost-
2344 effectiveness [Internet]. Ottawa: CADTH; 2012 Jun 22. [cited 2017 Mar 8]. (Rapid response report: summary
2345 with critical appraisal). Available from: [https://www.cadth.ca/sites/default/files/pdf/htis/june-](https://www.cadth.ca/sites/default/files/pdf/htis/june-2012/RC0358%20Dental%20amalgam%20Final.pdf)
2346 [2012/RC0358%20Dental%20amalgam%20Final.pdf](https://www.cadth.ca/sites/default/files/pdf/htis/june-2012/RC0358%20Dental%20amalgam%20Final.pdf)
- 2347 24. Dursun E, Fron-Chabouis H, Attal JP, Raskin A. Bisphenol A release: survey of the composition of dental
2348 composite resins. *Open Dent J* [Internet]. 2016 [cited 2017 Jun 26];10:446-53. Available from:
2349 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039892>
- 2350 25. Joint FAO/WHO expert meeting to review toxicological and health aspects of bisphenol A: final report,
2351 including report of stakeholder meeting on bisphenol A, 1-5 November 2010, Ottawa, Canada [Internet].
2352 Geneva: World Health Organization; 2011. [cited 2018 Jan 15]. Available from:
2353 http://apps.who.int/iris/bitstream/10665/44624/1/97892141564274_eng.pdf
- 2354 26. Scientific opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs:
2355 executive summary. *EFSA Journal.* 2015 Mar 25;13(1):3978.
- 2356 27. Composite resin versus amalgam for dental restorations: a health technology assessment — project
2357 protocol [Internet]. Ottawa: CADTH; 17 A.D. Aug. (CADTH health technology assessment). [cited 2018 Jan
2358 15]. Available from: <https://www.cadth.ca/sites/default/files/pdf/HT0021-Dental-Amalgam-Protocol.pdf>
- 2359 28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for
2360 reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:
2361 explanation and elaboration. *BMJ* [Internet]. 2009 Jul 21 [cited 2017 Jul 5];339:b2700. Available from:
2362 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714672>
- 2363 29. Demarco FF, Correa MB, Cenci MS, Moraes RR, Opdam NJ. Longevity of posterior composite restorations:
2364 not only a matter of materials. *Dent Mater.* 2012 Jan;28(1):87-101.
- 2365 30. DistillerSR [Internet]. Ottawa: Evidence Partners; 2017. [cited 2017 May 9]. Available from:
2366 <https://www.evidencepartners.com/products/distillersr-systematic-review-software/>
- 2367 31. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics.* 1977
2368 Mar;33(1):159-74.
- 2369 32. Higgins JPT, Altman DG, Sterne AC, editors. Chapter 8: assessing risk of bias in included studies. In:
2370 *Cochrane handbook for systematic reviews of interventions* [Internet]. Version 5.1.0. Oxford (GB): The

- 2371
2372
- Cochrane Collaboration; 2011 [cited 2017 Jul 5]. Available from: http://handbook-5-1.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm
- 2373
2374
2375
33. Kemaloglu H, Pamir T, Tezel H. A 3-year randomized clinical trial evaluating two different bonded posterior restorations: amalgam versus resin composite. *Eur J Dent* [Internet]. 2016 Jan [cited 2017 Oct 11];10(1):16-22. Available from: http://www.eurjdent.com/temp/EurJDent10116-418122_113652.pdf
- 2376
2377
2378
2379
34. Maserejian NN, Hauser R, Tavares M, Trachtenberg FL, Shrader P, McKinlay S. Dental composites and amalgam and physical development in children. *J Dent Res* [Internet]. 2012 Nov [cited 2017 Jul 20];91(11):1019-25. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470777/pdf/nihms401265.pdf>
- 2380
2381
2382
2383
35. Bellinger DC, Trachtenberg F, Zhang A, Tavares M, Daniel D, McKinlay S. Dental amalgam and psychosocial status: the New England Children's Amalgam Trial. *J Dent Res* [Internet]. 2008 May [cited 2017 Dec 1];87(5):470-4. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741096/pdf/nihms-65910.pdf>
- 2384
2385
2386
36. Woods JS, Martin MD, Leroux BG, DeRouen TA, Bernardo MF, Luis HS, et al. Urinary porphyrin excretion in children with mercury amalgam treatment: findings from the Casa Pia Children's Dental Amalgam Trial. *J Toxicol Environ Health A*. 2009;72(14):891-6.
- 2387
2388
2389
37. Shenker BJ, Maserejian NN, Zhang A, McKinlay S. Immune function effects of dental amalgam in children: a randomized clinical trial. *J Am Dent Assoc* [Internet]. 2008 Nov [cited 2017 Jul 20];139(11):1496-505. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908994/pdf/nihms213262.pdf>
- 2390
2391
2392
2393
38. Woods JS, Martin MD, Leroux BG, DeRouen TA, Bernardo MF, Luis HS, et al. Biomarkers of kidney integrity in children and adolescents with dental amalgam mercury exposure: findings from the Casa Pia children's amalgam trial. *Environ Res* [Internet]. 2008 Nov [cited 2018 Jan 16];108(3):393-9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236600/pdf/nihms-78395.pdf>
- 2394
2395
2396
39. Barregard L, Trachtenberg F, McKinlay S. Renal effects of dental amalgam in children: the New England children's amalgam trial. *Environ Health Perspect* [Internet]. 2008 Mar [cited 2017 Nov 1];116(3):394-9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2265055/pdf/ehp0116-000394.pdf>
- 2397
2398
2399
40. Lauterbach M, Martins IP, Castro-Caldas A, Bernardo M, Luis H, Amaral H, et al. Neurological outcomes in children with and without amalgam-related mercury exposure: seven years of longitudinal observations in a randomized trial. *J Am Dent Assoc*. 2008 Feb;139(2):138-45.
- 2400
2401
41. Woods JS, Martin MD, Leroux BG, DeRouen TA, Leitao JG, Bernardo MF, et al. The contribution of dental amalgam to urinary mercury excretion in children. *Environ Health Perspect*. 2007 Oct;115(10):1527-31.
- 2402
2403
2404
2405
42. Bellinger DC, Daniel D, Trachtenberg F, Tavares M, McKinlay S. Dental amalgam restorations and children's neuropsychological function: the New England Children's Amalgam Trial. *Environ Health Perspect* [Internet]. 2007 Mar [cited 2017 Dec 1];115(3):440-6. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1849920/pdf/ehp0115-000440.pdf>
- 2406
2407
43. Children's Amalgam Trial Study Group. The Children's Amalgam Trial: design and methods. *Control Clin Trials*. 2003 Dec;24(6):795-814.
- 2408
2409
2410
44. DeRouen TA, Leroux BG, Martin MD, Townes BD, Woods JS, Leitao J, et al. Issues in design and analysis of a randomized clinical trial to assess the safety of dental amalgam restorations in children. *Control Clin Trials*. 2002 Jun;23(3):301-20.
- 2411
2412
2413
45. Bellinger DC, Trachtenberg F, Barregard L, Tavares M, Cernichiari E, Daniel D, et al. Neuropsychological and renal effects of dental amalgam in children: a randomized clinical trial. *JAMA*. 2006 Apr 19;295(15):1775-83.
- 2414
2415
46. Maserejian NN, Trachtenberg FL, Assmann SF, Barregard L. Dental amalgam exposure and urinary mercury levels in children: the New England Children's Amalgam Trial. *Environ Health Perspect* [Internet].

- 2416 2008 [cited 2017 Dec 1];116(2):256-62. Available from:
2417 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2235235/pdf/ehp0116-000256.pdf>
- 2418 47. DeRouen TA, Martin MD, Leroux BG, Townes BD, Woods JS, Leitao J, et al. Neurobehavioral effects of
2419 dental amalgam in children: a randomized clinical trial. *JAMA*. 2006 Apr 19;295(15):1784-92.
- 2420 48. Townes BD, Martins IP, Castro-Caldas A, Rosenbaum G, Derouen T. Repeat test scores on
2421 neurobehavioral measures over an eight-year period in a sample of Portuguese children. *Int J Neurosci*.
2422 2008 Jan;118(1):79-93.
- 2423 49. Cheng J, Pullenayegum E, Marshall JK, Iorio A, Thabane L. Impact of including or excluding both-armed
2424 zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study.
2425 *BMJ Open* [Internet]. 2016 Aug 16 [cited 2018 Jan 3];6(8):e010983. Available from:
2426 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013416>
- 2427 50. Beazoglou T, Eklund S, Heffley D, Meiers J, Brown LJ, Bailit H. Economic impact of regulating the use of
2428 amalgam restorations. *Public Health Rep* [Internet]. 2007 Sep [cited 2017 Jul 17];122(5):657-63. Available
2429 from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936958/pdf/phr122000657.pdf>
- 2430 51. Elhennawy K, Jost-Brinkmann PG, Manton DJ, Paris S, Schwendicke F. Managing molars with severe
2431 molar-incisor hypomineralization: a cost-effectiveness analysis within German healthcare. *J Dent*. 2017 Jun
2432 1.
- 2433 52. Kanzow P, Wiegand A, Schwendicke F. Cost-effectiveness of repairing versus replacing composite or
2434 amalgam restorations. *J Dent*. 2016 Nov;54:41-7.
- 2435 53. Kelly PG, Smales RJ. Long-term cost-effectiveness of single indirect restorations in selected dental
2436 practices. *Br Dent J*. 2004 May 22;196(10):639-43.
- 2437 54. Maryniuk GA, Schweitzer SO, Braun RJ. Replacement of amalgams with crowns: a cost-effectiveness
2438 analysis. *Community Dent Oral Epidemiol*. 1988 Oct;16(5):263-7.
- 2439 55. Schwendicke F, Meyer-Lueckel H, Stolpe M, Dorfer CE, Paris S. Costs and effectiveness of treatment
2440 alternatives for proximal caries lesions. *PLoS One* [Internet]. 2014 [cited 2017 Jul 17];9(1). Available from:
2441 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903601/pdf/pone.0086992.pdf>
- 2442 56. Schwendicke F, Stolpe M. Secondary treatment for asymptomatic root canal treated teeth: a cost-
2443 effectiveness analysis. *J Endod*. 2015 Jun;41(6):812-6.
- 2444 57. Sjogren P, Halling A. Survival time of Class II molar restorations in relation to patient and dental health
2445 insurance costs for treatment. *Swed Dent J*. 2002;26(2):59-66.
- 2446 58. Tobi H, Kreulen CM, Vondeling H, van Amerongen WE. Cost-effectiveness of composite resins and
2447 amalgam in the replacement of amalgam Class II restorations. *Community Dent Oral Epidemiol*. 1999
2448 Apr;27(2):137-43.
- 2449 59. Warren E, Curtis BH, Jia N, Evans RW. The caries management system: updating cost-effectiveness with 4-
2450 year posttrial data. *Int J Technol Assess Health Care*. 2016 Jan;32(3):107-15.
- 2451 60. Warren E, Pollicino C, Curtis B, Evans W, Sbaraini A, Schwarz E. Modeling the long-term cost-effectiveness
2452 of the caries management system in an Australian population. *Value Health*. 2010 Sep;13(6):750-60.
- 2453 61. Guidelines for the economic evaluation of health technologies: Canada [Internet]. 4th ed. Ottawa: CADTH;
2454 2017. [cited 2017 May 8]. Available from: [https://www.cadth.ca/about-cadth/how-we-do-it/methods-and-](https://www.cadth.ca/about-cadth/how-we-do-it/methods-and-guidelines/guidelines-for-the-economic-evaluation-of-health-technologies-canada)
2455 [guidelines/guidelines-for-the-economic-evaluation-of-health-technologies-canada](https://www.cadth.ca/about-cadth/how-we-do-it/methods-and-guidelines/guidelines-for-the-economic-evaluation-of-health-technologies-canada)
- 2456 62. Report on the findings of the oral health component of the Canadian Health Measures Survey 2007-2009
2457 [Internet]. Ottawa: Health Canada; 2010. [cited 2017 Dec 15]. Available from:
2458 http://publications.gc.ca/collections/collection_2010/sc-hc/H34-221-2010-eng.pdf

- 2459 63. Soncini JA, Maserejian NN, Trachtenberg F, Tavares M, Hayes C. The longevity of amalgam versus
2460 compomer/composite restorations in posterior primary and permanent teeth: findings From the New England
2461 Children's Amalgam Trial. *J Am Dent Assoc.* 2007 Jun;138(6):763-72.
- 2462 64. Table 051-0001 estimates of population, by age group and sex for July 1, Canada, provinces and territories
2463 annual. In: CANSIM [Internet]. Ottawa: Statistics Canada; 2017 Sep 26 [cited 2017 Dec 15]. Available from:
2464 [http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=0510001&&pattern=&stByVal=1&p1=1&](http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=0510001&&pattern=&stByVal=1&p1=1&p2=37&tabMode=dataTable&csid)
2465 [p2=37&tabMode=dataTable&csid](http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=0510001&&pattern=&stByVal=1&p1=1&p2=37&tabMode=dataTable&csid)
- 2466 65. Life Tables, Canada, Provinces and Territories (2011 to 2013, no. 1) [Internet]. Ottawa: Statistics Canada;
2467 2017 Dec 15. [cited 2017 Dec 15]. Available from:
2468 http://www5.statcan.gc.ca/access_acces/alternative_alternatif.action?l=eng&loc=/pub/84-537-
2469 [x/2017001/xls/2011-2013_Tbl-eng.xlsx](http://www5.statcan.gc.ca/access_acces/alternative_alternatif.action?l=eng&loc=/pub/84-537-x/2017001/xls/2011-2013_Tbl-eng.xlsx)
- 2470 66. Bernardo M, Luis H, Martin MD, Leroux BG, Rue T, Leitao J, et al. Survival and reasons for failure of
2471 amalgam versus composite posterior restorations placed in a randomized clinical trial. *J Am Dent Assoc.*
2472 2007 Jun;138(6):775-83.
- 2473 67. Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of
2474 health technologies. *BMC Med Res Methodol* [Internet]. 2011 Oct 10 [cited 2018 Jan 16];11:139. Available
2475 from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198983>
- 2476 68. Tierney JF, Stewart LA, Gherzi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-
2477 to-event data into meta-analysis. *Trials* [Internet]. 2007 Jun 7 [cited 2017 Dec 15];8:16. Available from:
2478 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920534>
- 2479 69. Kolker JL, Damiano PC, Armstrong SR, Bentler SE, Flach SD, Caplan DJ, et al. Natural history of treatment
2480 outcomes for teeth with large amalgam and crown restorations. *Oper Dent.* 2004 Nov;29(6):614-22.
- 2481 70. Kopperud SE, Tveit AB, Gaarden T, Sandvik L, Espelid I. Longevity of posterior dental restorations and
2482 reasons for failure. *Eur J Oral Sci.* 2012 Dec;120(6):539-48.
- 2483 71. Miyamoto T, Morgano SM, Kumagai T, Jones JA, Nunn ME. Treatment history of teeth in relation to the
2484 longevity of the teeth and their restorations: outcomes of teeth treated and maintained for 15 years. *J*
2485 *Prosthet Dent.* 2007 Mar;97(3):150-6.
- 2486 72. Opdam NJ, Bronkhorst EM, Roeters JM, Loomans BA. A retrospective clinical study on longevity of posterior
2487 composite and amalgam restorations. *Dent Mater.* 2007 Jan;23(1):2-8.
- 2488 73. Laccabue M, Ahlf RL, Simecek JW. Frequency of restoration replacement in posterior teeth for U.S. Navy
2489 and Marine Corps personnel. *Oper Dent.* 2014 Jan;39(1):43-9.
- 2490 74. Arenholt-Bindslev D. Dental amalgam--environmental aspects. *Adv Dent Res.* 1992 Sep;6:125-30.
- 2491 75. Advokaat JG, Van 't Hof MA, Akerboom HB, Borgmeijer PJ. Treatment times of amalgam restorations.
2492 *Community Dent Oral Epidemiol.* 1992 Aug;20(4):200-3.
- 2493 76. Tan SS, Ken Redekop W, Rutten FF. Costs and prices of single dental fillings in Europe: a micro-costing
2494 study. *Health Econ.* 2008 Jan;17(1 Suppl):S83-S93.
- 2495 77. McManus KR, Fan PL. Purchasing, installing and operating dental amalgam separators: practical issues. *J*
2496 *Am Dent Assoc.* 2003 Aug;134(8):1054-65.
- 2497 78. Dental health services in Canada: facts and figures [Internet]. Ottawa: Canadian Dental Association; 2010.
2498 [cited 2017 Sep 8]. Available from:
2499 https://www.med.uottawa.ca/sim/data/Dental/Dental_Health_Services_in_Canada_June_2010.pdf
- 2500 79. Average hourly wages of employees by selected characteristics and occupation, unadjusted data, by
2501 province (monthly) (Canada) [Internet]. Ottawa: Statistics Canada; 2017 Dec 1. [cited 2017 Dec 15].
2502 Available from: <http://www.statcan.gc.ca/tables-tableaux/sum-som/I01/cst01/labr69a-eng.htm>

- 2503 80. Labour force, employment and unemployment, levels and rates, by province (Newfoundland and Labrador,
2504 Prince Edward Island, Nova Scotia, New Brunswick) [Internet]. Ottawa: Statistics Canada; 2017 Jan 6. [cited
2505 2017 Dec 15]. Available from: [http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labor07a-
eng.htm](http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labor07a-
2506 eng.htm)
- 2507 81. Historical data. Inflation (year-over-year percentage change) [Internet]. Ottawa: Bank of Canada; 2017.
2508 [cited 2017 Dec 15]. Available from: [http://www.bankofcanada.ca/rates/indicators/capacity-and-inflation-
pressures/inflation/historical-data/](http://www.bankofcanada.ca/rates/indicators/capacity-and-inflation-
2509 pressures/inflation/historical-data/)
- 2510 82. Duncan L, Bonner A. Effects of income and dental insurance coverage on need for dental care in Canada. J
2511 Can Dent Assoc [Internet]. 2014 [cited 2017 Dec 15];80:e6. Available from: <http://www.jcda.ca/article/e6>
- 2512 83. Mjör IA, Burke FJ, Wilson NH. The relative cost of different restorations in the UK. Br Dent J. 1997 Apr
2513 26;182(8):286-9.
- 2514 84. Estimating lifetime costs of a cavity [Internet]. Oak Brook (IL): Delta Dental Data & Analysis Center; 2004
2515 Jun. [cited 2017 Dec 15]. Available from: [https://www.cdhp.org/resources/298-lifetime-costs-of-a-cavity-by-
delta-dental](https://www.cdhp.org/resources/298-lifetime-costs-of-a-cavity-by-
2516 delta-dental)
- 2517 85. Roulet JF. Benefits and disadvantages of tooth-coloured alternatives to amalgam. J Dent. 1997
2518 Nov;25(6):459-73.
- 2519 86. Covidence online software. Melbourne (AU): Covidence; 2018. [cited 2018 Jan 29]. Available from:
2520 <https://www.covidence.org/about-us>
- 2521 87. The System for the Unified Management, Assessment and Review of Information (SUMARI). North Adelaide
2522 (AU): The Joanna Briggs Institute; 2018 (Software).
- 2523 88. Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: methodological guidance for systematic
2524 reviewers utilizing meta-aggregation. Int J Evid Based Healthc. 2015 Sep;13(3):179-87.
- 2525 89. Munn Z, Porritt K, Lockwood C, Aromataris E, Pearson A. Establishing confidence in the output of qualitative
2526 research synthesis: the ConQual approach. BMC Med Res Methodol [Internet]. 2014 Sep 20 [cited 2017 Jun
2527 5];14:108. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190351>
- 2528 90. Sjursen TT, Binder PE, Lygre GB, Helland V, Dalen K. How unexplained health complaints were attributed
2529 to dental amalgam. Nord Psychol. 2014;66(3):216-29.
- 2530 91. Heintze SD, Faouzi M, Rousson V, Ozcan M. Correlation of wear in vivo and six laboratory wear methods.
2531 Dent Mater. 2012 Sep;28(9):961-73.
- 2532 92. Marell L, Lindgren M, Nyhlin KT, Ahlgren C, Berglund A. "Struggle to obtain redress": Women's experiences
2533 of living with symptoms attributed to dental restorative materials and/or electromagnetic fields. Int J Qual
2534 Stud Health Well-being [Internet]. 2016 [cited 2018 Jan 16];11:32820. Available from:
2535 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149706/pdf/QHW-11-32820.pdf>
- 2536 93. Sjursen TT, Binder PE, Lygre GB, Helland V, Dalen K, Bjorkman L. Patients' experiences of changes in
2537 health complaints before, during, and after removal of dental amalgam. Int J Qual Stud Health Well -being
2538 [Internet]. 2015 [cited 2017 Nov 1];10:28157. Available from:
2539 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481046/pdf/QHW-10-28157.pdf>
- 2540 94. Jones LM. Focus on fillings: a qualitative health study of people medically diagnosed with mercury
2541 poisoning, linked to dental amalgam. Acta Neuropsychiatr. 2004 Jun;16(3):142-8.
- 2542 95. CCME Council of Ministers. Canada-wide standard on mercury for dental amalgam waste [Internet].
2543 Winnipeg (MB): Canadian Council of Ministers of the Environment; 2001 Sep 22. [cited 2017 Sep 8].
2544 Available from: http://www.ccme.ca/files/Resources/mercury/cws_merc_amalgam_e.pdf
- 2545 96. Pfadenhauer L, Rohwer A, Burns J, Booth A, Lysdahl LB, Hofmann B. Guidance for the assessment of
2546 context and implementation in health technology assessments (HTA) and systematic reviews of complex

- 2547 interventions: the Context and Implementation of Complex Interventions (CICI) framework [Internet]. Bremen
 2548 (Germany): INTEGRATE-HTA; 2016. [cited 2017 May 10]. Available from: [http://www.integrate-hta.eu/wp-](http://www.integrate-hta.eu/wp-content/uploads/2016/02/Guidance-for-the-Assessment-of-Context-and-Implementation-in-HTA-and-Systematic-Reviews-of-Complex-Interventions-The-Co.pdf)
 2549 [content/uploads/2016/02/Guidance-for-the-Assessment-of-Context-and-Implementation-in-HTA-and-](http://www.integrate-hta.eu/wp-content/uploads/2016/02/Guidance-for-the-Assessment-of-Context-and-Implementation-in-HTA-and-Systematic-Reviews-of-Complex-Interventions-The-Co.pdf)
 2550 [Systematic-Reviews-of-Complex-Interventions-The-Co.pdf](http://www.integrate-hta.eu/wp-content/uploads/2016/02/Guidance-for-the-Assessment-of-Context-and-Implementation-in-HTA-and-Systematic-Reviews-of-Complex-Interventions-The-Co.pdf)
- 2551 97. Dutton DJ, Fyie K, Faris P, Brunel L, Emery JH. The association between amalgam dental surfaces and
 2552 urinary mercury levels in a sample of Albertans, a prevalence study. J Occup Med Toxicol [Internet]. 2013
 2553 Aug 29 [cited 2017 Jul 19];8(1):22. Available from:
 2554 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766055/pdf/1745-6673-8-22.pdf>
- 2555 98. Gordan VV, Abu-Hanna A, Mjor IA. Esthetic dentistry in North American dental schools. J Can Dent Assoc
 2556 [Internet]. 2004 Apr [cited 2017 Aug 23];70(4):230. Available from: [http://www.cda-adc.ca/jcda/vol-70/issue-](http://www.cda-adc.ca/jcda/vol-70/issue-4/230.pdf)
 2557 [4/230.pdf](http://www.cda-adc.ca/jcda/vol-70/issue-4/230.pdf)
- 2558 99. Colson DG. A safe protocol for amalgam removal. J Environ Public Health [Internet]. 2012 Jan [cited 2017
 2559 Jul 19];1-4. Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270415/pdf/JEPH2012-](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270415/pdf/JEPH2012-517391.pdf)
 2560 [517391.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270415/pdf/JEPH2012-517391.pdf)
- 2561 100. Lynch CD, Frazier KB, McConnell RJ, Blum IR, Wilson NH. Minimally invasive management of dental caries:
 2562 contemporary teaching of posterior resin-based composite placement in U.S. and Canadian dental schools.
 2563 J Am Dent Assoc. 2011 Jun;142(6):612-20.
- 2564 101. Lynch CD, McConnell RJ, Hannigan A, Wilson NH. Teaching the use of resin composites in Canadian dental
 2565 schools: how do current educational practices compare with North American trends? J Can Dent Assoc
 2566 [Internet]. 2006 May [cited 2017 Jul 19];72(4):321. Available from: [http://www.cda-adc.ca/jcda/vol-72/issue-](http://www.cda-adc.ca/jcda/vol-72/issue-4/321.pdf)
 2567 [4/321.pdf](http://www.cda-adc.ca/jcda/vol-72/issue-4/321.pdf)
- 2568 102. McComb D. Class I and Class II silver amalgam and resin composite posterior restorations: teaching
 2569 approaches in Canadian faculties of dentistry. J Can Dent Assoc [Internet]. 2005 Jun [cited 2017 Jul
 2570 19];71(6):405-6. Available from: <http://www.cda-adc.ca/jcda/vol-71/issue-6/405.pdf>
- 2571 103. Varughese RE, Andrews P, Sigal MJ, Azarpazhooh A. An assessment of direct restorative material use in
 2572 posterior teeth by American and Canadian pediatric dentists: I. Material choice. Pediatr Dent. 2016 Nov
 2573 15;38(7):489-96.
- 2574 104. Lombard R, du Preez I, Oberholzer TG, Gugushe TS. Teaching approaches in South African dental schools:
 2575 direct restorative procedures. SADJ. 2009 Feb;64(1):16-20.
- 2576 105. Lynch CD, Blum IR, Frazier KB, Haisch LD, Wilson NH. Repair or replacement of defective direct resin-
 2577 based composite restorations: contemporary teaching in U.S. and Canadian dental schools. J Am Dent
 2578 Assoc. 2012 Feb;143(2):157-63.
- 2579 106. Memorandum of understanding respecting the implementation of the Canada-wide standard on mercury for
 2580 dental amalgam waste [Internet]. Ottawa (ON): Environment and Climate Change Canada; 2002 Feb 18.
 2581 [cited 2017 Mar 8]. Available from: [https://www.ec.gc.ca/mercure-mercury/5910BAFF-FA15-40F9-B680-](https://www.ec.gc.ca/mercure-mercury/5910BAFF-FA15-40F9-B680-7195AD689A4D/EC_CDA_MOU.pdf)
 2582 [7195AD689A4D/EC_CDA_MOU.pdf](https://www.ec.gc.ca/mercure-mercury/5910BAFF-FA15-40F9-B680-7195AD689A4D/EC_CDA_MOU.pdf)
- 2583 107. Dental services [Internet]. Québec (QC): Régie de l'assurance maladie; 2018. [cited 2018 Jan 15]. Available
 2584 from: <http://www.ramq.gouv.qc.ca/en/citizens/health-insurance/healthcare/Pages/dental-services.aspx>
- 2585 108. Basics of environmental assessment [Internet]. Ottawa: Government of Canada; 2017 Jun 5. [cited 2017 Jul
 2586 5]. Available from: [https://www.canada.ca/en/environmental-assessment-agency/services/environmental-](https://www.canada.ca/en/environmental-assessment-agency/services/environmental-assessments/basics-environmental-assessment.html)
 2587 [assessments/basics-environmental-assessment.html](https://www.canada.ca/en/environmental-assessment-agency/services/environmental-assessments/basics-environmental-assessment.html)
- 2588 109. Ecological risk assessment [Internet]. Washington (DC): United States Environmental Protection Agency;
 2589 2016. [cited 2017 May 9]. Available from: <https://www.epa.gov/risk/ecological-risk-assessment>
- 2590 110. Clarkson TW, Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol. 2006
 2591 Sep;36(8):609-62.

- 2592 111. Global mercury assessment 2013: sources, emissions, releases, and environmental transport [Internet].
2593 Nairobi (KE): United Nations Environment Programme; 2013. [cited 2017 Sep 8]. Available from:
2594 <http://wedocs.unep.org/handle/20.500.11822/7984>
- 2595 112. Scheuhammer AM, Basu N, Evers DC, Heinz GH, Sandheinrich MB, Bank MS. Toxicology of mercury in fish
2596 and wildlife: recent advances. In: Bank M, editor. Mercury in the environment: pattern and process. Berkeley
2597 (CA): University of California Press; 2012. Chapter 11.
- 2598 113. Ha E, Basu N, Bose-O'Reilly S, Dorea JG, McSorley E, Sakamoto M, et al. Current progress on
2599 understanding the impact of mercury on human health. *Environ Res.* 2017 Jan;152:419-33.
- 2600 114. Vandeven JA, Mcginnis SL. An assessment of mercury in the form of amalgam in dental wastewater in the
2601 United States. *Water Air Soil Pollut.* 2005;164(1):349-66.
- 2602 115. Adegbembo AO, Watson PA. Estimated quantity of mercury in amalgam waste water residue released by
2603 dentists into the sewerage system in Ontario, Canada. *J Can Dent Assoc* [Internet]. 2004 Dec [cited 2017
2604 Jul 4];70(11):759a-f. Available from: <https://www.cda-adc.ca/jcda/vol-70/issue-11/759.pdf>
- 2605 116. Batchu H, Rakowski D, Fan PL, Meyer DM. Evaluating amalgam separators using an international standard.
2606 *J Am Dent Assoc.* 2006 Jul;137(7):999-1005.
- 2607 117. Kennedy CJ. Uptake and accumulation of mercury from dental amalgam in the common goldfish, *Carassius*
2608 *auratus*. *Environ Pollut.* 2003;121(3):321-6.
- 2609 118. Bayne S, Petersen PE, Piper D, Schmalz G, Meyer D. The challenge for innovation in direct restorative
2610 materials. *Adv Dent Res.* 2013 Nov;25(1):8-17.
- 2611 119. Toxicological and health aspects of bisphenol A: final report, including report of stakeholder meeting on
2612 bisphenol A, 1-5 November 2010, Ottawa, Canada [Internet]. Geneva (CH): World Health Organization;
2613 2011. [cited 2017 Sep 28]. Available from:
2614 http://apps.who.int/iris/bitstream/10665/44624/1/97892141564274_eng.pdf
- 2615 120. Bushnik T, Haines D, Levallois P, Levesque J, Van OJ, Viau C. Lead and bisphenol A concentrations in the
2616 Canadian population. *Health Rep* [Internet]. 2010 Sep [cited 2017 Sep 29];21(3):7-18. Available from:
2617 <http://www.statcan.gc.ca/pub/82-003-x/2010003/article/11324-eng.pdf>
- 2618 121. Myers DE, Hutz RJ. Current status of potential bisphenol toxicity in dentistry. *Gen Dent.* 2011 Jul;59(4):262-
2619 5.
- 2620 122. Kingman A, Hyman J, Masten SA, Jayaram B, Smith C, Eichmiller F, et al. Bisphenol A and other
2621 compounds in human saliva and urine associated with the placement of composite restorations. *J Am Dent*
2622 *Assoc.* 2012 Dec;143(12):1292-302.
- 2623 123. Staples CA, Dorn PB, Klecka GM, O'Block ST, Harris LR. A review of the environmental fate, effects, and
2624 exposures of bisphenol A. *Chemosphere.* 1998 Apr;36(10):2149-73.
- 2625 124. Canadian Environmental Protection Act, 1999. Federal environmental quality guidelines: bisphenol A
2626 [Internet]. Gatineau (QC): Environment and Climate Change Canada; 2017. [cited 2017 Sep 29]. Available
2627 from: [http://www.ec.gc.ca/ese-ees/CB1CEFFB-983E-4113-805E-86A74C6824D0/FEQG%20BPA%2015-02-
2628 2017%20clean.pdf](http://www.ec.gc.ca/ese-ees/CB1CEFFB-983E-4113-805E-86A74C6824D0/FEQG%20BPA%2015-02-2017%20clean.pdf)
- 2629 125. Wong TC, Eisele JL. FDI World Dental Federation: responding to new realities of oral health. *J Dent Res.*
2630 2015 Apr;94(4):519-21.
- 2631 126. Minamata Convention on Mercury [Internet]. New York: United Nations; 2013 Oct. [cited 2017 Oct 1].
2632 Available from: <https://treaties.un.org/doc/Treaties/2013/10/20131010%2011-16%20AM/CTC-XXVII-17.pdf>
- 2633 127. Anderson MH, McCoy RB. Dental amalgam. The state of the art and science. *Dent Clin North Am.* 1993
2634 Jul;37(3):419-31.

- 2635 128. Crawford PR. The story of silver amalgam (and how a Canadian changed it all)! J Can Dent Assoc. 1989
2636 Nov;55(11):887-90.
- 2637 129. ALLEN AJ. The amalgam war. Dent Stud. 1965 May;43:656-9.
- 2638 130. Meyerhof PG. Early struggles to identify ethical standards in dentistry: Dr. Benjamin Brown and the
2639 amalgam war of the 1840s. J Hist Dent. 2007;55(3):139-49.
- 2640 131. Shapka NB. Letter to: The Director, Waste Reduction and Management Division, Department of the
2641 Environment. Bonnyville (AB): International Academy of Oral Medicine and Toxicology, Canadian Council of
2642 Oral Medicine and Toxicology; 2011 Apr 26. Notice of objection, and request for board of review, respecting
2643 the notice published in Canada Gazette Part 1, volume 45, No. 9, dated February 26, 2011, regarding
2644 proposed Regulations Respecting Products Containing Certain Substances Listed in Schedule 1 to the
2645 Canadian Environmental Protection Act, 1999.
- 2646 132. Kall J, Robertson K, Sukel P, Just A. Position statement against dental mercury amalgam fillings for medical
2647 and dental practitioners, dental students, dental patients, and policy makers [Internet]. ChampionsGate (FL):
2648 The International Academy of Oral Medicine and Toxicology; 2016. [cited 2017 Nov 1]. Available from:
2649 <https://iaomt.org/wp-content/uploads/IAOMT-Position-Statement-Update-2016-6.16.16.pdf>
- 2650 133. Chirba-Martin MA, Welshhans CM. An uncertain risk and an uncertain future: assessing the legal
2651 implications of mercury amalgam fillings. Health Matrix Clevel. 2004; Summer;14(2):293-324.
- 2652 134. CDA adopts new ethical statement on amalgam replacement. Canadian Dental Association. J Dent Assoc S
2653 Afr. 1995 Dec;50(12):593.
- 2654 135. Adams DC. Amalgam woes. Dent Today. 2002 Feb;21(2):18.
- 2655 136. Katz HS. Unwarranted and unprofessional: the superfluous removal of clinically acceptable amalgams. Oper
2656 Dent. 1991 May;16(3):113-5.
- 2657 137. Berry J. Watchdog group says amalgam is safe. Ada News. 2002 Oct 21;33(19):1-19.
- 2658 138. MacAllan S. The mercury papers--the most expensive medical mistake in the history of the world. Positive
2659 Health [Internet]. 2011 Jan [cited 2017 Jul 27];(178):1. Available from:
2660 [http://www.positivehealth.com/article/dentistry/the-mercury-papers-the-most-expensive-medical-mistake-in-](http://www.positivehealth.com/article/dentistry/the-mercury-papers-the-most-expensive-medical-mistake-in-the-history-of-the-world)
2661 [the-history-of-the-world](http://www.positivehealth.com/article/dentistry/the-mercury-papers-the-most-expensive-medical-mistake-in-the-history-of-the-world)
- 2662 139. Moss J. Mercury revisited - part V -- the latest assault in the amalgam wars. Nutr Perspect. 2008
2663 Oct;31(4):8-14.
- 2664 140. Himmelberger LK. Justifiable criticism and dental amalgam. J Am Dent Assoc. 2015 Aug;146(8):646-7.
- 2665 141. Berry J. Lawsuits dismissed: amalgam rulings are tripartite victory. Ada News. 2003 Mar 3;34(5):3-23.
- 2666 142. Berry J. Two more amalgam cases dismissed: total now at 33 and counting. Ada News. 2004 Mar
2667 15;35(6):1-11.
- 2668 143. Berthold M. Oregon repeals policy on amalgam removal. Ada News. 2002 Apr;33(7):6.
- 2669 144. Berthold M. Amalgam lawsuits dismissed. Ada News. 2003 Aug 18;34(15):8.
- 2670 145. Edlich RF, Cross CL, Wack CA, Long WB, III, Newkirk AT. The food and drug administration agrees to
2671 classify mercury fillings. J Environ Pathol Toxicol Oncol. 2008;27(4):303-5.
- 2672 146. Gold SA. Amalgam, autism, and the beauty of Holland. J Calif Dent Assoc [Internet]. 2002 Jun [cited 2017
2673 Jul 27];30(6):405-6. Available from: https://www.cda.org/Portals/0/journal/journal_062002.pdf

- 2674 147. Hoyle J. State ban excludes dentists: Connecticut law does not include amalgam in mercury ban. *Ada News*.
2675 2005 Sep 19;36(17):25.
- 2676 148. Jones DW. A Scandinavian tragedy. *Br Dent J*. 2008 Mar 8;204(5):233-4.
- 2677 149. Conley JF. The cost of the amalgam issue. *J Calif Dent Assoc*. 2001 Aug;29(8):548-9.
- 2678 150. Clappison RA. The amalgam controversy: lost by scientific evidence or media misinformation? *Oral Health*.
2679 1996 Feb;86(2):37-9.
- 2680 151. Avoaka-Boni MC, dou-Assoumou NM, Sinan AA, bouattier-Mansilla EC. Dental amalgams and mercury
2681 polemic in Abidjan. *Odontostomatol Trop*. 2007 Dec;30(120):7-14.
- 2682 152. Porter SA, Grey WL. Ethical dilemmas confronting dentists in Queensland, Australia. *Aust Dent J*. 2002
2683 Sep;47(3):241-8.
- 2684 153. Han DH, Lim SY, Sun BC, Janket SJ, Kim JB, Paik DI, et al. Mercury exposure and periodontitis among a
2685 Korean population: the Shihwa-Banwol environmental health study. *J Periodontol*. 2009 Dec;80(12):1928-
2686 36.
- 2687 154. Harakeh S, Sabra N, Kassak K, Doughan B. Factors influencing total mercury levels among Lebanese
2688 dentists. *Sci Total Environ*. 2002 Oct 7;297(1-3):153-60.
- 2689 155. WHO/FDI consensus statement on dental amalgam. *J Dent Assoc S Afr*. 1995 Aug;50(8):371.
- 2690 156. Huang YQ, Wong CK, Zheng JS, Bouwman H, Barra R, Wahlstrom B, et al. Bisphenol A (BPA) in China: a
2691 review of sources, environmental levels, and potential human health impacts. *Environ Int*. 2012 Jul;42:91-9.
- 2692 157. Mortazavi G, Mortazavi SM. Increased mercury release from dental amalgam restorations after exposure to
2693 electromagnetic fields as a potential hazard for hypersensitive people and pregnant women. *Rev Environ*
2694 *Health*. 2015;30(4):287-92.
- 2695 158. Nakata M. Update of dental amalgam in Japan. In: Mjor IA, Pakhornov GN, editors. *Dental amalgam and*
2696 *alternative direct restorative materials*. Geneva (CH): World Health Organization; 1997. p. 228-31.
- 2697 159. FDI World Dental Federation. World Health Organization. Consensus statement on dental amalgam. *Fdi*
2698 *world*. 1995 Jul;4(4):9-10.
- 2699 160. FDI World Dental Federation. FDI policy statement on dental amalgam and the Minamata Convention on
2700 Mercury: adopted by the FDI General Assembly: 13 September 2014, New Delhi, India. *Int Dent J*. 2014
2701 Dec;64(6):295-6.
- 2702 161. FDI World Dental Federation. FDI resolution on global legally binding instrument on mercury: adopted by the
2703 FDI General Assembly: 31 August 2012, Hong Kong, SAR China. *Int Dent J*. 2013 Feb;63(1):6.
- 2704 162. Beauchamp TL, Childress JF. *Principles of biomedical ethics*. 7th ed. New York: Oxford University Press;
2705 2013.
- 2706 163. Brookfield JR. Reconsidering dental amalgam. *J Can Dent Assoc*. 1996 Jul;62(7):547.
- 2707 164. Edlich RF, Cochran AA, Cross CL, Wack CA, Long WB, III, Newkirk AT. Legislation and informed consent
2708 brochures for dental patients receiving amalgam restorations. *Int J Toxicol*. 2008 Jul;27(4):313-6.
- 2709 165. Brandstatter R. How independent are those independent studies? *Cds rev*. 2006 Sep;99(5):5.
- 2710 166. Chiodo GT, Tolle SW. Can a patient make an irrational choice? The dental amalgam controversy. *Gen Dent*.
2711 1992 May;40(3):184, 186-4, 187.

- 2712 167. Edlich RF, Greene JA, Cochran AA, Kelley AR, Gubler KD, Olson BM, et al. Need for informed consent for
2713 dentists who use mercury amalgam restorative material as well as technical considerations in removal of
2714 dental amalgam restorations. *J Environ Pathol Toxicol Oncol*. 2007;26(4):305-22.
- 2715 168. Ethical considerations of removing serviceable amalgams. *J Gt Houst Dent Soc*. 1996 Sep;68(2):29.
- 2716 169. Gamba TW. Am I ethically bound to discuss amalgam restorations with my patients? *J Am Dent Assoc*.
2717 2009 Dec;140(12):1544-6.
- 2718 170. Hasegawa TK, Jr., Matthews M, Jr., Hirsh M. Anxious (patient) about amalgam. Response to ethical
2719 dilemma #43. *Tex Dent J*. 2003 Apr;120(4):365-6.
- 2720 171. Maihofer MG. 'Amalgam-free' dental practices: are they ethical? *J Mich Dent Assoc*. 2011 Mar;93(3):24.
- 2721 172. Meskin LH. Do no harm. *J Am Dent Assoc*. 2001 Sep;132(9):1200, 1202.
- 2722 173. Meyerhof PG. Discussion. *J Hist Dent*. 2007;55(3):171-85.
- 2723 174. Naidoo S. Dental ethics case 18: use of amalgam for dental restorations. *SADJ*. 2012 Feb;67(1):36-8.
- 2724 175. Odom JG. Ethics and dental amalgam removal. *J Am Dent Assoc*. 1991 Jun;122(6):69-71.
- 2725 176. Tanchyk A. Ethics and dental amalgam removal. *J Am Dent Assoc*. 1991 Oct;122(10):10.
- 2726 177. Tickner J, Coffin M. What does the precautionary principle mean for evidence-based dentistry? *J Evid Based
2727 Dent Pract*. 2006 Mar;6(1):6-15.
- 2728 178. Turner S, Gilpin J. If you don't believe mercury is safe, should you inform your client/patient? *J Dent Hyg*.
2729 1991 Jul;65(6):260-2.
- 2730 179. Mackey TK, Contreras JT, Liang BA. The Minamata Convention on Mercury: attempting to address the
2731 global controversy of dental amalgam use and mercury waste disposal. *Sci Total Environ*. 2014 Feb
2732 15;472:125-9.
- 2733 180. Hylander LD, Goodsite ME. Environmental costs of mercury pollution. *Sci Total Environ*. 2006;368(1):352-
2734 70.
- 2735 181. Quiñonez C. Wicked problems: policy contradictions in publicly financed dental care. *J Public Health Dent*.
2736 2012;72(4):261-4.
- 2737 182. Lessons from countries phasing down amalgam use [Internet]. Geneva: United Nations Environment
2738 Programme; 2016 Mar. [cited 2017 Nov 14]. Available from:
2739 [https://wedocs.unep.org/bitstream/handle/20.500.11822/11624/Dental.Amalgam.10mar2016.pages.WEB.pdf](https://wedocs.unep.org/bitstream/handle/20.500.11822/11624/Dental.Amalgam.10mar2016.pages.WEB.pdf?sequence=1&isAllowed=y)
2740 [?sequence=1&isAllowed=y](https://wedocs.unep.org/bitstream/handle/20.500.11822/11624/Dental.Amalgam.10mar2016.pages.WEB.pdf?sequence=1&isAllowed=y)
- 2741 183. Correa MB, Peres MA, Peres KG, Horta BL, Barros AD, Demarco FF. Amalgam or composite resin? Factors
2742 influencing the choice of restorative material. *J Dent*. 2012;40(9):703-10.
- 2743 184. Edlich RF, Cross CL, Dahlstrom JJ, Long WB, III, Newkirk AT. Implementation of revolutionary legislation for
2744 informed consent for dental patients receiving amalgam restorations. *J Environ Pathol Toxicol Oncol*.
2745 2008;27(1):1-3.
- 2746 185. Malkiewicz K, Owoc A, Kluska M, Grzech-Lesniak K, Turlo J. HPLC analysis of potentially harmful
2747 substances released from dental filling materials available on the EU market. *Ann Agric Environ Med*
2748 [Internet]. 2014 [cited 2017 Jul 27];21(1):86-90. Available from: [http://www.aaem.pl/HPLC-analysis-of-
2749 potentially-harmful-substances-released-from-dental-filling-materials-available-on-the-EU-
2750 market.72064.0.2.html](http://www.aaem.pl/HPLC-analysis-of-potentially-harmful-substances-released-from-dental-filling-materials-available-on-the-EU-market.72064.0.2.html)

- 2751 186. Manojlovic D, Dramicanin MD, Miletic V, Mitic-Culafic D, Jovanovic B, Nikolic B. Cytotoxicity and
2752 genotoxicity of a low-shrinkage monomer and monoacylphosphine oxide photoinitiator: Comparative
2753 analyses of individual toxicity and combination effects in mixtures. *Dent Mater.* 2017 Apr;33(4):454-66.
- 2754 187. Maserejian NN, Trachtenberg FL, Hauser R, McKinlay S, Shrader P, Tavares M, et al. Dental composite
2755 restorations and psychosocial function in children. *Pediatrics* [Internet]. 2012 Aug [cited 2017 Jul
2756 20];130(2):e328-e338. Available from:
2757 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3408688/pdf/peds.2011-3374.pdf>
- 2758 188. Richardson GM. An assessment of adult exposure and risks from components and degradation products of
2759 composite resin dental materials. *Hum Ecol Risk Assess.* 1997;3(4):683-97.
- 2760 189. Canadian Longitudinal Study on Aging [Internet]. Hamilton (ON): Canadian Longitudinal Study on Aging.
2761 2018 [cited 2018 Jan 11]. Available from: <https://www.clsa-elcv.ca/>
- 2762 190. CDA principles of ethics [Internet]. Ottawa: Canadian Dental Association; 2018. [cited 2018 Jan 11].
2763 Available from: <https://www.cda-adc.ca/en/about/ethics/>
- 2764 191. Fisher AA. A "current contact news" follow-up: controversial subjects and those resulting in litigation. *Cutis.*
2765 1993 Nov;52(5):254-6.
- 2766 192. Flecker CA. Who should place amalgam restorations? *Dent Econ.* 1992 Nov;82(11):19-20.
- 2767 193. Engel D. The ADA opposes a worldwide ban on mercury products. *J Mich Dent Assoc.* 2011 May;93(5):20.
- 2768 194. Christensen GJ. The all-ceramic restoration dilemma: where are we? *J Am Dent Assoc.* 2011
2769 Jun;142(6):668-71.
- 2770 195. Jokstad A, Fan PL. Amalgam waste management. *Int Dent J.* 2006 Jun;56(3):147-53.
- 2771 196. Health Canada position statement on dental amalgam. In: *The Safety of Dental Amalgam* [Internet]. Ottawa:
2772 Health Canada; 1996 [cited 2018 Jan 11; revised 2006]. Available from: [https://www.canada.ca/en/health-
2773 canada/services/drugs-health-products/reports-publications/medical-devices/safety-dental-amalgam-health-
2774 canada-1996.html#a12](https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medical-devices/safety-dental-amalgam-health-canada-1996.html#a12)
- 2775 197. Rekow ED, Fox CH, Petersen PE, Watson T. Innovations in materials for direct restorations: why do we
2776 need innovations? Why is it so hard to capitalize on them? *J Dent Res.* 2013 Nov;92(11):945-7.
- 2777 198. Sfikas PM. Can a dentist ethically remove serviceable amalgam restorations? *J Am Dent Assoc.* 1996
2778 May;127(5):685-7.
- 2779 199. Schissel MJ. Autonomy could be dangerous. *J Am Dent Assoc.* 1991 Sep;122(9):14-5.
- 2780 200. Logan MK. Informed consent. Does doctrine apply to HIV, amalgam, fluoride? *J Am Dent Assoc.* 1991
2781 Aug;122(8):18-21.
- 2782 201. When your patients ask about mercury in amalgam. *J Am Dent Assoc.* 1990 Apr;120(4):395-8.
- 2783 202. Dlugokinski M, Browning WD. Informed consent: direct posterior composite versus amalgam. *J Am Coll
2784 Dent.* 2001;68(2):31-40.
- 2785 203. Meisel A. BMPs and dentistry. *J N J Dent Assoc.* 2008;79(3):5, 2008.
- 2786 204. Reibl v. Hughes, [1980] 2 S.C.R. 880. 1980 Jul 10 [cited 2018 Jan 24]. In: *Judgments of the Supreme Court
2787 of Canada* [Internet]. Montreal (QC): Lexum. Available from: [https://scc-csc.lexum.com/scc-csc/scc-
2788 csc/en/item/2563/index.do](https://scc-csc.lexum.com/scc-csc/scc-csc/en/item/2563/index.do).

- 2789 205. Homme KG, Kern JK, Haley BE, Geier DA, King PG, Sykes LK, et al. New science challenges old notion
2790 that mercury dental amalgam is safe. *Biometals* [Internet]. 2014 Feb [cited 2017 Jul 27];27(1):19-24.
2791 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905169/pdf/10534_2013_Article_9700.pdf
- 2792 206. Echeverria D, Woods JS, Heyer NJ, Martin MD, Rohlman DS, Farin FM, et al. The association between
2793 serotonin transporter gene promotor polymorphism (5-HTTLPR) and elemental mercury exposure on mood
2794 and behavior in humans. *J Toxicol Environ Health A* [Internet]. 2010 [cited 2018 Jan 16];73(15):1003-20.
2795 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882654/pdf/nihms192483.pdf>
- 2796 207. Kern JK, Geier DA, Bjorklund G, King PG, Homme KG, Haley BE, et al. Evidence supporting a link between
2797 dental amalgams and chronic illness, fatigue, depression, anxiety, and suicide. *Neuroendocrinol Lett*.
2798 2014;35(7):537-52.
- 2799 208. Capozza LE, Bimstein E. Preferences of parents of children with autism spectrum disorders concerning oral
2800 health and dental treatment. *Pediatr Dent*. 2012 Nov;34(7):480-4.
- 2801 209. Bjorkman L, Weiner J, Gjerdet NR. Improvement of health after replacement of amalgam fillings? *J*
2802 *Psychosom Res*. 2005 Sep;59(3):189-90.
- 2803 210. Gottwald B, Kupfer J, Traenckner I, Ganss C, Gieler U. Psychological, allergic, and toxicological aspects of
2804 patients with amalgam-related complaints. *Psychother Psychosom*. 2002 Jul;71(4):223-32.
- 2805 211. Grandjean P, Guldager B, Larsen IB, Jorgensen PJ, Holmstrup P. Placebo response in environmental
2806 disease. Chelation therapy of patients with symptoms attributed to amalgam fillings. *J Occup Environ Med*.
2807 1997 Aug;39(8):707-14.
- 2808 212. Bratel J, Haraldson T, Ottosson JO. Potential side effects of dental amalgam restorations. (II). No relation
2809 between mercury levels in the body and mental disorders. *Eur J Oral Sci*. 1997 Jun;105(3):244-50.
- 2810 213. Herrström P, Högstedt B. Clinical study of oral galvanism: no evidence of toxic mercury exposure but anxiety
2811 disorder an important background factor. *Scand J Dent Res*. 1993 Aug;101(4):232-7.
- 2812 214. CDA position on dental amalgam [Internet]. Ottawa: Canadian Dental Association; 2014 Mar. [cited 2018
2813 Jan 5]. Available from: https://www.cda-adc.ca/files/position_statements/amalgam.pdf
- 2814 215. Lamacki WF. What is the ADA doing about amalgam? *Cds rev*. 2011 Mar;104(2):48.
- 2815 216. Know your dental mercury facts: here's why [Internet]. ChampionsGate (FL): International Academy of Oral
2816 Medicine & Technology; 2018. [cited 2018 Jan 4]. Available from: <https://iaomt.org/resources/dental-mercury-facts/>
2817
- 2818 217. Friedlander AH, Rosenbluth SC, Freymiller EG, Braddock CH, III. When clinical evidence is conflicted, who
2819 decides how to proceed? An opportunity for shared decision making. *J Am Dent Assoc*. 2015
2820 Oct;146(10):713-4.
- 2821 218. Bartold PM. Is amalgam ready to be buried? *Aust Dent J*. 2014 Mar;59(1):1.
- 2822 219. Smith R. The Cochrane collaboration at 20. *BMJ*. 2013 Dec 18;347:f7383.
- 2823 220. Cates CJ, Stovold E, Welsh EJ. How to make sense of a Cochrane systematic review. *Breathe* [Internet].
2824 2014 [cited 2017 Dec 15];10:134-4. Available from: <http://breathe.ersjournals.com/content/10/2/134>
- 2825 221. 2017 abbreviated general practitioner's suggested fee guide, effective February 1, 2017 [Internet].
2826 Vancouver: British Columbia Dental Association; 2017. [cited 2017 Mar 21]. Available from:
2827 <http://www.bcdental.org/WorkArea/DownloadAsset.aspx?id=13824>
- 2828 222. Kristoffersen AE, Musial F, Hamre HJ, Bjorkman L, Stub T, Salamonsen A, et al. Use of complementary and
2829 alternative medicine in patients with health complaints attributed to former dental amalgam fillings. *BMC*

- 2830 Altern Med [Internet]. 2016 Jan 22 [cited 2018 Jan 4];16:22. Available from:
2831 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722717/pdf/12906_2016_Article_996.pdf
- 2832 223. Lygre GB, Helland V, Gjerdet NR, Bjorkman L. [Health complaints related to dental filling materials]. Tidsskr
2833 Nor Laegeforen [Internet]. 2007 May 31 [cited 2018 Jan 4];127(11):1524-8. Available from:
2834 <http://tidsskriftet.no/sites/default/files/pdf2007--1524-8.pdf> Norwegian.
- 2835 224. Sundstrom A, Bergdahl J, Nyberg L, Bergdahl M, Nilsson LG. Stressful negative life events and amalgam-
2836 related complaints. Community Dent Oral Epidemiol. 2011 Feb;39(1):12-8.
- 2837 225. Naimi-Akbar A, Svedberg P, Alexanderson K, Carlstedt-Duke B, Ekstrand J, Englund GS. Health-related
2838 quality of life and symptoms in patients with experiences of health problems related to dental restorative
2839 materials. Community Dent Oral Epidemiol. 2013 Apr;41(2):163-72.
- 2840 226. Woods JS, Heyer NJ, Russo JE, Martin MD, Farin FM. Genetic polymorphisms affecting susceptibility to
2841 mercury neurotoxicity in children: summary findings from the Casa Pia Children's Amalgam clinical trial.
2842 Neurotoxicology [Internet]. 2014 Sep [cited 2017 Jul 20];44:288-302. Available from:
2843 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176692/pdf/nihms-620111.pdf>
- 2844 227. Andreoli V, Sprovieri F. Genetic aspects of susceptibility to mercury toxicity: an overview. Int J Environ Res
2845 Public Health [Internet]. 2017 Jan 18 [cited 2017 Dec 18];14(1). Available from:
2846 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295343>
- 2847 228. Pettini F, Savino M, Corsalini M, Cantore S, Ballini A. Cytogenetic genotoxic investigation in peripheral blood
2848 lymphocytes of subjects with dental composite restorative filling materials. J Biol Regul Homeost Agents.
2849 2015 Jan;29(1):229-33.
- 2850 229. Rekow ED, Fox CH, Watson T, Petersen PE. Future innovation and research in dental restorative materials.
2851 Adv Dent Res. 2013 Nov;25(1):2-7.
- 2852 230. Public dental programs and reimbursement for dental restorative procedures. Ottawa (ON): CADTH; 2018.
2853 (Environmental scan). Forthcoming.
- 2854 231. Liu H, Baldwin J, Tanguay M. The Canadian Productivity Review – An Update on Depreciation Rates for the
2855 Canadian Productivity Accounts, no. 39 [Internet]. Ottawa: Statistics Canada; Table 4 Depreciation rates for
2856 select machinery and equipment categories. [cited 2017 Dec 19]. Available from:
2857 <http://www.statcan.gc.ca/pub/15-206-x/2015039/t/tbl04-eng.htm>
- 2858 232. Stahlnacke K, Soderfeldt B. An interview study of persons who attribute health problems to dental filling
2859 materials--part two in a triangulation study on 65 and 75 years old Swedes. Swed Dent J. 2013;37(3):121-
2860 30.
- 2861 233. Moss J. Mercury revisited - part II: does body burden tell the whole story? Nutr Perspect. 2008 Jan;31(1):8-
2862 16.
- 2863 234. Science versus emotion in dental filling debate: who should choose what goes in your mouth? J N J Dent
2864 Assoc. 2003;74(2):16.
- 2865 235. The mercury scare. J Dent Que. 1988 Mar;25:139-42.
- 2866 236. An ethical problem. Br Dent J. 1984 Apr 7;156(7):238.
- 2867 237. Arnetz BB, Horte LG, Hedberg A, Malaker H. Suicide among Swedish dentists. A ten-year follow-up study.
2868 Scand J Soc Med. 1987;15(4):243-6.
- 2869 238. Anderson PE. Study shows long-term mercury exposure harmful to dentists, not patients. Dent Econ. 1983
2870 May;73(5):65-6.
- 2871 239. Johnson KF. Mercury hygiene. Dent Clin North Am. 1978 Jul;22(3):477-89.


- 2872 240. Wilson J. Reduction of mercury vapour in a dental surgery. *Lancet*. 1978 Jan 28;1(8057):200-1.
- 2873 241. Gelband H. The science and politics of dental amalgam. *Int J Technol Assess Health Care*. 1998;14(1):123-34.
- 2874
- 2875 242. Vimy MJ, Lorscheider FL. Serial measurements of intra-oral air mercury: estimation of daily dose from dental amalgam. *J Dent Res*. 1985 Aug;64(8):1072-5.
- 2876
- 2877 243. Siblingud RL. A comparison of mental health of multiple sclerosis patients with silver/mercury dental fillings and those with fillings removed. *Psychol Rep*. 1992 Jun;70(3 Pt 2):1139-51.
- 2878
- 2879 244. Jones DW. Giving science a bad name. *J Can Dent Assoc*. 1991 Apr;57(4):291-3.
- 2880 245. Sheilds ED. Unscientific bias. *J Can Dent Assoc*. 1991 Apr;57(4):259.
- 2881 246. Miller A, Okabe T, DePaola DP, Cole JS. Amalgam and mercury toxicity: an update. *Tex Dent J*. 1991 May;108(5):25-9.
- 2882
- 2883 247. Schissel MJ, Dodes JE. Dentistry and alternative therapy. *N Y State Dent J*. 1997 Mar;63(3):32-7.
- 2884 248. Corbin SB, Kohn WG. The benefits and risks of dental amalgam: current findings reviewed. *J Am Dent Assoc*. 1994 Apr;125(4):381-8.
- 2885
- 2886 249. Levy M. Dental amalgam: toxicological evaluation and health risk assessment. *J Can Dent Assoc*. 1995 Aug;61(8):667-8.
- 2887
- 2888 250. Eley BM. The future of dental amalgam: a review of the literature. Part 6: possible harmful effects of mercury from dental amalgam. *Br Dent J*. 1997 Jun 28;182(12):455-9.
- 2889
- 2890 251. Ahlqwist M, Bengtsson C, Lapidus L. Number of amalgam fillings in relation to cardiovascular disease, diabetes, cancer and early death in Swedish women. *Community Dent Oral Epidemiol*. 1993 Feb;21(1):40-4.
- 2891
- 2892 252. Sobczak G. Dental amalgam toxicity. *Wda j*. 1990 Sep;66(9):472-4.
- 2893 253. Meyer CB. Amalgam revisited. *J Am Dent Assoc*. 1994 Aug;125(8):1048-452.
- 2894 254. Rice DC. Evidence for delayed neurotoxicity produced by methylmercury. *Neurotoxicology*. 1996;17(3-4):583-96.
- 2895
- 2896 255. McGrother CW, Dugmore C, Phillips MJ, Raymond NT, Garrick P, Baird WO. Multiple sclerosis, dental caries and fillings: a case-control study. *Br Dent J*. 1999 Sep 11;187(5):261-4.
- 2897
- 2898 256. Malt UF, Nerdrum P, Oppedal B, Gundersen R, Holte M, Lone J. Physical and mental problems attributed to dental amalgam fillings: a descriptive study of 99 self-referred patients compared with 272 controls. *Psychosom Med*. 1997 Jan;59(1):32-41.
- 2899
- 2900
- 2901 257. Anusavice KJ, Mjor IA. Response to patients who inquire about the safety of dental amalgam. *Quintessence Int*. 1991 Apr;22(4):249-50.
- 2902
- 2903 258. Refusal to replace amalgams does not constitute malpractice. *J Can Dent Assoc*. 1993 Sep;59(9):721-2.
- 2904 259. Tanchyk AP. Patient- or physician-initiated amalgam removal for treatment of arthritis. *Gen Dent*. 1994 Jul;42(4):354-8.
- 2905
- 2906 260. Brennan DS, Spencer AJ. Responsibility loadings for dental services by general dentists. *BMC health services research*. 2010;10:177.
- 2907
- 2908 261. Fallowfield MG. 'Dental amalgam: a review'. *Br Dent J*. 1993 Nov 6;175(9):313.

- 2909 262. Vimy MJ, Lorscheider FL. Intra-oral air mercury released from dental amalgam. *J Dent Res.* 1985
2910 Aug;64(8):1069-71.
- 2911 263. Vimy MJ, Takahashi Y, Lorscheider FL. Maternal-fetal distribution of mercury (203Hg) released from dental
2912 amalgam fillings. *Am J Physiol.* 1990 Apr;258(4 Pt 2):R939-R945.
- 2913 264. Lorscheider FL, Vimy MJ, Summers AO. Mercury exposure from "silver" tooth fillings: emerging evidence
2914 questions a traditional dental paradigm. *FASEB J.* 1995 Apr;9(7):504-8.
- 2915 265. Richardson GM. Assessment of mercury exposure and risks from dental amalgam. Ottawa: Health Canada,
2916 Environmental Health Directorate, Medical Devices Bureau; 1995 Aug 18.
- 2917 266. Brookfield JR. Good news on amalgam. *J Can Dent Assoc.* 1996 Mar;62(3):197.
- 2918 267. Update on amalgam from around the world. *J Dent Assoc S Afr.* 1997 Jan;52(1):47-8.
- 2919 268. Sweden Ministry of the Environment. Press release, Government bans all use of mercury in Sweden.
2920 Stockholm (SE): Sweden Ministry of the Environment; 2009 Jan 15.
- 2921 269. Maxson P. Mercury in dental use: environmental implications for the European Union, Concorde [Internet].
2922 Brussels: European Environmental Bureau; 2007. [cited 2017 Nov 16]. Available from:
2923 <http://www.zeromercury.org/phocadownload/Events/Maxson%20Dental%2014May2007%20-%20A5colour.pdf>
2924
- 2925 270. Restrictions on the use of amalgam in Europe. *Community Dent Health.* 1998 Jun;15(2):128, 1998.
- 2926 271. Clarkson TW, Magos L, Myers GJ. The toxicology of mercury--current exposures and clinical manifestations.
2927 *N Engl J Med.* 2003 Oct 30;349(18):1731-7.
- 2928 272. Mutter J, Naumann J, Guethlin C. Comments on the article "the toxicology of mercury and its chemical
2929 compounds" by Clarkson and Magos (2006). *Crit Rev Toxicol.* 2007;37(6):537-49.
- 2930 273. Bedir Findik R, Celik HT, Ersoy AO, Tasci Y, Moraloglu O, Karakaya J. Mercury concentration in maternal
2931 serum, cord blood, and placenta in patients with amalgam dental fillings: effects on fetal biometric
2932 measurements. *J Matern Fetal Neonatal Med.* 2016 Nov;29(22):3665-9.
- 2933 274. Golding J, Steer CD, Gregory S, Lowery T, Hibbeln JR, Taylor CM. Dental associations with blood mercury
2934 in pregnant women. *Community Dent Oral Epidemiol* [Internet]. 2016 Jun [cited 2017 Jul 27];44(3):216-22.
2935 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840325/pdf/CDOE-44-216.pdf>
- 2936 275. Guzzi G, Grandi M, Cattaneo C, Calza S, Minoia C, Ronchi A, et al. Dental amalgam and mercury levels in
2937 autopsy tissues: food for thought. *Am J Forensic Med Pathol.* 2006 Mar;27(1):42-5.
- 2938 276. Moss J. Mercury revisited -- part 1. *Nutr Perspect.* 2007 Oct;30(4):30-8.
- 2939 277. Allison P, Bedos C. What are the research priorities of Canadian dentists? *J Can Dent Assoc* [Internet].
2940 2002 Dec [cited 2017 Jul 27];68(11):662. Available from: <http://www.cda-adc.ca/jcda/vol-68/issue-11/662.pdf>
- 2941 278. Mortazavi SM, Neghab M, Anoosheh SM, Bahaeddini N, Mortazavi G, Neghab P, et al. High-field MRI and
2942 mercury release from dental amalgam fillings. *Int J Occup Environ Med* [Internet]. 2014 Apr [cited 2017 Aug
2943 22];5(2):101-5. Available from: <http://www.theijoem.com/ijoem/index.php/ijoem/article/view/316/469>
- 2944 279. Mortazavi SM, Daiee E, Yazdi A, Khiabani K, Kavousi A, Vazirinejad R, et al. Mercury release from dental
2945 amalgam restorations after magnetic resonance imaging and following mobile phone use. *Pak J Biol Sci.*
2946 2008 Apr 15;11(8):1142-6.
- 2947 280. Rossi MS. Amalgam under attack. *N Y State Dent J.* 2002 Dec;68(10):6-7.

- 2948
2949
2950
281. Food and Drug Administration, HHS. Dental devices: classification of dental amalgam, reclassification of dental mercury, designation of special controls for dental amalgam, mercury, and amalgam alloy. Final rule. Fed Regist. 2009 Aug 4 [cited 2017 Jul 27];74(148):38685-714.
- 2951
2952
282. Roberts C, Lee JY, Wright JT. Clinical evaluation of and parental satisfaction with resin-faced stainless steel crowns. *Pediatr Dent*. 2001 Jan;23(1):28-31.
- 2953
2954
283. Burk JW. The impact of mercury on the environment. *J Calif Dent Assoc* [Internet]. 2004 Nov [cited 2017 Jul 27];32(11):885. Available from: https://www.cda.org/Portals/0/journal/journal_112004.pdf
- 2955
2956
284. Groopman J. The plastic panic: how worried should we be about everyday chemicals? *New Yorker*. 2010 May;26-31.
- 2957
285. Briggs P. An amalgam-free world--are we and our patients ready? *Dent Update*. 2016 Jan;43(1):5-6.
- 2958
2959
2960
286. Austin R, Eliyas S, Burke FJ, Taylor P, Toner J, Briggs P. British Society of Prosthodontics debate on the implications of the Minamata Convention on Mercury to dental amalgam--should our patients be worried? *Dent Update*. 2016 Jan;43(1):8-10.
- 2961
2962
287. Ferracane J, Fisher J, Eisele JL, Fox CH. Ensuring the global availability of high-quality dental restorative materials. *Adv Dent Res*. 2013 Nov;25(1):41-5.
- 2963

2964
2965

Appendix 1: Analytical Framework



2966
2967

2968

Appendix 2: Literature Search Strategy

2969

Clinical Review Database Search

| OVERVIEW | |
|-----------------|--|
| Interface: | Ovid |
| Databases: | EBM Reviews - Cochrane Central Register of Controlled Trials May 2017 Embase 1974 to present MEDLINE Daily and MEDLINE 1946 to Present MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations Note: Subject headings have been customized for each database. Duplicates between databases were removed in Ovid. |
| Date of Search: | June 26, 2017 |
| Alerts: | Monthly search updates were run until project completion; only citations retrieved before February 12, 2018 were incorporated into the analysis. |
| Search filters: | Clinical effectiveness search: no filters were applied Safety search: safety filters |
| Limits: | Date limits: Clinical effectiveness search: 2012 – present Safety search: none for dental amalgam search; 2006-present for composite resin search Language limits: none applied Conference abstracts: Clinical effectiveness search: included Safety search: excluded |
| SYNTAX GUIDE | |
| / | At the end of a phrase, searches the phrase as a subject heading |
| exp | Explode a subject heading |
| * | Before a word, indicates that the marked subject heading is a primary topic; or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings |
| \$ | Before a word, indicates that the marked subject heading is a primary topic; or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings Requires words are adjacent to each other (in any order) |
| adj | Adjacency within # number of words (in any order) |
| adj# | |
| .ti | Title |
| .ab | Abstract |
| .kf | Author keyword heading word (MEDLINE) |
| .af | All fields (Cochrane Central) |
| .kw | Author keyword (Embase); keyword (Cochrane Central) |
| .jw | Journal word (MEDLINE) |
| .jx | Journal word (Embase) |
| .pt | Publication type |
| /ae | Subject heading qualifier (MEDLINE); adverse effects Subject heading qualifier (Embase); adverse drug reaction |
| /tu | Subject heading qualifier (MEDLINE); therapeutic use |
| /th | Subject heading qualifier; therapy |
| /ct | Subject heading qualifier (MEDLINE); contraindications |
| /po | Subject heading qualifier (MEDLINE); poisoning |
| /to | Subject heading qualifier (MEDLINE); toxicity Subject heading qualifier (Embase); drug toxicity |
| /bl | Subject heading qualifier (MEDLINE); blood |
| /mo | Subject heading qualifier (MEDLINE); mortality |
| /co | Subject heading qualifier (MEDLINE); complications |
| /am | Subject heading qualifier (Embase); adverse device effect |
| ppez | Ovid database code: MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE Daily and Ovid MEDLINE 1946 to Present |
| oemezd | Ovid database code: Embase 1974 to present, updated daily |
| cctr | Ovid database code: Cochrane Central Register of Controlled Trials |

2970

2971

Research Question 1: Clinical Efficacy

| MULTI-SEARCH STRATEGY | |
|-----------------------|---|
| # | Searches |
| 1 | exp Dental restoration, permanent/ |
| 2 | Dental restoration, temporary/ |
| 3 | ((tooth or teeth or molar\$ or bicuspid\$ or "Class I" or "Class II") and (restor\$ or fill\$)).ti,ab,kf. |
| 4 | or/1-3 |
| 5 | Dental amalgam/ |
| 6 | amalgam\$.ti,ab,kf. |
| 7 | or/5-6 |
| 8 | exp Composite resins/ |
| 9 | ((resin\$ adj3 composite\$) or "bisphenol A-Glycidyl methacrylate" or compomer\$ or Bis-GMA).ti,ab,kf. |
| 10 | (enamel bond\$ or (concise adj3 resin\$) or (white adj3 sealant\$) or conclude resin\$ or Adaptic or Delton or EpoxyLite-9075 or (Kerr adj5 seal\$) or Nuva-seal or Panavia or Retroplast or Silux).ti,ab,kf. |
| 11 | or/8-10 |
| 12 | 4 and 7 and 11 |
| 13 | 12 use ppez |
| 14 | exp Dental Restoration, Permanent/ |
| 15 | exp Dental Restoration, Temporary/ |
| 16 | ((tooth or teeth or molar\$ or bicuspid\$ or "Class I" or "Class II") and (restor\$ or fill\$)).af. |
| 17 | or/14-16 |
| 18 | Dental amalgam/ |
| 19 | amalgam\$.ti,ab,kw. |
| 20 | or/18-19 |
| 21 | exp Composite resins/ |
| 22 | ((resin\$ adj3 composite\$) or "bisphenol A-Glycidyl methacrylate" or compomer\$ or Bis-GMA).ti,ab,kw. |
| 23 | (enamel bond\$ or (concise adj3 resin\$) or (white adj3 sealant\$) or conclude resin\$ or Adaptic or Delton or EpoxyLite-9075 or (Kerr adj5 seal\$) or Nuva-seal or Panavia or Retroplast or Keywords or Silux).ti,ab,kw. |
| 24 | or/21-23 |
| 25 | 17 and 20 and 24 |
| 26 | 25 use cctr |
| 27 | Tooth filling/ |
| 28 | ((tooth or teeth or molar\$ or bicuspid\$ or "Class I" or "Class II") and (restor\$ or fill\$)).ti,ab,kw. |
| 29 | or/27-28 |
| 30 | exp Dental alloy/ |
| 31 | amalgam\$.ti,ab,kw. |
| 32 | or/30-31 |
| 33 | exp Resin/ |
| 34 | ((resin\$ adj3 composite\$) or "bisphenol A-Glycidyl methacrylate" or compomer\$ or Bis-GMA).ti,ab,kw. |
| 35 | (enamel bond\$ or (concise adj3 resin\$) or (white adj3 sealant\$) or conclude resin\$ or Adaptic or Delton or EpoxyLite-9075 or (Kerr adj5 seal\$) or Nuva-seal or Panavia or Retroplast or Silux).ti,ab,kw. |
| 36 | or/33-35 |
| 37 | 29 and 32 and 36 |
| 38 | 37 use oemez |

| | |
|----|--------------------------------|
| 39 | 13 or 26 or 38 |
| 40 | limit 39 to yr="2012 -Current" |
| 41 | remove duplicates from 40 |

2974

2975

Research Question 2: Safety

| MULTI-SEARCH STRATEGY | |
|-----------------------|--|
| # | Searches |
| 1 | Dental amalgam/ |
| 2 | (exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/tu or exp Dental caries/th) and (Silver/ or Mercury/ or (amalgam or amalgams or silver or mercury).ti,ab,kf,kw.) |
| 3 | ((silver or mercury) and (dental or dentist* or tooth or teeth or filling* or premolar* or molar* or bicuspid* or incisor* or cuspid*)).ti,ab,kf,kw. |
| 4 | (amalgam or amalgams).ti,ab,kf,kw. and (Silver/ or Mercury/ or (dental or dentist* or tooth or teeth or silver or mercury or filling* or restor* or premolar* or molar* or bicuspid* or incisor* or cuspid*).ti,ab,kf,kw.) |
| 5 | (amalgam or amalgams).ti. and (dentist* or dental or oral biology or oral bioscience* or oral health or oral research or endodont* or oral science or caries research or oral medical or dentaire or stomatolog*).jw. |
| 6 | or/1-5 |
| 7 | 6 use ppez |
| 8 | 6 use cctr |
| 9 | Dental amalgam/ |
| 10 | Dental alloy/ and Amalgam/ |
| 11 | (Dental restoration/ or Dental Material/ or Tooth Filling/ or exp Dental Caries/th) and (Silver/ or Mercury/ or (amalgam or amalgams or silver or mercury).ti,ab,kw.) |
| 12 | ((silver or mercury) and (dental or dentist* or tooth or teeth or filling* or premolar* or molar* or bicuspid* or incisor* or cuspid*)).ti,ab,kw. |
| 13 | (amalgam/ or (amalgam or amalgams).ti,ab,kw.) and (Silver/ or Mercury/ or (dental or dentist* or tooth or teeth or silver or mercury or filling* or restor* or molar* or bicuspid* or incisor* or cuspid*).ti,ab,kw.) |
| 14 | (amalgam or amalgams).ti. and (dentist* or dental or oral biology or oral bioscience* or oral health or oral research or endodont* or oral science or caries research or oral medical or dentaire or stomatolog*).jx. |
| 15 | or/9-14 |
| 16 | 15 use oomezd |
| 17 | conference abstract.pt. |
| 18 | 16 not 17 |
| 19 | 7 or 8 or 18 |
| 20 | exp safety/ |
| 21 | equipment safety/ |
| 22 | exp equipment failure/ |
| 23 | consumer product safety/ |
| 24 | "product recalls and withdrawals"/ |
| 25 | medical device recalls/ |
| 26 | "safety-based medical device withdrawals"/ |
| 27 | product surveillance, postmarketing/ |
| 28 | postmarketing surveillance/ |
| 29 | clinical trial, phase iv.pt. |
| 30 | phase 4 clinical trial/ |
| 31 | clinical trials, phase iv as topic/ |

| | |
|----|---|
| 32 | "phase 4 clinical trial (topic)"/ |
| 33 | exp postoperative complications/ |
| 34 | exp postoperative complication/ |
| 35 | exp intraoperative complications/ |
| 36 | peroperative complication/ |
| 37 | exp side effect/ |
| 38 | "side effects (treatment)"/ |
| 39 | exp adverse drug reaction/ |
| 40 | exp drug safety/ |
| 41 | exp "drug toxicity and intoxication"/ |
| 42 | exp "drug-related side effects and adverse reactions"/ |
| 43 | exp drug-induced liver injury/ |
| 44 | exp drug hypersensitivity/ |
| 45 | drug recalls/ |
| 46 | drug recall/ |
| 47 | safety-based drug withdrawals/ |
| 48 | abnormalities, drug-induced/ |
| 49 | exp "side effects (drug)"/ |
| 50 | (hazard* or defect* or misuse* or failure* or malfunction* or error*).ti,kf,kw. |
| 51 | (safe* or adverse* or undesirable or harm* or injurious or risk or risks or reaction* or complication* or poison*).ti,kf,kw. |
| 52 | (side effect* or safety or unsafe).ti,ab,kf,kw. |
| 53 | ((adverse or undesirable or harm* or toxic or injurious or serious or fatal) adj3 (effect* or reaction* or event* or outcome* or incident*)).ab. |
| 54 | ((drug or chemically) adj induced).ti,ab,kf,kw. |
| 55 | (toxic or toxicit* or toxicologic* or intoxication or noxious or tolerability or teratogen*).ti,ab,kf,kw. |
| 56 | (warning* or recall* or withdrawn* or withdrawal*).ti,kf,kw. |
| 57 | (death or deaths or fatal or fatality or fatalities).ti,kf,kw. |
| 58 | exp environmental exposure/ |
| 59 | or/20-58 |
| 60 | 19 and 59 |
| 61 | Dental amalgam/ae, ct, po, to |
| 62 | exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/ or exp Dental caries/th or Dental amalgam/ or (amalgam or amalgams or dental or dentist* or tooth or teeth or filling* or premolar* or molar* or bicuspid* or incisor* or cuspid*).ti,ab,kf,kw. |
| 63 | Silver/ae, ct, to or Mercury/ae, to, bl or exp Mercury poisoning/ or exp Mercury poisoning, nervous system/ |
| 64 | 62 and 63 |
| 65 | exp Dental Restoration, Permanent/ae, ct, mo or Dental Restoration, Temporary/ae, ct or Dental Materials/ae, co, ct, po, to |
| 66 | Dental amalgam/ or Silver/ or Mercury/ or (amalgam or amalgams or silver or mercury).ti,ab,kf,kw. |
| 67 | 65 and 66 |
| 68 | 61 or 64 or 67 |
| 69 | 68 use ppez |
| 70 | 68 use cctr |
| 71 | Dental amalgam/ae, to |
| 72 | Dental alloy/ae, to and amalgam/am, ae, to |
| 73 | Dental restoration/ or Dental Material/ or Tooth Filling/ or exp Dental Caries/th or Dental alloy/ or dental amalgam/ or (amalgam or amalgams or dental or dentist* or tooth or teeth or filling* or premolar* or molar* or bicuspid* or incisor* or cuspid*).ti,ab,kw. |

| | |
|-----|---|
| 74 | Silver/ae, to or Mercury/ae, to or Mercurialism/ |
| 75 | 73 and 74 |
| 76 | amalgam/am, ae, to and (dental or dentist* or tooth or teeth or silver or mercury or filling* or restor* or molar* or bicuspid* or incisor* or cuspid*).ti,ab,kw. |
| 77 | Dental procedure/ae or Dental Material/am, ae, to |
| 78 | Amalgam/ or Dental amalgam/ or (amalgam or amalgams or silver or mercury).ti,ab,kw. |
| 79 | 77 and 78 |
| 80 | 71 or 72 or 75 or 76 or 79 |
| 81 | 80 use oomezd |
| 82 | 81 not 17 |
| 83 | 69 or 70 or 82 |
| 84 | 60 or 83 |
| 85 | exp Composite Resins/ |
| 86 | (exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/tu or exp Dental caries/th) and composite*.ti,ab,kf,kw. |
| 87 | (composite* adj3 (resin* or restor* or filling* or dental or dentist* or conventional or microfilled or macrofilled or hybrid or flowable or packable or nanofilled or direct or indirect or small particle* or condensable or bonded or non-bonded or nonbonded)).ti,ab,kf,kw. |
| 88 | (composite* adj3 (poly-acid or polyacid or polyacrylate or polyacrylic or acrylic)).ti,ab,kf,kw. |
| 89 | ((resin or resins) adj3 (filled or unfilled or synthetic* or dental or restor*)).ti,ab,kf,kw. |
| 90 | ((tooth-colored or tooth-coloured) adj3 (filling* or restor*)).ti,ab,kf,kw. |
| 91 | (White adj3 filling*).ti,ab,kf,kw. |
| 92 | exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/tu or exp Dental caries/th or (composite* or resin or resins).ti,ab,kf,kw. |
| 93 | Bisphenol A-Glycidyl Methacrylate/ or (alumino silicate polyacrylic acid or "bisphenol A-Glycidyl methacrylate" or Bis-GMA or BisGMA or triethylene glycol dimethacrylate or urethane dimethacrylate*).ti,ab,kf,kw. |
| 94 | 92 and 93 |
| 95 | Compomer*.ti,ab,kf,kw. |
| 96 | composite*.ti. and (dentist* or dental or oral biology or oral bioscience* or oral health or oral research or endodont* or oral science or caries research or oral medical or dentaire or stomatolog*).jw. |
| 97 | or/85-91,94-96 |
| 98 | 97 use ppez |
| 99 | 97 use cctr |
| 100 | exp Resin/ and composit*.ti,ab,kw. |
| 101 | (Dental restoration/ or Dental Material/ or Tooth Filling/ or exp Dental Caries/th) and composite*.ti,ab,kw. |
| 102 | (composite* adj3 (resin* or restor* or filling* or dental or dentist* or conventional or microfilled or macrofilled or hybrid or flowable or packable or nanofilled or direct or indirect or small particle* or condensable or bonded or non-bonded or nonbonded)).ti,ab,kw. |
| 103 | (composite* adj3 (poly-acid or polyacid or polyacrylate or polyacrylic or acrylic)).ti,ab,kw. |
| 104 | ((resin or resins) adj3 (filled or unfilled or synthetic* or dental or restor*)).ti,ab,kw. |
| 105 | ((Tooth-colored or tooth-coloured) adj3 (filling* or restor*)).ti,ab,kw. |
| 106 | (White adj3 filling*).ti,ab,kw. |
| 107 | Dental restoration/ or Dental Material/ or Tooth Filling/ or exp Dental Caries/th or (composite* or resin or resins).ti,ab,kw. |
| 108 | "bisphenol A bis(2 hydroxypropyl) ether dimethacrylate"/ or (alumino silicate polyacrylic acid or "bisphenol A-Glycidyl methacrylate" or Bis-GMA or BisGMA or triethylene glycol dimethacrylate or urethane dimethacrylate*).ti,ab,kw. |
| 109 | 107 and 108 |
| 110 | Compomer*.ti,ab,kw. |
| 111 | composite*.ti. and (dentist* or dental or oral biology or oral bioscience* or oral health or oral research or endodont* or oral science or |

| | |
|-----|---|
| | caries research or oral medical or dentaire or stomatolog*).jx. |
| 112 | or/100-106,109-111 |
| 113 | 112 use oomezd |
| 114 | 113 not 17 |
| 115 | 98 or 99 or 114 |
| 116 | 59 and 115 |
| 117 | exp Composite Resins/ae, ct, to |
| 118 | exp Dental Restoration, Permanent/ae, ct, mo or Dental Restoration, Temporary/ae, ct or Dental Materials/ae, co, ct, po, to |
| 119 | Composite resins/ or (composite* or resin or resins).ti,ab,kf,kw. |
| 120 | 118 and 119 |
| 121 | exp Dental Restoration, Permanent/ae, ct, mo or Dental Restoration, Temporary/ae, ct or Dental Materials/ae, co, ct, po, to |
| 122 | ("bisphenol A-Glycidyl methacrylate" or Bis-GMA or BisGMA).ti,ab,kf,kw. |
| 123 | 121 and 122 |
| 124 | 117 or 120 or 123 |
| 125 | 124 use ppez |
| 126 | 124 use cctr |
| 127 | exp Resin/am, ae, to and composit*.ti,ab,kw. |
| 128 | Dental procedure/ae or Dental Material/am, ae, to |
| 129 | exp Resin/ or (composite* or resin or resins).ti,ab,kw. |
| 130 | 128 and 129 |
| 131 | Dental procedure/ae or Dental Material/am, ae, to |
| 132 | ("bisphenol A-Glycidyl methacrylate" or Bis-GMA or BisGMA).ti,ab,kw. |
| 133 | 131 and 132 |
| 134 | 127 or 130 or 133 |
| 135 | 134 use oomezd |
| 136 | 135 not 17 |
| 137 | 125 or 126 or 136 |
| 138 | 116 or 137 |
| 139 | limit 138 to yr="2006 -Current" |
| 140 | 84 or 139 |
| 141 | limit 140 to yr="2005 -Current" |
| 142 | 140 not 141 |
| 143 | remove duplicates from 141 |
| 144 | remove duplicates from 142 |
| 145 | 143 or 144 |
| 146 | from 145 keep 1-3870 |
| 147 | from 145 keep 3871-5871 |

2977

| OTHER DATABASES | |
|------------------|---|
| PubMed | Searched to capture records not found in MEDLINE. Same MeSH, keywords, limits, and study types used as per MEDLINE search, with appropriate syntax used. |
| Cochrane Library | Searched to capture records not indexed in MEDLINE. Same MeSH, keywords and limits used as per MEDLINE search, with appropriate syntax used |
| CINAHL | Searched to capture records not indexed in MEDLINE. Same MeSH, keywords and limits used as per MEDLINE search, with appropriate syntax used, including the addition of CINAHL headings. |

| | |
|--|--|
| Scopus | Searched to capture records not indexed in MEDLINE. Keyword search and limits based on MEDLINE search, with appropriate syntax used. |
| Cochrane Oral Health Group's Trials Register | Searched to capture records not indexed in MEDLINE. Same keywords used as per MEDLINE search. Syntax adjusted for Cochrane Oral Health Group's Trials Register. (Database not publically available; search completed by the Information Specialist at the Cochrane Oral Health group) |
| LILACs | Searched to capture records not indexed in MEDLINE. Same MeSH, keywords, and date limits used as per MEDLINE search. Syntax adjusted for LILACs database. (LILACs search completed only for Q1 Clinical Effectiveness) |

2978

2979

Patients' Perspectives and Experience Database Searches

| OVERVIEW | |
|-----------------|--|
| Interface: | Ovid |
| Databases: | MEDLINE Daily and MEDLINE 1946 to Present MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations |
| Date of Search: | Qualitative studies search: June 8, 2017 Patient preferences search: July 20, 2017 |
| Alerts: | Monthly search updates were run until project completion; only citations retrieved before February 12, 2018 were incorporated into the analysis |
| Search filters: | Qualitative studies; patient preferences |
| Limits: | Date limit: none Language limit: none |
| SYNTAX GUIDE | |
| / | At the end of a phrase, searches the phrase as a subject heading |
| exp | Explode a subject heading |
| * | Before a word, indicates that the marked subject heading is a primary topic; or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings Truncation symbol for one or no characters only |
| ? | Before a word, indicates that the marked subject heading is a primary topic; |
| \$ | or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings |
| adj | Requires words are adjacent to each other (in any order) |
| adj# | Adjacency within # number of words (in any order) |
| .ti | Title |
| .ab | Abstract |
| .kf | Author keyword heading word |
| .jw | Journal title word |
| .jn | Journal name |
| freq=2 | Frequency (must appear at least two times) |
| /tu | Subject heading qualifier: therapeutic use |
| /th | Subject heading qualifier: therapy |
| ppsz | Ovid database code: MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE Daily and Ovid MEDLINE 1946 to Present |

2980

2981

Qualitative Studies Database Search

| MULTI-SEARCH STRATEGY | |
|-----------------------|---|
| # | Searches |
| 1 | Dental amalgam/ |
| 2 | (exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/tu or exp Dental caries/th) and (Silver/ or Mercury/ or (amalgam or amalgams or silver or mercury).ti,ab,kf.) |
| 3 | ((silver or mercury) and (dental or dentist* or tooth or teeth or filling* or premolar* or molar* or bicuspid* or incisor* or |

| | |
|----|--|
| | cuspid*).ti,ab,kf. |
| 4 | (amalgam or amalgams).ti,ab,kf. and (Silver/ or Mercury/ or (dental or dentist* or tooth or teeth or silver or mercury or filling* or restor* or premolar* or molar* or bicuspid* or incisor* or cuspid*).ti,ab,kf.) |
| 5 | (amalgam or amalgams).ti. and (dentist* or dental or oral biology or oral bioscience* or oral health or oral research or endodont* or oral science or caries research or oral medical or dentaire or stomatolog*).jw. |
| 6 | or/1-5 |
| 7 | exp Composite Resins/ |
| 8 | (exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/tu or exp Dental caries/th) and composite*.ti,ab,kf. |
| 9 | (composite* adj3 (resin* or restor* or filling* or dental or dentist* or conventional or microfilled or macrofilled or hybrid or flowable or packable or nanofilled or direct or indirect or small particle* or condensable or bonded or non-bonded or nonbonded)).ti,ab,kf. |
| 10 | (composite* adj3 (poly-acid or polyacid or polyacrylate or polyacrylic or acrylic)).ti,ab,kf. |
| 11 | ((resin or resins) adj3 (filled or unfilled or synthetic* or dental or restor*).ti,ab,kf. |
| 12 | ((tooth-colored or tooth-coloured) adj3 (filling* or restor*).ti,ab,kf. |
| 13 | (White adj3 filling*).ti,ab,kf. |
| 14 | exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/tu or exp Dental caries/th or (composite* or resin or resins).ti,ab,kf. |
| 15 | Bisphenol A-Glycidyl Methacrylate/ or (alumino silicate polyacrylic acid or "bisphenol A-Glycidyl methacrylate" or Bis-GMA or BisGMA or triethylene glycol dimethacrylate or urethane dimethacrylate*).ti,ab,kf. |
| 16 | 14 and 15 |
| 17 | Compomer*.ti,ab,kf. |
| 18 | composite*.ti. and (dentist* or dental or oral biology or oral bioscience* or oral health or oral research or endodont* or oral science or caries research or oral medical or dentaire or stomatolog*).jw. |
| 19 | 7 or 8 or 9 or 10 or 11 or 12 or 13 or 16 or 17 or 18 |
| 20 | 6 or 19 |
| 21 | exp Empirical Research/ or Interview/ or Interviews as Topic/ or Personal Narratives/ or Focus Groups/ or Narration/ or Nursing Methodology Research/ |
| 22 | Interview/ |
| 23 | interview*.ti,ab,kf. |
| 24 | qualitative.ti,ab,kf,jn. |
| 25 | (theme* or thematic).ti,ab,kf. |
| 26 | ethnological research.ti,ab,kf. |
| 27 | ethnograph*.ti,ab,kf. |
| 28 | ethnonursing.ti,ab,kf. |
| 29 | phenomenol*.ti,ab,kf. |
| 30 | (grounded adj (theor* or study or studies or research or analys?s)).ti,ab,kf. |
| 31 | (life stor* or women* stor*).ti,ab,kf. |
| 32 | (emic or etic or hermeneutic* or heuristic* or semiotic*).ti,ab,kf. |
| 33 | (data adj1 saturat\$).ti,ab,kf. |
| 34 | participant observ*.ti,ab,kf. |
| 35 | (social construct* or postmodern* or post-structural* or post structural* or poststructural* or post modern* or post-modern* or feminis*).ti,ab,kf. |
| 36 | (action research or cooperative inquir* or co operative inquir* or co-operative inquir*).ti,ab,kf. |
| 37 | (humanistic or existential or experiential or paradigm*).ti,ab,kf. |
| 38 | (field adj (study or studies or research)).ti,ab,kf. |

| | |
|----|---|
| 39 | human science.ti,ab,kf. |
| 40 | biographical method.ti,ab,kf. |
| 41 | theoretical sampl*.ti,ab,kf. |
| 42 | ((purpos* adj4 sampl*) or (focus adj group*)).ti,ab,kf. |
| 43 | (open-ended or narrative* or textual or texts or semi-structured).ti,ab,kf. |
| 44 | (life world or life-world or conversation analys?s or personal experience* or theoretical saturation).ti,ab,kf. |
| 45 | ((lived or life) adj experience*).ti,ab,kf. |
| 46 | cluster sampl*.ti,ab,kf. |
| 47 | observational method*.ti,ab,kf. |
| 48 | content analysis.ti,ab,kf. |
| 49 | (constant adj (comparative or comparison)).ti,ab,kf. |
| 50 | ((discourse* or discours*) adj3 analys?s).ti,ab,kf. |
| 51 | narrative analys?s.ti,ab,kf. |
| 52 | (heidegger* or colaizzi* or spiegelberg* or merleau* or husserl* or foucault* or ricoeur or glaser*).ti,ab,kf. |
| 53 | (van adj manen*).ti,ab,kf. |
| 54 | (van adj kaam*).ti,ab,kf. |
| 55 | ((corbin* adj2 strauss*) or mixed method*).ti,ab,kf. |
| 56 | or/21-55 |
| 57 | 20 and 56 |

2983

2984

Patient Perspectives Database Search

| MULTI-SEARCH STRATEGY | |
|-----------------------|--|
| # | Searches |
| 1 | Dental amalgam/ |
| 2 | (exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/tu or exp Dental caries/th) and (Silver/ or Mercury/ or (amalgam or amalgams or silver or mercury)).ti,ab,kf.) |
| 3 | ((silver or mercury) and (dental or dentist* or tooth or teeth or filling* or premolar* or molar* or bicuspid* or incisor* or cuspid*)).ti,ab,kf. |
| 4 | (amalgam or amalgams).ti,ab,kf,kw. and (Silver/ or Mercury/ or (dental or dentist* or tooth or teeth or silver or mercury or filling* or restor* or premolar* or molar* or bicuspid* or incisor* or cuspid*)).ti,ab,kf.) |
| 5 | (amalgam or amalgams).ti. and (dentist* or dental or oral biology or oral bioscience* or oral health or oral research or endodont* or oral science or caries research or oral medical or dentaire or stomatolog*).jw. |
| 6 | or/1-5 |
| 7 | exp Composite Resins/ |
| 8 | (exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/tu or exp Dental caries/th) and composite*.ti,ab,kf. |
| 9 | (composite* adj3 (resin* or restor* or filling* or dental or dentist* or conventional or microfilled or macrofilled or hybrid or flowable or packable or nanofilled or direct or indirect or small particle* or condensable or bonded or non-bonded or nonbonded)).ti,ab,kf. |
| 10 | (composite* adj3 (poly-acid or polyacid or polyacrylate or polyacrylic or acrylic)).ti,ab,kf. |
| 11 | ((resin or resins) adj3 (filled or unfilled or synthetic* or dental or restor*)).ti,ab,kf. |
| 12 | ((tooth-colored or tooth-coloured) adj3 (filling* or restor*)).ti,ab,kf. |
| 13 | (White adj3 filling*).ti,ab,kf. |
| 14 | exp Dental Restoration, Permanent/ or Dental Restoration, Temporary/ or Dental Materials/tu or exp Dental caries/th or (composite* or resin or resins).ti,ab,kf. |
| 15 | Bisphenol A-Glycidyl Methacrylate/ or (alumino silicate polyacrylic acid or "bisphenol A-Glycidyl methacrylate" or Bis-GMA or BisGMA or triethylene glycol dimethacrylate or urethane dimethacrylate*).ti,ab,kf. |

| | |
|----|---|
| 16 | 14 and 15 |
| 17 | Compomer*.ti,ab,kf. |
| 18 | composite*.ti. and (dentist* or dental or oral biology or oral bioscience* or oral health or oral research or endodont* or oral science or caries research or oral medical or dentaire or stomatolog*).jw. |
| 19 | or/7-13,16-18 |
| 20 | 6 or 19 |
| 21 | exp patient acceptance of health care/ or caregivers/ |
| 22 | ((patient or patients or proband* or individuals or survivor* or family or families or familial or kindred* or relative or relatives or care giver* or caregiver* or carer or carers or personal or spous* or partner or partners or couples or users or participant* or people or child* or teenager* or adolescent* or youth or girls or boys or adults or elderly or females or males or women* or men or men's or mother* or father* or parents or parent or parental or maternal or paternal) and (preference* or preferred or input or experience or experiences or value or values or perspective* or perception* or perceive or perceived or expectation* or choice* or choose* or choosing or "day-to-day" or lives or participat* or acceptance or acceptability or acceptable or accept or accepted or adheren* or adhere or nonadheren* or complian* or noncomplian* or willingness or convenience or convenient or challenges or concerns or limitations or quality of life or satisfaction or satisfied or dissatisfaction or dissatisfied or burden or attitude* or knowledge or belief* or opinion* or understanding or lessons or reaction* or motivation* or motivated or intention* or involvement or engag* or consult* or interact* or dialog* or conversation* or decision* or decide* or deciding or empower* or survey* or questionnaire* or Likert or barrier* or facilitator*)).ti. |
| 23 | ((patient or patients or proband* or individuals or survivor* or family or families or familial or kindred* or relative or relatives or care giver* or caregiver* or carer or carers) adj2 (preference* or preferred or input or experience or experiences or value or values or perspective* or perception* or perceive or perceived or expectation* or choice* or choose* or choosing or "day-to-day" or lives or participat* or acceptance or acceptability or acceptable or accept or accepted or adheren* or adhere or nonadheren* or complian* or noncomplian* or willingness or convenience or convenient or challenges or concerns or limitations or quality of life or satisfaction or satisfied or dissatisfaction or dissatisfied or burden or attitude* or knowledge or belief* or opinion* or understanding or lessons or reaction* or motivation* or motivated or intention* or involvement or engag* or consult* or interact* or dialog* or conversation* or decision* or decide* or deciding or empower* or survey* or questionnaire* or Likert or barrier* or facilitator*)).ab,kf. |
| 24 | ((patient or patients or proband* or individuals or survivor* or family or families or familial or kindred* or relative or relatives or care giver* or caregiver* or carer or carers) adj7 (preference* or preferred or input or experience or experiences or value or values or perspective* or perception* or perceive or perceived or expectation* or choice* or choose* or choosing or "day-to-day" or lives or participat* or acceptance or acceptability or acceptable or accept or accepted or adheren* or adhere or nonadheren* or complian* or noncomplian* or willingness or convenience or convenient or challenges or concern or limitations or quality of life or satisfaction or satisfied or dissatisfaction or dissatisfied or burden or attitude* or knowledge or belief* or opinion* or understanding or lessons or reaction* or motivation* or motivated or intention* or involvement or engag* or consult* or interact* or dialog* or conversation* or decision* or decide* or deciding or empower* or survey* or questionnaire* or Likert or barrier* or facilitator*)).ab. /freq=2 |
| 25 | ((personal or spous* or partner or partners or couples or users or participant* or people or child* or teenager* or adolescent* or youth or girls or boys or adults or elderly or females or males or women* or men or men's or mother* or father* or parents or parent or parental or maternal or paternal) adj2 (preference* or preferred or input or experience or experiences or value or values or perspective* or perception* or perceive or perceived or expectation* or choice* or choose* or choosing or "day-to-day" or lives or participat* or acceptance or acceptability or acceptable or accept or accepted or adheren* or adhere or nonadheren* or complian* or noncomplian* or willingness or convenience or convenient or challenges or concerns or limitations or quality of life or satisfaction or satisfied or dissatisfaction or dissatisfied or burden or attitude* or knowledge or belief* or opinion* or understanding or lessons or reaction* or motivation* or motivated or intention* or involvement or engag* or consult* or interact* or dialog* or conversation* or decision* or decide* or deciding or empower* or survey* or interview* or questionnaire* or Likert or barrier* or facilitator*)).ab. /freq=2 |
| 26 | (patient adj (reported or centered* or centred* or focused)).ti,ab,kf. |
| 27 | (treatment* adj2 (satis* or refus*)).ti,ab,kf. |
| 28 | ((lived experience* or shared decision making).ti,ab,kf. |
| 29 | or/21-28 |
| 30 | 20 and 29 |

2986

| OTHER DATABASES | |
|-----------------|---|
| CINAHL | Searched to capture records not indexed in MEDLINE. Same MeSH, keywords and limits used as per MEDLINE search, with appropriate syntax used, including the addition of CINAHL headings. |
| Scopus | Searched to capture records not indexed in MEDLINE. Keyword search and limits based on MEDLINE search, with appropriate syntax used. |


2987 **Grey Literature**

| | |
|-------------------|---|
| Dates for Search: | July 2017 |
| Keywords: | Dental amalgam, composite resin |
| Limits: | Date limit: for guidelines only: 2000-present Language limit: none |


- 2988
- 2989 Relevant websites from the following sections of the CADTH grey literature
- 2990 checklist, "Grey matters: a practical tool for searching health-related grey
- 2991 literature" (<https://www.cadth.ca/grey-matters>) will be searched:
- 2992
- Health Technology Assessment Agencies
- 2993
- Health Economics
- 2994
- Clinical Practice Guidelines
- 2995
- Databases (free)
- 2996
- Internet Search
- 2997
- Open Access Journals
- 2998

2999 **Appendix 3: Study Selection Flow Diagrams —**
3000 **Clinical Reviews**

3001 **Research Question 1**



3002
3003



3007 **Appendix 4: List of Included Studies — Clinical** 3008 **Review**

3009 **Research Question 1**

3010
3011 Kemaloglu H, Pamir T, Tezel H. A 3-year randomized clinical trial evaluating two different bonded posterior
3012 restorations: amalgam versus resin composite. *Eur J Dent* 3869 [Internet]. 2016 Jan [cited 2017 Oct 11];10(1):16-22.
3013 Available from: http://www.eurjdent.com/temp/EurJDent10116-418122_113652.pdf

3014 **Research Question 2**

3015 Kemaloglu H, Pamir T, Tezel H. A 3-year randomized clinical trial evaluating two different bonded posterior
3016 restorations: amalgam versus resin composite. *Eur J Dent* [Internet]. 2016 Jan [cited 2017 Oct 11];10(1):16-22.
3017 Available from: http://www.eurjdent.com/temp/EurJDent10116-418122_113652.pdf

3018 Maserejian NN, Hauser R, Tavares M, Trachtenberg FL, Shrader P, McKinlay S. Dental composites and amalgam
3019 and physical development in children. *J Dent Res* [Internet]. 2012 Nov [cited 2017 Jul 20];91(11):1019-25. Available
3020 from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470777/pdf/nihms401265.pdf>

3021 Bellinger DC, Trachtenberg F, Zhang A, Tavares M, Daniel D, McKinlay S. Dental amalgam and psychosocial status:
3022 the New England Children's Amalgam Trial. *J Dent Res* [Internet]. 2008 May [cited 2017 Dec 1];87(5):470-4.
3023 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741096/pdf/nihms-65910.pdf>

3024 Woods JS, Martin MD, Leroux BG, DeRouen TA, Bernardo MF, Luis HS, et al. Urinary porphyrin excretion in children
3025 with mercury amalgam treatment: findings from the Casa Pia Children's Dental Amalgam Trial. *J Toxicol Environ*
3026 *Health A*. 2009;72(14):891-6.

3027 Shenker BJ, Maserejian NN, Zhang A, McKinlay S. Immune function effects of dental amalgam in children: a
3028 randomized clinical trial. *J Am Dent Assoc* [Internet]. 2008 Nov [cited 2017 Jul 20];139(11):1496-505. Available from:
3029 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908994/pdf/nihms213262.pdf>

3030 Woods JS, Martin MD, Leroux BG, DeRouen TA, Bernardo MF, Luis HS, et al. Biomarkers of kidney integrity in
3031 children and adolescents with dental amalgam mercury exposure: findings from the Casa Pia children's amalgam
3032 trial. *Environ Res* [Internet]. 2008 Nov;108(3):393-9. Available from:
3033 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236600/pdf/nihms-78395.pdf>

3034 Barregard L, Trachtenberg F, McKinlay S. Renal effects of dental amalgam in children: the New England children's
3035 amalgam trial. *Environ Health Perspect* [Internet]. 2008 Mar [cited 2017 Nov 1];116(3):394-9. Available from:
3036 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2265055/pdf/ehp0116-000394.pdf>

3037 Lauterbach M, Martins IP, Castro-Caldas A, Bernardo M, Luis H, Amaral H, et al. Neurological outcomes in children
3038 with and without amalgam-related mercury exposure: seven years of longitudinal observations in a randomized trial. *J*
3039 *Am Dent Assoc*. 2008 Feb;139(2):138-45.

3040 Woods JS, Martin MD, Leroux BG, DeRouen TA, Leitao JG, Bernardo MF, et al. The contribution of dental amalgam
3041 to urinary mercury excretion in children. *Environ Health Perspect*. 2007 Oct;115(10):1527-31.

3042 Bellinger DC, Daniel D, Trachtenberg F, Tavares M, McKinlay S. Dental amalgam restorations and children's
3043 neuropsychological function: the New England Children's Amalgam Trial. *Environ Health Perspect* [Internet]. 2007
3044 Mar [cited 2017 Dec 1];115(3):440-6. Available from:
3045 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1849920/pdf/ehp0115-000440.pdf>

3046
3047
3048
3049

Appendix 5: List of Excluded Studies and Reasons for Exclusion — Clinical Review

Research Question 1

| Reference | Reason for Exclusion |
|--|---|
| Rodríguez-Farre E, Testai E, Bruzell E, De JW, Schmalz G, Thomsen M, et al. The safety of dental amalgam and alternative dental restoration materials for patients and users. <i>Regul Toxicol Pharmacol</i> . 2016 Aug;79:108-9. | Ineligible design i.e., not an RCT |
| Kreulen CM, Gerritsen AE, Creugers NH. Resin composite restorations for the elderly patient. <i>Gerodontology</i> . 2014 Dec;31(4):243-4. | Ineligible publication i.e., commentary |
| Lynch CD, McConnell RJ, Wilson NH. Posterior composites: the future for restoring posterior teeth? <i>Prim Dent J</i> . 2014 May;3(2):49-53. | Ineligible publication i.e., commentary |
| van de Sande FH, Opdam NJ, Truin GJ, Bronkhorst EM, de Soet JJ, Cenci MS, et al. The influence of different restorative materials on secondary caries development in situ. <i>J Dent [Internet]</i> . 2014 Sep [cited 2017 Jul 11];42(9):1171-7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134988/pdf/nihms-615209.pdf | Ineligible design |
| Wilson N, Lynch C. Amalgam and minimal intervention: an incompatible relationship. <i>Prim Dent J</i> . 2013 Oct;2(4):18. | Ineligible publication i.e., commentary |
| Gottlieb M. Restoring the difficult class II with composite. <i>Today's FDA</i> . 2013 Mar;25(2):18-21. | Ineligible publication i.e., narrative review |
| Maltz M, Jardim JJ, Mestrinho HD, Yamaguti PM, Podesta K, Moura MS, et al. Partial removal of carious dentine: a multicenter randomized controlled trial and 18-month follow-up results. <i>Caries Res</i> . 2013;47(2):103-9. | Ineligible intervention i.e., not dental restorations |
| Visalli G, Baluce B, La MS, Micale RT, Cingano L, De Flora S, et al. Genotoxic damage in the oral mucosa cells of subjects carrying restorative dental fillings. <i>Arch Toxicol</i> . 2013 Jan;87(1):179-87. | Ineligible timeframe i.e., published prior to 2012 |
| Martin J, Fernandez E, Estay J, Gordan VV, Mjor IA, Moncada G. Minimal invasive treatment for defective restorations: five-year results using sealants. <i>Oper Dent</i> . 2013 Mar;38(2):125-33. | Ineligible population i.e., not caries |
| Maserejian NN, Hauser R, Tavares M, Trachtenberg FL, Shrader P, McKinlay S. Dental composites and amalgam and physical development in children. <i>J Dent Res [Internet]</i> . 2012 Nov [cited 2017 Jul 20];91(11):1019-25. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470777/pdf/nihms401265.pdf | Ineligible outcome i.e., not efficacy |
| Maserejian NN, Trachtenberg FL, Hauser R, McKinlay S, Shrader P, Bellinger DC. Dental composite restorations and neuropsychological development in children: treatment level analysis from a randomized clinical trial. <i>Neurotoxicology [Internet]</i> . 2012 Oct [cited 2017 Jul 20];33(5):1291-7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470777/pdf/nihms401265.pdf | Ineligible outcome i.e., not efficacy |
| Kopperud SE, Tveit AB, Gaarden T, Sandvik L, Espelid I. Longevity of posterior dental restorations and reasons for failure. <i>Eur J Oral Sci</i> . 2012 Dec;120(6):539-48. | Ineligible design i.e., not an RCT |
| Dutra TT, Tapety ZI, Mendes RF, Moita Neto JM, Prado Junior RR. Survival time of direct dental restorations in adults. <i>Rev odontol UNESP [Internet]</i> . 2015 Aug [cited 2017 4502 Jul 11];44(4):213-7. Available from: http://www.scielo.br/pdf/rounesp/v44n4/1807-2577-4503_rounesp-44-4-213.pdf | Ineligible design i.e., not an RCT |
| Cardoso RM, Cardoso RM, Gomes MP, Guimaraes RP, Menezes Filho PF, Silva CH. [Onlay with direct composite resin: a case report]. <i>Odontol Clin -Cient [Internet]</i> . 2012 Sep [cited 2017 Jul 11];11(3):259-64. Available from: | Ineligible design i.e., not an RCT |

| | |
|---|--|
| http://revodonto.bvsalud.org/pdf/occ/v11n3/a16v11n3.pdf Portuguese. | |
| de las N Laplace Perez B, Castellanos Amestoy L, Legra Matos SM, Peñuela Pérez EB, Fernández Laplace J. [Presentation of a patient with radicular perforation as a complication of endodontic treatment]. <i>Correo Científico Médico de Holguín</i> . 2015 Mar;19(1):166-72. Spanish. | Ineligible design i.e., not an RCT |
| Ceballos Casanova M, Acevedo Atala C, Jans Muñoz A, Atala Acevedo C. [Comparative study of the indicated survival rate of restorative materials used in pediatric patients 4 to 9 years of age with high risk of developing caries]. <i>Int J Odontostomat</i> [Internet]. 2014 Dec [cited 2017 Jul 12];8(3):345-50. Available from: http://www.scielo.cl/pdf/ijodontos/v8n3/art05.pdf Spanish. | Ineligible design i.e., not an RCT |
| Biondi AM, Cortese SG. [Restitution of coronary integrity in primary parts]. <i>Boletín de la Asociación Argentina de Odontología para Niños</i> . 2014 Aug;42/43(1):55-9. | Other i.e., cannot retrieve |
| Ferreira MG, Camapum MC, Ferreira GC, Silva JA, de Carvalho Cardoso P, Perillo MV. [Perspectiva restauradora para dentes tratados endodenticamente: pino anatômico ^{ipt}]. <i>Dent press endod</i> [Internet]. 2014 Apr [cited 2017 Jul 12];4(1):34-45. Available from: http://www.equipedentistica.com.br/artigos/Perspectiva_Restauradora.pdf Portuguese. | Ineligible design i.e., not an RCT |
| Constâncio ST, de Souza Viana LB, Rodrigues Silva FC, da Silva JM, Gemaque ID. [Anatomic pins – description of the technique and radiographic control after six years]. <i>Full Dentistry in Science</i> . 2012 Sep;3(12):416-23. Portuguese. | Ineligible design i.e., not an RCT |
| Jardim JJ, Paula L, Garcia R, Mestrinho HD, Yamaguti P, Nascimento C. Restorations placed after partial caries removal - 36-month results [abstract]. <i>Proceedings of the General Session of the International Association for Dental Research</i> [Internet]. 2012 [cited 2017 Nov 7]. Available from: https://iadr.confex.com/iadr/2012rio/webprogram/Paper164844.html (Presented at IADR 4531 general session; 2012 Jun 20-23; Iguacu Falls, BR). | Ineligible publication i.e., conference abstract |
| Maserejian NN, Hauser R, Tavares M, Trachtenberg FL, Shrader P, McKinlay S. Dental composites and amalgam and physical development in children. <i>J Dent Res</i> [Internet]. 2012 Nov [cited 2017 Jul 20];91(11):1019-25. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470777/pdf/nihms401265.pdf | Ineligible publication i.e., conference abstract |

3050

3051
3052

Research Question 2

| Reference | Reason for Exclusion |
|---|--|
| Moller,B.,Granath,L.E.. Reaction of the human dental pulp to silver amalgam restorations. The effect of insertion of amalgam of high plasticity in deep cavities. #journal#. #year#. 31:1973 | Ineligible timeframe i.e., published prior to 2007 |
| Mortazavi,S.M.J.,Mortazavi,G.,Paknahad,M.. Comment on sundseth et al. Global sources and pathways of mercury in the context of human health. Int. J. Environ. Res. Public health 2017, 14, 105. International Journal of Environmental Research and Public Health. 2017///. 14:#pages# | Ineligible publication i.e., commentary |
| Cabana-Munoz,M.E.,Parmigiani-Izquierdo,J.M.,Bravo-Gonzalez,L.A.,Kyung,H.-M.,Merino,J.J.. Increased Zn/glutathione levels and higher superoxide dismutase-1 activity as biomarkers of oxidative stress in women with long-term dental amalgam fillings: Correlation between mercury/aluminium levels (in hair) and antioxidant systems in plasma. #journal#. 2015///. 10:#pages# | Ineligible comparison i.e., no composite resin |
| Bjorklund,G.,Bengtsson,U.,Chirumbolo,S.,Kern,J.K.. Concerns about environmental mercury toxicity: do we forget something else?. Environmental Research. 2017///. 152:514 | Ineligible publication i.e., commentary |
| Bombeccari,G.P.,Guzzi,G.,Spadari,F.,Gianni,A.B.. Diagnosis of metal allergy and management of oral lichenoid reactions. Journal of Oral Pathology and Medicine. 2016///. 45:237 | Ineligible publication i.e., letter to the editor |
| Goulle,J.-P.,Guerbet,M.. Is mercury from dental amalgams toxic?. Toxicologie Analytique et Clinique. 2014///. 26:181 | Ineligible publication i.e., commentary |
| Zwicker,J.D.,Dutton,D.J.,Emery,J.C.H.. Longitudinal analysis of the association between removal of dental amalgam, urine mercury and 14 self-reported health symptoms. Environmental Health: A Global Access Science Source. 2014///. 13:#pages# | Ineligible comparison i.e., no composite resin |
| Geier,D.A.,Carmody,T.,Kern,J.K.,King,P.G.,Geier,M.R.. A dose-dependent relationship between mercury exposure from dental amalgams and urinary mercury levels: A further assessment of the Casa Pia Children's Dental Amalgam Trial. Human and Experimental Toxicology. 2012///. 31:11 | Ineligible comparison i.e., no composite resin |
| Webster,P.C.. Not all that glitters: Mercury poisoning in Colombia. The Lancet. 2012///. 379:1379 | Ineligible publication i.e., commentary |
| Maserejian,N.N.,Tavares,M.A.,Hayes,C.,Soncini,J.A.,Trachtenberg,F.L.. Prospective study of 5-year caries increment among children receiving comprehensive dental care in the New England children's amalgam trial. Community dentistry and oral epidemiology. 2009///. 37:9 | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Maserejian,N.N.,Trachtenberg,F.L.,Assmann,S.F.,Barregard,L.. Dental amalgam exposure and urinary mercury levels in children: The New England Children's Amalgam Trial. Environmental Health Perspectives. 2008///. 116:256 | Ineligible comparison i.e., no composite resin |
| Daniels,J.L.,Rowland,A.S.,Longnecker,M.P.,Crawford,P.,Golding,J.. Maternal dental history, child's birth outcome and early cognitive development: Childhood outcomes. Paediatric and Perinatal Epidemiology. 2007///. 21:448 | Ineligible comparison i.e., no composite resin |
| Trachtenberg,F.,Barregard,L.. The Effect of Age, Sex, and Race on Urinary Markers of Kidney Damage in Children. American Journal of Kidney Diseases. 2007///. 50:938 | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Yin,L.,Yu,K.,Lin,S.,Song,X.,Yu,X.. Associations of blood mercury, inorganic mercury, methyl mercury and bisphenol A with dental surface restorations in the U.S. population, NHANES 2003-2004 and 2010-2012. Ecotoxicol Environ Saf. 2016/12//. 134P1:213-225, 2016 Dec:#pages# | Ineligible comparison i.e., not comparing dental materials |
| Dutton,D.J.,Fyie,K.,Faris,P.,Brunel,L.,Emery,J.H.. The association between amalgam dental surfaces and urinary mercury levels in a sample of Albertans, a prevalence study. J. 2013/08/29/. occup. med. toxicol.. 8:22, 2013 | Ineligible comparison i.e., no composite resin |

3053

| | |
|---|--|
| Mackert,J.R.,Jr.. Randomized controlled trial demonstrates that exposure to mercury from dental amalgam does not adversely affect neurological development in children. J. 2010/03//. evid.-based dent. pract.. 10:25 | Ineligible publication i.e., commentary |
| Roumanas,E.D.. The frequency of replacement of dental restorations may vary based on a number of variables, including type of material, size of the restoration, and caries risk of the patient. J. 2010/03//. evid.-based dent. pract.. 10:23 | Ineligible publication i.e., commentary |
| Abt,E.. The risk of failure is higher for composites than for amalgam restorations. J. 2008/06//. evid.-based dent. pract.. 8:83 | Ineligible publication i.e., commentary |
| Qasaymeh,M.M.,Myers,G.J.. The safety of amalgam compared with resin composite restorations in children older than 6 years showed no significant differences on neurobehavioral or renal studies during a 5-year follow-up. J. 2007/09//. evid.-based dent. pract.. 7:138 | Ineligible publication i.e., commentary |
| Qasaymeh,M.M.,Myers,G.J.. The safety of amalgam compared with resin composite restorations in children older than 8 years showed no significant differences on neurobehavioral or nerve conduction studies during a 7-year follow-up. J. 2006/12//. evid.-based dent. pract.. 6:280 | Ineligible publication i.e., commentary |
| Oviir,T.,Ibarra,G.. Amalgams lead to more catastrophic failures in endodontically treated premolars with class II cavities. J. 2006/06//. evid.-based dent. pract.. 6:176 | Ineligible publication i.e., commentary |
| Bedir,Findik R.,Celik,H.T.,Ersoy,A.O.,Tasci,Y.,Moraloglu,O.,Karakaya,J.. Mercury concentration in maternal serum, cord blood, and placenta in patients with amalgam dental fillings: effects on fetal biometric measurements. Journal of Maternal-Fetal & Neonatal Medicine. 2016/11//. 29:3665 | Ineligible comparison i.e., cannot ascertain composite resin |
| Golding,J.,Steer,C.D.,Gregory,S.,Lowery,T.,Hibbeln,J.R.,Taylor,C.M.. Dental associations with blood mercury in pregnant women. Community dentistry and oral epidemiology. 2016/06//. 44:216 | Ineligible comparison i.e., no composite resin |
| Pigatto,P.D.,Spadari,F.,Bombeckari,G.P.,Guzzi,G.. Oral lichenoid reactions, patch tests, and mercury dental amalgam. Journal of Oral Pathology & Medicine. 2016/02//. 45:153, 2016 | Ineligible publication i.e., letter to the editor |
| Rooney,J.P.,Frissen,M.N.,Bass,G.A.,Dorea,J.G.. Dental amalgam fillings and Helicobacter pylori eradication rates: wide-ranging implications. European Journal of Gastroenterology and Hepatology. 2015/10//. 27:1231, 2015 | Ineligible publication i.e., letter to the editor |
| Sakallioglu,E.E.,Lutfioglu,M.,Sakallioglu,U.,Ceylan,G.K.,Pamuk,F.,Dede,F.O.,Dede,D.. Gingival crevicular fluid levels of neuropeptides following dental restorations. J Appl Biomater Function Mater. 2015/07/04/. 13:e186 | Ineligible outcome i.e., not safety |
| Kwang,S.,Aminoshariae,A.,Harding,J.,Montagnese,T.A.,Mickel,A.. The critical time-lapse between various restoration placements and subsequent endodontic intervention. Journal of Endodontics. 2014/12//. 40:1922 | Ineligible outcome i.e., not safety |
| Woods,J.S.,Heyer,N.J.,Russo,J.E.,Martin,M.D.,Farin,F.M.. Genetic polymorphisms affecting susceptibility to mercury neurotoxicity in children: summary findings from the Casa Pia Children's Amalgam clinical trial. Neurotoxicology. 2014/09//. 44:288-302, 2014 Sep:#pages# | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Maserejian,N.N.,Shrader,P.,Trachtenberg,F.L.,Hauser,R.,Bellinger,D.C.,Tavares,M.. Dental sealants and flowable composite restorations and psychosocial, neuropsychological, and physical development in children. Pediatric Dentistry. 2014/01//. 36:68 | Ineligible intervention i.e., sealants |
| Woods,J.S.,Heyer,N.J.,Russo,J.E.,Martin,M.D.,Pillai,P.B.,Bammler,T.K.,Farin,F.M.. Genetic polymorphisms of catechol-O-methyltransferase modify the neurobehavioral effects of mercury in children. Journal of Toxicology and Environmental Health.Part A. 2014//. 77:293 | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Trachtenberg,F.L.,Shrader,P.,Barregard,L.,Maserejian,N.N.. Dental composite materials and renal function in children. British Dental Journal. 2014/01//. 216:E4, 2014 | Ineligible comparison i.e., no amalgam |
| Visalli,G.,Baluce,B.,La,Maestra S.,Micale,R.T.,Cingano,L.,De,Flora S.,Di,Pietro A.. Genotoxic damage in the oral mucosal cells of subjects carrying restorative dental fillings. Arch Toxicol. 2013/12//. 87:2247 | Ineligible publication i.e., letter to the editor |

| | |
|---|---|
| Watson,G.E.,van,Wijngaarden E., Love,T.M., McSorley, E.M.,Bonham, M.P., Mulhern,M.S., et al. Neurodevelopmental outcomes at 5 years in children exposed prenatally to maternal dental amalgam: the Seychelles Child Development Nutrition Study. <i>Neurotoxicol Teratol.</i> 2013/09//. 39:57-62, 2013 Sep-Oct:#pages# | Ineligible comparison i.e., no composite resin |
| Woods,J.S.,Heyer,N.J.,Russo,J.E.,Martin,M.D.,Pillai,P.B.,Farin,F.M.. Modification of neurobehavioral effects of mercury by genetic polymorphisms of metallothionein in children. <i>Neurotoxicol Teratol.</i> 2013/09//. 39:36-44, 2013 Sep-Oct:#pages# | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Correa,M.B.,Peres,M.A.,Peres,K.G.,Horta,B.L.,Barros,A.J.,Demarco,F.F.. Do socioeconomic determinants affect the quality of posterior dental restorations? A multilevel approach. <i>Journal of Dentistry.</i> 2013/11//. 41:960 | Ineligible outcome i.e., not safety |
| Geier,D.A.,Carmody,T.,Kern,J.K.,King,P.G.,Geier,M.R.. A significant dose-dependent relationship between mercury exposure from dental amalgams and kidney integrity biomarkers: a further assessment of the Casa Pia children's dental amalgam trial. <i>Human & Experimental Toxicology.</i> 2013/04//. 32:434 | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Visalli,G.,Baluce,B.,La,Maestra S.,Micale,R.T.,Cingano,L.,De,Flora S.,Di,Pietro A.. Genotoxic damage in the oral mucosa cells of subjects carrying restorative dental fillings. <i>Arch Toxicol.</i> 2013/01//. 87:179 | Ineligible population i.e., no explicit comparison of composite resin and amalgam |
| Maserejian,N.N.,Trachtenberg,F.L.,Hauser,R.,McKinlay,S.,Shrader,P.,Tavares, M.,Bellinger,D.C.. Dental composite restorations and psychosocial function in children. <i>Pediatrics.</i> 2012/08//. 130:e328 | Ineligible comparison i.e., no amalgam |
| Maserejian,N.N.,Trachtenberg,F.L.,Hauser,R.,McKinlay,S.,Shrader,P.,Bellinger ,D.C.. Dental composite restorations and neuropsychological development in children: treatment level analysis from a randomized clinical trial. <i>Neurotoxicology.</i> 2012/10//. 33:1291 | Ineligible comparison i.e., no amalgam |
| . Dental restoration materials and physical development in children. <i>Journal of the Canadian Dental Association.</i> 2012///. 78:c138, 2012:#pages# | Ineligible publication i.e., not a report of study findings |
| Watson,G.E.,Evans,K.,Thurston,S.W.,van,Wijngaarden E., Wallace,J.M., McSorley,E.M.,et al. Prenatal exposure to dental amalgam in the Seychelles Child Development Nutrition Study: associations with neurodevelopmental outcomes at 9 and 30 months. <i>Neurotoxicology.</i> 2012/12//. 33:1511 | Ineligible comparison i.e., no composite resin |
| Ababnaeh,K.T.,Al-Omari,M.,Alawneh,T.N.. The effect of dental restoration type and material on periodontal health. <i>Oral health prev.</i> 2011///. dent.. 9:395 | Ineligible outcome i.e., not safety |
| Al-Saleh,I.,Al-Sedairi,A.A.. Mercury (Hg) burden in children: the impact of dental amalgam. <i>Sci Total Environ.</i> 2011/07/15/. 409:3003 | Ineligible comparison i.e., no composite resin |
| Geier,D.A.,Carmody,T.,Kern,J.K.,King,P.G.,Geier,M.R.. A significant relationship between mercury exposure from dental amalgams and urinary porphyrins: a further assessment of the Casa Pia children's dental amalgam trial. <i>Biometals.</i> 2011/04//. 24:215 | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Lygre,G.B.,Bjorkman,L.,Haug,K.,Skjaerven,R.,Helland,V.. Exposure to dental amalgam restorations in pregnant women. <i>Community dentistry and oral epidemiology.</i> 2010/10//. 38:460 | Ineligible comparison i.e., no composite resin |
| Trachtenberg,F.,Barregard,L.,McKinlay,S.. The influence of urinary flow rate on mercury excretion in children. <i>J Trace Elem Med Biol.</i> 2010/01//. 24:31 | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |

3054

| | |
|---|---|
| Surkan,P.J.,Wypij,D.,Trachtenberg,F.,Daniel,D.B.,Barregard,L.,McKinlay,S.,Bellinger,D.C.. Neuropsychological function in school-age children with low mercury exposures. <i>Environmental Research</i> . 2009/08//. 109:728 | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Ye,X.,Qian,H.,Xu,P.,Zhu,L.,Longnecker,M.P.,Fu,H.. Nephrotoxicity, neurotoxicity, and mercury exposure among children with and without dental amalgam fillings. <i>International Journal of Hygiene and Environmental Health</i> . 2009/07//. 212:378 | Ineligible comparison i.e., no composite resin |
| Rothwell,J.A.,Boyd,P.J.. Amalgam dental fillings and hearing loss. <i>Int J Audiol</i> . 2008/12//. 47:770 | Ineligible comparison i.e., no explicit comparison of composite resin and amalgam |
| Hajizadeh,H.,Akbari,M.,Ghavamnasiri,M.,Abedini,S.. Clinical evaluation of a resin-based desensitizing agent and a self-etching adhesive on the reduction of postoperative sensitivity of amalgam restorations. <i>Journal of Contemporary Dental Practice</i> . 2008/11/01/. 9:9 | Ineligible intervention i.e., liners (not restorations) |
| Di,Pietro A.,Visalli,G.,La,Maestra S.,Micale,R.,Baluce,B.,Matarese,G.,Cingano,L.,Scoglio,M.E.. Biomonitoring of DNA damage in peripheral blood lymphocytes of subjects with dental restorative fillings. <i>Mutation Research</i> . 2008/02/29/. 650:115 | Ineligible comparison i.e., no explicit comparison of composite resin and amalgam |
| Dunn,J.E.,Trachtenberg,F.L.,Barregard,L.,Bellinger,D.,McKinlay,S.. Scalp hair and urine mercury content of children in the Northeast United States: the New England Children's Amalgam Trial. <i>Environmental Research</i> . 2008/05//. 107:79 | Ineligible comparison i.e., no explicit comparison of composite resin and amalgam |
| Surkan,P.J.,Zhang,A.,Trachtenberg,F.,Daniel,D.B.,McKinlay,S.,Bellinger,D.C.. Neuropsychological function in children with blood lead levels <10 microg/dL. <i>Neurotoxicology</i> . 2007/11//. 28:1170 | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Bellinger,D.C.,Trachtenberg,F.,Daniel,D.,Zhang,A.,Tavares,M.A.,McKinlay,S.. A dose-effect analysis of children's exposure to dental amalgam and neuropsychological function: the New England Children's Amalgam Trial. <i>Journal of the American Dental Association</i> . 2007/09//. 138:1210 | Ineligible population i.e., secondary analyses not considering originally randomized treatment groups |
| Bernardo,M.,Luis,H.,Martin,M.D.,Leroux,B.G.,Rue,T.,Leitao,J.,DeRouen,T.A.. Survival and reasons for failure of amalgam versus composite posterior restorations placed in a randomized clinical trial. <i>Journal of the American Dental Association</i> . 2007/06//. 138:775 | Ineligible outcome i.e., not safety |
| DeRouen,T.A.,Martin,M.D.,Leroux,B.G.,Townes,B.D.,Woods,J.S.,Leitao,J.,Castro-Caldas,A.,Luis,H.,Bernardo,M.,Rosenbaum,G.,Martins,I.P.. Neurobehavioral effects of dental amalgam in children: a randomized clinical trial. <i>JAMA</i> . 2006/04/19/. 295:1784 | Ineligible timeframe i.e., published prior to 2007 |
| Bellinger,D.C.,Trachtenberg,F.,Barregard,L.,Tavares,M.,Cernichiari,E.,Daniel,D.,McKinlay,S.. Neuropsychological and renal effects of dental amalgam in children: a randomized clinical trial. <i>JAMA</i> . 2006/04/19/. 295:1775 | Ineligible timeframe i.e., published prior to 2007 |
| Whitworth,J.M.,Myers,P.M.,Smith,J.,Walls,A.W.,McCabe,J.F.. Endodontic complications after plastic restorations in general practice. <i>Int Endod J</i> . 2005/06//. 38:409 | Ineligible timeframe i.e., published prior to 2007 |
| Evens,C.C.,Martin,M.D.,Woods,J.S.,Soares,H.L.,Bernardo,M.,Leitao,J.,Simmonds,P.L.,Liang,L.,Derouen,T.. Examination of dietary methylmercury exposure in the Casa Pia Study of the health effects of dental amalgams in children. <i>Journal of Toxicology and Environmental Health.Part A</i> . 2001/12/07/. 64:521 | Ineligible timeframe i.e., published prior to 2007 |

3055

3056 **Appendix 6: Critical Appraisal — Clinical Review**

3057 **Research Question 1**

3058

| | Random sequence generation | Allocation concealment | Blinding participants & personnel | Blinding outcome assessors | Incomplete outcome data | Selective reporting | Other sources of bias |
|------------------------------|----------------------------|------------------------|-----------------------------------|----------------------------|-------------------------|---------------------|-----------------------|
| Kemaloglu 2016 ³³ | + | ? | — | — | ? | ? | — |

3059 + = low risk of bias; ? = unclear risk of bias; — = high risk of bias

3059

3060

3061 **Research Question 2**

3062

| | Random sequence generation | Allocation concealment | Blinding participants & personnel | Blinding outcome assessors | Incomplete outcome data | Selective reporting | Other sources of bias |
|------------------------------|-------------------------------|------------------------|-----------------------------------|----------------------------|-------------------------|---------------------|-----------------------|
| NECAT | Barregard, 2008 ³⁹ | + | + | — | + | — | + |
| | Bellinger, 2007 ⁴² | + | + | — | + | + | ? |
| | Bellinger 2008 ³⁵ | + | + | — | + | + | + |
| | Maserejian 2012 ³⁴ | + | + | — | + | + | + |
| | Shenker 2008 ³⁷ | ? | ? | — | + | ? | — |
| Casa Pia | Lauterbach 2008 ⁴⁰ | ? | ? | — | ? | — | + |
| | Woods 2007 ⁴¹ | ? | ? | — | ? | + | ? |
| | Woods 2008 ³⁸ | ? | ? | — | ? | + | + |
| | Woods 2009 ³⁶ | ? | ? | — | ? | ? | — |
| Kemaloglu 2016 ³³ | + | ? | — | ? | ? | ? | — |

3063 **Appendix 7: Study and Report Characteristics — Clinical Review**

3064 **Research Question 1**

3065

| First Author, Publication Year, Country, Funding Source | Study Design, Analytical Method | Number of teeth and/or /restorations | Study Duration, Follow-Up, Loss to Follow-up | Intervention and Comparator, or Exposure(s) | Eligible Outcomes and Measures Reported | Subgroup Analyses |
|---|--|---|--|---|---|-------------------|
| Kemaloglu 2016 ³³ Turkey Financial support reported as “Nil” (p. 22) | Single-centre RCT, split-mouth design Proportion of restorations per treatment group rated as Alpha, Bravo, Charlie tallied and overall failure rate calculated | N=50 teeth randomized Amalgam = 20 restorations Composite = 20 restorations | Study duration = 3yr Median follow-up = NR Follow-up evaluations at 2wks, 6mos, 1 and 3yrs Loss to F/U = 5/25 consented patients (analyses based on 40 teeth) | Dispersed alloy amalgam (Cavex) placed with Amalgambond bonding agent Posterior resin composite (Quixfil) placed with etch-and-rinse adhesive system (XP Bond) | 1. Restoration performance (i.e., retention, marginal adaptation, anatomic form, surface texture and secondary caries) measured at baseline (i.e., 2wks post-intervention), 6, 12 and 36mos i.e., (i) Modified US Public Health Service (USPHS) Ryge criteria, Alpha (best), Bravo, Charlie (worst) assessed by two evaluators not involved in placing the restorations (ii) Inter-rater agreement, Cohen’s Kappa (iii) Overall failure, calculated as: (previous failures + new failures)/(previous failures + currently recalled restorations) | None |

3066

3067
3068

Research Question 2

| First Author, Publication Year, Country, Funding Source | Study Design, Analytical Method | Number, Age, Sex, of Study Patients | Study Duration, Follow-Up, Loss to Follow-up | Intervention and Comparator, or Exposure(s) | Eligible Outcomes, Ascertainment of Harm(s), Measurement Time Points, and Measures Reported | Subgroup Analyses |
|---|--|---|---|---|--|-------------------|
| Kemaloglu 2016 ³³ Turkey Financial support reported as "Nil" (p. 22) | Single-centre RCT, split-mouth design Difference in post-operative sensitivity evaluated by treatment group using Wilcoxon signed rank test | N=20 participants N=40 teeth, Amalgam = 20 teeth, Composite = 20 teeth Age range = 18-60yrs Sex = NR | Study duration = 3yr Median follow-up = NR Follow-up evaluations at 2wks, 6mos, 1 and 3yrs Loss to F/U = 5/25 consented patients (analyses based on 20 patients with 40 teeth) | Dispersed alloy amalgam (Cavex) placed with Amalgambond bonding agent Posterior resin composite (Quixfil) placed with etch-and-rinse adhesive system (XP Bond) | 1. Post-operative sensitivity, measured actively at baseline, 6, 12 and 36mos i.e., (i) Visual Analog Scale (VAS) 0-10 | None |
| Bellinger, 2007 ⁴² USA Trial funded by a cooperative agreement, (U01 DE11886), between the New England Research Institutes and the National Institute of Dental and Craniofacial | Multi-centre RCT (NECAT) stratified by geographic location and number of teeth with caries (2-4 vs. ≥ 5), using randomly permuted blocks within each stratum ITT analyses using ANCOVA adjusted for randomization stratum, age, sex, race, socioeconomic status, baseline | N=534 (variable numbers analyzed per measure/subscale) Amalgam = 267 Composite = 267 Age in years, mean (SD) range Amalgam = 7.9 (1.3) 5.9-11.4 Composite = 7.9 (1.4) 5.9-11.5 Amalgam, female: 131, 49.1% Composite, female: 156, 58.4% | Study duration = 5yr Semi-annual visits Follow-up = NR Loss to F/U = NR | Dispersed phase amalgam Resin composite material (white filling) | 1. Amalgam exposure, measured actively i.e., (i) Mean number of restored surfaces (ii) Mean number of amalgam surfaces (iii) Cumulative number of restored surfaces (5yr follow up) (iv) Cumulative number of amalgam surfaces 2. Urinary elemental mercury levels, measured actively i.e., (i) µg/g creatinine 3. Neuropsychological function i.e., active, annual administration of ≥1 of the following tests: (i) Wechsler Intelligence Scale for Children-Third Edition (WISC-III) | None |

| First Author, Publication Year, Country, Funding Source | Study Design, Analytical Method | Number, Age, Sex, of Study Patients | Study Duration, Follow-Up, Loss to Follow-up | Intervention and Comparator, or Exposure(s) | Eligible Outcomes, Ascertainment of Harm(s), Measurement Time Points, and Measures Reported | Subgroup Analyses |
|--|--|---|---|--|--|-------------------|
| Research | hair mercury level, baseline blood lead level, lean body mass, type of specimen (overnight vs. spot daytime urine sample), urinary creatinine concentration, storage time, and baseline γ -GT (for γ -GT models only) | | | | <ul style="list-style-type: none"> (ii) Wechsler Individual Achievement Test (WIAT) (iii) Wide Range Assessment of Memory and Learning (WRAML) (iv) Wide Range Assessment of Visual-Motor Ability (WRAVMA) (v) Trail-Making Test (vi) WPS Electronic Tapping Test (vii) ordered and unordered verbal cancellation (viii) category fluency (ix) Controlled Oral Word Association Test (x) Simple visual reaction time (xi) Stroop Color-Word Interference Test (xii) Wisconsin Card Sorting Test | |
| Bellinger 2008 ³⁵ USA Trial supported by a cooperative agreement (U01 DE11886) between the New England Research Institutes and the National Institute of Dental and Craniofacial Research | Multi-centre RCT (NECAT) stratified by geographic location and number of teeth with caries (2 to 4 vs. ≥ 5), with randomly permuted blocks within each stratum Analyses using ANCOVA adjusted for baseline score, age, gender, race, socio-economic status, primary caregiver's marital status, birth weight, maternal exposure during pregnancy to tobacco, alcohol, and drugs, family stress, baseline child Full-Scale IQ, | N = 534 (N = 395 included in the CBCL analyses, Amalgam = 197, Composite = 198; N=426 included in the BASC-SR analyses, Amalgam n= 213, Composite n = 213) Age in years, mean (SD) range Amalgam = 7.9 (1.4) 6.1-11.5 Composite = 7.8 (1.3) 6.0-11.2 Amalgam, female: 96/197, 48.7% Composite female: 106/198, 53.5% | Study duration = 5yr Semi-annual visits Median follow-up = NR Loss to F/U = NR | Dispersed-phase amalgam Composite resin | <ul style="list-style-type: none"> 1. Psychosocial function measured actively i.e., <ul style="list-style-type: none"> (i) Child Behavior Checklist (CBCL), change in scores, measured at baseline and 5yrs – primary outcome, parent-reported (ii) Behavior Assessment System for Children (BASC-SR) measured at 5yrs – secondary outcome, child-reported | None |

| First Author, Publication Year, Country, Funding Source | Study Design, Analytical Method | Number, Age, Sex, of Study Patients | Study Duration, Follow-Up, Loss to Follow-up | Intervention and Comparator, or Exposure(s) | Eligible Outcomes, Ascertainment of Harm(s), Measurement Time Points, and Measures Reported | Subgroup Analyses |
|---|---|--|--|--|---|-------------------|
| | and randomization stratum | | | | | |
| Lauterbach 2008 ⁴⁰ Portugal Trial funded by the National Institute of Dental Craniofacial Research Cooperative Agreement grant U01 DE11894; additional funding from the National Institute of Environmental Health Sciences via the University of Washington (Center grant P30ES07033 and by Superfund Program Project grant P42ES04696) | RCT (Casa Pia) Descriptive, unadjusted analyses with comparisons using Fisher's exact test (proportions) and two-sample Student t-test (means) | N = 507 (N = 506 included in this analysis Amalgam = 253 Composite = 253) Age in years, mean (SD) Amalgam = 10.2 (0.98) Composite = 10.1 (0.94) Amalgam, female: 116/253, 45.8% Composite, female: 112/253, 44.3% | Study duration = 7yr Median follow-up = NR Annual neurological evaluations Loss to F/U = NR | Dental amalgam (posterior restorations; resin-based composite restorations elsewhere) Composite restorations only | 1. Neurological hard signs (NHS), active, annual assessment of absence/presence within 8 categories: (i) mental status (consciousness; language; and orientation to person, time and place) (ii) observation of the function of the 12 cranial nerves (iii) gross motor function (muscle strength and tone and deep tendon reflexes) (iv) plantar responses (v) cerebellar functions (including limb and gait coordination) (vi) touch (vii) joint position and vibration senses (viii) involuntary movements (such as athetosis or chorea) 2. Positional tremor, active, annual assessment of absence/presence 3. Neurological soft signs (NSS), active, annual assessment of absence/presence and severity (i.e., 0 to 3) of 6 features: (i) mirror movements (ii) synkinesias (iii) clumsiness of fine finger movements (iv) tandem gait (v) motor impersistence (vi) restlessness/hyperactivity | None |
| Shenker 2008 ³⁷ USA Analyses | Multi-centre RCT (NECAT) ANCOVA adjusted for baseline corresponding | N=534 (N = 66 randomized into this sub-study; N = 59 included in the analyses, Amalgam = 29, | Study duration = 5yr Median follow-up = NR | Amalgam (i.e., Dispersalloy) Resin-based composite (i.e., Z100) | 1. Amalgam exposure, measured actively and annually (i) Number of surfaces restored with amalgam 2. Urinary elemental mercury levels, | None |

| First Author, Publication Year, Country, Funding Source | Study Design, Analytical Method | Number, Age, Sex, of Study Patients | Study Duration, Follow-Up, Loss to Follow-up | Intervention and Comparator, or Exposure(s) | Eligible Outcomes, Ascertainment of Harm(s), Measurement Time Points, and Measures Reported | Subgroup Analyses |
|---|--|--|--|---|--|-------------------|
| supported by USPHS grant N01 DE 72622 | immune function measurement, age, gender, socioeconomic status, hair mercury, and blood lead level | Composite = 30) Age in years, mean (SD) Amalgam = 8.1 (1.3) Composite = 8.0 (1.4) Amalgam, female: 10/29 (34.5%) Composite, female: 19/30 (63.3%) | Semi-annual visits Loss to F/U = 5/66 Amalgam = 4 Composite = 1 | | measured actively and annually i.e., (i) $\mu\text{g/g}$ creatinine 3. Immune function i.e., values measured actively at baseline, 5-7 days, 6, 12 and 60 months post-intervention (i) White blood cell (WBC) count (ii) T-cell function following incubation with phytohemagglutinin (PHA), 5 $\mu\text{g/ml}$ a. CD25 activation marker expression (%CD25+ (PHA)) b. CD69 activation marker expression (%CD69+ (PHA)) c. cell cycle distribution (iii) B-cell function following stimulation with pokeweed mitogen (PWM), 10 $\mu\text{g/ml}$ a. CD23 activation marker expression (%CD23+ (PHA)) b. CD69 activation marker expression (%CD69+ (PWM)) (iv) Monocyte and neutrophil function by measuring phorbol myristate acetate (PMA), 0.5 $\mu\text{g/ml}$ -induced oxidative burst a. O_2 generation assessed by dihydroethidium fluorescent probe (% Eth+(PMA)) b. H_2O_2 generation assessed by dihydrorhodmine fluorescent probe (% Rho+(PMA)) | |
| Barregard, 2008 ³⁹ USA Trial funded by the National Institute of Dental and Craniofacial | Multi-centre RCT (NECAT) stratified by geographic location and number of teeth with caries (2–4 vs. ≥ 5) Repeated-measures analyses | N=534 (N=490 included in this analysis) Amalgam = 267 Composite = 267 Age in years, mean (SD) range Amalgam = 7.9 (1.3) 5.9-11.4 | Study duration = 5yr Semi-annual visits Median follow-up = NR Loss to F/U = | Dispersed phase amalgam Resin composite material (white filling) | 1. Renal biomarkers, measured actively i.e., urinary excretion at yrs 1 (γ -GT only), 3 and 5 of: (i) albumin (mg/g creatinine) (ii) alpha-1-microglobulin (A1M) (mg/g creatinine) (iii) γ -glutamyl transpeptidase (γ -GT) (U/g creatinine) (iv) N-acetyl- β -D-glucosaminidase (NAG) (U/g creatinine) | None |

| First Author, Publication Year, Country, Funding Source | Study Design, Analytical Method | Number, Age, Sex, of Study Patients | Study Duration, Follow-Up, Loss to Follow-up | Intervention and Comparator, or Exposure(s) | Eligible Outcomes, Ascertainment of Harm(s), Measurement Time Points, and Measures Reported | Subgroup Analyses |
|---|--|---|---|---|--|-------------------------|
| Research (U01 DE11886) | using ANCOVA and logistic regression models adjusted for randomization stratum, age, sex, race, socioeconomic status, baseline hair mercury level, baseline blood lead level, lean body mass, type of specimen (overnight vs. spot daytime urine sample), urinary creatinine concentration, storage time, and baseline γ -GT (for γ -GT models only) | Composite = 7.9 (1.4) 5.9-11.5 Amalgam, female: 131/267, 49.1% Composite female: 156/267, 58.4% | 19% at 5yr | | | |
| Woods 2008 ³⁸ Portugal Trial funded by the National Institute of Dental Craniofacial Research Cooperative Agreement grant U01 DE11894; additional funding from the National Institute of Environmental | RCT (Casa Pia) Descriptive statistics for log-transformed concentrations of renal biomarkers; linear regression models, (i) unadjusted and (ii) adjusted for log-transformed creatinine concentration in the sample, year of age (i.e., 9-18, ordinal), age at baseline (i.e., years), sex and race (i.e., | N=507 Age range = 8-12 Female = 46% Male = 54% | Study duration = 7yr Median follow-up = NR Loss to F/U = NR | Amalgam Composite resin | 1. Urinary mercury at baseline, measured actively i.e., $\mu\text{g/g}$ creatinine 2. Renal function measured actively per annual age cohort i.e., urinary: (i) Glutathione S-transferases (GST)- α i.e., $\mu\text{g/g}$ creatinine (ii) Glutathione S-transferases (GST)- π i.e., $\mu\text{g/g}$ creatinine (iii) albumin i.e., mg/g creatinine (iv) microalbuminuria i.e., proportion of participants with albumin >30 mg/g creatinine | Treatment group and sex |

| First Author, Publication Year, Country, Funding Source | Study Design, Analytical Method | Number, Age, Sex, of Study Patients | Study Duration, Follow-Up, Loss to Follow-up | Intervention and Comparator, or Exposure(s) | Eligible Outcomes, Ascertainment of Harm(s), Measurement Time Points, and Measures Reported | Subgroup Analyses |
|---|--|---|---|--|--|--|
| Health Sciences via the University of Washington (Center grant P30ES07033 and by Superfund Program Project grant P42ES04696) | 'white' versus 'non-white') | | | | | |
| Maserejian 2012 ³⁴ USA Analyses funded by Award Number R01ES019155 from the National Institute of Environmental Health Sciences (NIEHS); data collection supported by a cooperative agreement (U01 DE11886) between the New England Research Institutes and the National Institute of Dental and | Multi-centre RCT (NECAT) stratified by number of teeth with caries (2-4 vs. ≥ 5) and rural/urban location ITT using linear mixed-effects, repeated-measures regression models adjusted for randomization stratum, age, and relevant baseline anthropometric measure | N = 534 (N = 474 included in these analyses, Amalgam = 238, Composite = 236) Age in years, mean (SD) Amalgam = 7.5 (1.3) Composite = 7.4 (1.4) Amalgam, female: 121/238, 50.8% Composite, female: 135/236, 57.2% | Study duration = 5yr Median follow-up = NR Loss to F/U, Amalgam n= 24 Composite n=26 | Amalgam (i.e., Dispersalloy) Resin-based composite (i.e., Z100) | 1. Physical development in males and in females, measured annually and actively and presented as 5-year changes in: (i) BMI (kg/m ²)-for-age Z-score (ii) Body fat (%) (iii) Height (cm) (iv) Menarche (females from 1 site only) <ul style="list-style-type: none"> • Number who reached menarche • Age at first menarche | All analyses run in consideration of sex |

| First Author, Publication Year, Country, Funding Source | Study Design, Analytical Method | Number, Age, Sex, of Study Patients | Study Duration, Follow-Up, Loss to Follow-up | Intervention and Comparator, or Exposure(s) | Eligible Outcomes, Ascertainment of Harm(s), Measurement Time Points, and Measures Reported | Subgroup Analyses |
|---|--|---|--|---|--|--|
| Craniofacial Research (NIDCR) | | | | | | |
| Woods 2007 ⁴¹ Portugal Trial funded by the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health through Cooperative Agreement U01DE11894 | RCT (Casa Pia) Descriptive i.e., means, 95% CIs and t-tests for treatment group comparisons | N=507 (Amalgam = 253, Composite = 254) Age in years, mean (SD) range Amalgam = 10.1 (1.0) 8.0-12.4 Composite = 10.0 (0.9) 8.2-12.0 Amalgam, female: 116/253, 46% Composite, female: 112/254, 44% | Study duration = 7yr Median follow-up = NR Annual visits Loss to F/U = NR | Amalgam (i.e., Dispersalloy) Composite resin | 1. Urinary mercury actively measured annually: (i) unadjusted µg/L (ii) creatinine-adjusted µg/g | Treatment group, race, sex and number of amalgam surface areas |
| Woods 2009 ³⁶ Portugal Trial funded by the National Institute of Dental Craniofacial Research Cooperative Agreement grant U01 DE11894; additional funding from the National Institute of Environmental | RCT (Casa Pia) Mixed, linear regression models adjusted for age, sex, race (white/non-white), follow-up year, log-transformed urinary creatinine, and baseline log-transformed porphyrin/creatinine ratio | N=507 Age range = 8-12 Female = 46% Male = 54% | Study duration = 7yr Median follow-up = NR Loss to F/U = NR | Amalgam Composite resin | 1. Urinary mercury at baseline, measured actively and annually i.e., (i) µg/g creatinine 2. Urinary porphyrins, measured actively and annually i.e., (i) log-transformed µg/L | 8 and 9 year olds only |

| First Author, Publication Year, Country, Funding Source | Study Design, Analytical Method | Number, Age, Sex, of Study Patients | Study Duration, Follow-Up, Loss to Follow-up | Intervention and Comparator, or Exposure(s) | Eligible Outcomes, Ascertainment of Harm(s), Measurement Time Points, and Measures Reported | Subgroup Analyses |
|--|---------------------------------|-------------------------------------|--|---|---|-------------------|
| Health Sciences via the University of Washington (Center grant P30ES07033 and by Superfund Program Project grant P42ES04696) | | | | | | |

3069

3070 **Appendix 8: Detailed Outcome Data — Clinical Review**

3071 **Summary of Efficacy Outcomes (Research Question 1)**

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|------------------------------|--|--|
| Kemaloglu 2016 ³³ | <p>1. Restoration performance (Modified USPHS (Ryge) criteria), % restorations rated Alpha and Bravo at baseline, 6, 12 and 36mos</p> <ul style="list-style-type: none"> • Amalgam <ul style="list-style-type: none"> ○ Retention <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 100, 100 ▪ Bravo, 0, 0, 0, 0 ○ Marginal adaptation <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 90, 85 ▪ Bravo, 0, 0, 10, 15 ○ Anatomical form <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 85, 50 ▪ Bravo, 0, 0, 15, 50 ○ Marginal discoloration <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 95, 95 ▪ Bravo, 0, 0, 5, 5 ○ Surface texture <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 75, 40 ▪ Bravo, 0, 0, 25, 60 ○ Secondary caries <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 100, 100 ▪ Bravo, 0, 0, 0, 0 • Composite <ul style="list-style-type: none"> ○ Retention <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 100, 100 ▪ Bravo, 0, 0, 0, 0 ○ Marginal adaptation <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 90, 80 ▪ Bravo, 0, 0, 10, 20 ○ Anatomical form <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 95, 75 ▪ Bravo, 0, 0, 5, 25 ○ Marginal discoloration <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 80, 70 ▪ Bravo, 0, 0, 20, 30 ○ Surface texture <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 65, 35 | <p>“In our study, the clinical success of bonded amalgam and direct resin composite restorations in deep and large sized cavities was evaluated for 3 years. Judging from the results, survival rate was 100% for both of the restoration types and they were found to be successful.”</p> |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------|---|----------------------|
| | <ul style="list-style-type: none"> ▪ Bravo, 0, 0, 35, 65 ○ Secondary caries <ul style="list-style-type: none"> ▪ Alpha, 100, 100, 100, 100 ▪ Bravo, 0, 0, 0, 0 2. Inter-rater agreement for all restorations, Cohen's Kappa <ul style="list-style-type: none"> • 0.97 3. Overall failure, proportion of restorations <ul style="list-style-type: none"> • Detailed calculation NR • Reported as: "Overall failure rate of this study was 0% (100% acceptance for 3 years)..." (p. 19) for both groups | |

3072

mos = months

Summary of Safety Outcomes (Research Question 2)

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------------------------------|---|--|
| Bellinger, 2007 ⁴² | <ol style="list-style-type: none"> 1. Amalgam exposure at 5yr follow-up, mean \pmSD (range) <ul style="list-style-type: none"> • Restored surfaces <ul style="list-style-type: none"> ○ Amalgam, 5.3 \pm 5.2 (0–36) ○ Composite, 6.1 \pm 6.0 (0–36) ○ No significant difference (method NR) between groups $P = 0.16$ • Restored amalgam surfaces <ul style="list-style-type: none"> ○ Amalgam, 4.0 \pm 4.0 (0–21) ○ Composite, 0.05 \pm 0.6 (0–9) ○ $P = NR$ • Cumulative restored surfaces <ul style="list-style-type: none"> ○ Amalgam, 14.8 \pm 9.5 (2–55) ○ Composite, 16.0 \pm 9.8 (2–51) ○ No significant difference (method NR) between groups $P = 0.10$ • Cumulative restored amalgam surfaces <ul style="list-style-type: none"> ○ Amalgam, 11.7 \pm 7.0 (0–35) ○ Composite, 0.05 \pm 0.6 (0–9) ○ $P = NR$ 2. Urinary elemental mercury levels at 5yr follow up, median (range) <ul style="list-style-type: none"> • Amalgam, 0.9 (0.1-5.7) • Composite, 0.6 (0.1-2.9) • Significant difference (method NR) between groups $P < 0.001$ 3. Neuropsychological function, change in score from baseline/1yr to end of study follow-up i.e., 4/5 years <ul style="list-style-type: none"> • WISC-III, adjusted mean coefficient \pmSE (n) <ul style="list-style-type: none"> ○ Verbal Comprehension <ul style="list-style-type: none"> ▪ Amalgam, 2.2 \pm 0.6 (219) ▪ Composite, 1.5 \pm 0.6 (217) ○ Perceptual Organization <ul style="list-style-type: none"> ▪ Amalgam, 3.6 \pm 0.7 (219) ▪ Composite, 3.1 \pm 0.7 (216) ○ Freedom from Distractibility <ul style="list-style-type: none"> ▪ Amalgam, 3.9 \pm 0.7 (219) ▪ Composite, 2.4 \pm 0.7 (216) ○ Processing Speed <ul style="list-style-type: none"> ▪ Amalgam, 7.2 \pm 0.9 (216) ▪ Composite, 5.1 \pm 0.9 (217) ○ No significant difference (ANCOVA) between groups, all subscales $P = NS$ | <p>“Exposure to elemental mercury in amalgam at the levels experienced by the children who participated in the trial did not result in significant effects on neuropsychological function within the 5-year follow-up period.”</p> |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------|--|----------------------|
| | <ul style="list-style-type: none"> • WIAT, adjusted mean coefficient \pmSE (n) <ul style="list-style-type: none"> ○ Reading <ul style="list-style-type: none"> ▪ Amalgam, -1.0 ± 0.7 (217) ▪ Composite, -1.7 ± 0.7 (215) ○ Mathematics <ul style="list-style-type: none"> ▪ Amalgam, -1.9 ± 0.7 (216) ▪ Composite, -3.0 ± 0.8 (207) ○ No significant difference (ANCOVA) between groups, all scales and subscales $P = NS$ • WRAML, adjusted mean coefficient \pmSE (n) <ul style="list-style-type: none"> ○ Verbal Memory Index <ul style="list-style-type: none"> ▪ Amalgam, 2.9 ± 0.6 (212) ▪ Composite, 2.2 ± 0.6 (202) ○ Visual Memory Index <ul style="list-style-type: none"> ▪ Amalgam, 6.3 ± 0.8 (212) ▪ Composite, 5.0 ± 0.8 (204) ○ Learning Index <ul style="list-style-type: none"> ▪ Amalgam, 10.2 ± 0.8 (212) ▪ Composite, 10.3 ± 0.8 (203) ○ Number-Letter Memory subscale <ul style="list-style-type: none"> ▪ Amalgam, 0.3 ± 0.1 (212) ▪ Composite, -0.3 ± 0.1 (203) ▪ Significant difference (ANCOVA, ITT) between groups favours amalgam $P = 0.002$ ○ No significant difference (ANCOVA) between groups, all indices and other subscales, $P = NS$ • WRAVMA, adjusted mean coefficient \pmSE (n) <ul style="list-style-type: none"> ○ Drawing <ul style="list-style-type: none"> ▪ Amalgam, -3.8 ± 0.9 (211) ▪ Composite, -3.1 ± 0.9 (203) ○ Matching <ul style="list-style-type: none"> ▪ Amalgam, 3.0 ± 0.8 (211) ▪ Composite, 3.5 ± 0.8 (203) ○ Pegboard <ul style="list-style-type: none"> ▪ Amalgam, 9.3 ± 0.9 (211) ▪ Composite, 8.4 ± 1.0 (203) ○ No significant difference (ANCOVA) between groups, all scales, $P = NS$ • Trail-Making Test, adjusted mean coefficient \pmSE (n) <ul style="list-style-type: none"> ○ Part B: time to complete <ul style="list-style-type: none"> ▪ Amalgam, -45.6 ± 1.0 (201) | |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|------------------------------|--|---|
| | <ul style="list-style-type: none"> ▪ Composite, -50.4 ± 1.1 (193) ▪ Significant difference (ANCOVA, ITT) between groups favours composite resin, $P = 0.002$ <ul style="list-style-type: none"> ○ No significant difference (ANCOVA) between groups, Parts A, C, D, $P = NS$ • All other secondary outcome measures <ul style="list-style-type: none"> ○ No significant difference (ANCOVA) between groups, $P = NS$ | |
| Bellinger 2008 ³⁵ | <ol style="list-style-type: none"> 1. Psychosocial function, <ul style="list-style-type: none"> • CBCL mean (SD) change in scores, baseline to 5 yrs <ul style="list-style-type: none"> ○ Composite Scores (i.e., subscales combined) <ul style="list-style-type: none"> ▪ Competence <ul style="list-style-type: none"> • Amalgam, 0.8 (0.6) • Composite, -0.9 (0.6) • No significant difference (ANCOVA) between groups $P = 0.13$ ▪ Internalizing <ul style="list-style-type: none"> • Amalgam, -3.8 (0.6) • Composite, -2.1 (0.6) • Significant difference (ANCOVA) between groups favours amalgam $P = 0.03$ ▪ Externalizing <ul style="list-style-type: none"> • Amalgam, -1.8 (0.6) • Composite, -1.5 (0.8) • No significant difference (ANCOVA) between groups $P = 0.06$ ▪ Total problem behaviors <ul style="list-style-type: none"> • Amalgam, -3.3 (0.7) • Composite, -2.1 (0.7) • Significant difference (ANCOVA) between groups favours amalgam $P = 0.007$ ○ Competence Subscale Scores <ul style="list-style-type: none"> ▪ Activities <ul style="list-style-type: none"> • Amalgam, 1.7 (0.7) • Composite, 0.2 (0.6) • Significant difference (ANCOVA) between groups favours amalgam $P = 0.03$ ▪ Social adaptation <ul style="list-style-type: none"> • Amalgam, -0.8 (0.7) • Composite, -2.0 (0.7) • No significant difference (ANCOVA) between groups $P = 0.11$ | "In summary, in NECAT, a randomized trial, the psychosocial status of children in the dental amalgam group was not worse and, in some respects, was better than that of children in the non-amalgam group." |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------|--|----------------------|
| | <ul style="list-style-type: none"> ▪ School <ul style="list-style-type: none"> • Amalgam, 0.8 (0.7) • Composite, 1.3 (0.7) • No significant difference (ANCOVA) between groups P = 0.52 ○ Behaviour Subscale Scores <ul style="list-style-type: none"> ▪ Withdrawn <ul style="list-style-type: none"> • Amalgam, -1.0 (0.4) • Composite, -0.3 (0.4) • No significant difference (ANCOVA) between groups P = 0.16 ▪ Somatic complaints <ul style="list-style-type: none"> • Amalgam, -0.1 (0.6) • Composite, 0.0 (0.5) • No significant difference (ANCOVA) between groups P = 0.88 ▪ Anxious/depressed <ul style="list-style-type: none"> • Amalgam, -0.8 (0.4) • Composite, 0.1 (0.4) • Significant difference (ANCOVA) between groups favours amalgam P = 0.04 ▪ Social problems <ul style="list-style-type: none"> • Amalgam, -0.4 (0.5) • Composite, -0.2 (0.5) • No significant difference (ANCOVA) between groups P = 0.72 ▪ Thought problems <ul style="list-style-type: none"> • Amalgam, -1.5 (0.5) • Composite, -1.1 (0.5) • No significant difference (ANCOVA) between groups P = 0.44 ▪ Attention problems <ul style="list-style-type: none"> • Amalgam, -1.1 (0.4) • Composite, -0.6 (0.4) • No significant difference (ANCOVA) between groups P = 0.26 ▪ Delinquent behaviors <ul style="list-style-type: none"> • Amalgam, -1.8 (0.6) | |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------------------------------|--|--|
| | <ul style="list-style-type: none"> • Composite, -0.2 (0.5) • Significant difference (ANCOVA) between groups favours amalgam $P = 0.002$ ▪ Aggression <ul style="list-style-type: none"> • Amalgam, -0.3 (0.4) • Composite, 0.2 (0.4) • No significant difference (ANCOVA) between groups $P = 0.28$ • BASC-SR <ul style="list-style-type: none"> ○ Global scores (i.e., subscales combined) at 5yrs, mean (SD) <ul style="list-style-type: none"> ▪ School maladjustment <ul style="list-style-type: none"> • Amalgam, 50.8 (0.7) • Composite, 50.4 (0.7) • No significant difference (ANCOVA) between groups $P = 0.29$ ▪ Clinical maladjustment <ul style="list-style-type: none"> • Amalgam, 44.0 (0.6) • Composite, 45.7 (0.6) • No significant difference (ANCOVA) between groups $P = 0.08$ ▪ Personal adjustment <ul style="list-style-type: none"> • Amalgam, 53.3 (0.6) • Composite, 51.3 (0.6) • Significant difference (ANCOVA) between groups favours amalgam $P = 0.005$ ▪ Emotional symptoms index <ul style="list-style-type: none"> • Amalgam, 44.6 ± 0.6 • Composite, 46.3 ± 0.6 • Significant difference (ANCOVA) between groups favours amalgam $P = 0.05$ ○ Subscale scores NR | |
| Lauterbach 2008 ⁴⁰ | <ol style="list-style-type: none"> 1. Presence of neurological hard signs (NHS), n/pts evaluated (%) <ul style="list-style-type: none"> • Baseline <ul style="list-style-type: none"> ○ Amalgam, 9/253 (3.6) ○ Composite, 6/253 (2.4) ○ No significant difference (Fisher's exact) between groups $P = 0.60$ • Year 1 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 10/235 (4.3) ○ Composite, 11/231 (4.8) ○ No significant difference (Fisher's exact) between groups $P = 0.83$ | <p>“This study’s results show clearly that children exposed to elemental mercury from dental amalgam, a substance potentially toxic to the nervous system, do not differ from similar children without amalgam exposure in terms of gross and fine neurological development, as assessed in routine clinical</p> |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------|---|---|
| | <ul style="list-style-type: none"> • Year 2 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 12/230 (5.2) ○ Composite, 12/222 (5.4) ○ No significant difference (Fisher's exact) between groups $P > 0.99$ • Year 3 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 4/197 (2.0) ○ Composite, 7/185 (3.8) ○ No significant difference (Fisher's exact) between groups $P = 0.37$ • Year 4 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 7/197 (3.6) ○ Composite, 4/193 (2.1) ○ No significant difference (Fisher's exact) between groups $P = 0.54$ • Year 5 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 12/194 (6.2) ○ Composite, 15/200 (7.5) ○ No significant difference (Fisher's exact) between groups $P = 0.69$ • Year 6 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 13/146 (8.9) ○ Composite, 11/144 (7.6) ○ No significant difference (Fisher's exact) between groups $P = 0.83$ • Year 7 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 11/136 (8.1) ○ Composite, 20/142 (14.1) ○ No significant difference (Fisher's exact) between groups $P = 0.13$ <p>2. Presence of tremor, n/pts evaluated (%)</p> <ul style="list-style-type: none"> • Year 1 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 2/100 (2.0) ○ Composite, 1/105 (1.0) ○ No significant difference (Fisher's exact) between groups $P = 0.61$ • Year 2 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 4/230 (1.7) ○ Composite, 2/222 (0.9) ○ No significant difference (Fisher's exact) between groups $P = 0.69$ • Year 3 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 0/197 (0.0) ○ Composite, 1/185 (0.5) ○ No significant difference (Fisher's exact) between groups $P = 0.48$ • Year 4 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 0/197 (0.0) ○ Composite, 0/193 (0.0) | <p>neurological examinations. Thus, these data indicate the absence of a generalized negative effect on children's nervous system functions stemming from the presence of dental amalgam, and while we cannot rule out potential adverse reactions in individual children, we found no indications of any."</p> |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------|--|----------------------|
| | <ul style="list-style-type: none"> ○ No significant difference (Fisher's exact) between groups $P > 0.99$ • Year 5 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 5/194 (2.6) ○ Composite, 5/200 (2.5) ○ No significant difference (Fisher's exact) between groups $P > 0.99$ • Year 6 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 5/146 (3.4) ○ Composite, 5/144 (3.5) ○ No significant difference (Fisher's exact) between groups $P > 0.99$ • Year 7 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 6/135 (4.4) ○ Composite, 7/142 (4.9) ○ No significant difference (Fisher's exact) between groups $P > 0.99$ <p>3. Presence of NSS, n/pts evaluated (%)</p> <ul style="list-style-type: none"> • Year 2 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 155/228 (68.0) ○ Composite, 174/222 (78.4) ○ Significant difference (Fisher's exact) between groups favours amalgam $P = 0.02$ • Year 3 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 139/197 (70.6) ○ Composite, 130/185 (70.3) ○ No significant difference (Fisher's exact) between groups $P > 0.99$ • Year 4 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 119/197 (60.4) ○ Composite, 113/193 (58.5) ○ No significant difference (Fisher's exact) between groups $P = 0.76$ • Year 5 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 97/197 (50.0) ○ Composite, 113/200 (56.5) ○ No significant difference (Fisher's exact) between groups $P = 0.23$ • Year 6 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 65/146 (44.5) ○ Composite, 59/144 (41.0) ○ No significant difference (Fisher's exact) between groups $P = 0.56$ • Year 7 of follow-up <ul style="list-style-type: none"> ○ Amalgam, 43/135 (31.9) ○ Composite, 53/142 (37.3) ○ No significant difference (Fisher's exact) between groups $P = 0.38$ | |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|----------------------------|---|--|
| | <p>4. NSS score (0-3), (n) mean±SD</p> <ul style="list-style-type: none"> • Year 3 of follow-up <ul style="list-style-type: none"> ○ Amalgam, (175) 1.61±1.68 ○ Composite, (168) 1.79±1.65 ○ No significant difference (t-test) between groups P = 0.33 • Year 4 of follow-up <ul style="list-style-type: none"> ○ Amalgam, (197) 1.20±1.48 ○ Composite, (193) 1.20±1.32 ○ No significant difference (t-test) between groups P = 0.97 • Year 5 of follow-up <ul style="list-style-type: none"> ○ Amalgam, (194) 0.99±1.52 ○ Composite, (200) 1.16±1.59 ○ No significant difference (t-test) between groups P = 0.31 • Year 6 of follow-up <ul style="list-style-type: none"> ○ Amalgam, (146) 0.85±1.31 ○ Composite, (144) 0.75±1.25 ○ No significant difference (t-test) between groups P = 0.51 • Year 7 of follow-up <ul style="list-style-type: none"> ○ Amalgam, (135) 0.46±0.81 ○ Composite, (142) 0.57±0.94 ○ No significant difference (t-test) between groups P = 0.29 | |
| Shenker 2008 ³⁷ | <ol style="list-style-type: none"> 1. Amalgam exposure <ul style="list-style-type: none"> • Cumulative average number of surfaces restored with amalgam over the study's duration <ul style="list-style-type: none"> ○ Amalgam, 10.6 ○ Composite, 0 • Mean number of surfaces restored with amalgam at 5yr follow up <ul style="list-style-type: none"> ○ Amalgam, 4.2 ○ Composite, NR 2. Urinary elemental mercury levels <ul style="list-style-type: none"> • Mean µg/g creatinine, yrs 3, 4, 5 <ul style="list-style-type: none"> ○ Amalgam, 0.89, 0.81, 0.85 ○ Composite, 0.64, 0.50, 0.68 ○ Statistically significant difference between groups (method NR) in yr 4 P = 0.03 ○ No significant difference between groups (method NR) in yr 3 P = 0.07 and yr 5 P = 0.20 3. Immune function changes from baseline at 5-7 days; 6; 12; and 60 months post-intervention <ul style="list-style-type: none"> • Total WBC, (n) mean change±NR | <p>“This study confirms that treatment of children with dental amalgams leads to increased, albeit low level, exposure to mercury. In this exploratory analysis of immune function, amalgam exposure did not cause overt immune deficits, although small transient effects were observed 5–7 days post restoration... These findings suggest that immunotoxic effects of amalgam restorations in children need not be a concern when choosing this restorative dental material.”</p> |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------|--|----------------------|
| | <ul style="list-style-type: none"> ○ Amalgam, (23) -0 ± 3.6; (24) 0.6 ± 3.5; (17) 1.2 ± 5.8; (20) -1.0 ± 4.0 ○ Composite, (24) 0.4 ± 7.2; (29) 0.7 ± 3.8; (21) -0.4 ± 3.6; (23) -1.7 ± 5.5 ○ No significant difference (ANCOVA) between groups $P = NR$ • T-cell function <ul style="list-style-type: none"> ○ %CD25+ (PHA), (n) mean change\pmNR <ul style="list-style-type: none"> ▪ Amalgam, (23) -6.0 ± 25.3; (24) 2.0 ± 31.4; (17) 13.8 ± 18.6; (20) 14.8 ± 16.3 ▪ Composite, (24) 1.3 ± 28.1; (28) 4.7 ± 36.3; (21) 13.6 ± 30.7; (23) 14.0 ± 24.4 ▪ No significant difference (ANCOVA) between groups $P = NR$ ○ %CD69+ (PHA), (n) mean change\pmNR <ul style="list-style-type: none"> ▪ Amalgam, (23) -6.5 ± 23.6; (24) -1.5 ± 26.3; (17) 5.7 ± 9.6; (20) 0.9 ± 17.0 ▪ Composite, (24) 4.2 ± 20.8; (28) 4.5 ± 20.6; (21) 5.5 ± 28.4; (23) 4.0 ± 17.9 ▪ No significant difference (ANCOVA) between groups $P = NR$ ○ Cell cycle distribution at 72hrs <ul style="list-style-type: none"> ▪ Findings NR • B-cell function <ul style="list-style-type: none"> ○ %CD23+ (PHA), (n) mean change\pmNR <ul style="list-style-type: none"> ▪ Amalgam, (23) 2.5 ± 12.5; (24) 9.8 ± 25.7; (17) -1.3 ± 27.7; (20) -3.3 ± 26.9 ▪ Composite, (24) 1.5 ± 21.7; (28) 13.0 ± 28.4; (21) 3.8 ± 30.7; (23) 10.9 ± 23.5 ▪ No significant difference (ANCOVA) between groups $P = NR$ ○ %CD69+ (PWM), (n) mean change\pmNR <ul style="list-style-type: none"> ▪ Amalgam, (23) -5.2 ± 16.8; (24) -0.4 ± 24.9; (17) -5.9 ± 22.3; (20) -8.4 ± 24.9 ▪ Composite, (24) -2.2 ± 21.6; (28) 5.2 ± 21.9; (21) -1.3 ± 26.9; (23) 1.8 ± 14.1 ▪ No significant difference (ANCOVA) between groups $P = NR$ • Monocyte function <ul style="list-style-type: none"> ○ % Eth+(PMA), (n) mean change\pmNR <ul style="list-style-type: none"> ▪ Amalgam, (23) -7.8 ± 26.4; (24) -6.2 ± 19.9; (17) -30.7 ± 22.7; (20) 6.3 ± 21.1 ▪ Composite, (24) 5.7 ± 19.6; (27) -4.9 ± 30.1; (21) -18.4 ± 26.1; (22) 3.1 ± 26.8 ○ % Rho+(PMA), (n) mean change\pmNR <ul style="list-style-type: none"> ▪ Amalgam, (23) -8.4 ± 30.2; (24) -5.6 ± 27.7; (17) -22 ± 20.8; (20) 7.8 ± 24.5 ▪ Composite, (24) 0.4 ± 29.2; (27) -2.1 ± 29.7; (21) -15.3 ± 26.7; (22) 8.8 ± 28.7 • No significant difference (ANCOVA) between groups $P = NR$ • Neutrophil function, (n) mean change\pmNR <ul style="list-style-type: none"> ○ % Eth+(PMA) <ul style="list-style-type: none"> ▪ Amalgam, (23) -6.5 ± 20.4; (24) -8.3 ± 24.9; (17) -14.5 ± 23.6; (20) 2.3 ± 8.1 ▪ Composite, (24) 3.1 ± 21.1; (28) -9.8 ± 34.6; (21) -13.4 ± 36.6; (23) 6.1 ± 19.6 ○ % Rho+(PMA) | |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------------------------------|---|--|
| | <ul style="list-style-type: none"> ▪ Amalgam, (23) -8.0 ± 19.5; (24) -5.0 ± 29.7; (17) -7.3 ± 31.1; (20) 1.8 ± 13.0 ▪ Composite, (24) 7.2 ± 24.5; (28) -0.5 ± 26.3; (21) -2.0 ± 25.4; (23) 9.3 ± 25.4 • No significant difference (ANCOVA) between groups $P = NR$ | |
| Barregard, 2008 ³⁹ | <ol style="list-style-type: none"> 1. Renal biomarker values, median (n) range <ul style="list-style-type: none"> • Albumin <ul style="list-style-type: none"> ○ Amalgam, year 3: 6.8 (135) < DL-773; year 5: 6.0 (193) < DL-771 ○ Composite, year 3: 7.9 (148) < DL-208; year 5: 6.5 (186) < DL-687 ○ No significant difference between groups (ANCOVA) $P = 0.46$ • A1M <ul style="list-style-type: none"> ○ Amalgam, year 3: < DL (135) < DL-29; year 5: < DL (193) < DL-29 ○ Composite, year 3: < DL (148) < DL-21; year 5: < DL (186) < DL-29 ○ No significant difference between groups (ANCOVA) $P = 0.79$ • γ-GT <ul style="list-style-type: none"> ○ Amalgam, baseline: 19.5 (238) 2.1-66; year 5: 39.3 (204) 3.6-125 ○ Composite, baseline: 17.4 (223) 2.0-62; year 5: 40.2 (198) 2.6-143 ○ No significant difference between groups (ANCOVA) $P = 0.86$ • NAG <ul style="list-style-type: none"> ○ Amalgam, year 3: 1.4 (135) < DL-4.7; year 5: 1.2 (193) < DL-3.7 ○ Composite, year 3: 1.4 (148) < DL-4.8; year 5: 1.2 (186) < DL-7.8 ○ No significant difference between groups (ANCOVA) $P = 0.95$ 2. Prevalence of 'high' renal biomarker values (as defined), n/sample (%) <ul style="list-style-type: none"> • Albumin ('high' >30 mg/g creatinine) <ul style="list-style-type: none"> ○ Amalgam, year 3: 18/135 (13) year 5: 30/193 (16) ○ Composite, year 3: 15/148 (9.5); year 5: 18/186 (9.7) ○ No significant difference (logistic regression) between groups $P = 0.07$ ○ No significant difference (crude OR, yrs 3-5) OR = 1.6, 95% CI 0.98-2.5 $P = 0.06$ ○ Significant difference (repeat-measures logistic regression, yr 3 or yr 5) between groups favours composite resin, OR = 1.8, 95% CI 1.1-2.9 $P = 0.03$ • A1M ('high' >10.5 mg/g creatinine) <ul style="list-style-type: none"> ○ Amalgam, year 3: 5/135 (3.7); year 5: 5/193 (2.6) ○ Composite, year 3: 13/148 (8.8); year 5: 3/186 (1.6) ○ No significant difference (logistic regression) between groups $P = 0.89$ • γ-GT ('high' >71.9 U/g creatinine) <ul style="list-style-type: none"> ○ Amalgam, year 1: 2/186 (1.1); year 5: 20/204 (9.8) ○ Composite, year 1: 2/182 (1.1); year 5: 20/198 (10) ○ No significant difference (logistic regression) between groups $P = 0.85$ | "In summary, the present randomized clinical trial showed no effect of amalgam on renal tubular function. There was, however, an increased prevalence of [albumin] in children treated with dental amalgam. This may reflect a causal association or it may be a chance finding. This issue should be examined further." |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|--------------------------|---|--|
| | <ul style="list-style-type: none"> • NAG ('high' >3.1 U/g creatinine) <ul style="list-style-type: none"> ○ Amalgam, year 3: 5/135 (3.7); year 5: 5/193 (2.6) ○ Composite, year 3: 8/148 (5.4); year 5: 8/186 (4.3) ○ No significant difference (logistic regression) between groups $P = 0.59$ | |
| Woods 2008 ³⁸ | <ol style="list-style-type: none"> 1. Urinary mercury <ul style="list-style-type: none"> • Baseline urinary mercury, mean $\mu\text{g/g}$ creatinine <ul style="list-style-type: none"> ○ Amalgam, 1.8 ○ Composite, 1.9 2. Renal function <ul style="list-style-type: none"> • Log-transformed, creatinine-adjusted $\mu\text{g/g}$ GST-α, (n) mean\pmSD <ul style="list-style-type: none"> ○ Amalgam, age 9yrs (56) 1.85\pm1.15, age 10yrs (109) 2.14\pm1.17, age 11yrs (175) 1.98\pm1.17, age 12yrs (218) 1.82\pm1.11, age 13yrs (217) 1.94\pm0.96, age 14yrs (209) 1.70\pm0.99, age 15yrs (194) 1.58\pm0.95, age 16yrs (171) 1.65\pm0.96, age 17yrs (125) 1.68\pm0.94, age 18yrs (54) 1.60\pm0.90 ○ Composite, age 9yrs (59) 2.21\pm0.99, age 10yrs (135) 2.00\pm1.11, age 11yrs (192) 2.07\pm1.10, age 12yrs (208) 1.89\pm0.97, age 13yrs (212) 1.80\pm1.05, age 14yrs (208) 1.69\pm0.96, age 15yrs (205) 1.60\pm1.00, age 16yrs (159) 1.51\pm0.95, age 17yrs (97) 1.49\pm0.91, age 18yrs (54) 1.50\pm0.84 ○ No significant difference between treatment groups <ul style="list-style-type: none"> ▪ unadjusted (1.05, 95% CI 0.95-1.17) $P = 0.308$ ▪ adjusted (1.05, 95% CI 0.94-1.17) $P = 0.405$ • Log-transformed, creatinine-adjusted $\mu\text{g/g}$ GST-π, (n) mean\pmSD <ul style="list-style-type: none"> ○ Amalgam, age 9yrs (55) 0.68\pm1.12, age 10yrs (104) 0.59\pm1.16, age 11yrs (171) 0.61\pm1.05, age 12yrs (165) 0.87\pm1.19, age 13yrs (152) 1.25\pm1.04, age 14yrs (89) 1.38\pm1.03, age 15yrs (73) 1.73\pm1.03, age 16yrs (65) 2.25\pm0.91, age 17yrs (99) 2.25\pm0.93, age 18yrs (61) 2.33 0.99 ○ Composite, age 9yrs (51) 0.86\pm1.06, age 10yrs (117) 0.62\pm1.01, age 11yrs (167) 0.71\pm1.11, age 12yrs (164) 0.91\pm1.14, age 13yrs (139) 1.10\pm1.22, age 14yrs (90) 1.24\pm1.11, age 15yrs (92) 1.77\pm1.10, age 16yrs (69) 2.15\pm0.97, age 17yrs (80) 2.02\pm0.91, age 18yrs (60) 2.21 0.90 ○ No significant difference between treatment groups | <p>“In conclusion, we observed no significant effects of dental amalgam mercury on measures of renal tubular or glomerular functional integrity during a prolonged course of dental amalgam treatment in children and adolescents from 9 to 18 years of age. These findings are relevant within the context of children’s health risk assessment as relates to the safety of mercury exposure from dental amalgam on kidney function.”</p> |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------------------------------|---|--|
| | <ul style="list-style-type: none"> ▪ unadjusted (1.08, 95% CI 0.96-1.20) $P = 0.203$ ▪ adjusted (1.11, 95% CI 0.98-1.26) $P = 0.091$ • Log-transformed, creatinine-adjusted mg/g albumin, (n) mean±SD <ul style="list-style-type: none"> ○ Amalgam , age 9yrs (44) 2.43±0.74, 10yrs (106) 2.18±0.99, 11yrs (158) 2.06±1.09, 12yrs (228) 2.17±1.08, 13yrs (229) 2.33±0.93, 14yrs (214) 2.35±0.94, 15yrs (204) 2.36±1.01, 16yrs (172) 2.20±1.01, 17yrs (126) 2.18±1.06, 18yrs (60) 2.21 1.09 ○ Composite, age 9yrs (53) 2.46±0.91, 10yrs (125) 2.28 1.13, 11yrs (171) 2.23±1.24, 12yrs (222) 2.23±0.97, 13yrs (218) 2.42±1.09, 14yrs (219) 2.44±1.03, 15yrs (219) 2.31±1.01, 16yrs (158) 2.33±1.09, 17yrs (104) 2.13±0.87, age 18yrs (60) 2.16±1.11 ○ No significant difference between treatment groups <ul style="list-style-type: none"> ▪ unadjusted (0.92, 95% CI 0.82-1.04) $P = 0.179$ ▪ adjusted (0.91, 95% CI 0.78-1.07) $P = 0.274$ • Creatinine-adjusted urinary albumin > 30 mg/gm creatinine, OR (amalgam: composite) P-values (Wald test) <ul style="list-style-type: none"> ○ Age 9yrs 0.7 $P = 0.72$, 10yrs 0.3 $P = 0.52$, 11yrs 0.8 $P = 0.69$, 12yrs 0.8 $P = 0.67$, 13yrs 0.8 $P = 0.70$, 14yrs 0.9 $P = 0.78$, 15yrs 0.5 $P = 0.52$, 16yrs 0.8 $P = 0.72$, 17yrs 1.5 $P = 0.66$, 18yrs 1.0 $P = 0.83$ ○ No significant difference between treatment groups at any follow up time point | |
| Maserejian 2012 ³⁴ | <p>(v) BMI-for-age Z-score, 5-year difference (SE)</p> <ul style="list-style-type: none"> • Females <ul style="list-style-type: none"> ○ Amalgam, 0.21 (0.07) ○ Composite, 0.36 (0.06) ○ No significant difference (linear, mixed-effects model) between groups $P = 0.49$ • Males <ul style="list-style-type: none"> ○ Amalgam, 0.25 (0.07) ○ Composite, 0.13 (0.08) ○ No significant difference (linear, mixed-effects model) between treatment groups $P = 0.36$ | “Overall, there were no significant differences in physical development over 5 years in children treated with composites or amalgam. Additional studies examining these restoration materials in relation to age at menarche are warranted.” |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|--------------------------|---|--|
| | <p>(vi) Body fat %, 5-year difference (SE)</p> <ul style="list-style-type: none"> • Females, <ul style="list-style-type: none"> ○ Amalgam, 7.7 (0.8) ○ Composite, 8.8 (0.7) ○ No significant difference (linear, mixed-effects model) between treatment groups $P = 0.95$ • Males <ul style="list-style-type: none"> ○ Amalgam, 5.7 (0.9) ○ Composite, 4.9 (0.9) ○ No significant difference (linear, mixed-effects model) between treatment groups $P = 0.49$ <p>(vii) Height in cm , 5-year difference (SE)</p> <ul style="list-style-type: none"> • Females, <ul style="list-style-type: none"> ○ Amalgam, 31.2 (0.5) ○ Composite, 30.7 (0.5) ○ No significant difference (linear, mixed-effects model) between treatment groups $P = 0.51$ • Males, <ul style="list-style-type: none"> ○ Amalgam, 33.5 (0.6) ○ Composite, 34.4 (0.6) ○ No significant difference (linear, mixed-effects model) between treatment groups $P = 0.56$ <p>(viii) Menarche</p> <ul style="list-style-type: none"> • Females who reached menarche during 5yr study follow up, n (%) <ul style="list-style-type: none"> ○ Amalgam, 34 (66.7) ○ Composite, 30 (48.4) ○ Females in the amalgam group significantly more likely to reach menarche $HR = 0.57$ (95% CI) $P = 0.03$ • Age at first menarche, mean yrs (SD) <ul style="list-style-type: none"> ○ Amalgam, 12.3 (1.0) ○ Composite, 12.5 (1.1) ○ No significant difference (proportional hazards model) between treatment groups $P = 0.29$ | |
| Woods 2007 ⁴¹ | <p>1. Urinary mercury, by treatment group</p> <ul style="list-style-type: none"> • Mean creatinine-adjusted $\mu\text{g/g}$ (95% CI), baseline, years 1-7 of follow up <ul style="list-style-type: none"> ○ Amalgam, 1.8 (NR), NR ○ Composite, 1.9 (NR), NR ○ Statistically significant difference (t-test) between groups in all years of follow up $P < 0.01$ | <p>"Treatment groups were comparable in baseline urinary mercury concentration (~1.5 $\mu\text{g/L}$). Mean urinary mercury concentrations in the amalgam group increased to a peak of ~3.2 $\mu\text{g/L}$ at year 2 and then declined to</p> |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|------------------------------|---|---|
| | <ul style="list-style-type: none"> • Mean, unadjusted µg/L (95% CI), baseline, yr2 of follow up, years 1 and 3-7 of follow up <ul style="list-style-type: none"> ○ Amalgam, 1.5 (NR), 3.2 (NR), NR ○ Composite, NR(NR), NR(NR), NR ○ Statistically significant difference (t-test) between groups in years 2-6 of follow up $P < 0.001$ ○ No significant difference (t-test) between groups in year 7 of follow up $P = 0.07$ 2. Urinary mercury, by treatment group and sex <ul style="list-style-type: none"> • Mean, unadjusted µg/L (95% CI) <ul style="list-style-type: none"> ○ Amalgam <ul style="list-style-type: none"> ▪ Female, year 2 of follow up $P = 3.5$ (NR); all other years reported as "about 3" (p. 1529) (95% CI NR) ▪ Male, all years of follow up reported as "<3" (p. 1529) (95% CI NR) ▪ Significantly higher levels of urinary mercury in females in all years of follow up ($P < 0.05$), except year 3 ($P = NS$) ○ Composite <ul style="list-style-type: none"> ▪ Female, NR (NR) ▪ Male, NR (NR) ▪ No significant difference between females and males in any year of follow up $P = NS$ | <p>baseline levels by year 7 of follow-up.... Girls excrete significantly higher concentrations of mercury in the urine than boys with comparable treatment, suggesting possible sex-related differences in mercury handling and susceptibility to mercury toxicity."</p> |
| Woods 2009 ³⁶ | <ol style="list-style-type: none"> 1. Baseline urinary mercury, mean µg/g creatinine <ul style="list-style-type: none"> • Amalgam, 1.8 • Composite, 1.9 2. Urinary porphyrins, all children <ul style="list-style-type: none"> • "Slightly elevated" (p. 893) levels (values NR) of penta-, precopro-, and coproporphyrins in the amalgam group $P = NR$ • No significant differences between treatment groups in uro- (8-carboxyl), hepta- (7-carboxyl), or hexa- (6-carboxyl) porphyrins $P = NR$ 3. Urinary porphyrins, 8 and 9 year old children only <ul style="list-style-type: none"> • Increased levels (values NR) of penta-, precopro-, and coproporphyrins in the amalgam group • No significant differences between treatment groups $P = NS$ | <p>"In conclusion, the present findings describe incipient increases in the urinary concentrations of porphyrins previously defined in association with Hg body burden, in children and adolescents with dental amalgam Hg exposure. These findings attest to the sensitivity of porphyrin changes in relation to Hg exposure and may be useful within the context of risk assessment for low-level Hg exposure in children."</p> |
| Kemaloglu 2016 ³³ | <ol style="list-style-type: none"> 1. VAS scores, baseline, 6, 12, 36mos <ul style="list-style-type: none"> • Raw scores NR • No significant difference (Wilcoxon signed rank test) between groups at baseline, 6 and 12 mos $P > 0.05$ • Significant difference (Wilcoxon signed rank test) between groups at 36mos favours composite resin $P < 0.05$ | <p>"In postoperative sensitivity criteria, resin composites presented lower sensitivity levels than amalgams after 3 years. Within the limitations of this study, it can be concluded that resin composite can be an alternative for bonded amalgam restorations and can be used with</p> |

| Study | Quantitative Findings or Narrative Summary | Authors' Conclusions |
|-------|--|--|
| | | utmost assurance even in large size cavities.” |

3074
3075
3076

CI = confidence interval; DL = detection limit; HR = hazard ratio; NR = not reported; NS = not significant; OR = odds ratio; PHA = phytohemagglutinin; PMA = phorbol myristate acetate; PWM = pokeweed mitogen; SD = standard deviation; SE = standard error; yrs = years

3077 **Appendix 9: Supplemental health economics tables and figures**

3078 **Previously published models identified by the literature search**

3079

| ECONOMIC MODELS/ANALYSES | | | | | | |
|--------------------------|------|-----------|---|--|--------------------------------------|---|
| Author | Year | Country | Treatment compared | Type of analysis/ Type of model | Time horizon | Comments |
| Beazoglou ⁵⁰ | 2007 | USA | Amalgam and composite resin | Financial impact of amalgam ban | 15 years | Using 1992-2004 trends in usage of composite resin and amalgam in dental claims to project future usage and estimate the impact of a sudden amalgam ban |
| Elhennawy ⁵¹ | 2017 | Germany | Tooth removal & orthodontic alignment vs resin composite restoration vs crown for the management of molars with severe molar-incisor hypomineralization | Cost-effectiveness/ Markov | Lifetime in a 6 year old child | Transition probabilities (e.g., replacement of composite restoration, crown, implant) from literature Costs from German public tariffs |
| Kanzow ⁵² | 2016 | Germany | Repairing vs replacing composite or amalgam restorations in 4-surface defective permanent molars | Cost-effectiveness/ Markov | Lifetime in a 40 year old individual | Proportion of different re-treatments based on large practice-based study Costs from German public tariffs Assumptions of interest: <ul style="list-style-type: none"> • Complete replacement did not add additional surface to the restoration but was only possible twice before crown placement • 50% of extracted teeth were replaced by implant-supported single crown |
| Kelly ⁵³ | 2004 | Australia | Indirect restorations vs class II cusp-overlay amalgam vs class IV multisurface resin composite restorations | Cost-effectiveness using chart review data | 15 years in 40 year old adults | 15-year survival of amalgam and composite resin restorations No information on subsequent restorations |
| Maryniuk ⁵⁴ | 1988 | USA | Amalgam vs crown for the replacement of failed amalgam restoration | Cost-effectiveness/ Decision-tree | Lifetime in a 30 year old adult | Probabilities to progress to crown or have root canal treatment are not based on existing evidence |

| ECONOMIC MODELS/ANALYSES | | | | | | |
|---------------------------|------|-----------------|---|--|---------------------------------|--|
| Author | Year | Country | Treatment compared | Type of analysis/ Type of model | Time horizon | Comments |
| | | | | | | Costs of restorations based on tariffs |
| Schwendicke ⁵⁵ | 2014 | Germany | Non-invasive (prevention and fluoride) vs micro-invasive (resin infiltration) vs invasive (composite restoration) of proximal posterior lesion | Cost-effectiveness/ Markov | 20 year old adult | Details on transition probabilities Costs from public German tariffs |
| Schwendicke ⁵⁶ | 2015 | Germany | Immediate restoration without secondary root canal treatment vs secondary root canal treatment followed by restoration in a defective root canal restored tooth | Cost-effectiveness/ Markov | Lifetime in 50 year old patient | |
| Sjogren ⁵⁷ | 2002 | Sweden | Class II molar restorations | Cost per year of function | Restoration failure time | Reporting a cost per year of function Combining longevity from literature to Swedish tariffs |
| Tobi ⁵⁸ | 1999 | The Netherlands | Composite resin vs amalgam for the replacement of amalgam Class II restorations | Costs and effectiveness alongside a clinical study | 5 years | Treatment times from a study by Kreulen are used to calculate costs (dentist office perspective) |
| Warren E ⁵⁹ | 2016 | Australia | Caries Management System vs no intervention | Patient-level simulation | Lifetime | Age distribution similar to Australian population One Markov model per tooth (8 molars) Using combined anterior and posterior tooth data from a study. States: no disease, enamel caries, dentine caries, filling, repeat filling, root canal, crown extraction, bridge, Implant and death. Baseline values from Australian Institute of Health and Welfare. Subsequent events are assumed to increase by 1 when they enter the filling, repeat filling and tooth extraction states. Validation with 7-year study data shows the model under predicts |

| ECONOMIC MODELS/ANALYSES | | | | | | |
|--------------------------|------|-----------|---|------------------------------------|--------------|---|
| Author | Year | Country | Treatment compared | Type of analysis/ Type of model | Time horizon | Comments |
| | | | | | | the number of restorations. (note: suppl tables not available online) |
| Warren E ⁶⁰ | 2010 | Australia | Caries Management System vs no intervention | Patient-level simulation | Lifetime | Same as above but with 3-year data only. |


3080 Cost-consequence model inputs

| Parameter | Consequence | | | | Base case value | Values for PSA | Values for scenario/sensitivity analysis | Source |
|--|-------------|---|---|---|-----------------|--|--|--|
| | 1 | 2 | 3 | 4 | | | | |
| Time-to-failure (amalgam) | X | X | | | 132.5104 months | SD: 16.2416 (normal distribution) | Smallest difference scenario: 131.0994 months Largest difference scenario: 133.9214 months | NECAT figure on time-to-failure for permanent posterior teeth digitalized and extrapolated to identified average and SD. ⁶³ |
| Time-to-failure (composite resin) | X | X | | | 95.7682 months | SD: 6.5337 (normal distribution) | Smallest difference scenario: 96.2349 months Largest difference scenario: 95.3015 months | NECAT figure on time-to-failure for permanent posterior teeth digitalized and extrapolated to identified average and SD. ⁶³ |
| Costs of dental restorations –privately paid (amalgam) | X | X | | | \$170.74 | 99.7% CI: \$133.60 to \$207 (normal distribution of log transformed values) | All surfaces scenario: \$185.98 (99.7%CI: \$85.30, \$294.00) | Average of dental fees for 2- and 3-surface restoration of the premolars and molars (i.e., codes: 21212, 21213, 21222, 21223 for amalgam and 23312, 23313, 23322, 23323 for composite resin) from all public and private fee lists obtained ²³⁰ |
| Cost of dental restorations – privately paid (composite resin) | X | X | | | \$209.34 | 99.7% CI: \$134.10 to \$282.00 (normal distribution of log transformed values) | All surfaces scenario: \$229.41 (99.7%CI: \$92.36, \$401.00) | |
| Costs of dental restorations –publicly paid (amalgam) | X | X | | | \$130.46 | 99.7% CI: \$56.23 to \$180.95 (normal distribution of log transformed values) | All surfaces scenario: \$142.82 (99.7%CI: \$25.68, \$268.24) | |
| Cost of dental restorations – publicly paid (composite resin) | X | X | | | \$180.39 | 99.7% CI: \$74.33 to \$275.40 (normal distribution of log transformed values) | All surfaces scenario: \$196.10 (99.7%CI: \$51.34, \$370.53) | |
| Relative proportion of posterior tooth restorations | X | X | | | | | 21221 and 23311: 0.09798 21212 and 23312: 0.16661 21213 and 23313: 0.12086 21214 and 23314: 0.04888 21215 and 23315: 0.01194 21221 and 23321: 0.14641 21222 and 23322: 0.19239 21223 and 23323: 0.13157 21224 and 23324: 0.00647 21225 and 23325: 0.01819 | |
| Age at first restoration (amalgam) | | X | | | 7.9 years | SD: 1.3 (normal distribution) | | |

| Parameter | Consequence | | | | Base case value | Values for PSA | Values for scenario/sensitivity analysis | Source |
|--|-------------|---|---|---|-----------------------------|---|---|--|
| | 1 | 2 | 3 | 4 | | | | |
| Age at first restoration (composite resin) | | X | | | 7.9 years | SD: 1.4 (normal distribution) | | NECAT ⁶³ |
| Proportion of individuals covered by a public program | X | X | | | 0.055 | SE: 0.0072 (normal distribution) | | Oral Health Survey 2009 ⁶² |
| Probability of death at restoration failure | | X | | | As per Canadian life tables | | | Statistics Canada ⁶⁵ |
| Cost of a crown (privately paid) | | X | | | | 99.7%CI: \$147.76, \$1,428.34 (normal distribution of log transformed values) | Crown scenario: \$630.45 | Average of the following procedure codes: 22311, 22320, 27113, 27121, 27201, 27215, 27301, 27413 from all public and private fee lists obtained ²³⁰ |
| Cost of a crown (publicly paid) | | X | | | | 99.7%CI: \$96.26, \$801.06 (normal distribution of log transformed values) | Crown scenario: \$537.77 | |
| Cost of a tooth extraction (privately paid) | | X | | | | 99.7%CI: \$120.00, \$139.00 (normal distribution of log transformed values) | Crown & extraction scenarios: \$130.79 | Average of procedure code 71101 from all public and private fee lists obtained ²³⁰ |
| Cost of a tooth extraction (publicly paid) | | X | | | | 99.7%CI: \$38.51, \$130.30 (normal distribution of log transformed values) | Crown & extraction scenarios: \$97.64 | |
| Probability of crown failure at 10 years | | X | | | | | Crown scenario: 0.7795 | Kolker JL et al ⁶⁹ |
| Time to extraction | | X | | | | 99.7%CI: 1.20, 9.20 (normal distribution of log transformed values) | Crown scenario: 6.90 years | Kolker JL et al ⁶⁹ |
| Consumer price index | | X | X | | Multiple values | Not applicable | Not applicable | Bank of Canada ⁸¹ |
| Amalgam separator acquisition and installation costs | | | X | | \$2,000 | Not applicable | Not applicable | (Dr. Shahrokh Esfandiari: personal communication, 2017 Aug 08) |
| Amalgam separator maintenance and recycling annual costs | | | X | | \$2,200 | Not applicable | Not applicable | (Dr. Shahrokh Esfandiari: personal communication, 2017 Aug 08) |
| Useful time of amalgam separator | | | X | | 5 years | Not applicable | Not applicable | Statistics Canada ²³¹ |
| Number of dentist using amalgam in Canada | | | X | | 13,982 | Not applicable | Not applicable | Environmental Impact section |
| Average number of dentist per clinic | | | X | | 2.1 | Not applicable | Not applicable | CDA 2010 report ⁷⁸ |
| 2-surface amalgam restoration procedure time | | | | X | 24.3 minutes | 95%CI: 11.3, 46.5 | Lower limit of time scenario: 11.3 Higher limit of time scenario: 46.5 | Advokaat et al ⁷⁵ |

| Parameter | Consequence | | | | Base case value | Values for PSA | Values for scenario/sensitivity analysis | Source |
|--|-------------|---|---|---|-----------------|--|--|---------------------------------|
| | 1 | 2 | 3 | 4 | | | | |
| 3-surface amalgam restoration procedure time | | | | X | 30.0 minutes | 95%CI: 15.6, 59.0 | Lower limit of time scenario: 15.6 Upper limit of time scenario: 59.0 | Advokaat et al ⁷⁵ |
| Premolar 2-surface restoration multiplier | | | | X | 0.90 | Not applicable | Not applicable | Advokaat et al ⁷⁵ |
| Premolar 3-surface restoration multiplier | | | | X | 0.89 | Not applicable | Not applicable | Advokaat et al ⁷⁵ |
| Molar 2-surface restoration multiplier | | | | X | 1.13 | Not applicable | Not applicable | Advokaat et al ⁷⁵ |
| Molar 3-surface restoration multiplier | | | | X | 1.14 | Not applicable | Not applicable | Advokaat et al ⁷⁵ |
| Composite resin procedure time multiplier | | | | X | 1.15 | 99.7%CI: 1.05, 1.30 (normal distribution of log transformed values) | Lower limit of multiplier scenario: 1.05 Upper limit of multiplier scenario: 1.30 | Assumption |
| Average hourly wage | | | | X | \$26.96 | 99.7%CI: \$13.19, \$46.38 (normal distribution of log transformed values) | Lower limit of wage scenario: \$13.19 Upper limit of wage scenario: \$46.38 | Statistics Canada ⁷⁹ |
| Proportion of Canadians in labour force | | | | X | 0.6567 | SE: 0.0015 (beta distribution) | | Statistics Canada ⁸⁰ |


3081 **Figure 6: Curve fitting and extrapolation of time to restoration failure from the**
 3082 **Casa Pia study data**



3083

3084
3085
3086
3087

Appendix 10: Study Selection Flow Diagram — Patients' Perspectives and Experiences Review



3088
3089
3090
3091

Appendix 11: List of Excluded Studies and Reasons for Exclusion —Patients’ Perspectives and Experiences Review

Excluded studies based on full text read (n=147)

| Authors | Title | Published Year | Reason for exclusion |
|--|--|----------------|---|
| Maciel,R.; Salvador,D.; Azoubel,K.; Redivivo,R.; Maciel,C.; da,Franca C.; Amerongen,E.; Colares,V. | The opinion of children and their parents about four different types of dental restorations in a public health service in Brazil | 2017 | Exclusion reason: Wrong outcomes; |
| Faraj,B.M.; Mohammad,H.M.; Mohammad,K.M. | The Changes in Dentists' Perception and Patient's Acceptance on Amalgam Restoration in Kurdistan-Iraq: A Questionnaire-based Cross-Sectional Study | 2015 | Exclusion reason: Wrong study design; |
| Levey,E.; Carson,S.; Innes,N. | Patients give meaning to changes in health complaints before, during and after the replacement of amalgam restorations | 2015 | Exclusion reason: Commentary on study by Sjursen; |
| Mortazavi,G.; Mortazavi,S.M. | Increased mercury release from dental amalgam restorations after exposure to electromagnetic fields as a potential hazard for hypersensitive people and pregnant women | 2015 | Exclusion reason: Wrong study design; |
| Mallineni,S.K.; Nuvvula,S.; Matinlinna,J.P.; Yiu,C.K.; King,N.M. | Biocompatibility of various dental materials in contemporary dentistry: a narrative insight | 2013 | Exclusion reason: Wrong study design; |
| Tillberg,A.; Stenberg,B.; Berglund,A. | Reactions to resin-based dental materials in patients--type, time to onset, duration, and consequence of the reaction | 2009 | Exclusion reason: Wrong study design; |
| Dye,B.A.; Schober,S.E.; Dillon,C.F.; Jones,R.L.; Fryar,C.; McDowell,M.; Sinks,T.H. | Urinary mercury concentrations associated with dental restorations in adult women aged 16-49 years: United States, 1999-2000 | 2005 | Exclusion reason: Wrong outcomes; |
| Naumann,J. | Mercury as the suspected agent. Alzheimer disease due amalgam dental fillings? (interview by Dr. Judith Neumaier) | 2005 | Exclusion reason: editorial; |
| Westman,J.F. | Creating a supportive environment. An update from the Minnesota Dental Association's Committee on Environment, Wellness and Safety | 2003 | Exclusion reason: Wrong study design; |
| Casetta,I.; Invernizzi,M.; Granieri,E. | Multiple sclerosis and dental amalgam: case-control study in Ferrara, Italy | 2001 | Exclusion reason: Wrong study design; |
| McGrother,C.W.; Dugmore,C.; Phillips,M.J.; Raymond,N.T.; Garrick,P.; Baird,W.O. | Multiple sclerosis, dental caries and fillings: a case-control study | 1999 | Exclusion reason: Wrong study design; |
| Bergdahl,J.; Tillberg,A.; Stenman,E. | Odontologic survey of referred patients with symptoms allegedly caused by electricity or visual display units | 1998 | Exclusion reason: Wrong study design; |
| Bangsi,D.; Ghadirian,P.; Ducic,S.; Morisset,R.; Ciccocioppo,S.; McMullen,E.; Krewski,D. | Dental amalgam and multiple sclerosis: a case-control study in Montreal, Canada | 1998 | Exclusion reason: Wrong study design; |
| Chong,B.S.; Pitt Ford,T.R.; Kariyawasam,S.P. | Short-term tissue response to potential root-end filling materials in infected root canals | 1997 | Exclusion reason: Wrong outcomes; |
| Thomson,W.M.; Stewart,J.F.; Carter,K.D.; Spencer,A.J. | The Australian public's perception of mercury risk from dental restorations | 1997 | Exclusion reason: Wrong study design; |
| Koppel,C.; Fahron,G. | Toxicological and neuropsychological findings in patients presenting to an environmental toxicology service | 1995 | Exclusion reason: Wrong study design; |
| Lorscheider,F.L.; Vimy,M.J.; Summers,A.O. | Mercury exposure from "silver" tooth fillings: emerging evidence questions a traditional dental | 1995 | Exclusion reason: Wrong study design; |

| Authors | Title | Published Year | Reason for exclusion |
|---|--|----------------|---------------------------------------|
| | paradigm | | |
| Schuurs,A.H.; Eijkman,M.A.; Hoogstraten,J. | Patient views on dental amalgam. An exploratory questionnaire | 1994 | Exclusion reason: Wrong study design |
| Osborne,J.W. | The amalgam story continues. Interview by Stephen Hancocks | 1994 | Exclusion reason: editorial; |
| Drasch,G.; Schupp,I.; Hoff,H.; Reinke,R.; Roider,G. | Mercury burden of human fetal and infant tissues | 1994 | Exclusion reason: Wrong outcomes; |
| Williams,P.; Kasloff,Z. | Mercury (and the debate goes on) | 1991 | Exclusion reason: editorial; |
| Yontchev,E.; Hedegard,B.; Carlsson,G.E. | Reported symptoms, diseases, and medication of patients with orofacial discomfort complaints | 1986 | Exclusion reason: Wrong outcomes; |
| Khowassah,M.A.; Denehy,G.E. | A qualitative study of the interface between different dental amalgams and retentive pins | 1973 | Exclusion reason: Wrong outcomes; |
| Lygre,G.B.; Gjerdet,N.R.; Bjrkman,L. | A follow-up study of patients with subjective symptoms related to dental materials | 2005 | Exclusion reason: Wrong study design; |
| Furhoff,A.; Tomson,Y.; Ilie,M.; BÇ¼gedahl-Strindlund,M.; Larsson,K.S.; Sandborgh-Englund,G.; Torstenson,B.; Wretlind,K. | A multidisciplinary clinical study of patients suffering from illness associated with release of mercury from dental restorations: Medical and odontological aspects | 1998 | Exclusion reason: Wrong study design; |
| Rothwell,J.A.; Boyd,P.J. | Amalgam dental fillings and hearing loss | 2008 | Exclusion reason: Wrong study design; |
| Lye,Ellen; Legrand,Melissa; Clarke,Janine; Probert,Adam | Blood total mercury concentrations in the canadian population: canadian health measures survey cycle 1, 2007-2009 | 2013 | Exclusion reason: Wrong outcomes; |
| Sjursen,T.T.; Lygre,G.B.; Dalen,K.; Helland,V.; LGreid,T.; Svahn,J.; Lundekvam,B.F.; Bj-Rkman,L. | Changes in health complaints after removal of amalgam fillings | 2011 | Exclusion reason: Wrong study design; |
| Maserejian,Nancy N.; Trachtenberg,Felicia L.; Wheaton,Olivia Brown; Calafat,Antonia M.; Ranganathan,Gayatri; Hae-Young,Kim; Hauser,Russ | Changes in urinary bisphenol A concentrations associated with placement of dental composite restorations in children and adolescents | 2016 | Exclusion reason: Wrong study design; |
| Leistevuo,J.; Leistevuo,T.; Helenius,H.; Pyy,L.; -sterblad,M.; Huovinen,P.; Tenovuo,J. | Dental amalgam fillings and the amount of organic mercury in human saliva | 2001 | Exclusion reason: Wrong outcomes; |
| Wahl,Michael J. | Dental Amalgam Update--Part II: Biological Effects | 2013 | Exclusion reason: Wrong study design; |
| Naimi-Akbar,Aron; Svedberg,Pia; Alexanderson,Kristina; Carlstedt-Duke,Bodil; Ekstrand,Jan; Englund,Gunilla Sandborgh | Health-related quality of life and symptoms in patients with experiences of health problems related to dental restorative materials | 2013 | Exclusion reason: Wrong study design; |
| Shenker,B.J.; Maserejian,N.N.; Zhang,A.; McKinlay,S. | Immune function effects of dental amalgam in children: a randomized clinical trial | 2008 | Exclusion reason: Wrong study design; |
| Browning,W.D. | Incidence and severity of postoperative pain following routine placement of amalgam restorations | 1999 | Exclusion reason: Wrong outcomes |
| Bedir Findik,Rahime; Celik,Huseyin Tugrul; Ersoy,Ali Ozgur; Tasci,Yasemin; Moraloglu,Ozlem; Karakaya,Jale | Mercury concentration in maternal serum, cord blood, and placenta in patients with amalgam dental fillings: effects on fetal biometric measurements | 2016 | Exclusion reason: Wrong outcomes; |
| Factor-Litvak,P.; Hasselgren,G.; Jacobs,D.; Begg,M.; Kline,J.; Geier,J.; Mervish,N.; Schoenholtz,S.; Graziano,J. | Mercury derived from dental amalgams and neuropsychologic function | 2003 | Exclusion reason: Wrong outcomes; |
| Moss,J. | Mercury revisited - part II: does body burden tell the whole story? | 2008 | Exclusion reason: Wrong study design; |
| Crisp,R.J.; Burke,F.J.T. | One-year clinical evaluation of compomer restorations placed in general practice | 2000 | Exclusion reason: Wrong study design; |
| Ishitobi,H.; Stern,S.; Thurston,S.W.; Zareba,G.; Langdon,M.; Gelein,R.; | Organic and inorganic mercury in neonatal rat brain after prenatal exposure to methylmercury | 2010 | Exclusion reason: Wrong patient |

| Authors | Title | Published Year | Reason for exclusion |
|---|--|----------------|---------------------------------------|
| Weiss,B. | and mercury vapor | | population; |
| Weidenhammer,W.; Bornschein,S.; Zilker,T.; Eyer,F.; Melchart,D.; Hausteiner,C. | Predictors of treatment outcomes after removal of amalgam fillings: associations between subjective symptoms, psychometric variables and mercury levels | 2010 | Exclusion reason: Wrong study design; |
| Espelid,I.; Cairns,J.; Askildsen,J.E.; Qvist,V.; Gaarden,T.; Tveit,A.B. | Preferences over dental restorative materials among young patients and dental professionals | 2006 | Exclusion reason: Wrong study design; |
| Mackert,J.R.,Jr. | Randomized controlled trial demonstrates that exposure to mercury from dental amalgam does not adversely affect neurological development in children | 2010 | Exclusion reason: Wrong study design; |
| Browning,W.D.; Johnson,W.W.; Gregory,P.N. | Reduction of postoperative pain: a double-blind, randomized clinical trial | 1997 | Exclusion reason: Wrong outcomes; |
| Barregard,L.; Trachtenberg,F.; McKinlay,S. | Renal Effects of Dental Amalgam in Children: The New England Children's Amalgam Trial | 2008 | Exclusion reason: Wrong study design; |
| Lygre,G.B.; Gjerdet,N.R.; Grnningster,A.G.; Bjrkman,L. | Reporting on adverse reactions to dental materials -- intraoral observations at a clinical follow-up | 2003 | Exclusion reason: Wrong study design; |
| Kidd,R.F. | Results of dental amalgam removal and mercury detoxification using DMPS and neural therapy | 2000 | Exclusion reason: Wrong outcomes; |
| Sundstrm,A.; Bergdahl,J.; Nyberg,L.; Bergdahl,M.; Nilsson,L. | Stressful negative life events and amalgam-related complaints | 2011 | Exclusion reason: Wrong study design; |
| Keller,S.; Martin,C.G.; Evensen,C.T.; Mitton,C.R. | The development and testing of a survey instrument for benchmarking dental plan performance: using insured patients' experiences as a gauge of dental care quality | 2009 | Exclusion reason: Wrong study design; |
| Stejskal,V.D.; Danersund,A.; Lindvall,A.; Hudecek,R.; Nordman,V.; Yaqob,A.; Mayer,W.; Bieger,W.; Lindh,U. | Metal-specific lymphocytes: biomarkers of sensitivity in man | 1999 | Exclusion reason: Wrong outcomes; |
| Aljawad,A.; Rees,J.S. | Retrospective Study of the Survival and Patient Satisfaction with Composite Dahl Restorations in the Management of Localised Anterior Tooth Wear | 2016 | Exclusion reason: Wrong intervention; |
| Pawar,R.R.; Mattigatti,S.S.; Mahaparale,R.R.; Kamble,A.P. | Lichenoid reaction associated with silver amalgam restoration in a Bombay blood group patient: A case report | 2016 | Exclusion reason: duplicate; |
| Syed,M.; Chopra,R.; Sachdev,V. | Allergic Reactions to Dental Materials-A Systematic Review | 2015 | Exclusion reason: Wrong study design; |
| Rathore,M.; Singh,A.; Pant,V.A. | The dental amalgam toxicity fear: a myth or actuality | 2012 | Exclusion reason: Wrong study design; |
| Burke,F.J.; Crisp,R.J. | A practice-based assessment of patients' knowledge of dental materials | 2015 | Exclusion reason: Wrong outcomes; |
| Lynch,M.; Ryan,A.; Galvin,S.; Flint,S.; Healy,C.M.; O'Rourke,N.; Lynch,K.; Rogers,S.; Collins,P. | Patch testing in oral lichenoid lesions of uncertain etiology | 2015 | Exclusion reason: Wrong outcomes; |
| Wilson,J. | Amalgam as a filling material for the older person--a personal opinion | 2014 | Exclusion reason: editorial; |
| Berkowitz,G.; Spielman,H.; Matthews,A.; Vena,D.; Craig,R.; Curro,F.; Thompson,V. | Postoperative hypersensitivity and its relationship to preparation variables in Class I resin-based composite restorations: findings from the practitioners engaged in applied research and learning (PEARL) Network. Part 1 | 2013 | Exclusion reason: Wrong study design; |
| Parizi,J.L.; Nai,G.A. | Amalgam tattoo: a cause of sinusitis? | 2010 | Exclusion reason: Wrong outcomes; |
| Stahlnacke,K.; Soderfeldt,B. | Factors related to persons with health problems attributed to dental filling materials--part one in a triangular study on 65 and 75 years old Swedes | 2012 | Exclusion reason: Wrong study design; |
| Capozza,L.E.; Bimstein,E. | Preferences of parents of children with autism | 2012 | Exclusion reason: |

| Authors | Title | Published Year | Reason for exclusion |
|---|---|----------------|---------------------------------------|
| | spectrum disorders concerning oral health and dental treatment | | Wrong study design; |
| da Silva,G.R.; Roscoe,M.G.; Ribeiro,C.P.; da Mota,A.S.; Martins,L.R.; Soares,C.J. | Impact of rehabilitation with metal-ceramic restorations on oral health-related quality of life | 2012 | Exclusion reason: Wrong study design; |
| Bamise,C.T.; Oginni,A.O.; Adedigba,M.A.; Olagundoye,O.O. | Perception of patients with amalgam fillings about toxicity of mercury in dental amalgam | 2012 | Exclusion reason: Wrong study design; |
| Eyeson,J.; House,I.; Yang,Y.H.; Warnakulasuriya,K.A. | Relationship between mercury levels in blood and urine and complaints of chronic mercury toxicity from amalgam restorations | 2010 | Exclusion reason: Wrong study design; |
| Roberts,H.W.; Charlton,D.G. | The release of mercury from amalgam restorations and its health effects: a review | 2009 | Exclusion reason: Wrong study design; |
| Zimmerman,J.A.; Feigal,R.J.; Till,M.J.; Hodges,J.S. | Parental attitudes on restorative materials as factors influencing current use in pediatric dentistry | 2009 | Exclusion reason: Wrong study design; |
| Kovarik,R.E. | Restoration of posterior teeth in clinical practice: evidence base for choosing amalgam versus composite | 2009 | Exclusion reason: Wrong study design; |
| Mutter,J.; Naumann,J.; Guethlin,C. | Comments on the article "the toxicology of mercury and its chemical compounds" by Clarkson and Magos (2006) | 2007 | Exclusion reason: editorial; |
| Schedle,A.; Ortengren,U.; Eidler,N.; Gabauer,M.; Hensten,A. | Do adverse effects of dental materials exist? What are the consequences, and how can they be diagnosed and treated? | 2007 | Exclusion reason: Wrong study design; |
| Lygre,G.B.; Helland,V.; Gjerdet,N.R.; Bjorkman,L. | Health complaints related to dental filling materials | 2007 | Exclusion reason: Wrong study design; |
| Fan,P.L.; Meyer,D.M. | FDI report on adverse reactions to resin-based materials | 2007 | Exclusion reason: Wrong study design; |
| Fishman,R.; Guelmann,M.; Bimstein,E. | Children's selection of posterior restorative materials | 2006 | Exclusion reason: Wrong study design; |
| Bjorkman,L.; Weiner,J.; Gjerdet,N.R. | Improvement of health after replacement of amalgam fillings? | 2005 | Exclusion reason: Wrong study design; |
| Lygre,G.B.; Gjerdet,N.R.; Bjorkman,L. | Patients' choice of dental treatment following examination at a specialty unit for adverse reactions to dental materials | 2004 | Exclusion reason: Wrong study design; |
| Segura-Egea,J.J.; Bullon-Fernandez,P. | Lichenoid reaction associated to amalgam restoration | 2004 | Exclusion reason: Wrong study design; |
| Scott,A.; Egner,W.; Gawkrödger,D.J.; Hatton,P.V.; Sherriff,M.; van,Noort R.; Yeoman,C.; Grummitt,J. | The national survey of adverse reactions to dental materials in the UK: a preliminary study by the UK Adverse Reactions Reporting Project | 2004 | Exclusion reason: Wrong study design; |
| Dalen,K.; Lygre,G.B.; Klove,H.; Gjerdet,N.R. | Personality variables in patients with self-reported reactions to dental amalgam | 2003 | Exclusion reason: Wrong outcomes; |
| ADA Council on Scientific Affairs | Direct and indirect restorative materials | 2003 | Exclusion reason: Wrong study design; |
| Peretz,B.; Ram,D. | Restorative material for children's teeth: preferences of parents and children | 2002 | Exclusion reason: Wrong study design; |
| Lindh,U.; Hudecek,R.; Danersund,A.; Eriksson,S.; Lindvall,A. | Removal of dental amalgam and other metal alloys supported by antioxidant therapy alleviates symptoms and improves quality of life in patients with amalgam-associated ill health | 2002 | Exclusion reason: Wrong study design; |
| Gilmore,H.W. | Treat patients' concerns as well as their oral health | 2001 | Exclusion reason: Wrong study design; |
| Dlugokinski,M.; Browning,W.D. | Informed consent: direct posterior composite versus amalgam | 2001 | Exclusion reason: Wrong study design; |
| Evens,C.C.; Martin,M.D.; Woods,J.S.; Soares,H.L.; Bernardo,M.; Leitao,J.; Simmonds,P.L.; Liang,L.; DeRouen,T. | Examination of dietary methylmercury exposure in the Casa Pia Study of the health effects of dental amalgams in children | 2001 | Exclusion reason: Wrong intervention; |
| Sterzl,I.; Hrdá,P.; Prochazkova,J.; Bartova,J.; Matucha,P. | Reactions to metals in patients with chronic fatigue and autoimmune endocrinopathy | 1999 | Exclusion reason: Wrong study design; |

| Authors | Title | Published Year | Reason for exclusion |
|---|---|----------------|--|
| Melchart,D.; Wuhr,E.; Weidenhammer,W.; Kremers,L. | A multicenter survey of amalgam fillings and subjective complaints in non-selected patients in the dental practice | 1998 | Exclusion reason: Wrong study design; |
| Lofqvist,A. | Important to understand and manage reactions of people with problems connected to amalgam and electricity | 1998 | Exclusion reason: Wrong language; |
| Laine,J.; Kalimo,K.; Happonen,R.P. | Contact allergy to dental restorative materials in patients with oral lichenoid lesions | 1997 | Exclusion reason: Wrong study design; |
| Blomgren,J.; Axell,T.; Sandahl,O.; Jontell,M. | Adverse reactions in the oral mucosa associated with anterior composite restorations | 1996 | Exclusion reason: Wrong study design; |
| Henningsson,M.; Sundbom,E. | Defensive characteristics in individuals with amalgam illness as measured by the percept-genetic method Defense Mechanism Test | 1996 | Exclusion reason: Wrong study design; |
| Forss,H.; Widstrom,E. | Factors influencing the selection of restorative materials in dental care in Finland | 1996 | Exclusion reason: Wrong study design; |
| Alanko,K.; Kanerva,L.; Jolanki,R.; Kannas,L.; Estlander,T. | Oral mucosal diseases investigated by patch testing with a dental screening series | 1996 | Exclusion reason: Wrong study design; |
| Ostman,P.O.; Anneroth,G.; Skoglund,A. | Amalgam-associated oral lichenoid reactions. Clinical and histologic changes after removal of amalgam fillings | 1996 | Exclusion reason: Wrong study design; |
| Stoz,F.; Aicham,P.; Jovanovic,S.; Steuer,W.; Mayer,R. | Effects of new dental amalgam fillings in pregnancy on Hg concentration in mother and child. With consideration for possible interactions between amalgam and precious metals | 1995 | Exclusion reason: Wrong study design; |
| Henriksson,E.; Mattsson,U.; Hakansson,J. | Healing of lichenoid reactions following removal of amalgam. A clinical follow-up | 1995 | Exclusion reason: Wrong study design; |
| Bergdahl,J.; Ostman,P.O.; Anneroth,G.; Perris,H.; Skoglund,A. | Psychologic aspects of patients with oral lichenoid reactions | 1995 | Exclusion reason: Wrong study design; |
| Eijkman,M.A.; de,Jongh A. | Amalgam. XII. Amalgam removed and patient cured? | 1994 | Exclusion reason: Wrong study design; |
| Ostman,P.O.; Anneroth,G.; Skoglund,A. | Oral lichen planus lesions in contact with amalgam fillings: a clinical, histologic, and immunohistochemical study | 1994 | Exclusion reason: Wrong outcomes; |
| Blignaut,J.B.; Louw,N.P. | Replacing amalgam fillings with composite inlays--a case report | 1993 | Exclusion reason: Wrong study design; |
| Fallowfield,M.G. | 'Dental amalgam: a review' | 1993 | Exclusion reason: Wrong study design; |
| Anneroth,G.; Ericson,T.; Johansson,I.; Mornstad,H.; Ryberg,M.; Skoglund,A.; Stegmayr,B. | Comprehensive medical examination of a group of patients with alleged adverse effects from dental amalgams | 1992 | Exclusion reason: Wrong study design; |
| Chiodo,G.T.; Tolle,S.W. | Can a patient make an irrational choice? The dental amalgam controversy | 1992 | Exclusion reason: Wrong study design; |
| Nordlind,K.; Liden,S. | Patch test reactions to metal salts in patients with oral mucosal lesions associated with amalgam restorations | 1992 | Exclusion reason: Wrong study design; |
| Holtinen,T.; Murtomaa,H.; Meurman,J. | Expectant mothers opinion on the use of amalgam and the effect of pregnancy on dental health | 1991 | Exclusion reason: Wrong outcomes; |
| Skoglund,A.; Egelrud,T. | Hypersensitivity reactions to dental materials in patients with lichenoid oral mucosal lesions and in patients with burning mouth syndrome | 1991 | Exclusion reason: Wrong study design; |
| Meurman,J.H.; Porko,C.; Murtomaa,H. | Patients complaining about amalgam-related symptoms suffer more often from illnesses and chronic craniofacial pain than their controls | 1990 | Exclusion reason: Wrong study design; |
| Missias,P. | Biocompatibility of dental amalgam | 1990 | Exclusion reason: Wrong outcomes; |
| Taskinen,H.; Kinnunen,E.; Riihimaki,V. | A possible case of mercury-related toxicity resulting from the grinding of old amalgam restorations | 1989 | Exclusion reason: Wrong study design; |

| Authors | Title | Published Year | Reason for exclusion |
|---|---|----------------|--|
| Burke,F.J. | Patient acceptance of posterior composite restorations | 1989 | Exclusion reason: Wrong study design; |
| Bellinger,D.C.; Trachtenberg,F.; Daniel,D.; Zhang,A.; Tavares,M.A.; McKinlay,S. | A dose-effect analysis of children's exposure to dental amalgam and neuropsychological function. The New England Children's Amalgam Trial | 2007 | Exclusion reason: Wrong study design; |
| Moss,J. | A viewpoint on mercury-part III: how does mercury make us sick? | 2001 | Exclusion reason: Wrong outcomes; |
| Hiltunen,Neil S.; Lynch,Christopher D. | COMPOSITES AND AMALGAM...Makhija SK, Gordan VV, Gilbert GH, et al. Practitioner, patient and carious lesion characteristics associated with type of restorative material: findings from The Dental Practice-Based Research Network. C O M M E N T A R Y G U E S T E D I T O R I A L L E T T E R S 2004-03-30.ppt#256,1,NCPDP SCRIPT Standard Presentation | 2011 | Exclusion reason: Wrong outcomes; |
| Bellinger,D.C.; Daniel,D.; Trachtenberg,F.; Tavares,M.; McKinlay,S. | Dental amalgam restorations and children's neuropsychological function: the New England Children's Amalgam Trial | 2007 | Exclusion reason: Wrong study design; |
| Himmelberger,Linda K. | FEATURES. ETHICAL MOMENT. Justifiable criticism and dental amalgam | 2015 | Exclusion reason: editorial; |
| Issa,Y.; Brunton,P.A.; Glennly,A.M.; Duxbury,A.J. | Healing of oral lichenoid lesions after replacing amalgam restorations: a systematic review | 2004 | Exclusion reason: Wrong study design; |
| Hibberd,A.R.; Howard,M.A.; Hunnisett,A.G. | Mercury from dental amalgam fillings: studies on oral chelating agents for assessing and reducing mercury burdens in humans | 1998 | Exclusion reason: Wrong outcomes; |
| Munro-Hall,G.; Munro-Hall,L. | Mercury-free dentistry -- a passport to better health | 1999 | Exclusion reason: editorial; |
| McGovern,V. | Taking a bite out of amalgam concerns?: study shows no renal effects in children | 2008 | Exclusion reason: Wrong study design; |
| Aktas,Bora; Basyigit,Sebahat; YÇ-ksel,Osman; Akkan,Tolga; Atbas,Suna TÇ-lin; Uzman,Metin; Yılmaz,Bars; Simsek,G.; NazlgÇ-l,Yasar; AktaY,Bora; BaYyiYit,Sebahat; AtbaY,Suna TÇ-lin; Yılmaz,BarY; zimYek,G.; NazlgÇ-l,YaYar | The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies | 2015 | Exclusion reason: Wrong outcomes; |
| Bjrkman,L.; Sjursen,T.T.; Dalen,K.; Lygre,G.B.; Berge,T.L.L.; Svahn,J.; Lundekvam,B.F. | Long term changes in health complaints after removal of amalgam restorations | 2017 | Exclusion reason: Wrong study design; |
| Paknahad,M.; Mortazavi,S.M.J.; Shahidi,S.; Mortazavi,G.; Haghani,M. | Effect of radiofrequency radiation from Wi-Fi devices on mercury release from amalgam restorations | 2016 | Exclusion reason: Wrong outcomes; |
| Sharma,R.; Handa,S.; De,D.; Radotra,B.; Rattan,V. | Role of dental restoration materials in oral mucosal lichenoid lesions | 2015 | Exclusion reason: Wrong study design; |
| MÇ%rell,L.; Tillberg,A.; Widman,L.; Bergdahl,J.; Berglund,A. | Regression of oral lichenoid lesions after replacement of dental restorations | 2014 | Exclusion reason: Wrong study design; |
| Naimi-Akbar,A.; Svedberg,P.; Alexanderson,K.; Ekstrand,J.; Sandborgh-Englund,G. | Reliance on social security benefits by Swedish patients with ill-health attributed to dental fillings: A register-based cohort study | 2012 | Exclusion reason: Wrong outcomes; |
| Correa,M.B.; Peres,M.A.; Peres,K.G.; Horta,B.L.; Barros,A.D.; Demarco,F.F. | Amalgam or composite resin? Factors influencing the choice of restorative material | 2012 | Exclusion reason: Wrong study design; |
| Geier,D.A.; King,P.G.; Sykes,L.K.; Geier,M.R. | A comprehensive review of mercury provoked autism | 2008 | Exclusion reason: Wrong study design; |
| Lidmark,A.M.; Wikmans,T. | Are they really sick? A report on persons who are electrosensitive and/or injured by dental material in Sweden | 2008 | Exclusion reason: Wrong study design; |
| Hausteiner,C.; Bornschein,S.; Henningsen,P.; Nowak,D. | Psychosomatic aspects of environmentally related syndromes | 2008 | Exclusion reason: Wrong language; |

| Authors | Title | Published Year | Reason for exclusion |
|--|--|----------------|---------------------------------------|
| Melchart,D.; Vogt,S.; Khler,W.; Streng,A.; Weidenhammer,W.; Kremers,L.; Hickel,R.; Felgenhauer,N.; Zilker,T.; WÇ-hr,E.; Halbach,S. | Treatment of health complaints attributed to amalgam | 2008 | Exclusion reason: Wrong outcomes; |
| Hausteiner,C.; Bornschein,S.; Nowak,D.; Henningsen,P. | Psychosomatic aspects of environmentally related illnesses | 2007 | Exclusion reason: Wrong language; |
| Lygre,G.B.; Helland,V.; Gjerdet,N.R.; Bjrkman,L. | Health complaints related to dental materials - A followup study | 2007 | Exclusion reason: Wrong study design; |
| Frisk,P.; Lindvall,A.; Hudecek,R.; Lindh,U. | Decrease of trace elements in erythrocytes and plasma after removal of dental amalgam and other metal alloys | 2006 | Exclusion reason: Wrong study design; |
| Van Noort,R.; Gjerdet,N.R.; Schedle,A.; Bjrkman,L.; Berglund,A. | An overview of the current status of national reporting systems for adverse reactions to dental materials | 2004 | Exclusion reason: Wrong outcomes; |
| Vamnes,J.S.; Lygre,G.B.; Grnningster,A.G.; Gjerdet,N.R. | Four years of clinical experience with an adverse reaction unit for dental biomaterials | 2004 | Exclusion reason: Wrong study design; |
| Kao,R.T.; Dault,S.; Pichay,T. | Understanding the mercury reduction issue: the impact of mercury on the environment and human health | 2004 | Exclusion reason: Wrong outcomes; |
| Bailer,J.; Staehle,H.J.; Rist,F. | Sick from amalgam fillings? Selective review of findings from multi-disciplinary studies | 2003 | Exclusion reason: Wrong study design; |
| Dunsche,A.; KÇ%stel,I.; Terheyden,H.; Springer,I.N.G.; Christophers,E.; Brasch,J. | Oral lichenoid reactions associated with amalgam: Improvement after amalgam removal | 2003 | Exclusion reason: Wrong study design; |
| Gottwald,B.; Kupfer,J.; Traenckner,I.; Ganss,C.; Gieler,U. | Psychological, allergic, and toxicological aspects of patients with amalgam-related complaints | 2002 | Exclusion reason: Wrong study design; |
| Bauer,A.; sen-Hinrichs,C. | Evaluation of 916 suspected cases of environmentally related disorders - A Schleswig-Holstein model project of 1995-1999 | 2002 | Exclusion reason: Wrong study design; |
| Bauer,A.; sen-Hinrichs,C.; Wassermann,O. | Case study of 916 environmentally related disorders during the period 1995-1999 in Schleswig-Holstein | 2001 | Exclusion reason: Wrong study design; |
| Bauer,A.; sen-Hinrichs,C. | Environmental pollution--assessment of environmental medicine questionnaires and data in Schleswig-Holstein from 1995-1997 | 2000 | Exclusion reason: Wrong study design; |
| Lygre,G.B.; Grnningster,A.G.; Gjerdet,N.R. | Mercury and dental amalgam fillings | 1998 | Exclusion reason: Wrong study design; |
| Marcusson,J.A.; Jarstrand,C. | Oxidative metabolism of neutrophils in vitro and human mercury intolerance | 1998 | Exclusion reason: Wrong outcomes; |
| Langworth,S. | Experiences from the amalgam unit at Huddinge hospital - Somatic and psychosomatic aspects | 1997 | Exclusion reason: Wrong study design; |
| Wiltshire,W.A.; Ferreira,M.R.; Ligthelm,A.J. | Allergies to dental materials | 1996 | Exclusion reason: Wrong study design; |
| LÇ-bbe,J.; WÇ-thrich,B. | Dental amalgam: Allergy and controversy | 1996 | Exclusion reason: Wrong study design; |
| Hanson,M.; Pleva,J. | The dental amalgam issue. A review | 1991 | Exclusion reason: Wrong study design; |
| Meurman,J.H.; Porko,C.; Murtomaa,H. | Patients complaining about amalgam-related symptoms suffer more often from illnesses and chronic craniofacial pain than their controls | 1990 | Exclusion reason: Wrong study design; |
| Bolewska,J.; Reibel,J. | T lymphocytes, Langerhans cells and HLA__DR expression on keratinocytes in oral lesions associated with amalgam restorations | 1989 | Exclusion reason: Wrong outcomes; |

3092

3093 **Appendix 12: List of Included Studies —Patients’**
 3094 **Perspectives and ExperiencesReview**

3095 **List of included studies (n=4 studies, 5 papers)**

| Full Reference |
|---|
| Marell L, Lindgren M, Nyhlin KT, Ahlgren C, Berglund A. "Struggle to obtain redress": Women's experiences of living with symptoms attributed to dental restorative materials and/or electromagnetic fields. <i>Int J Qual Stud Health Well-being</i> , 2016, 11(32820): 1748-2631 |
| Sjursen TT, Binder P, Lygre GB, Helland V, Dalen K, Bjorkman L. Patients' experiences of changes in health complaints before, during, and after removal of dental amalgam. <i>Int J Qual Stud Health Well-being</i> , 2015, 10(1): 28157 |
| Sjursen TT, Binder P, Lygre GB, Helland V, Dalen K, Bjorkman L How unexplained health complaints were attributed to dental amalgam. <i>Nordic Psychology</i> , 2014, 66(3): 216-229. |
| Stahlnacke K and Soderfeldt B. An interview study of persons who attribute health problems to dental filling materials--part two in a triangulation study on 65 and 75 years old Swedes. <i>Swedish Dental Journal</i> , 2013, 37(3): 121-130. |
| Jones LM. Focus on fillings: a qualitative health study of people medically diagnosed with mercury poisoning, linked to dental amalgam. <i>Acta Neuropsychiatrica</i> , 2004, 16(3): 142-148. |

3096

3097 **Appendix 13: Characteristics of Included Studies and their**
 3098 **Participants — Patients’ Perspectives and Experiences Review**

3099 **Characteristics of included studies (n=4 studies, 5 papers)**

| Author/ Year /Country | Purpose | Methodology/ Method/ Analysis | Participant Details | Author’s Conclusion |
|--|---|---|--|---|
| Marell L, et al., 2016 ⁹² Sweden | To explore the experiences of illness and encounters with health care professionals among a group of women with symptoms attributed to dental restorative materials and/or electromagnetic fields | Grounded Theory Semi-structured individual interviews Constant comparative method of analysis | N=13 Female n=13 Age range 37-63 years (Mean 49 years) Inclusion criteria a) belief that symptoms were caused by dental restorations and/or electromagnetic fields; (b) no known signs of contact allergic reaction to dental materials | The core category represents the women’s fight for approval and arose in the conflict between their experience of developing a severe illness and the doctors’ or dentists’ rejection of the symptoms as a disease, which made the women feel like malingerers. They experienced better support and confirmation from alternative medicine practitioners. However, the need for sick-leave certificates led to a continuous cycle of visits in the health care system. To avoid conflicting encounters, it is important for caregivers to listen to the patient’s explanatory models and experience of illness, even if a medical answer cannot be given. |
| Sjursen TT, et al., 2015 ⁹³ Norway | To explore how patients experienced and gave meaning to changes in health complaints before, during, and after amalgam removal | Qualitative Semi-structured in-depth interviews Explorative and reflexive thematic analysis | N=12 Women = 7 Men = 5 Age range 45-65 years (Mean 54 years) Participants were interviewed 5 years after they had completed removal of all amalgam fillings | The dental amalgam was certainly important to get rid of, but it is uncertain how important the removal was for the experienced changes in health complaints. Patients were very happy to have had all their amalgam fillings removed, but they did not believe that they could credit all the positive changes to the amalgam removal |
| Sjursen TT, et al., 2014 ⁹⁰ | To explore a group of patients’ experiences of how they came to attribute their health | Qualitative Semi-structured in-depth | N=12 Women = 7 Men = | The presence of unexplained, or partially explained, health complaints compels patients to search for an explanation and thereby also a cure. Participants tried to go about this search |

| Author/ Year /Country | Purpose | Methodology/ Method/ Analysis | Participant Details | Author's Conclusion |
|--|--|--|--|---|
| Norway | complaints to dental amalgam | interviews Explorative and reflexive thematic analysis | 5 Age range 45-65 years (Mean 54 years) Participants were interviewed 5 years after they had completed removal of all amalgam fillings | for an answer in a logical and to a certain extent also hypothesis-testing manner. Forming such an attribution influenced emotions and initiated actions such as contacting the specialty unit and having amalgam fillings replaced |
| Stahlnacke K and Soderfeldt B, 2013 ²³² Sweden | To understand the experience of living with health problems attributed to dental materials. The study considered the type of problem, general and oral health problems, causes of the problems, their effect on life and the reception by health professionals | Qualitative Semi-structured interviews. Participants interviewed until saturation reached Content analysis | N= 11 Women = 7 Men = 4 Focus group people (n=?) representing "Dental Care Injury Association" | People who attribute their health problems to dental materials have a complex picture of symptoms – somatic, mental and oral – with the first two types dominating. All participants believed that it was the amalgam that was the cause of the problems they experienced, and they all had their amalgam fillings replaced, with varying results. Reception from the healthcare system was generally good with isolated cases of not being treated with respect and consideration |
| Jones LM. 2004 ⁹⁴ New Zealand | To document themes from patients' collective, subjective experience; and explore links between illness and dental amalgam | Qualitative 7 focus groups Thematic analysis | N=35 Selected by random, criteria sampling from computerized patient records from one medical practice | Four principal findings of this study: (i) people who linked amalgams and health were not an homogeneous group, but fell into categories differentiated by their sets of symptoms, fiscal resources, and motivation; (ii) there was a major positive relationship between amalgam removal with detoxification, and the recovery of psychological and physical health, although the detoxification process is problematic; (iii) GP or psychiatric consultations created problems in addition to the physical symptoms; and (iv) the placebo effect is not supported as an exclusive explanation for positive health outcomes. |

3100

3101 **Appendix 14: Quality Assessment of Included**
 3102 **Studies — Patients’ Perspectives and**
 3103 **Experiences Review**

3104 **Assessment of methodological quality (n=4 studies, 5 papers)**


| Author/ date | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Total |
|--|----|-----|-----|-----|-----|----|----|----|-----|-----|-------|
| Marell L et al., 2016 ⁹² | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | 9/10 |
| Sjursen TT et al., 2015 ⁹³ Sjursen TT et al., 2014 ⁹⁰ | N | Y | Y | Y | Y | N | Y | Y | Y | Y | 8/10 |
| Stahlnacke K and Soderfeldt B 2013 ²³² | N | Y | Y | Y | Y | U | Y | Y | Y | Y | 8/10 |
| Jones LM 2004 ⁹⁴ | N | Y | Y | Y | Y | N | N | U | Y | Y | 6/10 |
| % | 0 | 100 | 100 | 100 | 100 | 25 | 75 | 75 | 100 | 100 | |

3105
3106

3107
3108
3109
3110
3111

Appendix 15: Meta-Synthesis — Patient Preferences Review

Meta-synthesis of the results



3112
3113

3114
3115

Meta-Synthesis Details

The relationship of synthesized findings, categories and findings

| Synthesized Finding 1 | |
|--|---|
| Something is not working: trying to understand health complaints | |
| Category 1 | Range of ill health experiences – oral, somatic, mental, long term |
| | Long-term problems of varying character caused by dental amalgam: Oral problems, somatic problems, mental problems, long-term problems |
| | Psychological problems of mercury poisoning: i) problems directly attributed to mercury toxicity: memory loss, mood swings, and loss of sensation; ii) problems related to the consequences of having symptoms that were not readily diagnosed namely self-efficacy; the social stigma of being labelled a hypochondriac; the concomitant loss of social support; or being referred for psychological or psychiatric assessment |
| | The four diverse patterns of experience: a) chronic illness experience |
| | The four diverse patterns of experience: b) experiencing minor worries |
| | The four diverse patterns of experience: c) still experiencing chronic illness and still with amalgam |
| | The four diverse patterns of experience: d) single, major illness experience |
| | Feeling puzzled: participants stressed how they were baffled and to some degree overwhelmed by their complaints. Feeling their whole bodily and psychological functioning was influenced by something from the outside, which was described as a feeling of being poisoned |
| | Powerful effect on life, mostly negative, but also some strengthening effects |
| Category 2 | Identifying the source of the symptoms |
| | Feeling a resonance with descriptions of amalgam poisoning |
| | Struggle to obtain redress: Stricken with Illness. The women were convinced that their symptoms were caused by external agents such as dental materials and/or electromagnetic fields. In most cases, they attributed the onset of their symptoms to a dental treatment. |
| | Temporal relationship between dental treatment and episodes of ill health |
| | Feeling puzzled: participants stressed how they were baffled and to some degree overwhelmed by their complaints. Feeling their whole bodily and psychological functioning was influenced by something from the outside, which was described as a feeling of being poisoned |
| | Something is not working: betrayed by the body: the experience of something not working inside their bodies. Some had struggled with health complaints from an early age, whereas others experienced onset of complaints as adults. |
| | You are out there on your own: actively trying to find explanation for their complaints. Several were disappointed by how little the medical profession had to offer when it came to health complaints in the absence of corresponding objective findings |
| Category 3 | Input from trusted others as guidance |
| | A trusted person suggested dental amalgam as an explanation for complaints: sometimes physicians or dentists made the link based on either severe intraoral complaints, such as dry mouth, pain, and a stinging sensation, or repeated episodes of ill health after dental treatment |
| | Picking up anecdotal evidence: anecdotal evidence was important for their first suspicion of dental amalgam as being behind their complaints |
| Synthesized Finding 2 | |
| Struggle to obtain redress: searching for help, treatment and a reliable diagnosis | |
| Category 4 | Encounters with health care professionals |
| | Struggle to obtain redress: experiences of encounters with doctors and dentists. Although they felt severely ill, they perceived that they were being told they were physically healthy when no somatic pathology could be found. |
| | Good reception from health professionals on the whole: isolated encounters were often the cause of the negative experiences. |
| | You are out there on your own: actively trying to find explanation for complaints. Several were disappointed by how little the medical profession had to offer when it came to health complaints in the absence of corresponding objective findings |
| Synthesized Finding 3 | |
| Amalgam removal and the journey toward health | |
| Category 5 | Deamalgamation and detox |
| | Change in dental materials in fillings: resulting in anything from no improvement to noticeable improvement. Treatments included odontological treatment, medical treatment and alternative medical treatment |
| | Deamalgamation and detoxification: a variety of experiences following the removal of amalgam |
| | No longer having any amalgam fillings in their teeth associated with being able to cross worry off the list |
| | Not being sure of the importance of amalgam removal: some participants were uncertain of the role of amalgam removal in their change of health status |
| | To accept, to give up, or to continue the search: despite feeling better, as reported by the majority of the participants, none of them had become symptom-free after the amalgam removal |
| | The relief experienced after amalgam removal: despite some uncertainties, the majority of the participants concluded that they were in a much better place in their lives at the time of the interview than they had been before the amalgam removal |

3116

3117 **Appendix 16: Descriptive Themes and**
 3118 **Associated Categories — Patients’ Perspectives**
 3119 **and Experiences Review**

3120 **Findings and illustrations from each study (n= 5)**

Marell L, et al., "Struggle to obtain redress": Women's experiences of living with symptoms attributed to dental restorative materials and/or electromagnetic fields. *Int J Qual Stud Health Well-being*, 2016, 11(32820): 1748-2631

| Findings | Sub-themes | Quotes |
|---|--|--|
| <p>Struggle to obtain redress: Stricken with illness</p> <p>The women were convinced that their symptoms were caused by external agents such as dental materials and/or electromagnetic fields. In most cases, they attributed the onset of their symptoms to a dental treatment. P 3</p> | <p>Be in mortal danger</p> <p>Multiple symptoms difficult to describe</p> <p>Extrinsic factors invading the body</p> | <p>"When she started her computer, my heart began to beat so fast that I felt I was going to die." p. 3</p> <p>"I got ache in the head, the neck and the back. My eyes turned red. I could hardly see. I got slime in my throat . . . and everything came at the same time." p. 4</p> <p>"When it got worse, I had a hard time at work. I also had an unusual situation at home, but that was still not a contributing factor. In fact, I was ill." p. 4</p> |
| <p>Struggle to obtain redress: A blot in the protocol</p> <p>Describes the women's experiences of encounters with doctors and dentists when they searched for help, treatment, and a reliable diagnosis. Although they felt severely ill, they perceived that they were being told they were physically healthy when no somatic pathology could be found.</p> | <p>Ill but sound as a bell</p> <p>No acceptable diagnosis</p> | <p>"I remember I was crying when I walked away from the doctor. I figured there was something wrong with me, but nothing was shown, all the investigations and tests showed nothing. They said that I'm healthy even though I feel like this!" p. 4</p> <p>"You only cause trouble. In fact, you are only a blot in the protocol." P 4</p> <p>"It is nothing mental, you know. We know that we are right. That is the problem with us." p. 4</p> |

3121 Sjursen TT, et al., Patients' experiences of changes in health complaints before, during, and after removal of dental amalgam. *Int J Qual Stud Health Well-being*, 2015, 10(1): 28157

| Findings | Quotes |
|---|--|
| <p>Something is not working: betrayed by the body:</p> <p>The starting point for all participants was the experience of something not working inside their bodies. Some had struggled with health complaints from an early age, whereas others experienced onset of complaints as adults.</p> | <p>"I was in so much pain, and I also felt, for a while, that I had such a poor memory (sighs). I cannot say if that was because of stress caused by having to fight the pain, but I did feel "out of it" in a way. I really did." p. 4</p> |
| <p>You are out there on your own: actively trying to find explanation for their complaints. Several were disappointed by how little the medical profession had to offer when it came to health complaints in the absence of corresponding objective findings</p> | <p>"I'm not quite able to sort it out, and the doctors are not very good at helping with these things when they do not find anything specific. . . . So in a way, you have to sort it out on your own." p. 4</p> |
| <p>Not being sure of the importance of amalgam removal: some participants were uncertain of the role of amalgam removal in their change of health status.</p> | <p>"Well, what I think is that I don't really know what (pause). I think that the amalgam removal at least has had an effect on my mouth and the pain I had there. But I (pause) when it comes to the other complaints, I think that it is kind of impossible to know if it is [the amalgam removal] that has made me better or if it is other things. I have tried a lot of different things. I have had different treatments, and I have changed my diet, you know, and I have started to take Omega-3 supplements, which is also supposed to be good for the joints, for instance. So, I really have done other things as well, and I really can't say if it is the teeth or if it is the other things or if it is (pause). I find this to be very difficult." p. 5/6</p> |
| <p>The relief experienced after amalgam removal:</p> <p>Despite some uncertainties, the majority</p> | <p>"This amalgam removal, I do believe it has had an effect, together with all the other things. But I would have to have psychic abilities to know exactly how. As I have told you, there are still periods in which I feel quite poorly and beside myself, but I do feel much better now. I really do."</p> |

Sjursen TT, et al., Patients' experiences of changes in health complaints before, during, and after removal of dental amalgam. *Int J Qual Stud Health Well-being*, 2015, 10(1): 28157

| Findings | Quotes |
|--|---|
| of the participants concluded that they were in a much better place in their lives at the time of the interview than they had been before the amalgam removal. | p. 6 |
| No longer having any amalgam fillings in their teeth associated with being able to cross worry off the list | "You know, some (pause). There are many people with the same complaints that I have had who are talking about amalgam and such. So it is possible that if I still had those fillings left, I could have been constantly thinking "Yes, it really could be those fillings keeping me from feeling well." But it is not like that anymore, is it?" p. 6 |
| To accept, to give up, or to continue the search: Despite feeling better, as reported by the majority of the participants, none of them had become symptom-free after the amalgam removal | "Well, in a way I have accepted that I will always have some complaints. I am not like I used to be when I thought that if only I could find the right solution, then I would also get cured. I have kind of given up on that. It is more about finding the best possible way to live with [the complaints]." p.7 |

3122

Sjursen TT, et al., How unexplained health complaints were attributed to dental amalgam. *Nordic Psychology*, 2014, 66(3): 216-229

| Findings | Quotes |
|--|--|
| Feeling puzzled Participants stressed how they were baffled and to some degree overwhelmed by their complaints. Some of these participants described how they felt that their whole bodily and psychological functioning, and not just specific complaints, was influenced by something from the outside. From this, which was described as a feeling of being poisoned, a growing suspicion that dental amalgam could be behind their complaints arose. For others, dental amalgam was not considered a likely cause until it seemed to be the only explanation left after all other options had been exhausted. | "I thought a lot about whether it could be the amalgam. Because, you know, when you're feeling so miserable over time, you'll try everything. You'll try homeopathy and you'll try all sorts (laughs) of other things to figure it out. But when that didn't help, you know, what could it be?" p. 220 |
| Picking up anecdotal evidence: the importance of anecdotal evidence for their first suspicion of dental amalgam as being behind their complaints | "Actually, it was when I was at the rehabilitation center that there was such a huge focus on it, on amalgam. When I came back I told my dentist. He wasn't convinced, but he did contact [the specialty unit] and arranged for me to be examined. So, I've never been absolutely sure about it, if there really has been [a connection]. But it has been a possibility." p. 221 |
| Temporal relationship between dental treatment and episodes of ill health | "Sometimes when I had amalgam fillings replaced I felt absolutely terrible afterwards. Sometimes I even had to stay home from work. (. . .) I was in pain, I was frightfully tired, and I felt nauseated. (Short pause) It was obnoxious." p. 221 |
| A trusted person suggested dental amalgam as an explanation for my complaints: Sometimes physicians or dentists make the link. Participants' dentists suggested the link based on either severe intraoral complaints, such as dry mouth, pain, and a stinging sensation, or repeated episodes of ill health after dental treatment | "Well, it was the dentist who first put me on to the idea, you know. (. . .) He saw how bad my teeth were and how much pain I was in. (. . .) I described how I felt at the time, how painful it was and how it burned and ached, you know. " p. 222 |
| Feeling a resonance with descriptions of amalgam poisoning | "And when I was at the specialty unit, I contacted the organization for amalgam poisoning and I read everything I could get my hands on. And then I felt that I had all the complaints (laughs)." p. 223 |

3123

Stahlnacke K and Soderfeldt B. An interview study of persons who attribute health problems to dental filling materials--part two in a triangulation study on 65 and 75 years old Swedes. *Swedish Dental Journal*, 2013, 37(3): 121-130

| Findings | Sub-themes | Quotes |
|---|---------------|--|
| Long-term problems of varying character | Oral problems | Oral - "you feel sore and have so many, many blisters in the mouth, I had, |

Stahlacke K and Soderfeldt B. An interview study of persons who attribute health problems to dental filling materials--part two in a triangulation study on 65 and 75 years old Swedes. Swedish Dental Journal, 2013, 37(3): 121-130

| Findings | Sub-themes | Quotes |
|---|--|---|
| caused by dental amalgam | Somatic problems Mental problems Dental materials Long-term problems | you know" p. 125 Somatic - "that it might have some connection with my teeth that I was often so terribly tired, had pains in my body and felt dizzy and nauseous, had problems roughly like what you think of if you get the flu" p. 125 Mental - "one aspect of it all is that you have a tendency to get terribly depressed" p. 125 Dental - "that there could be a link with the mercury in the amalgam, and so I began to look into this and then I started talking to doctors and dentists and so on, that I was a textbook case of amalgam, eh, mercury poisoning." p. 125 Long term - "so these problems had actually been with me since birth because my mother had huge problems with her teeth and had many amalgam fillings" p. 127 |
| Problems treated mainly with change in dental materials in fillings resulting in anything from no improvement to noticeable improvement | Odontological treatment Medical treatment Alternative medical treatment Varying results of measures taken | "I had all the amalgam removed and my dentist said, you have to get rid of it, you won't get better before that, he said." P. 127 "I can still feel a little now but I've become much better, but it probably took, once all the amalgam was away, it took about two years." p. 127 |
| Powerful effect on life, mostly negative, but also some strengthening effects | Life restricted Life strengthened Not affected | "I felt so bad that I didn't have the strength for any social life" p. 127 |
| Good reception from health professionals on the whole, isolated encounters were often the cause of the negative experiences | Pleased with the reception Displeased with the reception | Pleased - "I got affirmation, she told me a lot about the disease, she told me exactly how to act and, and what, what was important to do" p. 128 Displeased - "met a doctor who didn't listen to me one second but just asked about the divorce and wanted to prescribe nerve tablets and the like for me" p. 128 |

3124

Jones LM. Focus on fillings: a qualitative health study of people medically diagnosed with mercury poisoning, linked to dental amalgam. Acta Neuropsychiatrica, 2004, 16(3): 142-148

| Findings | Sub-themes | Quotes |
|---|------------|--|
| Participants did not conform to an anticipated stereotype of a chronically ill person who had shopped around doctors, specialists and alternative health providers, and 'passed through' the medical practice that was the target of the present study, without regaining health p. 145 | | |
| Deamalgamation and detoxification: experiences following the removal of amalgam | | Majority experienced a full return to health and the activities of daily life. Every group had some participants who mentioned a 'bath' metaphor as a heuristic that explained deamalgamation and detox. Their body was likened to a bath, and dental amalgams likened to a dripping tap. For a person with dental amalgams, the tap was turned on, but with amalgam removal the tap was turned off. In the metaphor, this left 'water in the bath' and it needed to be drained. To detox was to 'pull the plug'. p. 144 |
| Psychological problems of mercury poisoning: First there were the problems directly attributed to mercury toxicity: memory loss, mood swings, and loss of sensation. Second there were the problems related to the consequences of having symptoms that were not readily diagnosed. The issues here were self-efficacy; the social stigma of being labelled a hypochondriac; the concomitant loss of social support; of being referred for psychological or psychiatric assessment | | Suicidal thoughts were also referred to during discussion in other groups, including praying to die and dreaming of death. p. 145 |

| Jones LM. Focus on fillings: a qualitative health study of people medically diagnosed with mercury poisoning, linked to dental amalgam. Acta Neuropsychiatrica, 2004, 16(3): 142-148 | | |
|--|---|--|
| Findings | Sub-themes | Quotes |
| The four diverse patterns of Experience | Chronic illness experience | They had 'every test in the book' from blood counts to scans. As the tests never showed anything abnormal, many had been told by doctors that they were 'making it up'... As illness persisted without a medical label or as a psychosomatic condition, these people experienced the negative social stigma of being labelled 'a hypochondriac'. p. 146 |
| | Experiencing minor worries | They had not considered they were ill when they consulted the medical practice, reporting only minor health worries including having a metallic taste in the mouth, tinnitus, and a reduced cognitive efficiency that some referred to as 'brain fog' and others as 'a bad memory'. They also reported having frequent tonsillitis, colds and 'flu'; and noticing a minimal sense of taste and smell. Their decision to have the urine test and to remove amalgam was for future illness prevention, linked for some with 'mercury suppressing the immune system'. p. 145 After deamalgamation and detoxification, these people were surprised both at the return of lost sensation and the speed of recovery. They had not anticipated any immediate benefits but reported the lifting of the 'brain fog', improved smell and taste, an absence of colds and flu symptoms and the end of the metallic taste. This was equated with a major health gain. p. 146 |
| | Still experiencing chronic illness and still with amalgam | Two expressed reservations about the likelihood of amalgam removal being a cure for them...Although there were only a few in this category, there was still a pattern that one needs both a conviction about the efficacy of deamalgamation, and money. p. 146 |
| | Single, major illness experience. | Several participants reported having an original medical diagnosis of something other than mercury poisoning, which they accepted (i.e. thyroid problems, cancers), but in the course of complying with orthodox treatment for this, they had explored amalgam removal as a way of minimizing a perceived threat to their immune system...When they did decide to try amalgam removal, the results were dramatic (i.e. no surgery or chemotherapy) and their return to health has been enduring, albeit with disease-in-remission diagnoses. p. 146 |

3125
3126

3127
3128
3129
3130
3131
3132
3133
3134
3135
3136
3137
3138
3139
3140
3141
3142
3143
3144
3145
3146
3147
3148
3149
3150
3151
3152
3153
3154
3155
3156
3157
3158
3159
3160
3161
3162
3163
3164
3165
3166
3167
3168
3169
3170
3171
3172
3173
3174
3175

Appendix 17: Invitation to participate in consultations – Implementation Issues Review

1. Invitation to participate in consultations regarding implementation issues for using dental amalgams and composite resin for dental restorations in Canada

“Dear Dr. X,

I am connecting with you regarding a Health Technology Assessment project comparing dental amalgams and resin composites currently underway at CADTH (Canadian Agency for Drugs and Technologies in Health). Here is the project page with a brief introduction to the project: <https://cadth.ca/dental-amalgams-compared-resin-composites>

In addition to clinical effectiveness and cost effectiveness, the review will assess evidence on patient experiences, ethical considerations, environmental impact and implementation issues related to using these materials in the treatment of patients. As the Knowledge Mobilization Officer for the project, I will be leading the review of implementation issues as well as any subsequent knowledge mobilization activity of the research results after the completion of the project.

Here are the questions we are trying to address in our implementation issues review:

1. What is the current use of amalgam restorations in Canadian dental practices or programs?
2. What is the current use of composite resin restorations in Canadian dental practices or programs?
3. What factors influence the use of amalgam or composite resin restorations in Canadian dental practices or programs?

We are wondering whether we could connect with you to discuss your perspectives on this issue, other considerations that we should be taking into account when we are looking at this issue as well as your suggestions on others with whom we should connect in order to discuss relevant implementation issues. We are also looking for any literature regarding implementation issues on this subject (our information specialists have already identified a list of articles that we are currently reviewing for relevant information).

Would you please let me know whether you are interested in a brief phone consultation and if so, what is your availability?

I look forward to hearing from you and hearing your perspectives.

With many thanks in advance.”


3176
3177
3178
3179
3180
3181
3182
3183
3184
3185
3186
3187
3188
3189
3190
3191
3192
3193
3194
3195
3196
3197
3198
3199
3200

2. Questions for Consultations with Stakeholders re Implementation Issues

- Do you have any information around the current use of amalgam restorations in Canadian dental practices or programs? Would you know where we can retrieve this type of information/data from?
- Do you have any information around the current use of composite resin restorations in Canadian dental practices or programs? Would you know where we can retrieve this type of information/data from?
- We are interested in understanding the context of use of these materials. According to your experience and knowledge, what factors influence the use of amalgam or composite resin restorations in Canadian dental practices or programs?
 - o It would be helpful if you could describe factors that may affect use such as:
 - relevant policies
 - issues related to the dental practice setting
 - cost considerations
 - considerations that relate to the dental providers (e.g. education, training, other)
 - considerations that relate to patients
 - other factors that you are aware of as contributing to the use of these materials in Canadian practices/programs.

3201 **Appendix 18: Flow Diagram of Literature Search**
3202 **and Selection Process – Ethics, Legal and Social**
3203 **Issues Review**

3204
3205
3206
3207
3208



Appendix 19: Historical Background and Context

3209
3210

3211
3212
3213
3214
3215
3216

This appendix provides a brief overview of key historical aspects of the on-going debate within the dental profession and in society more generally about the continuing use of dental amalgam as a restorative material. Understanding and appreciating this history has implications for the kinds of recommendations that may gain moral traction in the current debate, as well as in developing implementation strategies for such recommendations.

3217
3218
3219
3220
3221
3222
3223
3224
3225
3226

Early experimentations with various combinations of mercury amalgam were conducted in France and Britain in the early part of the 19th century, and amalgam was eventually introduced to America in the 1830s.^{128,138} From the outset there was controversy amongst dentists as to the safety of mercury amalgams. When the American Society for Dental Surgeons (ASDS) was formed in 1840 its members were required to sign a pledge never to use mercury amalgam because of the known toxicity of mercury. Enforcing that pledge proved problematic, however, leading to much dissension within the dental profession. Eventually the controversy led to the dissolution of the ASDS in 1856.^{128,129,138}

3227
3228
3229
3230
3231
3232

Then, as now, there were conflicting opinions as to the motives of the parties holding opposing views. Anti-amalgamists maintained that monetary self-interest was the primary motive for amalgam supporters who in turn downplayed the potential toxic effects of mercury.¹³⁸ Amalgam supporters, on the other hand, claim that early anti-amalgamists were driven primarily by jealousy, prejudice and poor judgment.^{129,233}

3233
3234
3235
3236
3237
3238
3239
3240

When the American Dental Association (ADA) was formed to replace the defunct ASDS it judiciously expressed no opinion on the safety of dental amalgam. In the meantime there were ongoing efforts to develop a better amalgam, and in the late 1870's, in what came to be known as 'the new departure', a movement began within dentistry to promote amalgam as a valuable filling material even as reports of its potential deleterious effects were debunked.¹²⁹ By 1895 the ADA was expressing support for the use of amalgam, a position it has held consistently until the present.^{193,234}

3241
3242
3243
3244
3245
3246
3247
3248

Detractors to amalgam were active throughout the 20th century,¹³⁸ and speculation about potential links between amalgam and various ailments were ongoing.^{235,236} Concerns were also raised about potential occupational hazards for dentists and dental assistants who were exposed to mercury on an on-going basis.²³⁷⁻²⁴⁰ For the most part, however, the safety of amalgam was largely assumed until the 1980's when methods were developed that confirmed the steady release of mercury vapours from amalgam fillings.^{241,242}

3249
3250
3251
3252
3253
3254
3255

Although the ADA acknowledged the persistent off-gassing of mercury vapour in the mouths of patients with amalgam fillings, it maintained that any mercury levels were clinically insignificant while reasserting its confidence in amalgam.²⁰¹ Nevertheless, the American news program *60 Minutes* aired an exposé in December 1990 proposing potential links to multiple sclerosis and other ailments due to poisoning from amalgam, placing the debate squarely in the public sphere once again.²⁴³⁻²⁴⁵

3256 The 1990s was a decade of heightened activity in the amalgam debate.
3257 While some within dentistry maintained that no scientific studies showed
3258 amalgam to be unsafe,²⁴⁶ complained that media hype was undermining a
3259 good product,^{150,245} and even went so far as to equate amalgam concerns
3260 with witchcraft and astrology,²⁴⁷ others doggedly questioned the evidence in
3261 support of amalgam safety. Indeed a persistent theme throughout the
3262 controversy involves conflicting interpretations both of what constitutes
3263 evidence, and what any supposed evidence means. Although numerous
3264 studies and supporting statements throughout the 90's from North America
3265 and abroad affirmed the supposed safety of mercury amalgam while
3266 debunking any connections to chronic diseases,^{155,176,212,213,246,248-252} others
3267 questioned those conclusions: "The comparison of mercury exposure levels
3268 from dental amalgam with occupational exposure is illusive," states one
3269 commentator. "Occupational exposure is 40 hours per week (while amalgam
3270 exposure is 154 hours per week) . . . and continues uninterrupted during the
3271 entire lifetime of the restoration."²⁵³ Another detractor argued that the
3272 interpretation of mercury toxicity is extremely difficult, due to the variable
3273 half-life of mercury which can vary between tissues in the same individual.¹²⁷
3274 Yet another refers to 'good evidence' for delayed neurotoxicity from mercury
3275 exposure that may only be manifested many years later.²⁵⁴ Others simply
3276 question the long-term safety of amalgam.²⁵⁰ The potential connection
3277 between amalgam and chronic diseases such as multiple sclerosis²⁵⁵ or
3278 mental illness^{243,256} is never far from view.

3279 Given the media attention and apparent lack of scientific or professional
3280 consensus, some patients insisted that their amalgams be removed.
3281 Dentists struggled to know how to respond.²⁵⁷ Contrary to available
3282 evidence, one leading professional journal advised that if asked patients
3283 should be informed that when combined with other metals mercury becomes
3284 "a biologically inactive substance"²⁰¹ Some dentists simply refused to comply
3285 with patient requests resulting in a 1993 case in Canada in which a dentist
3286 was charged with malpractice for refusing to replace a patient's amalgam
3287 fillings. While the Ontario Health Disciplines Board found that dentist
3288 innocent,²⁵⁸ other dentists were more willing to grant their patients' requests,
3289 leading to charges of quackery and suggestions of exploitation.^{175,176,259} The
3290 on-going controversy prompted The American Dental Association to revise
3291 its Principles of Ethics and Code of Professional Conduct to state: "The
3292 removal of amalgam restorations from the nonallergic patient for the alleged
3293 purpose of removing toxic substances from the body, when such treatment
3294 is performed solely at the recommendation or suggestion of the dentist, is
3295 improper and unethical."¹⁶⁶ The Canadian Dental Association followed suit
3296 with similar statements maintaining that amalgam removal was unwarranted
3297 and unprofessional.^{10,134,136,260} Meanwhile dentists who questioned the use
3298 of amalgam continued to voice concerns and in some cases questioned the
3299 professional competency of those who maintained the status quo. Inasmuch
3300 as amalgam is relatively easy to work with compared to resin, some
3301 speculated that it was lack of skill that in part motivated many to resist the
3302 move to resin. "Amalgam is a material that is ideal for mediocre dentistry"
3303 opined one anti-amalgam dentist.²⁶¹

3304 The Canadian contribution during this particular period was significant. While
3305 the official position of the Canadian Dental Association in support of
3306 amalgam has been documented, there were strong dissenting voices within
3307 the Canadian scientific community. University of Calgary researchers M.J.
3308 Vimy and F.L. Lorscheider were instrumental in developing techniques to

3309 measure concentrations of mercury vapour released by amalgams^{242,262} and
3310 published a number of papers in medical and scientific journals throughout
3311 the 80's and 90's that raised concerns about mercury toxicity.^{162,263} Their
3312 consistent conclusion was that research evidence does not support the
3313 notion of amalgam safety.²⁶⁴ Indeed Professor Vimy was one of the
3314 scientists interviewed in the *60 Minutes* exposé of 1990.

3315 As the public controversy grew the Medical Devices Bureau of Health
3316 Canada started its own investigation.¹⁰ That effort included the
3317 commissioning of Dr. Mark Richardson to attempt a calculation of the
3318 fraction of total exposure and relative risk due to mercury exposure from
3319 amalgam. Richardson's report, released in 1995, was the first
3320 comprehensive risk assessment in Canada of mercury exposure from
3321 amalgam.²⁶⁵ Richardson's study did not include laboratory research or
3322 clinical investigations, but relied instead on sophisticated computer
3323 modelling techniques to arrive at a tolerable daily intake level (TDI) for
3324 mercury. His initial simulations and calculations indicated that amalgam
3325 contributes about 50% of the daily mercury exposure of the average
3326 Canadian.^{10,265}

3327 Before releasing Richardson's study Health Canada asked a group of
3328 international experts in toxicology, public health and risk assessment to
3329 review it. While the reviewers generally agreed Richardson's methodology
3330 was sound, concerns were expressed over the lack of data on many of the
3331 crucial factors in his assessment model. Doubts were raised whether
3332 probabilistic estimation techniques that relied on assumptions in lieu of data,
3333 could provide a reliable TDI.¹⁰ Health Canada subsequently convened a
3334 committee of stakeholders to review the report. That committee initially
3335 included Professor Vimy, but when it became apparent the Committee would
3336 not recommend accepting Richardson's calculation of the TDI, Vimy
3337 resigned, complaining that the committee was stacked in favour of the pro-
3338 amalgam side.²⁶⁶ Health Canada subsequently decided not to follow
3339 Richardson's recommendation,¹⁰ and the CDA declared it "good news on
3340 amalgam." "Science, not misinformation and zealotry, must be the
3341 determining factors," declared the then president of the CDA.²⁶⁶

3342 Although Health Canada did not endorse Richardson's TDI estimate, the
3343 stakeholder committee did approve eight recommendations including one
3344 related to potential amalgam toxicity. That recommendation is carefully
3345 phrased, however, and emphasizes that "there is no evidence that dental
3346 amalgams contribute to immunological, neurological or kidney disease."
3347 However, given that there is some evidence that mercury exposure from all
3348 sources could have potential negative effects, dentists and physicians were
3349 advised to consider these concerns in their choice of dental materials,¹⁰
3350 although even these somewhat innocuous recommendations were
3351 challenged by Canadian dentists.²⁶⁷ This Canadian response contrasted
3352 starkly with what was occurring in many European countries.

3353 Even as WHO and FDI were issuing a 1995 consensus statement
3354 reaffirming the safety of amalgam while emphasizing its cost-
3355 effectiveness,¹⁵⁹ the conversation had taken a somewhat different turn and
3356 tone in Europe. Already in 1987 the Federal Office of Public Health in
3357 Germany issued a series of recommendations against the use of amalgam
3358 for pregnant women, children and people suffering from kidney disease. By
3359 1992 the Swedish parliament was considering a total ban on amalgam, and

3360 had already disallowed its use for patients under 20 years of age.¹⁰ The
3361 total Swedish ban did not occur, however, until 2009, and when announced
3362 was primarily out of environmental as opposed to patient safety concerns.²⁶⁸
3363 This shift in focus to emphasize public health and environmental concerns
3364 was to become a common theme as the amalgam controversy moved into
3365 the new millennium.^{182,269} Nevertheless, in the 1990's patient safety was still
3366 the motivating factor throughout Europe. In 1998 the Department of Health
3367 in Britain advised dentists against using amalgam during pregnancy,
3368 following the leads of Sweden and Norway where such restrictions had been
3369 in place since the late 1980s. While Finland and Denmark did not specifically
3370 highlight pregnancy, they had issued general recommendations against
3371 amalgam use. Germany and Austria followed suit, issuing recommendations
3372 to reduce amalgam use in young children, pregnant women, and in
3373 individuals with kidney disease²⁷⁰, this last ostensibly based on evidence
3374 that mercury accumulates in solid organs of the body and especially the
3375 kidneys and liver.²⁶³

3376 As the amalgam controversy moved into the 21st century the lines of
3377 disagreement with regard to patient safety have remained essentially the
3378 same. While various studies maintaining either that mercury toxicity from
3379 amalgam is not clinically significant²⁷¹ or purportedly demonstrating that
3380 those exposed to mercury vapours did not exhibit any particular deleterious
3381 effects from such exposure,^{44,45} others continue to dispute both the findings
3382 and the methods used in reaching those conclusions.^{139,272} "Although the
3383 issue of amalgam safety is still under debate," says one recent review, "the
3384 preponderance of evidence suggests that mercury exposure from dental
3385 amalgams may cause or contribute to many chronic conditions."²⁰⁷ Yet the
3386 temptation to cast aspersions on the opposing position is ever present:
3387 "Google amalgam" complains one pro-amalgamist, "and you'll be
3388 overwhelmed by junk science and fraud."²¹⁵ Nevertheless, the calls for
3389 further research on the long term effects of mercury exposure remain
3390 constant.²⁷³⁻²⁷⁶ Despite the CDA's continuing support for the use of
3391 amalgam, a 2002 survey of Canadian dentists identified the development of
3392 materials other than amalgam to be a research priority.²⁷⁷

3393 Other areas of potential research have emerged in recent years including
3394 the role of genetics in identifying patients who may be more susceptible to
3395 mercury toxicity,^{205,206} as well as the potential impact of electromagnetic
3396 fields including MRIs in elevating mercury toxicity levels for those with
3397 amalgam fillings.^{92,157,278,279}

3398 While the ongoing questions regarding patient safety have remained
3399 consistent, there are three areas of heightened activity in the 21st century
3400 worth noting. The first concerns the increased level of litigation. Due in part,
3401 no doubt, to the heightened public awareness around amalgam throughout
3402 the 1990's, a number of lawsuits were launched in a various jurisdictions
3403 (primarily in the US) against dental associations, either claiming harm due to
3404 the continued use of amalgams or seeking legislative restrictions on such
3405 use.^{141,142,146,147} Characterized at times as unscientific attacks by disgruntled
3406 lawyers,²⁸⁰ virtually all such cases were dismissed. However not everything
3407 went in favour of the pro-amalgamists. Cases in both Oregon and California
3408 challenged the relevant dental association's attempts to restrict the kinds of
3409 information dentists could share with their patients about potential amalgam
3410 toxicity, which the plaintiffs perceived as 'gag orders.' In both cases the
3411 courts ruled in favour of the plaintiffs.^{143,144} Such legal proceedings were

3412 instrumental in the FDA's 2009 decision to reclassify amalgam fillings.^{145,281}
3413 In particular, the FDA documentation reports that 70-80% of inhaled mercury
3414 vapour is absorbed by the lungs and distributes to several organ systems in
3415 the body, including a fraction that crosses the blood-brain barrier. Although
3416 the FDA reclassification document concludes there is inadequate evidence
3417 to conclude that vulnerable populations are at risk, it includes "special
3418 controls" for developing fetuses, breastfed infants, and children under six.²⁸¹

3419 The second development which bears noting is the rise in the use of
3420 composite resins as an alternative to amalgam. Whether out of concern for
3421 safety or simply as a matter of aesthetic preference, composite resins have
3422 been gaining in popularity over the past two decades. While concerns have
3423 also been raised about the potential toxic effects of Bisphenol A (BPA) as a
3424 by-product of composites^{165,282,283} the evidentiary basis for these concerns is
3425 also disputed.²⁸⁴

3426 Finally, a rise in concerns about environmental protection in general, and
3427 about mercury toxicity from all sources in particular, has had a significant
3428 impact on the amalgam discussion in the 21st Century. Canada has recently
3429 ratified the Minamata Convention, an international effort to reduce human
3430 generated mercury emissions.¹²⁶ Such international efforts have raised
3431 questions about the future role for amalgam in dentistry,²⁸⁵ and about the
3432 potential impact on dental patients.^{286,287} While international bodies still
3433 maintain the safety of amalgam as a dental material, it nevertheless
3434 supports a phase down in use^{160,161}

3435 The controversy over the safety of dental amalgam as a restorative material
3436 has been long and sustained and is unlikely to be resolved anytime soon. If
3437 there is any semblance of common or neutral ground, it is around the
3438 growing consensus that dental amalgam contributes to the overall
3439 environmental load of mercury toxicity, and efforts to limit and reduce its
3440 impacts are appropriate.

3441

3442